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Abstract
The control of bovine trypanosomiasis in Africa continues to rely heavily on 
the chemoprophylactic drug isometamidium chloride (Samorin®). However, 
despite many years of use, no methods are available which are sufficiently 
sensitive to measure drug levels in treated cattle. Two new enzyme-linked 
immunosorbent assay (ELISA) procedures for the detection and quantification 
of isometamidium in bovine serum were developed and validated. The first of 
these, an indirect competition ELISA (ICE) was capable of detecting 
isometamidium to approximately 0.1 ngmM. Following the treatment of cattle 
with isometamidium chloride by intramuscular injection at the recommended 
prophylactic dose rate of 1.0 mgkg-1, the drug could be detected in serum 
samples for up to four months.
In a controlled laboratory experiment, Boran cattle injected intramuscularly 
with isometamidium chloride (dose 1.0 mgkg-1 body weight) were challenged at 
monthly intervals with Glossina morsitans centralis infected with one of three 
populations of 7. congolense (IL 3893, IL 3889 or IL 1180) until all animals 
became infected. Untreated control cattle confirmed the infectivity of challenge. 
All cattle challenged with IL 3893 or IL 3889 developed infection following the 
first challenge, at which time the mean serum drug concentration was 6 ngmM. 
Cattle challenged with IL 1180 became infected following 6 to 8 challenges. 
The mean serum drug concentration in these cattle at the time of their third 
challenge with IL 1180 was 0.75 ngmM. Trypanosome populations IL 3893 and 
IL 3889 were considered to be highly resistant to isometamidium, while IL 1180, 
relatively sensitive. Hence, 7. congolense persisting at serum isometamidium 
concentrations greater than 0.75 ngmM can be considered moderately resistant, 
and at concentrations greater than 6 ngmM markedly resistant.
In a second, similar experiment isometamidium treated (1.0 mgkg-1) Boran 
cattle were with challenged monthly with 7. congolense IL 1180 or a moderately 
isometamidium resistant 7. congolense clone (IL 3343). Ten treated cattle 
challenged with IL 3343, were all refractory to infection one month after drug 
administration, but seven cattle succumbed at the second monthly challenge 
and three cattle at the third. All five treated cattle challenged with IL 1180 
resisted four monthly challenges. The mean isometamidium concentrations 
were 5.6 ± 2 . 8  ngmM and 2.0 ± 0.86 ngmM at the time of the first and second 
challenges respectively. The mean concentration in cattle refractory to 
challenge with IL 1180 at the time of the fourth challenge was 0.4 ±0 .18  ngmM.
T. congolense occurring in cattle under chemoprophylaxis may thus be 
considered moderately drug resistant if the, serum isometamidium concentration 
is 2.0 ngmM; between 0.4 and 2.0 ngmM a low level of drug resistance may be 
inferred; below 0.4 ngmM, no inference regarding resistance should be made.
An attempt was made to relate isometamidium concentrations measured by 
the ICE in serum from Jersey cattle under a failing chemoprophylactic regimen 
in coastal Kenya, to the incidence of trypanosome infection. The distribution of 
trypanosome challenge over a number of three month prophylactic periods was 
uneven, and almost all challenge (based on the infection rate in untreated 
control cattle) occurred at the end of such periods. At the time of challenge, 
concentrations in the treated group were at their lowest and no inferences could 
be made about drug resistance in trypanosome infections, all of which were 
caused by T. vivax.
A simpler, competitive enzyme immunoassay (CEIA) developed for 
isometamidium in bovine serum has several advantages over the ICE; fewer 
incubation steps; frozen storage of microtitre plates in batches; overnight 
competition incubation. The response variance of 57 untreated cattle was small 
(CV approximately 10%); partitioning showed 77% of this variance to be 
intrinsic to the samples, and 23% due to procedure (CV of duplicates wells 
approximately 5%). The CEIA could detect isometamidium in serum of treated 
cattle for up to ten weeks following treatment, with a high level of reproducibility. 
The limit of detection is approximately 0.5 ngmM.
The CEIA was used to investigate the pharmacokinetics of isometamidium 
in Friesian cattle (Bos taurus) treated intravenously and intramuscularly (dose 
rate 1.0 mgkg-1 body weight). The major pharmacokinetic parameters were 
calculated using standard pharmacokinetic equations. The large VSs (mean 24 
Ikg-1), and the prolonged MRT (83 h) and terminal phase half-life (136 h) 
following intravenous injection were consistent with extensive uptake of the drug 
into tissues such as liver, kidney and spleen. The relatively low bioavailability 
(60%), and prolonged MAT (7.8 days) following intramuscular injection was 
consistent with a primary depot at the site of injection.
Isometamidium could be detected using the CEIA in the sera of all but one 
of 24 cattle treated intramuscularly (1.0 mgkg-1 body weight) in an area of 
natural tsetse challenge; for up to 14 weeks in five cattle; for 12 weeks in 12 
cattle; for 10 weeks in 20 cattle; and for eight weeks in 22 cattle. The geometric 
mean apparent half-life of isometamidium in 22 cattle was 23.2 days. Treated
cattle were protected against trypanosome infections for at least 18 weeks; 
thereafter three trypanosome infections were detected, between 20 and 22 
weeks following treatment. In contrast, in 18 untreated control cattle, nine 
trypanosome infections were detected over the first 18 weeks. While there was 
no evidence of drug-resistant trypanosomes, the CEIA was capable of 
quantifying drug-levels in 20 out of 23 cattle for at least 70 days.
Finally, the CEIA was used to investigate the role of isometamidium in an 
experimentally induced wasting syndrome in Maasai Zebu cattle under a 
regimen of frequently repeated isometamidium treatments. Significant weight 
loss and mortality occurred in poorly nourished cattle after three or four 
isometamidium treatments and additional treatments with diminazene. Weight 
losses and glutamate dehydrogenase levels were correlated with 
isometamidium concentrations which showed small but significant elevations 
with successive treatments, but no marked increases. Such frequently repeated 
treatment regimens must be considered inadvisable.
In conclusion, the two ELISAs are capable of determining isometamidium 
concentrations in sera from cattle in the field, and promise to provide a practical 
means of rationalising chemoprophylactic drug regimens, particularly where 
they can assist in identifying the development of trypanocidal drug resistance.
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Chapter 1:
African Bovine Trypanosomiasis
1
Introduction
Geographic distribution
The trypanosomiases of domestic animals occur over a vast area occupying 
the greater part of the tropics and subtropics of the Americas, Africa and Asia. 
Tsetse-transmitted trypanosomiasis occurs in the sub-Saharan region of Africa 
where the distribution of the disease approximates to that of the tsetse fly vector 
species, over an area of 11 million km2 (Jordan 1986). In the north the limit of 
distribution depends on rainfall, being close to the 500mm isohyet, and extends 
from 14° N in Senegal in West Africa, across the southern boundaries of the 
Sahara desert, to 4° N in East Africa at the southern edge of the Somali desert. 
The southern limits of distribution vary in the west between 10 and 20° S, 
following the northern limits of the Kalahari and Namib deserts, while further to 
the east, the southern limit, which depends on minimum temperature, is 
approximately 20° S although on the East African coast it extends as far as 29° 
S. Between the northern and southern limits of the tsetse belts the precise 
distribution of the tsetse fly is not ubiquitous, but depend on factors influencing 
its survival, namely rainfall, vegetation and temperature. Altitude has a 
significant influence on all three of these factors, such that few tsetse survive 
above approximately 1800m in the equatorial region, and correspondingly lower 
altitudes closer to the southern limits of the fly belts.
Economic importance
In the majority of the 37 sub-Saharan countries affected by tsetse- 
transmitted trypanosomiasis the problem is classified as severe, and figures 
among the first three priority veterinary diseases (Anon, 1992). Tsetse flies 
pose a threat of trypanosomiasis over almost 40% of the continent of Africa 
(FAO/WHO/OIE, 1982). Seven million km2 of this area would probably be 
suitable for livestock and agricultural development if trypanosomiasis were 
controlled (Finelle, 1974; MacLennan, 1980), and an extra 120 million cattle 
and an equivalent number of small ruminants might be supported (FAO, 1987; 
FAO/WHO/OIE, 1982). However, heavily infested fly belts are virtually devoid 
of cattle: for example, in Tanzania the distribution of cattle is almost exactly the 
converse of that of the tsetse (Jordan, 1986). Of a total African population of 
approximately 173 million cattle, only 25% is located in tsetse-infested zone 
(IBAR, 1989).
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Where cattle are kept in areas of tsetse challenge, it is generally on the 
fringes of the tsetse belts; livestock owners have to balance the need for better 
nutrition for their animals, which is usually available within the fly-infested 
areas, with the associated threat of disease (Jordan, 1986). In these areas, 
losses in livestock production and performance include poor growth, weight 
loss, lowered milk yield, reduced animal traction output, infertility, high abortion 
rates, and mortality (FAO/WHO/OIE, 1963; McDowell, 1977). Losses in food 
production from mixed agriculture due to lack of manure, draught power, and 
cash income are incalculable (Stewart, 1986). For example, in Africa 80% of 
traction is non-mechanical; it has been estimated that a draught ox can increase 
the agricultural output of a family six-fold (McDowell, 1977). Moreover, the 
manure provided by livestock is essential for the production of food and cash 
crops.
Trypanosomiasis is thus the most economically important disease of Africa 
(Jawara, 1990), and the most significant factor in Africa's deteriorating food 
production situation (Trail, Sones, Jibbo, Durkin, Light and Murray, 1985). It 
has been estimated that controlling trypanosomiasis in tsetse-infested areas 
could generate an additional US$ 750M annually (Finelle, 1980).
Aetiology
Tsetse transmitted trypanosomiasis of domestic livestock in Africa is caused 
by various species of the genus Trypanosoma, which are parasitic protozoa 
found in the blood and tissues of their hosts. Within this genus a large number 
of species occur, of which only a few are recognised as disease causing 
parasites of man and his domestic animals. Other species infect non-domestic 
animals and / or are considered to be harmless. These parasites are generally 
transmitted by an arthropod vector, although exceptions to this rule occur. Of 
greatest importance as vectors of disease-causing Trypanosoma sp. in sub- 
Saharan Africa are blood-sucking flies of the genus Glossina, known collectively 
as the tsetse flies. The eminent British medical scientist David Bruce (1895) 
working in Southern Africa around the turn of the century described a 
trypanosome (Trypanosoma brucei) as being the aetiological agent of both the 
disease of cattle known as "Nagana" and tsetse fly disease. The importance of 
the genus Trypanosoma as disease causing parasites of domestic animals was, 
however, discovered fifteen years earlier by a British Army veterinary surgeon 
Griffith Evans (1880) posted to the Royal Artillery in the Punjab Frontier Force, 
who recognised a parasite (today known as Trypanosoma evansi) in the blood
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of horses suffering from a disease known locally as "Surra" (lit. rotten), and 
shortly afterwards in the blood of diseased camels.
The trypanosomes of the genus Trypanosoma are, in the trypomastigote 
form in which they occur in the mammalian host, unicellular mononuclear 
flagellate protozoa approximately 10 - 35 pm in length. These organisms are 
elongate and motile by virtue of the flagellum which originates from a basal 
body (usually in association with a kinetoplast) at the posterior end of the 
trypanosome and extends the length of the organism to which is loosely 
attached by a fold of the pellicle, known as the undulating membrane. There 
may be a variable length of free flagellum extending beyond the anterior end of 
the trypanosome, depending on the species of trypanosome. These 
morphological features, visible under the light microscope, particularly in 
Romanowski stained slide preparations have been the traditional basis of the 
sub-classification of the genus, although more recently, newer molecular 
techniques have been used to investigate the phylogenetic relationships of 
various trypanosome isolates (Hide and Tait, 1991).
The genus Trypanosoma can be divided into two sections on the basis of 
the mode of transmission, the Salivaria and the Stercoraria (Hoare, 1964). The 
pathogenic trypanosomes of Africa and Asia are generally transmitted by the 
bites of the vector arthropod, and are therefore classified in the section 
Salivaria, while the important human parasite of South America Trypanosoma 
cruzi (Chagas, 1909) is transmitted in the faeces of the arthropod vectors, 
triatomid bugs of the family Reduviidae, and is thus an example of the 
Stercoraria. Non-pathogenic stercorarian trypanosomes are widely distributed 
an example being the common cattle parasite Trypanosoma theileri (Laveran, 
1902) important as a potential source of confusion in the diagnosis of bovine 
trypanosomiasis.
All the tsetse-transmitted trypanosomes of mammals are members of the 
Salivaria, which has been further divided into four sub-genera on the basis of 
the morphological and epidemiological characteristics of its members, these 
being Duttonella, Nannomonas, Trypanozoon and Pycnomonas. The first of the 
sub-genera, Duttonella contains the important parasite of cattle and other 
ungulates Trypanosoma vivax (Zeimann, 1905) and the less important 
Trypanosoma uniforme (Bruce, Hamerton, Bateman, Mackie and Bruce, 1911). 
The second sub-genus, Nannomonas, contains another important parasite of 
domestic ruminants, Trypanosoma congolense (Broden, 1904), and a second
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species Trypanosoma simiae (Bruce, Harvey, Hamerton, Davey and Bruce, 
1912) important as a parasite of domestic and wild pigs. The sub-genus 
Trypanozoon contains three morphologically indistinguishable forms, all 
classified as sub-species of a single species, T. brucei, which are distinct in 
terms of their epidemiology, particularly in relation to their role in human African 
trypanosomiasis or sleeping sickness. Trypanosoma brucei brucei (Plimmer 
and Bradford, 1899) is distinguished by its inability to infect man, while it causes 
acute disease in dogs and horse, and chronic disease in pigs and cattle. 
Trypanosoma brucei rhodesiense (Stephens and Fantham, 1910) appears to be 
very similar to T. b. brucei except that it has acquired the ability infect man, 
classically causing sporadic outbreaks of "Rhodesian" sleeping sickness, a 
relatively acute disease in Eastern and Southern Africa. Trypanosoma brucei 
gambiense (Dutton, 1902), on the other hand, is a rather different organism 
which is not considered to be of significance in causing disease in domestic 
animals, although their role in its epidemiology is far from clear. In man it 
causes the more chronic "Gambian" form of sleeping sickness of central and 
west Africa. Also included in this subgenus are T. evansi (Steel, 1885) and 7. 
equiperdum (Doflein, 1901), important parasites of domestic animals, but not 
transmitted by tsetse flies. Finally, the fourth sub-genus of Trypanosoma, 
Pycnomonas, contains but a single species, Trypanosoma suis (Ochmann, 
1905), of limited distribution and pathogenic only to young domestic pigs.
The cycle development of trypanosomes in the invertebrate host differs 
between the three main sub-genera of tsetse-transmitted trypanosomes. 
Trypanosomes are ingested by the tsetse fly in a blood meal from a mammalian 
host as trypomastigote forms which are found exclusively in the fly gut. The 
parasites then undergo a transformation in the mouthparts or salivary glands of 
the fly into the epimastigote form, a form similar to the trypomastigote, but 
characterised by the close apposition of the basal body and kinetoplast to the 
nucleus (Hoare and Wallace 1966). Finally the parasites transform into 
metacyclic forms, which are infective for the mammalian host, the entire cycle 
taking between 5 and 35 days depending upon the species of trypanosome, 
species of tsetse fly, and the temperature (Jordan 1986; Vickerman, Tetley, 
Hendry and Turner, 1988). The importance of the species of trypanosome in 
the length of the development cycle in the fly is related to differences in the site 
of development within the fly of the various sub-genera of trypanosome. While 
Duttonella complete the cycle entirely within the fly's proboscis, Nannomonas 
develop in the midgut and proboscis, and Trypanozoon in the midgut and
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salivary glands. The site of development within the fly can be used together 
with morphological criteria to identify the infecting trypanosomes at least to the 
sub-genus level.
Transmission
Trypanosomes are generally transmitted by haematophageous arthropods, 
either mechanically as in the case of T. evansi, as suggested by Evans (1880), 
or cyclically, with replication in the arthropod host as discovered by Kleine 
(1909) in tsetse flies (Glossina sp.). A notable exception to this rule in Africa 
and elsewhere is the salivarian trypanosome parasite of the horse and donkey, 
T. equiperdum, which is transmitted by coitus and thus no longer requires an 
intermediate host for its propagation.
The tsetse flies comprise 22 species of Glossina, divided between three 
well-marked species groups (Newstead, 1911), and are the principal vectors of 
trypanosomiasis in sub-Saharan Africa. These three groups, distinguishable on 
the basis of differences between the male and female genital armature, are the 
fusca group, the palpalis group, and the morsitans group, containing 14, 9 and 7 
individual species and subspecies respectively (Jordan, 1986).
The fusca group generally occur in lowland rainforest habitats, and are the 
least important in terms of transmission of bovine trypanosomiasis. The palpalis 
group species also occur in lowland rainforest habitat but also extend into 
humid savannah, and along watercourses into drier savannah, and includes 
three species of importance in the transmission of bovine trypanosomiasis: G. 
palpalis, G. fuscipes, and G. tachynoides.
Species of the morsitans group are restricted to savannah woodlands and 
vegetation along watercourses. These species are therefore the ones most 
likely to come into contact with grazing herds of cattle. The three subspecies of 
G. morsitans, Glossina m. morsitans, Glossina m. submorsitans and Glossina 
m. centralis (see Plate 4), together with G. pallidipes, occupy a very large area 
and are major vectors of animal trypanosomiasis. Three other species in this 
group, G. swynnertoni, G. longipalpis and G. austeni are also important vectors 
of bovine disease in particular areas, but are more restricted in their 
distributions.
The life-cycle of Glossina is remarkable in that the female gives birth to a 
fully formed larva of approximately its own size, which immediately burrows into 
the ground and forms a puparium, from which a single fly emerges after
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approximately 30 days (Jordan 1986). Once deposited the larvae do not feed, 
and thus the species is entirely dependent for nutrition on the blood meals of 
the adults.
Glossina species differ in their ability to transmit trypanosomes: all species 
can be infected with some species of trypanosomes, but not all can be infected 
with all trypanosomes (Jordan 1986). For example, palpalis group flies are 
rarely if ever infected with T. congolense. The ability of tsetse to support 
trypanosomes is hereditary (Maudlin, 1982), refractoriness to infection being 
associated with a midgut lectin, while susceptibility appears to be associated 
with the presence of rickettsia-like-organisms (RLO) in fly ovaries and midguts 
(Maudlin, 1993). RLO have been shown to posses endochitinase activity which 
results in the excess production of n-acetyl glucosamine which inactivates the 
lectin.
Finally, the occurrence of T. vivax well outside Africa, notably Central and 
South America, and the West Indies, is evidence of transmission of this species 
in the absence of tsetse, transmission being thought to be due to the non- 
cyclical, "mechanical" transfer of bloodstream-form trypanosomes directly from 
one host to another on the mouthparts of biting flies (Stephen 1986). T. vivax 
has also been found in areas of Africa far from the known distribution of tsetse, 
suggesting mechanical transmission of this species may also be important 
within Africa, although the interpretation of such findings remains controversial 
because of difficulties in detecting tsetse at very low densities.
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Pathogenesis, immunology and pathology
Pathogenesis
The pathogenesis of animal trypanosomiasis has been the subject of 
excellent reviews by Fiennes (1970), Murray, Morrison, Emery, Akol, Masake, 
and Moloo (1980), Stephen (1986), and Losos (1986).
The course and severity of the disease depends on a number of factors, of 
which the species and origin of infecting trypanosomes, the breed of cattle 
involved and the history of prior exposure to infection, and treatment with 
trypanocidal drugs are the most readily defined (Stephen, 1986). There is a 
spectrum of disease states ranging from the peracute haemorrhagic condition 
associated with some particularly virulent T. vivax infections which may result in 
death within two weeks of the infective tsetse fly bites, through the more usual 
chronic condition characterised by anaemia and progressive wasting common in 
T. congolense infections, to almost inapparent chronic infections which may 
occur with T. brucei, particularly in indigenous cattle. Spontaneous recovery 
from infection may also occur. It would however be a gross oversimplification to 
state that these clinico-pathological syndromes typify infections with each of the 
three species in the field. Different isolates of the same trypanosome species 
differ markedly in their virulence, so that in East Africa T. congolense has 
traditionally been considered the major parasite of cattle, whereas in West 
Africa T. vivax holds the same status. Moreover, in the field, as opposed to 
experimental situations, mixed infections with various combinations of the three 
species are common and the clinico-pathological picture is thus further 
confused. Finally, the effects of trypanosomiasis are most pronounced in pure­
bred, "exotic" breeds of imported cattle, less so in indigenous local breeds, and 
often mild or inapparent in the so called "trypanotolerant" taurine breeds of 
West Africa such as the N'dama, the Baoule and the West African Shorthorn.
Fiennes (1970) described bovine trypanosomiasis as a relapsing condition, 
with successive waves of parasitaemia, accompanied by pyrexia, being 
followed by parasite destruction and an afebrile period. He divided the disease 
caused by T. congolense and T. vivax into two distinct stages, an acute stage 
with pre-critical and critical phases, and a chronic stage which is post critical. 
Although a "crisis", or sudden resolution of fever, is not universally recognised 
as a feature of bovine trypanosomiasis, most workers describe the acute stage 
of disease as being characterised by febrile periods accompanying
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parasitaemic peaks, which become less frequent during the chronic stages in 
which parasites may be difficult to detect by conventional parasitological 
techniques.
Studies on the pathogenesis of bovine trypanosomiasis have centred on 
the development of anaemia, which is the single most significant lesion in this 
condition. The anaemia in bovine trypanosomiasis is essentially an 
extravascular haemolytic anaemia (Mamo and Holmes, 1975; Dargie, Murray, 
Murray, Grimshaw and McIntyre, 1979), with evidence of erythrophagocytosis in 
many tissues, and, initially, a vigorous secondary haemopoietic response 
characterised by erythroid hyperplasia and extramedullary haematopoiesis. 
The mechanism of development of anaemia is complex and only partially 
understood, and has been variously attributed to pyrexia, production of toxins 
by trypanosomes (Tizard, Nielsen, Seed, and Hall, 1978), the adsorption of 
trypanosome antigens or immune complexes on the erythrocyte surface, with 
complement fixation and erythrophagocytosis or complement-mediated lysis 
(Kobayashi and Tizard, 1976), disseminated intravascular coagulation, and 
overactivity of the mononuclear phagocytic system.
The second most obvious clinico-pathological feature of bovine 
trypanosomiasis is that it is a wasting condition, with progressive emaciation 
and cachexia which becomes increasingly apparent in cases progressing into 
the chronic stages of disease. Tracey (1992) reviewed the role of the cytokine 
tumour necrosis factor (TNF-a) in the pathogenesis of septic shock and 
cachexia. Through the action of a number of secondary mediators this cytokine 
can induce a range of biological responses including the clinico-pathological 
manifestations of septic shock syndrome (not unlike peracute haemorrhagic T. 
vivax infection) and also chronic cachexic states (not unlike chronic bovine 
trypanosomiasis). TNF-a together with other cytokines such as interleukin -2 
and interferon^/, has recently received increasing attention as an important 
immunological mediator in trypanosomiasis (de Baetselier, 1993). These 
cytokines have now been shown to have a potential role not only in the 
pathogenesis of the disease, but also as an important part of the mechanism by 
which trypanosomes regulate their own proliferation and suppress the host 
immune system.
Immunology
Generalised increases in immunoglobulin (Ig) G and particularly IgM have 
been shown to occur in trypanosome infections (Luckins 1972; Luckins, 1976;
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Luckins and Mehlitz, 1978). This hyperglobulinaemia occurs in spite of a 
generalised immunodepression which results in reduction in the responses of 
infected cattle to a range of bacterial and viral vaccines (Holmes, Mamo, 
Thompson, Knight, Lucken, Murray, Murray, Jennings and Urquhart, 1974; 
Scott, Pegram, Holmes, Pay, Knight, Jennings and Urquhart, 1977).The 
phenomenon of antigenic variation in trypanosomes is the principal means by 
which the trypanosome evades the host's immune response and was reviewed 
by Gray and Luckins (1976), and Vickerman (1978). Trypanosomes comprising 
a particular parasitaemic peak are usually a mixture of variable antigenic types 
(VATs) in various proportions (van Miervenne, Janssens, Magnus, Lumsden 
and Herbert, 1975). The host immune response may eliminate the predominant 
VATs by the action of specific immunoglobulin, while parasites possessing less 
well represented VATs are able to proliferate and generate the subsequent 
parasitaemic peak. The site of antigenic variation has been shown to be the 
variable surface glycoprotein (VSG) coating the plasma membrane or pellicle of 
trypanosomes. Individual trypanosomes may switch between a wide repertoire 
of VATs, by altering the VSG amino acid sequence, a process which is under 
genetic control (Borst, Arnberg, Bernards, Cross, Frasch, Hoeijmakers and van 
der Ploeg, 1980; Borst, Frasch, Bernards, Hoeijmakers, van der Ploeg, and 
Cross 1980; Borst, Fase-Fowler and Gibson, 1981). The destruction of 
trypanosomes associated with the production of specific immunoglobulin 
directed against their surface glycoprotein coat has been demonstrated in 
bovine infections with T. brucei (Nantulya, Musoke, Barbet and Roelants, 1979; 
Musoke, Nantulya, Barbet, Kironde and McGuire, 1981) and T. congolense 
(Masake, Musoke and Nantulya, 1983).
Gross pathology
Gross pathological lesions in trypanosomiasis are generally non-specific 
and most are secondary to the anaemia. They include emaciation, generalised 
pallor, atrophy of body fat, splenomegaly, fatty change in the liver, enlargement 
and flabbiness of the heart, and straw-coloured effusions in the body cavities. 
The lymph nodes may be enlarged, oedematous or haemorrhagic. More acute 
cases may show evidence of generalised petechial and ecchymotic 
haemorrhages (Stephen, 1986).
Histopathology
The principal histopathological lesions of bovine trypanosomiasis are 
hyperplasia of the mononuclear phagocyte system, hyperplasia or hypoplasia of
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the lymphoid system, disseminated intravascular coagulation, pulmonary 
alveolar septal thickening, and testicular degeneration (Anosa and Isoun,
1983). The principal changes affecting the haemopoietic system may be 
evidence of erythrophagocytosis and haemosiderosis in the lymph nodes, 
spleen, haemolymph nodes, liver and lungs, erythroid hyperplasia in the bone 
marrow, and extramedullary haematopoiesis (Stephen 1986).
Akol and Murray (1983) described the morphology and histopathology of 
local skin reactions in susceptible cattle, frequently termed "chancres" by 
analogy to similar lesions in primary human syphilis, which developed following 
the bites of T. congolense infected G. morsitans centralis. These reactions of 
delayed onset and variable duration are the first clinical indications of 
trypanosome infection, although they are rarely observed outside experimental 
settings. The chancres appeared as small nodules of a few millimetres at the 
site of challenge after as little as five days, reached maximum size after 10 to 
13 days, and had disappeared by 20 to 30 days. At their height, they were 
raised, indurated, hot, painful swellings up to 100 mm in diameter. An intense 
inflammatory reaction was observed histologically, with an increase in total 
cellularity up to 10-fold. This was caused initially by a polymorphonuclear 
leucocyte infiltration, which was later replaced by a mononuclear infiltrate of 
mainly small to medium lymphocytes. These changes preceded parasitaemia 
and other clinical signs by several days, and it was concluded that the skin was 
acting both a focus of infection and a site for local proliferation of parasites.
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Plate 1. Trypanosome-infected Zebu cow in 
Somalia, showing severe emaciation. Swellings 
due to the intramuscular injection of 
isometamidium chloride are visible on the neck. 
Photograph courtesy of Professor P.H. Holmes.
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Plate 2. A well-organised field arrangement 
for the diagnosis of bovine trypanosomiasis 
using the HCT-BCT in Busia District, Western 
Province, Kenya. Adequate facilities for 
restraining cattle, field microscopes and a 
microhaematocrit centrifuge, powered by a 
portable generator, are visible.
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Diagnosis
The diagnosis of trypanosomiasis in domestic animals, including tsetse- 
transmitted bovine trypanosomiasis has been the subject of a number of 
extensive reviews (Molyneux, 1975; Stephen, 1986; Nantulya, 1990; Luckins 
1992; Luckins 1993).
Clinical diagnosis
Clinical signs of acute bovine trypanosomiasis include anaemia, pyrexia, 
weight loss, abortion, and in the absence of treatment, death (Stephen, 1986). 
Cases progressing to a more chronic disease state may be characterised by 
anaemia, cachexia, poor productivity and infertility (see Plate 1). The clinical 
picture depends to some extent on the species of infecting trypanosomes, and 
the geographic location. Hyperacute disease associated with T. vivax may 
resemble an acute septicaemia or result in a haemorrhagic syndrome, cases of 
which may often be found dead.
Classically in West Africa, acute 7. vivax has been considered more 
important than 7  congolense, whereas in Central or East Africa T. congolense 
was considered the more important parasite (Stephen, 1986). Exceptions to 
this slightly simplistic view occur, such as outbreaks of acute haemorrhagic 
disease in Coastal Kenya caused by T. vivax (Maloo, 1993).
7. congolense infections tend to be less acute and less dramatic, and in 
that sense are less pathogenic than 7. vivax infections, although the end result 
is almost as lethal (Stephen, 1986). 7. brucei infections are generally regarded 
as being of low pathogenicity for African cattle which may be infected without 
showing overt clinical signs, although exotic breeds and imported cattle may be 
more susceptible (Jordan, 1986).
Under certain circumstances a presumptive diagnosis may be made on the 
basis of clinical signs alone, particularly anaemia (Luckins, 1992), and the 
administration of trypanocidal drugs may be warranted on this basis, with a 
positive response to treatment being interpreted as confirmation of the 
diagnosis. However, these signs are all non-specific and a number of other 
disease states which occur in the endemic area may result in the same clinical 
picture. Hence diagnosis is usually confirmed by the use of more specific 
diagnostic tests.
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Parasitological diagnosis
Blood films
The examination of wet blood films, and Giemsa-stained thick and thin fixed 
blood films with the aid of the light microscope have been used as diagnostic 
methods ever since they were first used to identify the aetiological agents of 
trypanosomiasis. The use of these methods has been reviewed by Killick- 
Kendrick (1968).
Concentration techniques
Major advances in the diagnosis of trypanosomiasis came with the 
haematocrit centrifugation technique (HCT) of Woo (1970) in which 
trypanosomes are visualised in the buffy coat layer of a microhaematocrit 
centrifuge tube, and its subsequent modification, the phase contrast / buffy coat 
technique (HCT-BCT), in which the buffy coat is expressed from the 
microhaematocrit tube onto a glass slide and examined microscopically using 
phase-contrast or dark ground illumination (Murray, Murray and McIntyre,
1977). A method using miniature anion-exchange columns for the separation of 
trypanosomes from erythrocytes prior to concentration by centrifugation 
(Lumsden, Kimber, Evans and Doig, 1979) has not seen widespread application 
under field conditions. Paris, Murray and McOdimba (1982), compared the 
effectiveness of some of these newer diagnostic methods with the traditional 
blood films, and found the HCT-BCT to be the most sensitive technique, 
followed in order of decreasing sensitivity by the HCT, stained thick film, stained 
thin film and wet blood film. The sensitivity of the HCT-BCT depended on the 
species of trypanosome, with the smallest numbers detectable per ml of blood 
being 2.5 x 102, 5 x 102 and 5 x 103, for 7. congolense, 7. vivax and 7. brucei 
respectively. A well-organised field diagnostic set-up is shown in Plate 2
Subinoculation methods
Subinoculation methods are those by which trypanosomes are 
demonstrated by transferring infection from the suspected case to another 
vertebrate host, an invertebrate host or to an in-vitro culture system. These 
methods have the additional advantage that stabilates of the isolated parasites 
may be prepared for further investigation.
Animal subinoculation
Subinoculation of blood from suspected cases into another species, 
especially laboratory rodents has been widely used, although not all
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trypanosomes are infectious for these species. Immunosupression of laboratory 
rodents either by irradiation or using chemical immunosuppressants such as 
cyclophosphamide may increase the proportion of trypanosomes resulting in 
infection (F.W. Jennings, personal communication). Inoculation of susceptible 
rodents may be more effective for some trypanosomes species, particularly 
Trypanozoon sp. (Godfrey and Killick-Kendrick, 1961), than others. Robson 
and Ashkar (1972), found far more cases of T. brucei infection in Kenya using 
mouse inoculation than using blood examination, although for T. congolense 
infections mouse inoculation revealed only half as many positive animals as 
were identified using blood examination. Mouse inoculation failed to pick up 
any 7  vivax infections. For this reason subinoculation of domestic ruminants 
(usually sheep or goats on grounds of expense) rather than rodents may be 
recommended. 7. vivax may vary in its ability to give rise to parasitaemias in 
goats, depending on the geographical origins of the parasites (Peregrine, Moloo 
and Whitelaw, 1991), and it may be necessary to subinoculate calves to 
maximise the chance of detecting this species of trypanosome.
Xenodiagnosis
Xenodiagnosis is the feeding of a clean susceptible vector species on a 
suspected case of trypanosomiasis, after which it is either dissected and 
examined for the presence of infection, or allowed to feed on a clean animal 
which is itself examined for the development of infection. It may be the only 
parasitological means of demonstrating chronic-phase human infection with 7  
cruzi (van Miervenne and le Ray, 1985). Because of the scarcity of laboratory- 
reared Glossina sp. in Africa, this method of diagnosis is rarely attempted for 
tsetse-transmitted bovine trypanosomiasis. However it may be warranted in 
particular circumstances if the presence of a trypanosome infection in a 
particular animal or cattle population is suspected on the basis of surrogate 
tests (i.e. tests which do not conclusively demonstrate the presence of the 
parasite, such as antigen-ELISA, see below), but cannot be conclusively 
demonstrated by other means. The differential susceptibility of different species 
of Glossina should be taken into account if this technique is used, for example, 
G. palpalis is unlikely to become infected with 7. congolense (Stephen, 1986).
In Vitro Culture methods
The first in vitro cultures of bloodstream form trypanosomes were initiated 
from an intermediate rodent host in which parasites were isolated. Zweygarth 
and Kaminsky (1990) described a method for isolating 7. brucei brucei and 7.
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evansi directly in culture from host animals with low parasitaemias which were 
in some cases not detectable on wet blood film or HCT. A kit for the in vitro 
isolation of trypanosomes (KIVI) has been developed as a means of isolating 7  
gambiense from man (Aerts, True, Penchenier, Claes and Le Ray, 1992) and 
has also been shown to be useful in diagnosis as it may demonstrate the 
presence of this organism at very low levels in patients' circulation (True and 
Formenty, 1993). The method has also been assessed for use in domestic 
animals, and shown to detect more T. brucei infections than conventional 
parasitological techniques (McNamara, 1993; True and Formenty, 1993).
Immunological diagnosis
Demonstration of trypanosomes, either directly in the blood, or indirectly by 
subinoculation of animals, culture media or xenodiagnosis all have their 
limitations in terms of sensitivity and practicability. This, together with a 
recognition of the invaluable contribution of serological methods to the control 
of diseases of viral and bacterial aetiologies, has led to considerable research 
into the development of immunological methods in the diagnosis of 
trypanosomiasis.
Detection of anti-trypanosomal antibodies
The complement fixation test (CFT) was used extensively and exclusively in 
the successful eradication campaign in North America (Watson, 1920) of equine 
7. equiperdum infection (dourine), in which trypanosomes are rarely 
demonstrable in blood or body fluids. Although it has been compared 
favourably with the indirect fluorescent antibody test in the diagnosis of 7. 
congolense infections in cattle (Lotzsch and Deindl, 1974), and has been used 
in the diagnosis of surra (7  evansi infection) in buffalo (Randall and Schwartz, 
1936), this test suffers problems in reagent preparation, standardisation and 
anticomplimentary activity in sera (Luckins, 1993), and has not found a useful 
role in the diagnosis of bovine trypanosomiasis. The indirect haemagglutination 
(IHA) test has also found some use in then diagnosis of 7. evansi infections 
(Shen, 1974), but was found to be unreliable for use for 7. vivax infection 
(Clarkson, Cottrell and Enayat, 1971).
The development of the indirect fluorescent antibody test (IFAT), a primary 
binding assay, and thus one in which the antibody-antigen reaction is measured 
directly, was a significant step forward in the detection of anti-trypanosomal 
antibodies. In this test, blood films from infected animals with high
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parasitaemias are fixed, and used as a source of trypanosomal antigens to 
which anti-trypanosomal antibodies in test sera may bind specifically. Bound 
antibodies are visualised using anti-species immunoglobulin (e.g. anti-bovine 
immunoglobulin) conjugated to a fluorescent dye which may be observed using 
an ultraviolet microscope. The IFAT has been shown to be both sensitive and 
specific in the detection of bovine anti-trypanosomal antibodies (Wilson, 1969; 
Luckins and Mehlitz, 1978). Although a degree of cross-reactivity between 7. 
brucei, 7. congolense and 7. vivax (Ashkar and Ochilo, 1972) means that the 
IFAT is not reliably species specific, cross-reactivity is not complete and thus all 
three antigens must be used for maximum efficiency (Luckins, 1993). Other 
disadvantages of IFAT are the requirement for an expensive ultraviolet 
microscope, and the subjectivity of the results.
The enzyme-linked immunosorbent assay (ELISA), another primary binding 
assay, was developed by Engvall and Perlmann (1971) and, in various forms, 
has since become one of the most widely used and useful techniques in 
biomedical science. In the ELISA, in its original form, antigens are immobilised 
by passive adsorption onto a solid-phase, frequently a 96-well polystyrene 
microtitre plate, and detected using specific antibody labelled with an enzyme 
which catalyses the conversion of a colourless substrate to a visible coloured 
product. A more useful variant, the indirect ELISA, is analogous to the IFAT, in 
that specific antibody in a test sample, if present, binds to the immobilised 
antigen, and is itself detected by means of enzyme-labelled anti-species (e.g. 
anti-bovine) conjugate and conversion of substrate to coloured product. In 
practical terms the attraction of the ELISA is twofold. Firstly the test may be 
performed without specialised equipment, so that it may be adapted to 
inexpensive versions for use in the field or under-resourced laboratories. 
Secondly, with suitable equipment various degrees of automation are possible, 
allowing a high throughput of test samples in suitably equipped laboratories 
(Luckins 1992).
The indirect ELISA was adapted for a number of protozoan diseases, 
including trypanosomiasis (Voller, Bidwell and Bartlett, 1975; Voller, Bidwell, 
Bartlett and Edwards, 1977), it was shown to be capable of detecting specific 
antibodies in trypanosome infected cattle (Luckins, 1977) and it was shown to 
detect more serologically positive cattle than the IFAT (Luckins and Mehlitz,
1978). As with the IFAT, cross reactivity between the three major tsetse- 
transmitted trypanosome species occurs in the indirect ELISA using crude
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antigen preparations, and sera must be screened against all three antigens for 
optimum sensitivity (Luckins and Mehlitz, 1978; Luckins 1992). The 
fractionation of trypanosomal antigens by column chromatography has 
improved the species specificity of antibody detection by ELISA (Ijagbone, 
Staak and Reinhard, 1989), although this approach has yet to see widespread 
application.
Another simple antibody detection method which is particularly suitable for 
field use in Africa is the card agglutination test (CATT), which has recently 
found widespread application in the diagnosis of T. gambiense sleeping 
sickness (Magnus, Vervoort, and van Miervenne, 1978). The use antigens from 
particular variable antigenic types (VATs) of T. gambiense which are highly 
conserved across the range of parasites, and thus the majority of infected 
individuals develop antibodies which cause visible agglutination when whole 
blood or serum is mixed with the antigen on a card. Although this test has been 
adapted for use for diagnosis of T. evansi in animals (Bajyana-Songa, Hamers- 
Casterman, Hamers, Pholpark, Pholpark, Leidl, Tangchaitrong, 
Chaichanopoonpol, Vitoorakool and Theirapataskum, 1987), it is less likely to 
be applicable to T. congolense or T. vivax than the Trypanozoon species 
because of the difficulty in identifying suitable VATs in these species (Luckins
1992).
Detection of trypanosomal antigens
While significant advances have been made in the detection of anti­
trypanosomal antibodies, all these techniques suffer the drawback that they are 
unable to distinguish current active infection from infections which have 
resolved spontaneously, or which have been treated successfully, as antibodies 
may persist (Luckins, Boid, Rae, Mahmoud, el Malik and Gray, 1979; Luckins
1992). Demonstration of the parasite itself rather than antibodies is necessary 
for the confirmation of active infection, although it is recognised that the 
conventional parasitological techniques are relatively insensitive. Modifications 
of the ELISA have enabled the technique to be used for the detection of 
antigens, which may be a better indicator of active infection than antibodies. 
The double sandwich ELISA method for the detection of antigens (Voller, 
Bidwell and Bartlett, 1976), was shown by Rae and Luckins (1984) to detect 
antigens in animals within 10 to 14 days of infection with T. congolense and T. 
evansi, and these antigens were shown to disappear within 21 days of 
trypanocidal drug treatment. In this ELISA, polyclonal antibodies raised against
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crude trypanosomal antigen preparations were used to coat microtitre plates, 
and antigen present in test sera bound to the antibody. The bound antigen was 
then detected using the same antibody conjugated with enzyme and a suitable 
substrate.
Antigen-detection ELISAs (Ag-ELISA) for tsetse-transmitted 
trypanosomiasis were developed at the International Laboratory for Research 
on Animal Diseases (ILRAD), Nairobi, Kenya, using the sandwich ELISA 
methodology, but incorporated trypanosome species-specific monoclonal 
antibodies (Kohler, and Milstein, 1975) which reacted with determinants of 7. 
brucei, 7. congolense or T. vivax (Nantulya, Musoke, Rurangirwa, Saigar and 
Minja, 1987). The aim of the development of these tests was to increase the 
sensitivity of diagnosis, in both the analytical sense (i.e. a smaller quantity of 
the analyte [trypanosome] can be detected), and in the epidemiological sense 
(i.e. a greater proportion of infected animals react in the test). In addition it was 
hoped to maximise the specificity of the tests (i.e. to minimise the number of 
false positive results). In practice this was equated to lack of cross-reactivity to 
other protozoon pathogens (Nantulya et a/., 1987), and lack of cross reactivity 
of each species specific test to the other two trypanosome species (Nantulya 
and Lindqvist, 1989).
Development of Monoclonal Antibodies
The monoclonal antibodies (Mabs) initially described for use in the Ag- 
ELISA (Nantulya et al.t 1987) were raised in Balb/c mice immunised using 
procyclic forms of 7. brucei brucei LUMP 427 (Lugala, Uganda), 7  brucei 
rhodesiense B704 (Lugala, Uganda), 7  congolense STIB 212 (Serengeti, 
Tanzania) and T. vivax IL 1392 (Zaria, Nigeria) propagated in-vitro. The 
hybridomas obtained after fusion of spleen cells of immunised mice with NS1 
myeloma cells were screened by indirect immunofluorescence (IFAT), and 
doubly cloned. Ascitic fluids produced in Balb/c mice were purified using 
protein-A sepharose (IgG Mabs) or Sepharose 6b filtration (IgM Mabs).
Subgroup specificity
Purified Mabs were tested by IFAT against formaldehyde-fixed whole 
procyclic trypanosomes. Interestingly, all of seven randomly selected Mabs all 
gave 100% positivity against homologous (with respect to subgenus) procyclics, 
and 0% positivity against heterologous procyclics (Nantulya et al., 1987). 
Within the 7. brucei subgroup, three IgM Mabs, of which two (TB7/8.1.48 and 
TB7/8/13.12) were raised against 7. b. brucei, and one (TR7/47.34.16) against
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T. b. rhodesiense, all bound in IFAT to all procyclics of six stocks of T. b. brucei, 
three stocks of T. b. rhodesiense and two stocks of T. b. gambiense, but not to 
any procyclics of five stocks of T. congolense, five stocks of T. vivax, or one 
stock of T. simiae. Tested by IFAT against the same panel of procyclics, an 
IgGi Mab (TC3/17.1.13) and an lgG3 Mab (TC6/25.25.4) raised against 7. 
congolense, bound to all Nannomonas procyclics, but not to any Duttonella or 
Trypanozoon procyclics; an lgG3 Mab (TV8/8.33.42) and an IgM Mab 
(TV8/8.5.38) raised against T. vivax, bound to all Duttonella procyclics, but not 
to any Nannomonas or Trypanozoon procyclics.
Later monoclonal antibodies
Another IgM Mab (TC40/31.15.45), was raised against procyclic 
trypomastigotes of T. congolense KILIFI/83/IL/97 which had been treated with 
periodate-lysine-paraformaldehyde fixative (periodate digestion was to destroy 
surface carbohydrates to enhance production of Mabs to protein epitopes), and 
was tested by ELISA using experimentally infected bovine sera (Nantulya and 
Lindqvist, 1989).
Later, two further Mabs raised against bloodstream forms were described. 
The IgM Mab TC39/30.38.16 was used in an attempt to assess test sensitivity 
by Masake and Nantulya (1991), who state it was raised against T. congolense 
(stock unspecified) as reported by Nantulya et al. (1987). However when Mab 
TC39/30.38.16, and yet another Mab (class unspecified), TV27/9.45.15, were 
used by Nantulya, Lindqvist, Stevenson, and Mwangi (1992) in Ag-ELISA for 
field diagnosis, they were described as having being raised against total lysates 
of bloodstream forms of T. congolense and 7. vivax respectively (stocks 
unspecified).
Monoclonal antibody specificity
There is now a confusing number of apparently species specific Mabs 
against salivarian trypanosomes (Table 1). Of these some have been tested in 
IFAT (Nantulya et al., 1987), some in Ag-ELISA using procyclic lysates 
(Nantulya et al., 1987), some in Ag-ELISA on samples derived from 
experimental infections of cattle and or goats, with (Nantulya and Lindqvist 
1989) and without treatment (Masake and Nantulya, 1991; Masake, Moloo, 
Nantulya, Minja, Makau and Njuguna, submitted), some in Ag-ELISA on bovine 
field samples (Nantulya et al., 1992) and one on field samples from camels 
(Waitumbi and Nantulya, 1993). In other, numerous publications, Ag-ELISA 
results from various species, including cattle, pigs, monkeys and man are
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presented (e.g. IAEA, 1993; OAU/STRC, 1993), without the precise identity of 
the Mabs used being identified. Clearly, it is difficult to assess the performance 
of an immunoassay technique in which there appears to be little consistency in 
the primary immunological reagents.
Antigen recognition
The first group of anti-trypanosomal Mabs to be described for use in Ag- 
ELISA (Nantulya et al., 1987), were shown by IFAT to react with molecules on 
the plasma membrane of live and formaldehyde-fixed homologous procyclic 
forms, but not bloodstream forms. In the same work, ELISA reactions were 
obtained with supernatants of procyclic lysates, procyclic culture supernatants 
and, significantly, lysates of bloodstream forms prepared from stocks isolated in 
various countries. This suggested that the antigens detected were water 
soluble, present in more than one stage of the life cycle, and relatively 
conserved over the parasites' geographic ranges. However, with regard to the 
bloodstream forms, neither the details of the species, number and origins of the 
trypanosome isolates tested, nor which Mabs they reacted with, were described.
FAO/IAEA Ag-ELISA kit
The antigen-detection ELISA developed at ILRAD has been introduced in 
the form of a standardised kit to a number of African institutes involved in tsetse 
and trypanosomiasis control during the period 1987 - 1992 under a Co­
ordinated Research Programme of the Joint FAO/IAEA Division of Nuclear 
Techniques in Food and Agriculture (Ooijen, 1993).
The FAO/IAEA trypanosomiasis Ag-ELISA kit uses three species-specific 
Mabs, directed against invariant surface antigens of T. brucei, T. congolense 
and T. vivax, these being of the IgM, IgM and IgGi classes respectively. It is 
understood that these are TR7/47.34.25, TC39/30.38.11 and TV27/9.45.15 
respectively (D. Rebeski, personal communication), of which the first two are 
assumed to be equivalent to TR7/47.34.16 and TC39/30.38.16 respectively.
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Table 1. Monoclonal antibodies to trypanosome invariant antigens.
Mab I.O. Immunogen Mab class Subgroup
specificity
TB7/8.1.481 T. b. brucei LUMP 427 pt IgM Trypanozoon
TB7/8/13.120 T. b. brucei LUMP 427 pt IgM Trypanozoon
TR7/47.34.160-2-4-58 T. b. rhodesiense B704 pt IgM Trypanozoon
TC3/17.1.130 T. congolense STIB 212 pt igGi Nannomonas
TC6/25.25.41 T. congolense STIB 212 pt igG3 Nannomonas
TC40/31.15.452 T. congolense KILIFI/83/ILV97pt IgM Nannomonas
TC39/30.38.163-5 T. congolense bf IgM Nannomonas
TV8/8.33.421,2 T. vivax IL 1392 pt lgG3 Duttonella
TV8/8.5.380 T. vivax IL 1392 pt IgM Duttonella
TV27/9.45.155 T. vivax bf IgGi? Duttonella
°Reactivity tested in IFAT but not Ag-ELISA against procyclic lysates (Nantulya et al., 1987).
’Reactivity tested in IFAT and Ag-ELISA against procyclic lysates (Nantulya et al., 1987).
2Reactivity tested in Ag-ELISA against infected cattle sera (Nantulya and Lindqvist, 1989).
3Used in Ag-ELISA for T. congolense in goats and cattle (Masake and Nantulya, 1991).
4Used in Ag-ELISA for T. evansi in dromedary camel (Nantulya ef al., 1989; Waitumbi and Nantulya, 1993). 
sUsed in Ag-ELISA for field diagnosis in cattle at Nguruman (Nantulya et al., 1992).
®Used in Ag-ELISA for T. brucei infections in cattle (Masake etal., in preparation).
bf = bloodstream forms
pt = procyclic trypomastigotes
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Molecular biological diagnosis
The molecular diagnosis of parasites was reviewed by Nantulya (1991). 
This approach to diagnosis is based on detection of specific evidence of the 
presence of the parasite genome, i.e. trypanosome nucleic acids, in samples 
obtained from the host.
DNA probes
DNA probes utilise nucleotide sequences of no known function, known as 
"satellites", which are repeated many thousands of times in the parasite 
genome and which show species-specific differences. The sequences in the 
probe, which is conveniently labelled with a tracer, usually a radioisotope a non­
nuclear label, are hybridised with complementary sequences in the DNA of the 
test sample which has previously been treated with denaturing agents and split 
into single strands.
DNA probes have been used to distinguish Trypanozoon species from other 
trypanosome species (Massamba and Williams, 1984), to identify T. brucei, T. 
vivax and two types of T. congolense in experimentally infected flies (Kukla, 
Majiwa, Young, Moloo and ole-MoiYoi, 1987), to distinguish the two species of 
Nannomonas and subspecific groups of T. congolense (Gibson, Dukes and 
Gashumba, 1988), and to differentiate T. congolense and T. simiae in wild 
caught tsetse flies (McNamara, Dukes, Snow and Gibson, 1989). They have 
also been used to detect DNA of T cruzi in mammalian blood samples 
(Nantulya, 1991).
Polymerase chain reaction (PCR)
DNA probes may suffer lack of sensitivity if there is an inadequate number 
of repeats of the diagnostic sequence, or there is insufficient nucleic acid in the 
test sample. The polymerase chain reaction (PCR) technique provides a means 
of massive amplification of the diagnostic signal. Segments of DNA flanking the 
diagnostic sequence, known as primers, are incubated with the test material, 
together with a DNA polymerase. If the diagnostic sequence is present the 
complementary strands will be synthesised by DNA chain extension in each 
direction from the opposing primers. The resulting double stranded DNA can 
again be split and the cycle repeated several times with an exponential increase 
in the number of copies of the diagnostic sequence until sufficient material is 
present to be detected using a hybridization probe. This technique has been 
applied to the diagnosis of bovine trypanosomiasis using plasma buffy coat
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samples from cattle which are aparasitaemic but antigenaemic on the basis of 
Ag-ELISA (Majiwa Maloo, Thatti and Moloo, 1993).
The main drawback of the PCR technique is its remarkable sensitivity. In 
theory, a single copy of the diagnostic sequence could be identified, and yet the 
presence of a minute quantity of trypanosome DNA is insufficient evidence for a 
viable active infection. Such DNA could have resulted from an infection which 
failed to become established, or an infection already cleared by self-cure or 
chemotherapy, or even laboratory contamination. More recent work had 
attempted to overcome this problem by detecting trypanosome-specific 
messenger RNA sequences which will only be present within metabolically 
active viable trypanosomes (Dr. J. Burke, personal communication).
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Control methods
Vector control
In spite of attempts to control tsetse flies for more than 60 years, the area of 
tsetse infestation is actually expanding in many areas of the African continent 
(MacLennan, 1980).
Bush Clearance
Selective bush clearance removes breeding habitats for tsetse flies, which 
are highly dependant on correct vegetation types for shelter. For example, 
clearance of medium sized bushes and trees from riverine vegetation belts may 
remove the dry season "concentration area" of savannah tsetse, although such 
techniques are rarely practised today (Jordan, 1986).
Clearance of entire tracts of land using bulldozers and chains, followed by 
firing of stumps and use of herbicides may be used to create barriers to tsetse 
re-invasion of cleared areas. However this is extremely costly as a zone as 
wide as 5 km may be required, with regular re-slashing of regenerating 
vegetation as.
Elimination of Wildlife
In many areas wildlife may be the main source of blood meals for tsetse. 
The great rinderpest panzootic of 1895 to 1896 in the Zambezi and Limpopo 
basins killed nearly all the wild ruminants, and this resulted in the elimination of 
tsetse and trypanosomiasis from the area (Jordan, 1986). This observation led 
to the use in the first half of this century of mass destruction of game animals in 
many countries, a method now considered unacceptable. Selective shooting of 
particular hosts such as warthog, based on the feeding preferences of particular 
tsetse species, and the use of fences to separate livestock areas from game 
sanctuaries may still play important roles in integrated tsetse and 
trypanosomiasis control programmes.
Insecticidal Spraying
Spraying campaigns have cleared sizeable areas of Nigeria, Zimbabwe, 
Botswana, and Zambia (Jordan, 1986). However complicated logistics and 
organisational infrastructure are required and these operations are generally 
costly. There are also problems related to the ever-present danger of re­
invasion of tsetse from adjacent areas and the environmental objections due to 
non-target effects of insecticides (Douthwaite, 1992).
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Residual insecticides
Ground spraying of tsetse habitat usually involves the use of residual 
insecticides, such as DDT, and dieldrin. Hand spraying of the tree trunks and 
undersides of low branches is aimed at depositing residual insecticide that will 
remain active for weeks or even months on tsetse resting sites. Detailed 
entomological and botanical data are required to achieve high selectivity for 
particular tsetse species in particular areas, and military-style logistical support 
is needed. Nevertheless this has been used successfully as the sole control 
method to clear large tracts of land of tsetse (Jordan, 1986). Some attempts 
have also been made to use helicopters to replace ground spraying of residual 
insecticides onto vegetation, but this is difficult and expensive.
Non-residual insecticides
The aim of non-residual insecticide spraying is to produce a fine aerosol 
mist which will drift through vegetation and kill tsetse directly in flight or on 
resting sites. Twin engined fixed wing aircraft or occasionally helicopters are 
used for this technique which is most effective against G. morsitans. Passively 
driven, spinning-cage type sprayers are used to produce droplets of exactly the 
right size. Ultra low volume applications of the organochlorine endosulphan or 
the synthetic pyrethroid deltamethrin are used to minimise flight times and 
thereby costs. Temperature inversion conditions are necessary for effective 
spraying, and this may require night flying and expensive navigational 
equipment. Detailed meteorological and entomological data are essential.
Biological control
Biological control is the deliberate use of predators, parasites or pathogens 
for the control of tsetse. Such techniques are potentially highly specific and 
environmentally non-contaminating, but have not generally passed beyond the 
experimental stage.
Sterile Insect Technique
This technique of control of insect pests has been used extremely 
successfully against the New World screw worm (Cochliomyia hominivorax) in 
the southern United States and Mexico, a serious ectoparasite of cattle in that 
region, and has been evaluated for use against tsetse in a number of countries 
(Jordan, 1986). Sterile insect technique (SIT) uses the fact that female tsetse 
mate only once, so that if the male is sterile, there will be no offspring. By 
saturating the environment with artificially reared males which have been 
sterilised by irradiation or chemical means, the tsetse population will no longer
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be sustained, and eradication will be the end result. The technique is 
theoretically attractive, but has a number of practical drawbacks, such as the 
number of different tsetse species involved, the difficulty in maintaining colonies 
of tsetse flies in sufficient numbers, and the need for the artificially-reared 
sterilised male tsetse to be competitive with wild males. Normally other 
methods, such as use of insecticides are required to reduce tsetse numbers to 
the level at which SIT is practicable, and pains must be taken to prevent re­
invasion from surrounding areas. A current FAO/IAEA project for the 
elimination of G. austeni from the island of Zanzibar is an example of a situation 
where the technique may likely to succeed, although the operation has been 
extremely costly.
Traps and Targets
Originally designed for the purpose of monitoring tsetse flies, various types 
of trap are now also employed for the control of tsetse numbers. Traps may be 
mono- or bi-conical, or mono- or bi-pyramidal in design, consisting of various 
combinations of white, blue and black fabric, and targets are usually simple 
screens of the same materials, impregnated with a residual insecticide with a 
knock-down effect, such as deltamethrin. These use visual (colour) and 
olfactory stimuli, such as bovine urine, acetone and octenol to attract flies. 
Traps and targets have been used successfully to control tsetse flies in a 
number of areas, such as the Upper Didessa river valley system in south­
western Ethiopia (Slingenbergh, 1992). Some recent tsetse control projects 
have placed emphasis on local community participation in the manufacture and 
maintenance of targets as an important element of sustainability (Williams,
1993).
Application of Insecticides onto Cattle
In what has effectively been a logical extension of the principle of 
insecticide-impregnated targets, the application of residual insecticides directly 
onto cattle has generated great interest in recent years (Wilson, 1993). This 
technique use cattle themselves a "walking targets" for tsetse flies, and thereby 
eliminates the requirement for, and costs of research, development and 
production of the targets themselves, and the chemoattractants for tsetse used 
with them: cattle themselves produce the necessary olfactory stimuli. Synthetic 
pyrethroid insecticides, such as deltamethrin (Okello-Onen, Heinonen, Ssekitto, 
Mwayi, Kakaire and Kabarema, 1993) and cypermethrin (Leak, Woudyalew 
Mulatu, Rowlands and d'leteren, 1993), which have both knock-down and cidal
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effects on tsetse, are used. The knock-down effect may last over two months 
following a single application of insecticide, and while the flies are not killed 
directly by this effect, in the natural environment they are normally predated by 
ants within minutes of falling to the ground (Wilson, 1993).
The aim is not to prevent infected tsetse biting the treated cattle, but to 
reduce and eventually eliminate tsetse populations in the grazing areas. It is 
therefore essential that a sufficient proportion of the tsetse obtains bloodmeals 
from cattle rather than untreated wildlife, which could sustain the fly population, 
and bloodmeal analysis of trapped tsetse is recommended prior to embarking 
on such a control programme (S.G.A. Leak, personal communication). The 
insecticides may be applied as pour-on preparations (Leak et a/., 1993), which 
require animals to be reasonably well restrained, or as dips (Okello-Onen et al.,
1993) or sprays, in which case the cost of the preparation is lowered because 
the expensive spreading agent is not required, but dipping and spraying 
facilities are themselves costly. Where dipping and spraying are in use as 
methods of control of ticks and tick-borne diseases, the overall cost of changing 
from a purely acaricidal dip to one which will control both tsetse and ticks may 
be relatively small, although there may be a conflict of interests in the control of 
these two types of parasitic diseases. In many areas, development of acaricidal 
resistance in ticks is considered to be a major threat, and synthetic pyrethroids 
are being held in reserve to be released for use only when significant resistance 
to the currently used organophosphorus and organochlorine dips becomes a 
serious problem. Finally there may be a conflict of interests where overt tick- 
borne disease, such as babesiosis and anaplasmosis, is held in check by 
maintaining a situation of enzootic stability within the cattle population. This 
requires that all stock are exposed to sufficient challenge to these diseases at a 
young age when they are relatively resistant, so that mild or inapparent 
infections of little economic consequence are followed by a lifelong state of 
premunity. Tsetse control programmes utilising applications of insecticides to 
cattle could potentially perturb the situation of enzootic stability and result in an 
increase in the incidence of overt tick-borne disease. In spite of these potential 
problems these techniques are becoming increasingly popular, probably 
because of the relatively small capital investment required and the fact that 
there is no need for the extensive organisational infrastructure of spraying or 
trapping campaigns. In some instances there are early signs of sustainability, 
as small-scale livestock owners are already seeing economic benefits sufficient
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to enable them to bear the costs of the insecticides themselves (Woudyalew 
Mulatu, personal communication).
Trypanotolerant livestock
The wild animals which are the reservoir of the tsetse-transmitted 
trypanosome species harbour the parasites without any apparent ill effects, and 
this is considered to be the result of a long ancestral association over which 
period the parasites have adapted to cause the minimum harm to their hosts 
and thereby improve their own chances of survival. Similarly those cattle which 
have been exposed the longest to tsetse-transmitted trypanosomiasis appear to 
be the most resistant to the effects of the disease. This trait, termed 
trypanotolerance is attributed to the taurine breeds (Bos taurus) of cattle in 
West and Central Africa, which can be divided into two groups, the long-homed 
N'dama breed, and the West African shorthorn breeds such as the Lagune, 
Baoule, and Muturu breeds. The N'dama is believed to be descended from the 
Hamitic longhorn breed which arrived in the Nile Delta from the Near East in 
about 5000 B.C., while the taurine shorthorn breeds arrived in the same area 
somewhat later between 2750 and 2500 B.C. (Murray, Trail, Davis and Black,
1984). The more widespread humped cattle (Bos indicus), now the most 
prevalent indigenous cattle in Africa and regarded as highly susceptible to 
trypanosomiasis did not become numerous in Africa until after the Arab invasion 
of 699 A.D.
Trypanotolerant cattle have the ability to survive and be productive in 
tsetse-infected areas without the aid of trypanocidal drugs. Nevertheless these 
cattle are susceptible to trypanosome infections, although like the wild animal 
reservoir hosts of trypanosomes they often show relatively few ill effects. The 
prevalence, level and duration of parasitaemia in trypanotolerant cattle such as 
N'dama is less than in susceptible Zebu (Bos indicus). Moreover, 
trypanotolerant cattle appear to have the ability to control the anaemia which is 
a central feature of the disease in susceptible cattle (Murray et a/., 1984). This 
resistance to trypanosomiasis appears to have a genetic basis, rather than 
being the result of acquired resistance to local strains of trypanosomes, as 
which have never previously been exposed to trypanosomes manifest the trait 
on experimental infection, and West African trypanotolerant cattle have been 
successfully established in distant areas of West and Central Africa where 
susceptible cattle could not survive.
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In spite of these advantages, the distribution of trypanotolerant cattle in 
Africa is limited, and these breeds only represent about 5% of the total 147 
million cattle in the 38 tsetse-infested countries (ILCA, 1979). There are 
various reasons why trypanotolerant cattle have not become more widespread. 
The trypanotolerant breeds of cattle are generally smaller than Zebu cattle, and 
in the past small size has been equated with poor productivity. Recent work, 
however, has shown productivity to be similar in both types of cattle in 
conditions of no or low tsetse challenge, and in areas of higher challenge, data 
could not be obtained because only trypanotolerant cattle survived (ILCA,
1979). The genetic basis of resistance to trypanosomiasis shown by these 
cattle has been misunderstood, and it has been assumed that trypanotolerance 
would break down if cattle were exposed to other than local strains of 
trypanosomes. Finally, cattle are kept for a number of reasons in Africa, 
including status and economic security, and in this context the size of livestock 
may have important social and cultural implications; for example, among some 
cattle herding people, such as the Ankole of Uganda, the size of an animal's 
horns may be a more important determinant of its perceived worth than any 
other biological measure of productivity.
The trypanotolerant trait is not absolute, and cattle of trypanotolerant 
breeds may succumb to the effects of the disease under circumstances of 
stress, such as poor nutrition, overwork, intercurrent disease or just particularly 
heavy tsetse challenge. Roelants (1986) analysed data from a number of 
experimental studies which compared the survival of Zebu and trypanotolerant 
cattle under different levels of natural tsetse challenge. Under conditions of 
light tsetse natural challenge, whereas 75% of Zebu cattle died, 98% of N'dama 
and cattle survived. However, under heavy natural tsetse challenge, overall 
mortality among Zebu cattle rose to 94%, and 31% of cattle of the 
trypanotolerant N'dama, Muturu and Baoule breeds also died. The use of 
trypanotolerant livestock is thus often supplemented by the use of trypanocidal 
drugs in areas of heavy tsetse challenge (Roelants, 1986; Otesile, Akpokodje 
and Ekwuruke, 1991).
Immunological control
The search for an effective vaccine against bovine trypanosomiasis has 
received considerable input from international research funding bodies in the 
latter half of the present century, but most workers now accept that one is 
unlikely to emerge in the foreseeable future. Attempts have been made to
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vaccinate cattle using living trypanosomes of low virulence, or attenuated by 
ionising radiation; using dead parasites exposed to or combined with various 
chemicals, and drugs; using trypanosome homogenates from organisms 
disrupted by presses, ultrasonication, lyophilisation, and freezing and thawing; 
using cell free exoantigens and trypanosomes altered by many other ingenious 
methods (Stephen, 1986). Although varying degrees of success have been 
claimed for these methods, a satisfactory vaccine affording protection against 
natural challenges has eluded all attempts.
The development of a vaccine protective against bovine tsetse-transmitted 
trypanosomiasis is probably one of the greatest challenges facing the veterinary 
immunologist. Firstly there are three distinct species of trypanosome involved 
in the disease complex, T. brucei, T. congolense and T. vivax. Secondly, each 
of these species is composed of a large but unknown number of antigenically 
distinct strains. Finally the phenomenon of antigenic variation which the 
trypanosome uses to evade the natural immune response of the host is as 
effective against artificially induced immune responses directed against the 
parasites surface. Immune responses against particular VATs may be induced 
which are effective against homologous challenge, but protection has not been 
achieved against heterologous strains or VATs (Akol and Murray, 1983). A 
vaccine incorporating components directed against the entire repertoire of VATs 
presented by all trypanosome strains of all species is most unlikely as a single 
clone of Trypanozoon has been shown capable of expressing over 100 distinct 
VATs (Capbem, Girond, Baltz and Mattern, 1977).
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Trypanocidal drugs
Introduction
Because of the difficulties associated with vector control, the absence of an 
effective vaccine, and the limited numbers and distribution of trypanotolerant 
cattle, in most tsetse-infected African countries the use of trypanocidal drugs is 
the mainstay of control of bovine trypanosomiasis (Jordan 1992), and is likely to 
remain for the foreseeable future. The use of trypanocidal drugs has been the 
subject of a number of valuable reviews (Davey, 1957; Whiteside, 1962a; 
Williamson, 1962, 1970, 1976; Hawking, 1966; Leach and Roberts, 1981; 
Stephen, 1986; and Losos, 1986).
There are two main strategies for the use of trypanocidal drugs in the 
control of bovine trypanosomiasis. Drugs may be used for the therapy of 
existing trypanosome infections, in which case they are termed 
chemotherapeutic, or alternatively drugs with a prolonged period of biological 
activity may be administered at intervals suitable to uninfected cattle at risk of 
becoming infected, in which case they are termed chemoprophylactic. Some 
drugs may be used for either purposes, although dose rates and routes of 
administration may be adjusted for the particular circumstances of use, while 
others, particularly those which are eliminated rapidly are limited to therapeutic 
use. The principal drugs used in the control of African bovine trypanosomiasis 
are listed in Table 2.
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Table 2. The principal drugs used in the control of African bovine 
trypanosomiasis (Adapted from Sones, 1988).
Chemical Name Chemical Class Use Commercial Names
Diminazene
aceturate
Aromatic
diamidine
Chemotherapy Berenil (Hoechst), 
Veriben 
Ganaseg
Homidium bromide 
Homidium chloride
Phenanthridine Chemotherapy Ethidium (Laprovet) 
Novidium 
(Rh6ne MSrieux)
Isometamidium
chloride
Phenanthridine Chemotherapy & 
Chemoprophylaxis
Samorin, 
Trypamidium 
(Rhone M£rieux)
Quinapyramine
sulphate
Quinoline - 
pyramidine
Chemotherapy Trypacide sulphate 
(Rhone M6rieux)
Quinapyramine
sulphate/chloride
Quinoline - 
pyramidine
Chemotherapy & 
Chemoprophylaxis
Trypacide Prosalt1 
(ICI)
Tribexin Prosalt2 
(Indian Drugs and 
Pharmaceuticals Ltd).
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Historical Perspective
Only a small number of trypanocidal drugs have survived preliminary field 
trials to become established for use in the control of bovine tsetse-transmitted 
trypanosomiasis (Williamson, 1970). These are tartar emetic, quinapyramine, 
the phenathridinium drugs homidium, prothidium and isometamidium, and the 
diamidine diminazene aceturate, and of these only three, homidium, 
isometamidium and diminazene remain in widespread use.
Tartar Emetic
The first trypanocidal agents to be used to any significant extent in cattle 
were potassium antimony tartrate (tartar emetic), and the more soluble, less 
irritant sodium analogue which were shown by Plimmer and Thompson (1908) 
to eliminate 7. brucei and 7  evansi in laboratory rodents. The drug was 
subsequently used in cattle, but severe tissue reactions meant the intravenous 
route of administration was necessary, with the attendant difficulties in range 
cattle unused to handling. A dose of 1.0 -1 .5 mg per animal as a 5% aqueous 
solution was given daily or weekly. The efficacy of tartar emetic against 7. 
congolense and 7. vivax in cattle was confirmed by Bevan (1928) and Curson 
(1928), but not against 7  brucei infections. Up to 6 % mortality occurred, but 
mortality rates in unprotected cattle exposed to tsetse challenge was 
considerably worse. In spite of the development of newer, safer drugs, tartar 
emetic continued to be used up to early 1950s (Leach and Roberts, 1981).
Suramin
Suramin synthesised by Bayer chemists in Germany during W W 1, became 
available 1920, and was shown to be effective against experimental 7. 
equiperdum infections and naturally occurring 7. evansi infections in camels 
(Knowles, 1925), and other species (Edwards, 1926). Suramin has significant 
prophylactic activity, conferring protection for up to two months (Findlay, 1930), 
and has been widely used human, equine, and cameline trypanosomiases, but 
not in cattle. On its own, suramin has no pronounced activity against 7  
congolense or 7. vivax infections, and is thus not particularly useful for bovine 
tsetse-transmitted disease.
The use of suramin complexes, or "suraminates" was discussed at length by 
Williamson (1970). The salts produced by complexing suramin with other 
trypanocidal drugs, originally the human trypanocide pentamidine (Guimaraes 
and Lourie, 1951), are insoluble and may confer long periods of prophylaxis
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with little systemic toxicity. However because of severe local reactions, 
including sloughing of the entire injection site (Stephen, 1986) these complexes 
have not been widely used in spite of their ability to confer long prophylactic 
periods in cattle.
Antimosan, Stibophen and the Styrylquinolines
Two other groups of compounds were investigated at about the same time 
as suramin. Antimosan, a sulphonated pyrocatechol was derived from trivalent 
antimony following research on tartar emetic, and its sodium salt, stibophen, 
were found to be effective against T. congolense or T. vivax , but not as 
effective against T. brucei (Parkin, 1931; 1935). This drug could be
administered intramuscularly or subcutaneously, but repeated doses were 
required at four weekly intervals. The styrylquinolines were found to be active 
against the subgenus Trypanozoon, but suffered problems of toxicity, both 
systemic, and at the site of injection (Browning, Cohen, Ellingworth and 
Gulbranson, 1926).
Phenanthridines: dimidium
A significant advance in the development of trypanocides came with the 
investigation of the phenanthridines. Browning, Morgan, Robb and Walls 
(1938) reported that phenidium chloride was active against Trypanozoon, and 
this activity was confirmed in field trials in Africa, although the drug was poorly 
soluble and had a narrow therapeutic index. Another phenathridine, dimidium 
had better solubility, and eliminated the majority of T. congolense infections in 
the field when administered subcutaneously at a dose rate of 1.0 mg per kg 
body weight (Carmichael and Bell, 1944). The use of this drug was applied in 
mass treatment campaigns in East and Central Africa, and heralded a new era 
in trypanocidal chemotherapy: by 1952 trypanosomes resistance to this drug 
were considered to be widespread. The narrow therapeutic index of the drug 
prevented increasing the dose rate as a means of overcoming drug resistance, 
as photosensitization occurred with doses of just 2.0 mgkg*1 (Randall and 
Beverage, 1946), and sometimes as little as 1.0 mgkg”1 (Evans, 1948).
Quinapyramine
The synthesis of quinapyramine by Barret, Curd and Hepworth (1953) 
followed earlier work on an unsuccessful trypanocide, the 4-aminoquinoline 
derivative, surfen C (Jensch, 1937). Surfen C had marked activity against T. 
congolense, but cattle treated in field trials in Africa suffered serious local and
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systemic toxicity, including death within 15 minutes of injection (Le Roux, 1936; 
van Rensberg, 1938). Quinapyramine, a bis-quartemary compound 
synthesised by restructuring the surfen C molecule, was far more successful as 
it retained the trypanocidal activity, but toxicity was far less of a problem as it is 
generally well tolerated in cattle. The dimethosulphate was shown 
experimentally by Curd and Davey (1949, 1950) to be active against most of the 
African trypanosomes pathogenic to livestock, and this was confirmed in field 
trials (Davey, 1950). The drug had a marked prophylactic activity, particularly 
when a mixture of three parts of quinapyramine dimethosulphate to four parts of 
the relatively insoluble quinapyramine chloride was used (the chloride alone 
would not attain curative blood levels). This mixture was marketed by ICI as 
Antrycide Prosalt, and the formulation was later changed in 1958 to three parts 
dimethosulphate to two parts chloride in the revised formulation (Prosalt RF) 
which was cheaper to produce and equally effective (Marshall, 1960). Prosalt 
RF provided three months protection to cattle in areas of low tsetse challenge 
and two months where challenge was rated medium (Davey, 1958). The 
prophylactic activity of quinapyramine was however seen partly as a 
disadvantage, as it was considered to be a possible factor in the development 
of resistance to this drug. By 1977 resistance was widespread, and Antrycide 
was withdrawn from the market, although quinapyramine has since been 
reintroduced by May and Baker as Trypacide®, for the treatment of T. evansi 
infections in camels and horses.
Homidium
Watkins and Woolfe (1952) reported the development of homidium 
bromide, a new aminophenanthridium compound, by the substitution of an ethyl 
for a methyl-group on the quaternary nitrogen atom of dimidine. Homidium 
bromide was as effective against 7. congolense and 7. vivax as dimidine 
bromide, but was significantly less toxic at 1.0 mgkg-1 (Ford, Wilmshurst and El 
Karib, 1953a,b). The new drug had limited prophylactic activity (Leach, El 
Karib, Ford and Wilmshurst, 1955). Homidium bromide was marketed as 
Ethidium® by Boots (later by Cameo, and more recently by Laprovet), while May 
and Baker patented the chloride salt, which had the advantage over the 
bromide of solubility in cold water (Wragg, 1955), as Novidium.
Quinapyramine and homidium were used in mass treatment campaigns of 
cattle exposed to tsetse challenge. In six years treatments in Northern Nigeria 
increased over ten-fold to 641 000 in 1957-8 (Wilson, 1960). The availability of
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these drugs allowed susceptible cattle to be kept commercially in tsetse- 
infested areas, such as Mkwaja ranch in north-east Tanzania (Ford and. Blazer,
1971). As usual, with the advent of mass treatment, reports of drug resistance 
soon followed, and by 1966 homidium-resistant strains of trypanosomes were 
reported to be widespread (Jones-Davies and Folkers, 1966). Antrycide and 
Ethidium were withdrawn from field use in Northern Nigeria on account of drug 
resistance in 1963 and 1965 respectively (Williamson, 1970).
Diminazene Aceturate
Another major development in the chemotherapy of bovine trypanosomiasis 
was the introduction of the aromatic diamidine, diminazene aceturate by 
chemists at Hoechst in Germany (Bauer 1955a,b; Fussganger, 1955). This 
followed earlier work which showed that synthalin, a synthetic hypoglycaemic 
agent, was active against trypanosomes in vivo (von Jansco and von Jansco, 
1935) and in vitro (Lourie and Yorke, 1937). The finding of trypanocidal activity 
in vitro was of significance, because showed the compound had direct 
trypanocidal activity, rather than merely an indirect effect on trypanosome 
metabolism secondary to the lowering of blood glucose levels. This focused 
synthetic activity on the diamidines, and led to the synthesis of pentamidine and 
many experimental compounds including, phenamidine, propamidine, 
stilbamidine, and M & B 2242 (Williamson, 1970).
Like quinapyramine, diminazene aceturate was developed from a 
systematic dissection of the structure of the surfen C molecule (Jensch, 1958). 
On the basis of earlier work, the inter-ring bridge grouping of symmetrical "bis 
guanylphenyl-Typ" molecules derived from structure-activity studies on surfen C 
was varied, and the maximal trypanocidal activity was found when two 
amidophenyl moieties were joined by a triazene bridge to produce the 
diminazene molecule. In extensive field trials, this compound was found to be 
active not only against trypanosomes, particularly 7. congolense and 7. vivax 
(Fussganger and Bauer, 1958), but also against Babesia, for which it is still 
used as one of the main therapeutic agents in cattle. The drug was less active 
against 7. brucei infections in cattle, which required an increase in dosage from 
the 3.5 mgkg*1 found to be effective for 7. congolense and 7. vivax to 5.0 mgkg- 
1. The use of this drug was quickly adopted in many parts of Africa, so that by 
1961 an average of 190 000 annual doses were being used in Kenya 
(Fairclough, 1963b), and in Northern Nigeria it replaced quinapyramine and
38
homidium (MacLennan, 1968) which were becoming less useful as a result of 
drug resistance.
Williamson (1970) considered the three reasons for the success of 
diminazene to be, firstly its higher therapeutic index than any other curative or 
prophylactic drug, secondly its efficacy against trypanosome infections resistant 
to other trypanocides, and finally the absence of any serious drug-resistance to 
the compound even after ten years of widespread use. The apparent inability 
of the compound to give rise to resistant trypanosomes was attributed to its 
rapid excretion and consequent lack of appreciable prophylactic activity 
(Fairclough, 1963b, c). Nevertheless, with continued use resistance even to 
diminazene became apparent, with isolates of resistant T. congolense 
(MacLennan and Jones-Davies, 1967) and T. vivax (Jones-Davies, 1967a).
Pyrithidium
By the substitution of the pyrimidyl moiety of quinapyramine into a 
phenathridine resembling phenidium, Watkins and Woolfe (1956) synthesised a 
new trypanocide, pyrithidium bromide (Prothidium, Boots) which was shown to 
possess therapeutic and prophylactic activity (Watkins, 1958). Doses of 0.2 to 
0.4 mgkg-1 were curative for T. congolense infections in cattle (Whiteside, 
Fairclough and Bax, 1960), and prophylaxis of cattle in an area of high tsetse 
challenge was demonstrated (Finelle and Lacotte, 1965). Toxicity problems 
were however observed, with severe local reactions when 2.5 mgkg-1 was 
administered subcutaneously (Stephen, 1962a), or deaths following 
intramuscular doses of 5.0 mgkg-1 (Leach and El Karib, 1960). The problem of 
local reactions could be reduced if the drug was incorporated into a mixture of 
lanolin and olive oil, and in this form doses of up to 6.0  mgkg-1 could be injected 
subcutaneously into the dewlap (Cawdery, 1963). Resistance to pyrithidium 
occurs readily, with cross-resistance to quinapyramine and homidium because 
of the close relationship of the chemical structures (Leach and Roberts, 1981) 
and the product was withdrawn from the market in 1985.
Isometamidium
The most recent trypanocide to be introduced for the chemoprophylaxis and 
chemotherapy of African bovine trypanosomiasis was isometamidium chloride, 
marketed by May and Baker (now Rhone-Merieux, France) in 1961 as 
Samorin® in Anglophone countries, and later as Trypamidium® (Specia, now 
Rhone-Merieux) in Francophone countries. This product resulted from work by 
Wragg, Washboume, Brown and Hill (1958), who prepared the p-
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amidinophenyldiazoamino derivative of homidium chloride. The linking group 
was selected on the basis of the similarity of the resulting product to 
diminazene. The reaction was reported to produce two isomers, a relatively 
water-insoluble purple isomer (melting point 287 - 289°C), and a red isomer 
(melting point 236 - 240°C), which could be separated by precipitation from 
water with sodium chloride, followed by fractional crystallisations from water and 
methanol. Extensive testing of structure-activity relationships between similar 
pairs of isomers with various substituents showed the most promising product to 
be a mixture of the purple and red isomers at a ratio of approximately 55% to 
44%, which was designated M & B 4404, and later called metamidum chloride 
hydrochloride. This product was highly active therapeutically and unlike 
homidium or diminazene, which had no appreciable prophylactic activity at 1/3 
of the LD5o, had significant prophylactic activity at 1/9 of its LDsq. The structure 
of the more water soluble and more active red isomer was described by Berg 
(1960, 1963), who isolated what he considered to be a purer form in sufficient 
quantities for field trials. The new product, 7-(m-amidinophenyldiazoamino)-2- 
amino 10-ethyl 9-phenylphenanthridinium chloride hydrochloride, 
(C28H25CIN7.HCI, molecular weight 531.5) was named isometamidium (M & B 
4180A) and marketed as Samorin® or Trypamidium®. The commercial product 
contains approximately 70% isometamidium chloride (i.e. the red isomer), 20% 
of the purple isomer, 10% of bis compound (Hutchinson, 1981) small quantities 
of another positional isomer, and traces of homidium (J. Wilkes, personal 
communication).
Fairclough (1958) reported the results of trials in Africa on the metamidium 
isomeric mixture (M & B 4404) in terms of tolerance, therapeutic activity, 
prophylactic activity and activity against drug-resistant trypanosomes. Sub­
cutaneous doses of 5.0 and 10 mgkg-1 were poorly tolerated and resulted in 
signs of local and systemic toxicity, but 1.0 mgkg-1 was considered to be "non­
toxic". Doses of 0.2 mgkg-1 were curative for 7. congolense infected cattle, 
while as little as 0.05 mgkg*1 was curative for 7  vivax. In other therapeutic trials 
doses of 0.5, 1.0 and 2.0 mgkg-1 of M & B 4404 resulted in pronounced local 
reactions, but the drug was considered curatively excellent (Kirkby, 1961a).
In prophylactic trials, 1.0 and 2.0 mgkg-1 doses of M & B 4404 gave periods 
of protection similar to, or slightly longer than those of Antrycide Prosalt (Kirkby 
1961c). In trials in West Africa with controlled infection, intramuscular doses of
3.0 mgkg-1 were found to give 19 weeks protection (Gray and Stephen, 1962),
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although in another trial in Northern Nigeria, Kirkby (1961b) concluded the 
same dose to be too toxic for use. Smith and Brown (1960) using the drug at
4.0 mgkg-1 obtained significantly longer periods of prophylaxis (mean 18 weeks) 
in an area of heavy tsetse challenge than that obtained using Antrycide Prosalt 
(mean 10 weeks). Finally, 29 weeks protection against West African 7. vivax 
were obtained using 5.0 mgkg-1 (Stephen, 1960).
Later attention focused on the newer formulation isometamidium (M & B 
4180A), which was recommended in 1961 by the manufacturers to be 
administered by deep intramuscular injection at dose rates of 0.5 mgkg-1 as a 
curative agent for normal trypanosome strains, at 1.0 - 2.0  mgkg-1, as a curative 
agent for drug-resistant strains, and at 2.0  mgkg-1 for prophylaxis.
Future Prospects
New trypanocidal drugs
Since the introduction of isometamidium chloride in 1961 no new 
trypanocides suitable for the control of African bovine trypanosomiasis have 
been released onto the market. Melarsenoxide cysteamine (MelCy, 
Cymelarsan, Rhone Merieux), an organic arsenical suitable for the treatment of 
Trypanozoon infections, was recently launched particularly for the treatment of 
7. evansi infections in camels (Raynaud, Sones, and Friedheim, 1989). 
However, this compound is not effective against 7. congolense or 7. vivax, and 
it also lacks significant prophylactic activity.
The scarcity over the last 30 years of new trypanocidal drugs suitable for 
the control of African bovine trypanosomiasis has been attributed to the high 
costs of drug development, licensing and marketing, which represents a large 
investment to pharmaceutical companies. The potential markets for these 
drugs are almost entirely confined to developing countries with limited foreign 
exchange and frequently uncertain political and economic stability (Williamson, 
1976; Holmes and Torr, 1988; Murray, Stear, Trail, d'leteran, Agyemang and 
Dwinger, 1991). These same countries may nevertheless have stringent drug 
registration requirements which necessitates a major investment with no 
guarantee of successful economic return. These factors combine to make this 
market relatively unattractive to the major multinational pharmaceutical 
companies, a few of whom somewhat reluctantly continue to manufacture the 
existing trypanocidal drugs. The lack of new drugs highlights the importance of 
optimising the use of the existing limited range of trypanocidal compounds,
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particularly in view of the ever present threat of the development of drug 
resistance.
New Formulations of Existing Drugs
New formulations of the existing trypanocidal drugs may provide a means of 
improving chemotherapy and chemoprophylaxis with as great an investment as 
the development of completely new drugs. Two aspects of drug delivery show 
considerable potential for improvement. Firstly many trypanocidal drugs, 
particularly those used for chemoprophylaxis cause considerable local side 
effects at the site of injection. Secondly, new administration strategies may 
increase the duration of action of trypanocidal drugs, thus extending the 
effective prophylactic period afforded by chemotherapeutic agents, or allowing 
chemotherapeutic agents to be used for prophylactic purposes.
Sustained release preparations
Hope-Cawdery and Simmons (1964) experimented with formulations of 
isometamidium in a high viscosity base, but with disappointing results. Other 
workers have used isometamidium-dextran complexes, with reduction in local 
toxicity and extended prophylaxis in rodents (James, 1978; Aliu and Sannusi, 
1979). Subcutaneous injections of isometamidium-dextran complexes produced 
small nodules at the site of injection in cattle, but there was no severe local 
reaction with either subcutaneous or intramuscular injection (Aliu and Sannusi, 
1979). There was no improvement in the cure rate of T. vivax infections in 
cattle using the complexes at 0.5 mgkg-1 , although it was concluded that the 
complex given at 1.0 or 2.0  mgkg-1 could be expected to protect cattle against 
infection, whilst yielding a good carcass and hide grading. Nevertheless, the 
use of isometamidium-dextran complexes has not progressed beyond the 
experimental stage.
Other investigators have experimented with the incorporation of 
isometamidium into multilamellar phospholipid lysosomes. This system of drug 
delivery was developed for treatment of leishmaniasis, and was found 
particularly suitable because the drug-containing lysosomes, once injected, are 
phagocytosed by the very cells of the mononuclear phagocytic system which 
are parasitised by the intracellular stages of Leishmania (Alving, Steck, 
Chapman, Waits, Hendricks, Swartz and Hansen). In experiments in goats 
using lyposomes incorporating tritiated isometamidium, Fluck (1985) found 
reduced tissue reactions on intramuscular injection, and more sustained blood 
levels based on plasma radioactivity, when the lysosomal preparation rather
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than the standard aqueous isometamidium solution was injected. Again this 
system of drug delivery has not progressed beyond the experimental stage.
Slow-Release devices
Slow release devices (SRDs) prepared by extrusion of a mixture of a 
polyester composed of a copolymer of s-caprolactone and L-lactide (molar ratio 
80:20) containing 25% by weight of homidium bromide as cylindrical fibres of 
1.7 mm diameter have been developed by Geerts, De Deken, Kageruka, 
Lootens and Schacht (1993). These SRDs were evaluated in prophylaxis 
experiments in rabbits challenged with different stocks of T. congolense, in 
which they were compared with conventional intramuscular injections of 1.0 
mgkg-1. Ninety-five percent of rabbits implanted with SRDs were protected 
against challenge for three months, whereas only 30.8% of rabbits which 
received the conventional intramuscular injection of homidium bromide at 1.0 
mgkg-1 were protected for one month.
Similar devices containing isometamidium chloride are currently being 
evaluated by the same workers in cattle under field tsetse challenge in Africa. 
The potential advantages of such devices are a longer, more uniform and more 
reliable prophylactic period, and a significant reduction in the local tissue 
reaction at the site of injection / implantation. A potential disadvantage of 
SRDs might be the prolongation of the period during which the drug is 
circulating at levels below the effective trypanocidal concentration, and which 
may therefore be conducive to the development of drug resistance. The 
economic constraints on the licensing and marketing of new trypanocidal drugs 
may however apply to some extent to these SRDs, and it is unlikely that their 
use will become widespread in the near future.
Chemotherapy
Chemotherapy of bovine tsetse-transmitted trypanosomiasis now relies on 
the use of three compounds, isometamidium, homidium and diminazene, of 
which isometamidium and possibly homidium also have significant prophylactic 
activity. Jordan, (1986) considered the ideal circumstances for chemotherapy 
to be when livestock are under occasional risk of trypanosomiasis, such as 
during the seasonal occupation of tsetse-infested areas, on the fly-infested 
margins of naturally fly-free or reclaimed areas, or following sporadic infection 
caused by flies carried by vehicles, or in limited foci of infestation.
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Properties of the ideal chemotherapeutic agent.
Stephen (1986) listed the properties of an ideal drug for the treatment of 
bovine trypanosomiasis as being that it should:
• cause a minimum of irritation and tissue necrosis at the site of injection
• have a wide therapeutic index, with special reference to T. congolense and
T. vivax infections.
• be transparent at normal concentrations
• be readily soluble in water
• be safe for human consumption in residual quantities
• be cheap
• be effective over a dose range proportional to the weight estimation error in 
the field.
Chemoprophylaxis
Since the withdrawal of prothidium and quinapyramine, isometamidium 
chloride is now the only widely used compound for the chemoprophylaxis of 
African bovine tsetse-transmitted trypanosomiasis. Jordan, (1986) considered 
the conditions necessary for effective chemoprophylaxis to be even more 
stringent than those necessary for effective chemotherapy, in particular the 
strict supervision of drug administration and animal husbandry. The 
administration of repeat doses before drug levels fall below trypanocidal levels 
is necessary to avoid conditions liable to induce the development of drug 
resistance (see below). Trained staff, reliable transport, and access to livestock 
are therefore important (Leach and Roberts, 1981). Hence, chemoprophylaxis 
is more appropriate for well organised ranches and probably inappropriate for 
nomadic or semi-nomadic livestock in pastoral management systems (Jordan, 
1986). Prophylactic administration of isometamidium chloride to a small East 
African Zebu cow by intramuscular injection is shown in Plate 3.
Properties of the ideal chemoprophyiactic agent.
Stephen (1986) listed the properties of an ideal chemoprophyiactic drug for 
the prevention of bovine trypanosomiasis as being that it should:
• cause a mild reaction at the site of injection - at least not more severe than 
that with Antrycide Pro-salt
• be non-toxic at the recommended dose, and produce no harmful effects in 
the developing embryo
• be easy to make up and administer
• be administered in modest total volumes e.g. 15 to 20  ml
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• be suitable for subcutaneous injection, without causing damage or injury to 
the skin or underlying muscles
• provide prophylaxis against T. vivax and T. congolense for periods 
satisfactory to the policy of the administering and control agency, by the 
expediency of the varying the dosage rate
• not induce resistant strains in 'breakthrough' trypanosomes
• have chemotherapeutic activity at the recommended prophylactic doses
• present a resolved or insignificant deposit by the end of the prophylactic 
period
• be reasonably cheap
• be effective over a dose range proportional to the weight estimation error in 
the field.
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Plate 3. Prophylactic administration of a 
dose of Samorin® (isometamidium chloride) by 
intramuscular injection to a small East African 
Zebu cow in Busia District, Western Province, 
Kenya.
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Pharmacology of Isometamidium
The pharmacology of isometamidium was reviewed by Kinabo and Bogan 
(1988d) and Kinabo (1993). The name "Isometamidium" has been used 
extensively in the literature to refer to the commercial preparation Samorin® 
(also Trypamidium®), rather than in the pure sense to refer to the red isomer 
present in the mixture. This usage will also be adopted in this thesis: where the 
red isomer is being referred to exclusively, this will be stated explicitly. The 
commercial preparation is presented as a dark reddish-brown powder with a 
solubility of 6 % (w/v) in water at 20°C, with lower solubility in pure organic 
solvents. It is labile under low and high pH conditions and at high temperatures 
(Kinabo and Bogan 1988d).
Studies on the pharmacokinetics of isometamidium have been hampered by 
the lack of an analytical method capable of measuring levels of the drug in 
animals for more than a few hours following treatment (Kinabo, 1993). 
Nevertheless, studies have been conducted in goats (Kinabo and McKellar, 
1990), pigs (Kinabo, McKellar and Eckersall, 1991), camels (Ali and Hassan, 
1984) and cattle (Kinabo and Bogan, 1988b).
Following intramuscular injection of cattle, isometamidium is detectable in 
plasma almost immediately, and maximal concentrations are observed within an 
hour, after which they fall rapidly to very low concentrations (Kinabo and Bogan, 
1988b). In goats, the mean bioavailability of isometamidium has been 
calculated to be very low, at around 27% (±13%) (Kinabo and McKellar, 1990). 
The low bioavailability was considered to be a reflection of binding of the drug 
to tissue macromolecules and ground matrix components at the injection site. 
This tissue-drug complex was considered to be analogous to a slow-release 
drug formulation and to constitute the primary depot from which drug was 
slowly absorbed at low levels to exert its prophylactic activity (and see Plate 6 ). 
The low bioavailability was therefore not necessarily as disadvantageous as 
would be held conventionally for other drugs.
The apparent volume of distribution of isometamidium in goats was greater 
than 1 Ikg*1, which indicates that the drug is accumulated in tissues at 
concentrations higher than those of the plasma (Kinabo and McKellar, 1990). 
High concentrations of the drug have been found at the injection site, in the 
liver, kidney and spleen of calves up to six weeks following intramuscular 
injection (Kinabo and Bogan, 1988b).
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The studies of Hill and McFadzean (1963) on rats and mice shed light on 
the relative importance of the primary deposit at the injection site and secondary 
drug deposits in other organs in maintaining prophylactic activity over a 
prolonged period. When mice were given subcutaneous injections of 
isometamidium they were protected against intraperitoneal challenge with T. 
congolense for four weeks as opposed to one week for mice which received the 
drug intravenously. Rats in which the drug was injected into the tail were 
protected against challenge for up to 16 weeks, but if the tail was amputated 24 
hours after treatment, the period of protection was reduced to one - two weeks. 
Fluorescence of the drug was observed at the injection site for several weeks 
following subcutaneous treatment of both rats and mice, but fluorescence in 
liver and kidney was only observed for up to one week. From these results it 
was concluded that the depot at the injection site was of primary importance for 
prophylaxis, while the depots in the liver and kidney were of secondary 
importance only.
The discovery that phenanthridinium derivatives, including isometamidium 
have activity against certain types of tumour cells led Philips, Sternberg, Cronin, 
Sodergren and Vidal (1967) to consider the drug as a potential anti-cancer 
agent in humans and to conduct extensive experiments to obtain information for 
use in initiating a clinical study. Using a spectrophotometric method to measure 
the level of isometamidium in the liver of rats, 41% of a 1.0 mgkg-1 intravenous 
dose was present within 1 minute of injection, and by 10 minutes this figure rose 
to 62%. In addition, approximately 5% of the administered dose was detected 
in kidney as early as 1 minute after injection. The drug was only detected in 
blood in the two earliest samples taken at one and 1.5 minutes following 
injection; none was detected thereafter. None of the drug could be detected in 
urine over three days following a 20  mgkg-1 subcutaneous injection, which was 
considered remarkable since the analysis was capable of detecting as little as 
0.07% of the dose administered. Amounts equivalent to 0.7 - 2.3% of the dose 
per day were detected in faeces over the same period. In other experiments 
isometamidium could not be detected in quite large volumes of bile (up to 4ml) 
obtained by cannulation bile ducts of treated rats, although it was readily 
detectable in the livers.
Experiments to investigate the distribution of isometamidium in sub-cellular 
fractions derived from rat hepatic cells obtained 24 hours following treatment, 
showed that 60% of the drug had been concentrated in the mitochondrial
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fraction, with the remainder distributed between the nuclei and the microsomal 
fractions, but essentially none was present in the supernatant (Philips et a/., 
1967). The binding of isometamidium to rat serum was also investigated, by 
partitioning between hexanol and aqueous phases, and measurement at the 
absorbance maximum of the drug in solvent saturated with Tris (380nm). At 
equilibrium, when the total concentration of isometamidium in the aqueous 
phase (serum) was 16 to 23 pgml-1, between 86% and 97% of the drug was 
bound (Philips et a/., 1967). Similar results were obtained using 2% bovine 
serum albumin (BSA) as the aqueous phase; at equilibrium when the drug 
concentration in the aqueous layer was 14 to 18 pgmM, 86% to 89% of the drug 
was bound. When the concentration of BSA was reduced to 0.2%, 
isometamidium concentrations in the aqueous phase fell to 9 to 13 pgmh1, of 
which 6 6 % to 74% was bound. Binding of isometamidium to dialysed rat serum 
was also found to alter the absorption spectrum of the drug by increasing the 
wavelength of absorption maxima and minima; BSA had a similar effect, 
suggesting that albumin was the major binding component in serum (Philips et 
al., 1967). Major spectral changes were also obtained using nucleic acids, 
heparin and hyaluronic acid, which were distinguishable from those of BSA and 
from each other.
Smith, Mayambo, Dunlop and Holmes (1991) used Western blotting and an 
enhanced chemiluminescence detection system to demonstrate the binding of 
isometamidium to bovine serum protein macromolecules. An isometamidium- 
positive band of approximate molecular weight 140 kD was observed in blots of 
either bovine serum albumin or normal bovine serum albumin which had been 
spiked with isometamidium. A maximum of one major 140 kD band and two 
minor bands were detected in blots of serum from cattle two and 16 days 
following isometamidium treatment. These results were suggestive of the fact 
that the major drug-binding serum macromolecule in isometamidium-treated 
cattle has an approximate molecular weight of 140 kD, and could be a dimer of 
albumin.
Studies by Kinabo and Bogan (1987) also demonstrated the binding of 
isometamidium to calf thymus DNA and to acid phospholipid. The binding of 
isometamidium to intracellular macromolecules may in part explain its rapid 
uptake into hepatocytes and other cells, which is otherwise difficult to 
understand for a cationic substance which appears to be firmly bound to serum 
proteins, although a mechanism, possibly an active transport system (Kinabo
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and Bogan, 1988d), capable of transporting isometamidium into cell has also 
been proposed (Philips et al., 1967). Similar active transport systems have 
been demonstrated to be responsible for hepatocellular uptake of other 
quartemary ammonium compounds (Solomon and Schanker, 1963).
The metabolism of isometamidium has not been reported, although studies 
have not been extensive. No putative metabolites have been detected in 
plasma or serum following injection of the drug in cattle (Kinabo and Bogan, 
1988b) or in rats (Philips et a/., 1967). The related phenanthridinium derivative 
homidium has been shown to be metabolised primarily by N-acetylation in the 
liver, with subsequent excretion via the bile (MacGregor and Clarkson, 1971;
1972). Although isometamidium could not be detected in bile of treated rats 
(Philips, 1967), excretion of ^^C-labelled isometamidium in faeces, but not 
urine, of intramuscularly treated cattle suggests the biliary route at the main 
excretory pathway of the drug or its metabolites (Kinabo, Bogan, McKellar and 
Murray, 1989; Kratzer, Turkson, Karanja, and Ondiek, 1989).
Mechanism of Action
On the basis of experimental work in vitro, a number of mechanisms of 
action have been proposed for the anti-trypanosomal activity of isometamidium, 
although none has been formally demonstrated as being of primary importance 
in vivo. Blockade of nucleic acid synthesis through intercalation between DNA 
base pairs (Wagner, 1971), inhibition of RNA polymerase (Richardson, 1973), 
inhibition of DNA polymerase (Marcus, Kopelman, Koll, and Bacchi, 1982), and 
incorporation of nucleic acid precursors into DNA and RNA (Lantz and Van 
Dyke, 1972) have all been proposed as mechanisms of action of the 
phenanthridinium drugs. Modulation of glycoprotein biosynthesis (Casero, 
Porter and Bernacki, 1982), of lipid metabolism (Dixon, Ginger and Williamson, 
1971), ATP metabolism (Frank-Henderson, Battel, Zombor and Khoo, 1977), 
membrane transport (Girgis-Takla and James, 1974) and alteration of 
kinetoplast DNA minicircles through the selective inhibition of mitochondrial 
type II topoisomerase (Shapiro and Englund 1990; Shapiro 1993) may also 
contribute to the effects of these drugs. The selective toxicity of isometamidium 
on trypanosomes as opposed to mammalian cells may be related to some of the 
biochemical peculiarities of trypanosomes (Kinabo, 1993), or alternatively to 
higher intracellular drug concentrations resulting from active drug uptake by 
trypanosomes (Sutherland, Mounsey and Holmes, 1992; Zilberstein, Wilkes, 
Hirumi and Peregrine, 1993).
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Isometamidium Chemoprophylaxis
The efficacy of isometamidium chloride as a chemoprophylactic agent for 
the prevention of tsetse-transmitted bovine trypanosomiasis has been 
recognised since its introduction in the 1960s. However, over most of the thirty 
odd years of its use in Africa the understanding of its efficacy and the duration 
of prophylaxis, and hence the selection of the optimal dosage strategy have 
been based on field observations. Investigations in which the prophylactic 
activity of isometamidium against trypanosomiasis has been investigated in 
cattle using naturally and experimentally infected tsetse challenge, and 
intravenous and intradermal needle challenge are summarised in Table 3.
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Table 3. Prophylactic activity of isometamidium against bovine 
trypanosomiasis (Modified from Kinabo and Bogan, 1988d).
Trypanosome
species
Mode of 
Transmission
Geographic 
location / 
origin
Dose*
(mgkg1)
Prophylactic
period
(months)
Reference
T. congoiense TN Kenya 0.5 3.5 Fairclough, 1963a
T. congoiense TN Tanzania 0.5 6.0 WiesenhQtter, et al., 1968
T. congoiense 
(IL 1180)
T E /ID Kenya 0.5 3.0 Peregrine et al., 1988
T. congoiense TN Nigeria 1.0 3.0 Kirkby, 1964
T. congoiense TN Tanzania 1.0 7.5 WiesenhQtter, etal., 1968
T. congoiense 
(IL 1180)
T E /ID Kenya 1.0 5.0 Whitelaw et al., 1986
T. congoiense 
(IL 1180)
T E /ID Kenya 1.0 4.0 Peregrine etal., 1988
T. congoiense 
(IL Nat 285)
T E /ID Kenya 1.0 5.0 Peregrine etal., 1988
T. congoiense TN Nigeria 2.0 4.0 Kirkby, 1964
T. vivax TN Kenya 0.5 3.5 Fairclough, 1963a
T. vivax TN Tanzania 0.5 6.0 WiesenhQtter et al., 1968
T. vivax 
(IL 2969)
TE Kenya 0.5 <1.0 Peregrine etal., 1987
T. vivax 
(IL 2982)
TE Kenya 0.5 <1.0 Peregrine etal., 1991
T. vivax 
(IL 2986)
TE Kenya 0.5 1.0 Peregrine ef al., 1991
T. vivax IV Senegal 0.5 (IV) 1.5-2.0 Tour6,1973
T. vivax 
(IL 2968)
TE Nigeria 0.5 2.0 Peregrine etal., 1987
T. vivax TN Nigeria 1.0 3.0 Kirkby, 1964
T. vivax IV Venezuela 1.0 5.5 Toro etal., 1983
T. bmcei IV Senegal 0.5 (IV) 1.0 Tour§, 1973
TN: tsetse challenge, natural
TE: tsetse challenge, experimental
ID: intradermal challenge using metacyclic trypanosomes
IV: intravenous challenge or drug administration
*Route of drug administration intramuscular unless indicated otherwise
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In the field, the use of intramuscular doses of 0.5 to 1.0 mgkg-1 
isometamidium chloride has been reported to afford from as long as 14 to 36 
weeks prophylaxis against natural tsetse challenge (Robson, 1962; Fairclough, 
1963a; Kirkby, 1964; WiesenhQtter, Turner and Kristensen, 1968), to as little as 
2 to 3 weeks (Dolan, Stevenson, Alusha and Okech, 1992; Munstermann, 
Mbura, Maloo and Lohr, 1992), although the reasons for this variation have not 
been adequately addressed. For example, Whiteside (1962a) suggested that 
the duration of chemoprophylaxis was directly related to the level of 
trypanosome challenge, whilst others have held the view that variation in the 
susceptibility of trypanosomes to this trypanocide, i.e. drug-resistance, is more 
significant.
Logan, Goodwin, Tembeley and Craig (1984) demonstrated that Zebu-type 
cattle could produce beef in an area of West Africa infested with G. palpalis 
gambiensis and G. morsitans submorsitans. Maure cattle treated with 
isometamidium at a dose rate of 0.5 mgkg-1 body weight at quarterly intervals 
were compared with a challenge control group which were treated with 
diminazene if found to be infected, over a period of 21 months. Whereas only 
one case of trypanosomiasis, but no losses, occurred in the isometamidium 
group, there was a total of 159 cases of trypanosomiasis with five fatalities in 
the diminazene group. Although the cost of drugs was almost identical under 
the two regimens, average daily weight gains were significantly higher in the 
isometamidium treated cattle than the diminazene group; overall weight gains 
were respectively 110 and 73 kg per head.
One of the most comprehensive studies of the use of isometamidium 
prophylaxis was that of Trail, Sones, Jibbo, Durkin, Light and Murray (1985) 
who examined a unique set of 10 years of matching productivity and health 
records from Mkwaja Ranch in Pangani District in Coastal Tanzania (Ford and 
Blaser, 1971), a commercial beef ranch infested with G. morsitans morsitans, G. 
pallidipes, G. brevipalpis and probably G. austeni. The data set equated to 134 
000  trait-years of new data, and amounted to approximately twenty times as 
much information on livestock productivity under chemoprophylaxis as had been 
available in the whole of Africa over the previous 25 years. Planned 
experiments demonstrated that cattle were unable to survive without 
trypanocidal drugs: untreated animals died or succumbed to predators. 
Isometamidium prophylaxis was shown to be clearly superior to chemotherapy 
using diminazene, even in pre-weaning cattle, in which isometamidium had not
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previously been used in large scale commercial herds. Boran cattle at Mkwaja 
under isometamidium prophylaxis were 80% as productive as Boran cattle on 
trypanosomiasis-free ranches in Kenya, and 35% more productive than ranched 
trypanotolerant N'dama cattle under medium to high trypanosomiasis risk in 
West Africa. It was therefore concluded that profitable cattle ranching is 
possible in Africa in areas of high risk of trypanosomiasis through the use of 
isometamidium prophylaxis.
Another significant study on the use of isometamidium prophylaxis in the 
field was that of Bourn and Scott (1978), who described the use of the drug to 
control trypanosomiasis among work-oxen introduced to Angar-Gutin, a lowland 
area of south western Ethiopia heavily infested with G. morsitans submorsitans. 
In 1972, as part of a resettlement project, 40 Zebu-type oxen, which, unusually 
for Africa, are widely used in the tsetse-free highlands of Ethiopia for ploughing, 
traction and other purposes. Over the next five years, the success of the 
project, which relied on high standards of management and veterinary 
supervision, was such that the number of oxen introduced had increased to 450. 
Initially, diminazene was employed in a strategic curative regime, on average 
every 28 days, but later isometamidium prophylaxis was used. When 
isometamidium prophylaxis was relied upon alone, there was evidence of the 
development of resistance to this drug, and its use was therefore alternated with 
diminazene (as a "sanative", see below), but only in animals clinically affected 
by trypanosomiasis. This regimen was used successfully for the final three 
years of the study, and it appeared that a degree of "non-sterile immunity" (see 
below) had developed since only 20% of the oxen required treatment at the end 
of every month, even though 50-69% had positive blood films (and, arguably, a 
higher percentage might have been found to be infected, had a more sensitive 
diagnostic technique been used).
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Plate 4. Laboratory-reared Glossina 
m orsitans centralis being applied to shaved areas 
of the abdominal flank of Kenyan Boran cattle. 
The presence of infective meta cyclic 
Trypanosoma congoiense in the saliva of each 
tsetse fly was confirmed by microscopic 
examination.
a) Method of application of individual tsetse 
flies.
b) Fed fly, showing abdomen engorged with host 
blood.

Factors Influencing the Success and Duration of Isometamidium
Chemoprophylaxis
Only in the last decade have some of the factors influencing the 
chemoprophylactic activity of isometamidium been investigated under controlled 
experimental conditions. This work has been performed at the International 
Laboratory for Research on Animal Diseases (ILRAD), in collaboration with the 
University of Glasgow veterinary School. Whitelaw , Bell, Holmes, Moloo, 
Hirumi, Urquhart and Murray, (1986) investigated the period of prophylaxis in 
Kenyan Boran cattle after intramuscular (i.m.) injection with isometamidium at a 
dose rate of 1.0 mgkg-1 body weight. Laboratory-reared tsetse flies (G. 
morsitans centralis) which had been fed on goats experimentally infected with a 
doubly-cloned isolate of T. congoiense (IL 1180 [also referred to as ILNat 3.1]) 
were used for challenge of cattle (see Plate 4). The presence of infectious 
metacyclic trypanosomes was confirmed for each fly used for challenge by 
microscopic examination of salivary probes onto a glass slide.
Twenty cattle were each challenged on a single occasion, using five 
infected tsetse flies; four cattle at one, two, three, four and five months after the 
isometamidium treatment had been administered. Another four cattle were 
challenged repeatedly at the same monthly intervals, using five similarly 
infected flies at each occasion. Whether challenged singly, or repeatedly, none 
of the cattle developed infections detectable using the buffy-coat technique, or 
by sub-inoculation of mice. In contrast to the responses of challenge control 
cattle, which became infected following every monthly challenge, skin lesions 
(chancres) and lymph node enlargement were not detectable in these cattle. 
Moreover, anti-trypanosomal antibody titres, as measured by immune-lysis of 
trypanosomes, and by neutralisation of trypanosome infectivity for mice, only 
developed in challenge control cattle but not cattle in which prophylaxis was 
effective.
In a second phase of the experiment, the same 24 cattle were again 
challenged at six months after the isometamidium treatment, either by the 
application of five infected flies, or by the intradermal injection of 5 x 10^, 5 x 
1C)3, 5 x 1C)4 or 5 x 10$ in vitro cultured metacyclic forms of the same challenge 
stock of trypanosomes. By this time, eight of the cattle were susceptible to 
infection, but the remaining 16 cattle were still apparently protected by the drug. 
No correlation was observed between susceptibility to infection the previous 
challenge history in the first phase of the experiment. Nor was there any
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correlation with the method of challenge or, in the case of challenge with in 
v/fro-derived metacyclic trypanosomes, the number of trypanosomes used. The 
apparent absence of any relationship between the level of challenge using 
intradermal inoculation of titrated doses of in-vitro derived metacyclic and the 
efficacy of prophylaxis was unexpected; the duration of chemoprophylaxis had 
previously been considered to be related to the level of challenge (Whiteside, 
1962a). In an attempt to relate the level of challenge with in v/fro-derived 
metacyclic trypanosomes to field challenge, the upper dose of 5 x 105 
metacyclic trypanosomes was equated to attack by 45,000 tsetse flies per 
month (Whitelaw et a/., 1986).
In this second phase of the experiment, it was again demonstrated that 
immune responses (measured in terms of skin reactions, local lymph node 
enlargement, and the development of anti-metacyclic trypanosome antibody 
activity) were not primed in isometamidium-treated animals which resisted 
challenge (Whitelaw et al., 1986). In those treated animals in which infections 
did develop, chancre development and lymph node enlargement were less 
severe than in untreated challenge controls, and prepatent periods of infection 
(i.e. the number of days between challenge, and the development of 
parasitaemia) were significantly longer in the isometamidium-treated cattle. 
These findings suggested that, in contrast to the situation with therapeutic use 
of trypanocidal drugs in the field (Bourn and Scott, 1978), non-sterile immunity 
was unlikely to play a role in the protection afforded by prophylactic 
isometamidium, provided that prophylaxis was effective in preventing infections 
from developing to the extent that priming of the immune system could occur.
They also indicated that the prophylactic effect of isometamidium is likely 
to be exerted at the site of inoculation, i.e. the skin, and for this reason, the 
authors, in concurrence with Stephen (1986), suggested that experiments on 
prophylactic drugs should use cyclical challenge; intravenous inoculation of 
trypanosomes, as used by many experimenters, not only represents an artificial 
route of infection, but may also bypass an important site of drug activity.
In a similar experiment, Peregrine, Ogunyemi, Whitelaw, Holmes, Moloo, 
Hirumi, Urquhart and Murray (1988) again examined factors influencing the 
duration of intramuscular isometamidium prophylaxis, in particular the dose of 
drug, the level of metacyclic challenge, and the influence of infection with an 
unrelated serodeme at the time of treatment. Again laboratory-reared G. 
morsitans centralis infected with T. congoiense IL 1180, and 5 x 10^ or 5 x 10^
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in w'fro-cultured metacyclic forms of the same 7. congoiense stock were used for 
challenge, as well as G. morsitans centralis infected with a doubly cloned stock 
of an unrelated serodeme of 7. congoiense (IL 285). Prophylactic doses of 1.0 
mgkg-1 afforded complete protection against both serodemes for four months, 
and seven out of eight cattle remained for uninfected following five monthly 
challenges. Even after the sixth and seventh monthly challenges two cattle 
challenged with each serodeme remained uninfected. Doses of isometamidium 
of 0.5 mgkg-1 protected all of 16 cattle challenged with 7. congoiense IL 1180 
for at least 3 months and 50% of the cattle for four months. Although the 
authors concluded there was no relationship between the method of challenge 
(infected tsetse compared with intradermal challenge with metacyclic forms), or 
the weight of challenge ( 5 x 10  ^ compared with 5 x 1 0 ^  metacyclic forms), the 
number of cattle in each treatment group (four) would suggest that the 
experiment would be a rather insensitive method of detecting one should it 
exist. This experiment also demonstrated that an established 7. congoiense 
infection (IL 285) at the time of isometamidium treatment did not influence the 
subsequent duration of prophylaxis against an unrelated serodeme (7. 
congoiense IL 1180) of the parasite.
The duration of prophylaxis conferred by isometamidium against 7. vivax 
has also been investigated (Peregrine, Moloo and Whitelaw, 1987, 1991). 
Using experimental tsetse challenge of cattle with stocks of 7  vivax from East 
Africa (IL 2982, Galana, Kenya, and IL2969, Kilifi, Kenya) and West Africa (IL 
2968, Zaria, Nigeria), protection after intramuscular isometamidium treatment at 
a dose rate of 0.5 mgkg-1 varied between less than one month (7. vivax IL 2982, 
and IL2969) and at least two months (7  vivax IL 2968). Three 7. vivax 
populations originating from locations in Kenya were shown to be sensitive to 
the therapeutic activity of isometamidium, but resistant to the prophylactic 
activity of the drug, as defined by "early" breakthroughs at dosages 
recommended for field use. The basis for this apparent difference in sensitivity 
to the prophylactic and therapeutic use of the drug was not established, 
although the authors suggested different isomers or metabolites of the drug 
might be responsible for its different activities.
Studies on a tsetse-transmitted drug-resistant clone of 7. congoiense 
derived from a field isolate (Burkina Faso) without drug selection (Sutherland, 
Moloo, Holmes and Peregrine, 1991) showed it to be insensitive to both the 
prophylactic and therapeutic activity of isometamidium; breakthrough infections
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occurred in cattle challenged 28 days following intramuscular (IM) prophylactic 
isometamidium (1.0 mgkg-1), and relapses occurred when the resulting 
infections were treated with isometamidium at 1.0 or 2.0 mgkg-1 IM, or 0.25, 
0.5, 0.75, or 1.0 mgkg-1 by the intravenous (IV) route. The route of 
administration has been shown to be of some significance in the therapeutic 
use of isometamidium against infection with a tsetse-transmitted clone of T. 
congoiense exhibiting a low level of drug resistance (Sutherland, Codjia, Moloo, 
Holmes and Peregrine, 1992). Cattle treated with 1.0 mgkg-1 IV all underwent 
relapse, while the same dose administered IM resulted in cure (follow-up period 
6  months).
Interactions Between Trypanocidal Drugs And The Host Immune 
System
The necessity for a functional immune system for the efficacy of 
chemotherapy and chemoprophylaxis is well recognised in a variety of parasitic 
and microbial infections (Doenhoff, Modha, Lambertucci, and McLaren, 1991). 
The connection between drugs and the immune response was recognised as 
early as 1909 by Paul Ehrlich (cited by Doenhoff et a/., 1991) who conducted 
pioneering work in the fields of both chemotherapy and immunology. In chicken 
malaria it was shown experimentally that acquired immunity played a key role in 
the effectiveness of quinine therapy (Taliaferro, 1948), and in a murine model 
significantly fewer Schistosoma mansoni worms were killed by four 
chemotherapeutic agents if mice were immunosuppressed prior to infection 
(Sabah, Fletcher, Webbe and Doenhoff, 1985; Brindlay and Sher, 1987). A 
similar relationship has been chemotherapy and the immune system has been 
shown to occur in trypanosomiasis; immunosuppression was shown to 
substantially reduce the efficiency of trypanocides, including isometamidium 
and diminazene, in curing T. evansi infections in mice (Osman, Jennings and 
Holmes, 1992).
Drug-stimulated immunity
It has been suggested by many workers that the exposure of cattle to 
natural trypanosome challenge, either while under chemotherapeutic regimens 
leads to a type of acquired immunity whereby the animals become increasingly 
resistant to trypanosome infections, to a degree greater than the could be 
explained by the action of the trypanocidal drugs alone. This somewhat 
controversial topic has been discussed by Williamson (1970), Leach and
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Roberts (1981), Homes and Scott (1982), Jordan (1986), and Holmes and Torr 
(1988).
Bevan (1928, 1936) working in Zimbabwe noticed that trypanosome- 
infected cattle treated with tartar emetic and then re-exposed to challenge in the 
same area, often subsequently remained uninfected. Later studies in the 
1970’s in Uganda and Kenya renewed interest in "acquired tolerance" to 
trypanosomiasis. This work showed that there appeared to be a relationship 
between the level of challenge and the degree of protection obtained. In the 
Ugandan study (Wilson, Paris and Dar, 1975), cattle were exposed to a 
relatively high level of tsetse challenge, and chemotherapy (diminazene) was 
administered to infected cattle on an individual basis only when the PCV fell 
below 20%, or when cattle became clinically ill. During the course of the two 
year study, the number of live calves born increased and calf mortality and the 
incidence of abortion decreased.
A similar system of chemotherapy produced even better results in an area 
of medium tsetse challenge in Kenya (Wilson, Le Roux, Paris, Davidson, and 
Gray, 1975; Wilson, Paris, Luckins, Dar and Gray, 1976). Over the course of 
the 29 month study, the interval between diminazene treatments increased from 
approximately 50 days to approximately 130 days, and some steers which were 
not treated at all during the last six months of the experiment continued to 
survive and grow as well as those which were treated. In contrast, the inter­
treatment interval for animals which were block treated as a group whenever an 
individual was detected parasitaemic required treatment remained 
approximately 26 days throughout the study. Nevertheless, this group 
produced better economic returns than the group in which infections were 
allowed to develop, because the latter group suffered poor growth during the 
early stages before immunity could develop. Interestingly, the best economic 
return was observed in a third group of cattle to which isometamidium (0.5mgkg- 
1) was administered when any individual was detected parasitaemic, because of 
a lower trypanocidal treatment requirement and improved growth rates. This 
group also showed slight evidence of development of immunity, although it 
appeared to be short-lived.
Leach and Roberts (1981) concluded from these experiments that 
demonstrable development of immunity is not necessary for successful 
maintenance of cattle in tsetse areas, provided drug treatment regimens are 
closely controlled (and significant drug resistance does not develop). In
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addition the development of trypanosomiasis in a host before drug treatment 
was considered necessary to induce a degree of immunity. The level of tsetse 
challenge was considered significant by these authors; medium tsetse 
challenge was more conducive than high challenge to the development of drug- 
stimulated immunity. This relationship was further supported by Jordan (1986) 
who considered relatively low levels of challenge to be optimal for the 
development of immunity under chemotherapeutic regimes. He described 
experiences on government stock farms in Southern Nigeria in the 1950's with 
small resident populations of G. p. pallidipes. Cattle could tolerate the local 
stains of trypanosomes of cattle if initially they were protected by drugs, 
although they were susceptible to other strains of trypanosomes if moved into a 
new area. Nevertheless, Bourn and Scott (1978) also showed that strategic 
administration of trypanocidal drugs to work oxen in a trypanosomiasis-endemic 
area of high tsetse challenge in south-western Ethiopia resulted in the 
development of a degree of non-sterile immunity; when trypanosome-infected 
animals were treated alternately with isometamidium and diminazene only on 
the basis of clinical signs of disease, although 50 - 69% of the oxen remained 
positive on blood-films, only approximately 20% per month required treatment.
It has been further suggested that because of the phenomenon of drug- 
stimulated immunity the optimum trypanocidal drug regime for the prevention of 
trypanosomiasis differs depending on the type of herd being treated (Leach and 
Roberts, 1981). While in ranch cattle the use of block prophylactic treatment 
with isometamidium at regular intervals, or treatment with diminazene on 
detection of parasitaemia, is likely to give the best economic return, for small 
breeding herds individual treatment with diminazene would be preferable in an 
attempt to allow the development of a degree of immunity. Holmes and Scott 
(1982) observed that for the successful development of non-sterile immunity in 
endemic areas high levels of veterinary supervision and cattle husbandry, 
adequate nutrition and relative freedom from concomitant infections are also 
required. Finally Holmes and Torr (1988) pointed out that in the absence of 
suitable drug assays it is not possible to identify the contribution accumulated 
drug residues may make to apparent immunity in repeatedly treated animals.
Drug-stimulated immunity is thought not to be significant under successful 
chemoprophylactic regimens (Holmes and Torr, 1988): the prevention of 
development of infection by the prophylactic drug precludes the development of 
an immune response. Experimental evidence to this effect has been obtained
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in laboratory studies in which cattle under isometamidium prophylaxis were 
challenged repeatedly with a clone of T. congoiense using infected tsetse flies 
or intradermal inoculation of metacyclic forms (Whitelaw, Bell, Holmes, Moloo, 
Hirumi, Urquhart and Murray (1986); Peregrine, Ogunyemi, Whitelaw, Holmes, 
Moloo, Hirumi, Urquhart and Murray, 1988). Antibodies to metacyclic 
trypanosomes did not appear in cattle which remained uninfected following up 
to seven monthly challenges, except when the highest level of intradermal 
challenge was used (5 x 10s parasites), in which case antibody titres were low 
and non-protective.
Trypanocidal drug resistance
The problem of trypanocidal drug resistance was reviewed by Williamson 
(1962 and 1970), Leach and Roberts (1981), Schillinger (1984), Holmes and 
Torr (1988), and Sutherland and Holmes (1991). As pointed out by Holmes and 
Torr (1988), drug resistance is only one reason for apparent failure of 
trypanocidal drugs.
The phenomenon of the development of resistance by trypanosomes to 
chemotherapeutic agents was first observed as early as 1907, when Ehrlich 
(1907) observed that with repeated injections of trypan red, trypanosomes 
became increasingly insensitive to this aniline dye. The early successes when 
quinapyramine, homidium, and diminazene were introduced led to mass 
treatment campaigns, which were initially very effective (Leach and Roberts,
1981). However the usefulness of these campaigns was later diminished by the 
successive appearance in turn of strains of trypanosomes resistant to each of 
these drugs. The problem of trypanocidal drug resistance is now seen as a 
cause for considerable concern as drug resistance has now also been 
demonstrated to isometamidium (see below), the only subsequently introduced 
bovine trypanocide.
Stephen (1986) defined two types of drug resistance in the context of 
trypanocidal chemotherapy and chemoprophylaxis. Natural drug resistance 
was defined as "abnormal resistance of strains or species of trypanosomes 
which have had no previous exposure to the drug". Trypanosoma simiae which 
is naturally resistant to most trypanocidal drugs is an example of this 
phenomenon. Induced drug resistance was defined as "the reduction in 
susceptibility of a strain of trypanosome to the lethal action of a drug of the 
same chemical composition, or of a drug of a different chemical composition, 
following exposure to the original drug". The latter part of this definition,
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referring to drugs of different chemical composition is important as there is a 
widely recognised phenomenon of cross resistance, in which trypanosomes 
resistant to one trypanocidal drug also express resistance to another drug to 
which they may never have previously been exposed.
Reasons for development of drug resistance
The acquisition of drug resistance by trypanosomes has been considered to 
be the result of prolonged exposure to less than trypanocidal drug 
concentrations and hence drug resistance has been considered to be more 
likely to occur with prophylactic drugs than therapeutic drugs. This is because 
following the administration of a prophylactic drug the level of drug in the blood 
and tissues of a treated animal will gradually decline to a level insufficient to kill 
all trypanosomes and but enough to induce resistance or exert a selection 
pressure for the more resistant members of the population. In contrast, 
following the administration of a therapeutic drug, the entire dose is likely to be 
eliminated far more rapidly, and the drug will be present at sub-therapeutic 
concentrations for only a very brief period. The fact that resistance to the 
therapeutic trypanocide diminazene aceturate is difficult to induce 
experimentally (Fussganger and Bauer, 1960; Bauer, 1962), and the early belief 
that resistance to diminazene did not occur in the field were considered to 
support this hypothesis. Nevertheless, soon after the initiation of mass 
treatment campaigns with diminazene, resistance was observed in the field in 
West Africa (Jones-Davies, 1967) and East Africa (Mwambu and Mayende, 
1971). The fact that the widespread use of isometamidium, which has 
pronounced prophylactic activity, has not often been followed by the clear-cut 
demonstration of the development drug resistance also fails to confirm the 
hypothesis. For example Folkers (1966) administered isometamidium 
repeatedly to cattle in an area of high natural tsetse challenge, at a dose rate of 
0.25 mgkg*1 IM. Although up to 7 such injections were given over a period of 15 
months, when animals were detected parasitaemic, no evidence of the 
development of drug resistance was found. Similarly, at Mkwaja ranch in 
Tanzania, a prophylactic regimen with isometamidium was followed for twenty 
years without evidence of the development of drug resistance (Trail, Sones, 
Jibbo, Durkin, Light and Murray, 1985).
It has been widely held that it is important to maintain effective trypanocidal 
levels of the drug in cattle under challenge, as the replication of trypanosomes 
in animals with less than effective drug levels would lead to the development of
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drug-resistant populations (Leach and Roberts, 1981). Stephen (1986) stated 
that "Drug-resistance is usually considered to arise when inadequate dosages 
with the same or similar drug is administered repeatedly", and that provided that 
re-infection could be ruled out, "the persistence of trypanosomes in the blood... 
subsequent to treatment at the recommended dosage indicates drug 
resistance".
Osman, Jennings and Holmes (1992) demonstrated that 
immunosuppression of the host considerably reduces the efficacy of 
trypanocidal drugs and can lead to the rapid development of high levels of drug 
resistance. Resistance to trypanocidal drugs, including isometamidium and 
diminazene, could be readily induced in T. evansi in immunosuppressed but not 
immunocompetant mice.
Mechanisms of drug resistance
The molecular basis of drug resistance has been recently reviewed by 
Hayes and Wolf (1990), who made the distinction between intrinsic and 
acquired drug resistance, on the basis of whether the organism or cell in 
question was resistant at the time treatment began, or whether it was initially 
sensitive and became resistant only after treatment was commenced. Reasons 
for intrinsic drug resistance included absence of target site; species-specific 
structure of target site; high detoxification capacity arising from tissue-specific 
function, ontogenic variations, sex-specific differences, population 
polymorphisms, self defence, or high repair capacity; low drug delivery; cell 
cycle effects; adaptive change; and stress response. Intrinsic resistance may 
not be possessed by all members of the 'wild type' population, but may exist in 
only a proportion, an example of this being the polymorphisms associated with 
certain drug-metabolising enzymes. Intrinsic resistance is likely to be the result 
of selection pressures entirely independent of the chemical agent against which 
resistance is observed, and may therefore be present in a significant proportion 
(10 - 100%) of the population prior to the application of drug selection pressure. 
The failure of most of the chemotherapeutic agents used in the treatment of 
other trypanosomiases of domestic animals to cure T. simiae infections in pigs 
(Stephen, 1986) may be considered to be an example of this type of drug 
resistance.
In contrast to the situation with intrinsic resistance, with acquired resistance 
the protective feature arises from a spontaneous mutation within the population, 
a very rare event (10-6), and hence is either absent from, or rarely expressed in
64
the 'wild type' population before drug selection, this form of resistance can 
arise by a number of mechanisms (Hayes and Wolf, 1990), although mutation 
and selection for protective genes are always central to this process. The 
essential difference between acquired and innate resistance is thus the 
frequency with which the mutated gene occurs within the 'wild type' population; 
in both cases the characteristic resulting in resistance arises independently of 
exposure to the drug and is part of biological variation. For example, antibiotic 
resistance has been demonstrated in strains of bacteria freeze-dried and stored 
prior to the commercial development of antibiotics.
The biochemical mechanisms responsible for drug resistance include 
reductions in drug influx into target cells; increases in drug efflux from target 
cells; reduced metabolic activation of the drug; sequestration of drug to prevent 
interaction with the target site; increase in intracellular concentration of target 
sites; structural alterations in target sites; duplication of the functions of the 
target site; and increased repair of damaged target sites (Hayes and Wolf, 
1990).
Of the possible mechanisms for drug resistance, those affecting drug 
uptake and efflux have received particular attention from workers on the 
parasitic protozoa, such as plasmodium falciparum (Fitch, Chevli and Gonzalez, 
1975; Krogstad, Gluzman, Kyle, Oduola, Martin, Milhous and Schlesinger, 
1987), Entamoeba hystolytica (Samuelson, Ayala, Orozco and Wirth, 1990), 
and T. brucei brucei and T. brucei rhodesiense (Damper and Patton, 1976; 
Frommel and Balber 1987), who found a relationship between reduced drug 
accumulation and resistance to the applied compound. Similarly, Sutherland, 
Peregrine, Lonsdale-Eccles and Holmes (1991) who took advantage of the 
intrinsic fluorescence of isometamidium to use fluorescence microscopy and 
flow cytometry to investigate accumulation of this trypanocide by a range of 
clones of T. congoiense, found evidence of an inverse relationship between 
drug accumulation and the degree of resistance expressed by the parasites. 
Investigations into the rates of 14C-isometamidium accumulation by drug- 
sensitive and drug resistant T. congoiense clones showed that drug uptake was 
significantly more rapid and quantitatively greater in drug sensitive parasites, 
and there was clear evidence that drug uptake in both sensitive and resistant 
parasites was by a specific receptor-mediated process (Sutherland, Mounsey 
and Holmes, 1992). Furthermore, drug uptake by the sensitive clone could be 
reduced by the addition of the metabolic inhibitor salicyl-hydroxamic acid and
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glycerol, which indicated that specific drug transport was energy dependant. 
Kinetic modelling of isometamidium uptake by 7. congoiense indicated that 
reduced accumulation of the drug was not likely to be due to reduce drug influx, 
and was likely to be due to either a reduction in affinity of the intracellular 
binding site for the drug, or to increase drug efflux (Sutherland, Mounsey, 
Eisler, and Holmes, 1992).
Cross resistance
Trypanocidal drug resistance and cross resistance were investigated in 
detail in Kenya by Whiteside (1961; 1962a), using strains of 7. congoiense and 
7. vivax. Earlier confusion surrounding cross resistance between 
quinapyramine and phenathridines was shown to be due to the degree of 
resistance expressed by various trypanosome strains, and it was reported that 
resistant strains could be produced in the laboratory by exposure of infected 
cattle to repeated subcurative doses of trypanocides. The greater the number 
of such exposures, the greater the degree of resistance that could be induced. 
Whiteside (1961) was able to produce a table of cross-resistance, based on 
strains of 7. congoiense prepared in cattle, which is reproduced with 
modifications in Table 4.
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Table 4. Cross resistance of trypanosomes to trypanocidal drugs (After 
Whiteside, 1961; and Leach and Roberts, 1981)
Trypanosomes 
resistant to:
Response of 
trypanosomes to:
Quinapyramine Homidium Prothidium Metamidium Diminazene
Quinapyramine R ++ + + ++
Homidium + R + + 0
Prothidium + ++ R + ?
Metamidium + ++ + R 0
Diminazene 0 0 0 0 R
R: Direct resistance 
+ : cross resistance to curative dose 
++ : cross resistance to higher dose 
0 : no cross resistance
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Whiteside (1958, 1961, 1962a) introduced the concept of "sanative pairs" of 
drugs; each of the two drugs comprising a sanative pair would be active against 
strains of trypanosomes resistant to the other drugs. The use of one member of 
the pair was recommended until resistant forms were detected, at which point 
the second member of the pair was substituted for the first, until the resistant 
strains had disappeared from both the cattle and the tsetse.
The lack of cross reactivity between the diamidine, diminazene aceturate, 
and the phenanthridines homidium, prothidium, and metamidium suggested the 
suitability of diminazene with one of the phenanthridines for use as sanative 
pairs. With the withdrawal from the market of prothidium, the only sanative 
combinations currently available are homidium and diminazene and 
isometamidium and diminazene.
Experimental induction of drug-resistant trypanosomes
Whiteside (1962a) was able to induce drug-resistance in strains of T. 
congoiense with "astonishing rapidity" by administering three to six successive 
subcurative treatments to infected steers with most trypanocides, the exception 
being diminazene aceturate. By this method the median curative dose (CD50) 
could be increased by 40 - 80 times above that of the original strain.
Stable resistance to mel Cy, diminazene aceturate, and isometamidium 
chloride was induced in clones of T. evansi by frequent passage in 
immunosuppressed mice given sub-curative drug treatments (Osman, Jennings 
and Holmes, 1992). Similarly, Ndoutamia, Maloo, Murphy, and Peregrine 
(1993) induced quinapyramine resistance in a cloned population of T. 
congoiense by repeatedly passaging in mice relapse populations which 
appeared following treatment with increasing dosages of the drug. A 40-fold 
increase in resistance to quinapyramine was shown to be associated with an 
eight-fold, 28-fold and 5.5 fold increases in resistance to isometamidium, 
homidium and diminazene respectively. The resistant populations were shown 
to be capable of full cyclical development in tsetse flies.
Field Occurrence of Drug-Resistant Trypanosomes
Mass treatment campaigns with quinapyramine and homidium were 
followed in relatively short time by appearance of refractory infections termed 
drug-resistant or "drug-fast" strains (Jones-Davies and Folkers, 1966). 
Following the introduction of diminazene aceturate, resistance to this 
trypanocide was initially thought not to occur; Williamson (1970) stated that "in
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ten years of widespread use it has not given rise to any serious degree of drug 
resistance". However, this is now also ample evidence that resistance to this 
trypanocide can develop (Jones-Davies, 1967; Mwambu and Mayende, 1971; 
Authie, 1984; Codjia, Mulatu, Majiwa, Leak, Rowlands, Authie, d'lteren and 
Peregrine, 1993).
Evidence for the development of isometamidium-resistant populations of 
trypanosomes in the field has been obtained in a number of countries. The 
earliest report of isometamidium-resistance in the literature is probably one of 
two cited by Lewis and Thompson (1974), from the 1967 and 1970 Annual 
Reports of the Branch of Tsetse and Trypanosomiasis Control of the Rhodesian 
Ministry of Agriculture, in which 7. congoiense and 7. vivax resistant to 
isometamidium at dose rates of 0.25 and 0.5 mgkg-1 body weight. Lewis and 
Thompson (1974) themselves described the isolation of isometamidium- 
resistant 7. congoiense from the Masumo and Logolo Valley region of 
Rhodesia, where chemoprophylaxis had been practised since 1958 initially 
using quinapyramine, and since 1967 using isometamidium. Resistance to 
isometamidium was first suspected from1970 onwards, when the period of 
protection afforded by the drug was reduced. Stabilates of 7. congoiense were 
shown to be resistant to the therapeutic use of isometamidium in cattle, which 
developed relapse infections when kept outside the tsetse infested area 
following treatment at 1.0 mgkg-1 body weight.
Isometamidium resistance was also demonstrated in the 1970's at a 
resettlement scheme in the Angar-Gutin Valley in south western Ethiopia, where 
450 work oxen were kept in an area of high tsetse challenge by the strategic 
use of trypanocidal drugs (Bourn and Scott, 1978). Drug-resistant 7. 
congoiense became a problem when attempts were made to rely solely on 
isometamidium prophylaxis at a dose rate of 1.0 mgkg-1 every eight weeks. 
Thirty-six days after the second treatment (which was in fact delayed until 12 
weeks after the first), two thirds of the oxen were found to be infected. Studies 
in mice on 7. congoiense from Angar-Gutin demonstrated that resistance to 
homidium (and thus the phenanthridine group) was indeed present (Scott and 
Pegram, 1974). Thereafter alternate treatments with isometamidium and 
diminazene were given only to the infected animals when clinically affected; that 
most remained in surprisingly good condition in spite of a significant infection 
rate (over 50%) was attributed to the development of non-sterile immunity.
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The isolation of a strain of 7. congoiense from the Shimba Hills Settlement 
Scheme, in Kwale District of Kenya's Coast Province which demonstrated 
multiple drug resistance against quinapyramine, diminazene aceturate, 
homidium chloride and bromide, and isometamidium (Gitatha, 1981) was of 
significance on two counts. Firstly, isometamidium resistance was 
demonstrated in spite of the fact that isometamidium had never been used at 
this site; quinapyramine methylsulphate and Prosalt, homidium bromide and 
diminazene aceturate had all been used between 1958 and 1971. Secondly, 
resistance to both phenanthridines (isometamidium and homidium) and to 
diminazene indicated that the usual sanative drug pairs (Whiteside, 1961) might 
not be effective. As in a similar situation described recently in south western 
Ethiopia, see below, the main factor implicated in the development of multiple 
drug resistance was the use, and possibly misuse of quinapyramine; up to 50% 
of cattle were not presented for treatment on some occasions.
In 1983, Kupper and Wolters (1983) carried out a study in a feedlot in 
Northern Ivory Coast. Although tsetse were scarce at the feedlot itself, the 
cattle had previously trekked through tsetse-infested bush. Following treatment 
with isometamidium at dose rates of 0.5 and 1.0 mgkg-1 body weight, relapse 
infections with 7. congoiense and 7. vivax were soon detected, and it was 
concluded that strains resistant to these doses of the drug were present.
Pinder and Authie (1984) investigated trypanocidal drug resistance in cattle 
in the pastoral zone of Samorogouan, Upper Volta (Burkina Faso), where, 
under a World Bank-funded programme started in 1978, 9000 head of Zebu 
cattle had been treated with isometamidium chloride at a dose rate of 0.5 mgkg- 
1 body weight four times a year, and with diminazene aceturate at 3.5 mgkg-1 
body weight twice a year, in May and November. The doses of both drugs were 
doubled when a resistance problem was suspected. Trypanosome infections, 
mainly with 7. congoiense, were detected as little as two weeks following 
isometamidium treatment at 1.0 mgkg-1, suggesting that resistance had 
developed. Tests in mice showed that 7. congoiense stocks isolated in 1982 
and 1983 were four to eight times less sensitive to isometamidium than others 
isolated three years earlier, prior to the widespread use of the drug.
Seven years later, the continued presence of multiple drug resistance at 
this location was confirmed when diminazene, homidium and isometamidium 
were all ineffective in treating 7  congoiense infections at Samorogouan 
(Clausen, Sidibe, Kabore and Bauer, 1992). Twenty Zebu steers, naturally
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infected with 7. congoiense, were moved into a fly-proof stable and treated with 
diminazene aceturate at 7.0 mgkg-1 body weight, and homidium bromide and 
isometamidium chloride, both at 1.0 mgkg*1 body weight). An isolate of 7  
congoiense obtained from one of these animals was used to experimentally 
infect three previously unexposed Zebu bulls and goats in which infections 
relapsed after treatment with diminazene aceturate at 7.0 (bulls) and 14 and 17 
(goats) mgkg-1 body weight. Attempts were also made to treat similarly infected 
goats infected with intravenously administered isometamidium chloride which 
was ineffective at dose rates of both 1.0 and 2.0 mgkg-1 body weight; five out of 
six goats treated at the lower dose rate, and two of six goats treated at the 
higher dose rate relapsed; one and three goats, treated at the lower and higher 
dose rates respectively, died within 24 hours of treatment.
Rottcher and Schillinger (1985) described isolates of 7. vivax from cattle 
possibly (Njogu and Heath, 1986) suffering a haemorrhagic form of the disease 
at Galana Ranch in Tana River District of Kenya. Stabilates of 7. vivax 
prepared from 11 cattle were pooled and used to infect 36 steers from a tsetse- 
free area which were subsequently treated with isometamidium chloride at 0.5, 
1.0 and 2.0 mgkg-1 body weight, homidium chloride (at the same dose rates), 
diminazene aceturate (1.75, 3.5 and 7.0 mgkg-1 body weight), or quinapyramine 
sulphate (1.5, 3.0 or 5.0 mgkg*1 body weight). Nine cattle were treated with each 
drug, three at each dose rate. Isometamidium was ineffective in all cattle 
treated at all three dose rates; no drop in parasitaemia was observed after 
treatment. Relapse of infections also followed treatment with quinapyramine 
and homidium at all three dose rates, and with diminazene at all but the highest 
dose rate used. Three untreated control steers which appeared likely to die 
following infection were also treated with isometamidium at 0.5 mgkg-1 
bodyweight by the intravenous route. After a brief period of remission of 
parasitaemia, relapses were observed within seven to ten days. The sensitivity 
of these and a further five 7. vivax isolates from other sites in Kenya (including 
four from the Coast Province, and one from Narok District) and one 7. vivax 
isolate from Buulobarde District, Somalia) to the same four trypanocides were 
examined in cattle by Schonefeld, Rottcher and Moloo (1987). The isolates 
were all resistant to the recommended dose rates of quinapyramine, homidium 
and isometamidium, but all were sensitive to diminazene aceturate at a dose 
rate of 7.0 mgkg-1. These findings suggested that multiple drug resistance had 
recently become widespread along the East African coast; in earlier sensitivity 
testing in 1981, 7. vivax isolated from cattle in two of the Kenyan Coast
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Province sites were fully susceptible to isometamidium (Schonefeld, Rottcher 
and Moloo, 1987).
Ainanshe, Jennings and Holmes, (1992) isolated T. congoiense from two 
areas in the Lower Shabelle Region of southern Somalia by injecting blood from 
infected cattle into a recipient calf. A novel aspect of this study was the 
expansion of the relapse infections which developed in the calves following 
treatment with isometamidium (0.5 mgkg-1 bodyweight), in cattle and mice for 
testing for sensitivity to isometamidium and diminazene aceturate. Both 
isolates showed high levels of resistance to both trypanocides, minimum 
curative doses in cattle for both isolates being above 2.0 mgkg-1 and 7.5 mgkg-1 
for isometamidium and diminazene respectively. While this unsophisticated 
approach precluded assessment of the number of drug-resistant infections at 
each site, its relatively low cost and simplicity were appropriate for the logistical 
and financial conditions pertaining in Somalia.
Dolan, Stevenson, Alusha and Okech (1992) reported the apparent failure 
of isometamidium to prevent infections in cattle at Galana ranch for more than 
two to three weeks following prophylactic injections of 1.0 mgkg-1 body weight 
during 1987/88. In the previous year (1986/87), a year of low to medium 
trypanosome challenge, prophylactic injections of homidium bromide (1.0 mgkg- 
1) had apparently protected cattle at Galana for as long as 8 to 17 weeks 
(Dolan, Okech, Alusha, Mutugi, Stevenson, Sayer and Njogu, 1990). In 
1987/88 an attempt was made to compare the prophylactic efficacy of homidium 
bromide with that of isometamidium chloride, the prophylactic drug usually used 
in Kenya. However that in that year (1987/88) trypanosome challenge was 
exceptionally high, and neither drug afforded much of a prophylactic period 
(mean for isometamidium, 28.4 days; mean for homidium, 25.4 days).
Codjia et al., (1993) characterised the drug sensitivity of field isolates of T. 
congoiense from the Ghibe valley in south western Ethiopia, where there 
appeared to be a rising occurrence of failure to respond to trypanocidal drug 
treatment. Twelve stabilates were shown to be resistant in calves to 
diminazene aceturate (7.0 mgkg-1 body weight), and of these eleven were also 
resistant to isometamidium chloride (0.5 mgkg-1 body weight) and homidium 
bromide (1.0 mgkg-1 body weight). Five clones derived from one of the isolates 
all expressed a high level of resistance to all three trypanocides, which 
indicated the multi-drug resistance phenotype was possessed by individual 
trypanosomes. This study was therefore significant in that although it was not
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the first occasion multi-drug resistant populations of 7. congolense have been 
demonstrated, it was shown that individual trypanosomes may express 
resistance to both phenanthridines (isometamidium and homidium) and 
diminazene aceturate, and thus infections with such parasites would not be 
cleared by the usual sanative combinations. Furthermore, the multi-drug- 
resistance phenotype was shown by molecular karyotyping and isoenzyme 
studies to be associated with many genetically distinct populations. It is 
believed that the use, and particularly misuse of quinapyramine may give rise to 
resistance to both phenanthridines and diminazene. It is understood that the 
use of quinapyramine was previously widespread in this area, and indeed there 
may be continued use of black-market stockpiles of the drug in south western 
Ethiopia as a whole (staff of National Tsetse and Trypanosomiasis Investigation 
and Control Co-ordination Office, Addis Ababa, personal communication).
Characteristics of Drug-Resistant Trypanosomes
Stability, infectivity and cyclical transmission
The stability of drug resistance in trypanosomes is likely to be important in 
determining their prevalence in wild populations, and in governing the rate of 
spread of resistance in the presence and absence of drug pressure. 
Considerable variability has been observed in the stability of drug resistance; 
atoxyl resistance was still present in a strain of 7  brucei rhodesiense 
maintained for 24 years by serial passage in the absence of this drug (Fulton 
and Grant), whereas a strain of 7. congolense showed a rapid loss of 
quinapyramine resistance after just 65 days.
Gray and Roberts (1971a) carried out a series of experiments which 
demonstrated that drug resistance (including resistance to isometamidium) in 7. 
congolense and 7  vivax is stable and transmissible on cyclical passage 
through tsetse flies. Following infection and treatment, breakthrough infections 
had reduced pathogenicity in their original bovine hosts, but pathogenicity was 
not necessarily reduced following sub-passage through the fly to other animals. 
Drug resistance was shown to persist for up to 29 months in the absence of 
drug treatment, while being passaged cyclically through cattle and tsetse. Drug 
resistance was altered by neither the length of time between the infection of an 
animal and transmission of the trypanosomes to a new host, nor by cyclical 
passage through antelope (Gray and Roberts, 1971b). These last observations 
were of significance as they suggested that the immune response of the host 
does not affect drug resistance once established in a trypanosome strain.
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Evidence of cyclical transmission of drug-resistant strains has also been 
obtained in the field (Fiennes, 1953; Williamson and Stephen, 1960; Jones- 
Davies, 1968). The stability of these resistant strains in the field are however 
variable. Quinapyramine resistance was detected in the field 5 - 7  months after 
the removal of all drug-treated cattle (Fiennes, 1953), and homidium-resistant 
T. congolense were reported in tsetse flies in Nigeria two years after the 
replacement of the drug by diminazene aceturate (Jones-Davies, 1968). 
However, other workers have found that resistant T. congolense and T. vivax 
disappear from tsetse 6 - 9  months after the removal of cattle and the 
discontinuation of drug use (Whiteside, 1961). These finding would be 
explicable on the basis that some resistant strains are examples of innate 
resistance and do not require the presence of drug pressure to maintain 
detectable levels in the population, while others represent acquired resistance 
which, in the absence of drug pressure, may be less viable than the non- 
resistant strains from which they developed.
Viability of drug-resistant Strains
The number of reports from the field of isometamidium-resistant 
trypanosomes are relatively few in number, when it is considered that the drug 
has been widely used for over 30 years, and having pronounced prophylactic 
activity might be expected to give rise readily to resistant forms (Whiteside, 
1962a). For example, the in spite of extended use of isometamidium at Mkwaja 
ranch, Tanzania, there was no evidence of the development of drug resistance 
for 20 years (Trail et a/., 1985). This is perhaps the more surprising considering 
the treatment regimens used, which involved re-treatment of herds after 
parasitaemia had been detected in a proportion of animals, and thus 
trypanosomes were presumably regularly exposed to sub-trypanocidal drug 
concentrations.
This lower than expected prevalence of resistant forms of trypanosomes 
could be explained if the isometamidium-resistant strains had reduced viability 
compared to the isometamidium-sensitive strains, and that in mixed infections 
the latter tend to overgrow the former, which then die out. Reduced growth of 
drug resistant bacteria (Mayr-Harting, 1955) and Plasmodium gallinaceum 
(Bishop and McConnachie, 1950) has been observed, compared to drug- 
sensitive parent strains. In mice, some drug-resistant stocks of T. equiperdum 
appear to be less able to survive in the absence of trypanocidal drugs than the 
drug-sensitive parent stocks (Cantrell, 1956).
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Further evidence for this hypothesis was obtained by Sones, Holmes and 
Urquhart (1989), who investigated the interference between isometamidium- 
sensitive and isometamidium-resistant stocks of 7. congolense when one and 
then the other was used to infect goats. It was demonstrated that when the 
goats were infected first with the isometamidium-sensitive and then the 
isometamidium-resistant stock, the resulting infection could be cleared by 
isometamidium treatment, indicating the resistant stock had not become 
established. If the goats were infected with the resistant stock first, followed by 
the sensitive stock, isometamidium treatment caused temporary remission, 
followed by relapse. In contrast, following infection with the resistant stock 
alone, treatment resulted in neither remission nor cure. This suggested that 
superinfection with the sensitive stock resulted in the establishment of infection 
which suppressed the resistant stock to below the limit of detection of the 
haematocrit centrifugation - buffy coat technique (Paris, Murray and McOdimba,
1982), until treatment eliminated the sensitive stock, and allowed the resistant 
stock to become re-established. In this context, the 'interference phenomenon' 
in ruminants in which the presence of an active infection with one serodeme of 
7. congolense inhibits the establishment of a subsequent second infection with 
a different serodeme (Morrison, Wells, Moloo, Paris and Murray 1982; 
Dwinger, Luckins, Murray and Moloo, 1986) is also of relevance. Although this 
phenomenon might explain why the resistant stock failed to become 
established when it followed infection with the drug-sensitive stock, it does not 
explain why superinfection with the drug-sensitive stock was able to suppress 
the previously established drug-resistant stock.
Parasitaemia and Pathogenicity
Differences between the course of infections with drug-sensitive and drug- 
resistant trypanosomes have been observed by many workers. For example, 
parasitaemia in rats infected with drug-resistant 7. brucei gambiense was 
intermittent rather than continuous as in infections with drug-sensitive parasites 
(Tobie and von Brand, 1953). The time to relapse following sub-curative 
treatment of trypanosome infections in rodents may also be reduced for drug- 
resistant strains, a phenomenon which has been proposed as the basis for a 
test for drug-resistance using sheep (Williamson and Stephen, 1960). In cattle, 
breakthrough infections with 7  congolense towards the end of a period of 
prophylaxis may be characterised by low or irregularly intermittent
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parasitaemias, although this may not hold for infections caused by T. vivax 
(Stephen, 1962b).
It has also been suggested by various workers that drug-resistant strains of 
trypanosomes may be of lesser pathogenicity than their drug-sensitive 
counterparts (Stephen, 1960; Leach and Roberts, 1981). These suggestions 
would have important implications for the future use of trypanocides, but have 
yet to be fully substantiated (Holmes and Torr, 1988).
Tests for trypanocidal drug resistance
It is clearly important in the control of African bovine trypanosomiasis, that 
information be obtained on the development, distribution and prevalence of 
trypanosomes resistant to the few extant trypanocidal drugs. The true 
incidence and practical importance of drug resistance is largely unknown, and a 
matter of considerable controversy (Holmes and Torr, 1988). Three main 
approaches have been used for the demonstration of drug-resistance, namely 
by conducting therapeutic tests either in domestic livestock or in rodents, and 
testing the drug sensitivities of trypanosome isolates in-vitro. Unfortunately 
each method has particular drawbacks (Sutherland and Holmes, 1991).
Drug Sensitivity testing in Livestock
Use of domestic livestock is time consuming and expensive, particularly in 
trypanosomiasis endemic areas where fly-proof accommodation is required. 
Furthermore, resistance to the prophylactic use of drugs may differ from 
resistance to their therapeutic use (Peregrine, Moloo and Whitelaw, 1987), but 
prophylaxis experiments are necessarily more difficult and prolonged, and 
therefore expensive. Cyclical challenge using tsetse flies may also be 
necessary to ensure experimental conditions realistically approximate natural 
challenge (Stephen, 1986), particularly for prophylactic drugs which may exert 
their effects at the level of inoculation of metacyclic trypanosomes into the skin 
(Whitelaw et al.t 1986).
Drug Sensitivity Testing in Rodents
Drug sensitivities in trypanosomes of domestic animals have been 
evaluated in mice for many years (Hawking, 1963). Mice are normally infected 
with the trypanosome stock in question, and then treated with various doses of 
trypanocidal drug on the appearance of patent parasitaemia. They are then 
monitored parasitologically for a prolonged period to assess the minimum drug 
doses necessary to achieve either a temporary clearance of parasites, the
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minimum effective dose (MED) or a permanent cure, the minimum curative dose 
(MCD). It has been suggested that Hawking's (1963) results showed a close 
relationship between mouse effective dose and cattle curative dose, with mouse 
curative doses being at least ten times those for cattle (Pinder and Authie, 
1984). However, Sones, Njogu and Holmes (1988), comparing the doses of 
isometamidium necessary to cure mice and cattle of infection with various 7. 
congolense stocks concluded that although the result of a mouse test may give 
a broad indication of the sensitivity of a strain, it cannot be used reliably to 
predict curative dose for cattle. In addition many trypanosomes, notably 7  
vivax but also many 7  congolense isolates, are non-infective for rodents. In 
addition large numbers of laboratory rodents must be sacrificed, and long 
observation periods of up to 100 days are involved.
Drug Sensitivity Testing in Vitro
In vitro techniques for assessment of drug resistance in trypanosomes have 
been reviewed by Kaminsky (1990) and Kaminsky and Brun (1993). Significant 
advances have been made in techniques of in-vitro culture of bloodstream forms 
of 7. brucei (Hirumi, Doyle and Hirumi, 1977), 7. vivax (Brun and Moloo, 1982), 
and 7. congolense (Hirumi and Hirumi, 1984; Gray, Ross, Taylor, Tetley and 
Luckins, 1985). Of particular importance in the development of tests for drug 
resistance has been the culture of bloodstream forms of 7. brucei (Baltz, Baltz, 
Giroud and Crocket, 1985), 7. congolense (Hirumi and Hirumi, 1991) and 7  
vivax (Zweygarth, Gray and Kaminsky, 1991) in cell-free systems.
In vitro tests for drug sensitivity may require adaptation of trypanosomes to 
culture, and possibly the prior expansion of the population in laboratory rodents. 
Successful initiation of in vitro culture of 7. brucei usually requires a minimum 
inoculum of 2 x 103 to 1 x 105 trypanosomes per ml from mouse blood during a 
rising parasitaemia (Hirumi et al, 1977; Baltz et al, 1985). Expansion of a 
trypanosome population in laboratory animals involves the possibility of a 
change in its drug sensitivity (Kaminsky and Brun 1993). However, Zweygarth 
and Kaminsky (1990) described a method of initiating cultures of bloodstream 
form 7. brucei directly from disease hosts with low parasitaemia. Stocks of 7  
congolense have been shown to have similar sensitivity to the therapeutic 
action of isometamidium in mice before and after adaptation to culture (Brown, 
Ross, Holmes, Luckins, and Taylor, 1987), and there was no significant change 
in susceptibility to a number of trypanocidal’drugs, including isometamidium, 
quinapyramine, and diminazene aceturate following in vitro maintenance of a
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multi-drug-resistant 7. brucei stock (Kaminsky and Zweygarth, 1989a). 
However if strains are kept in laboratories for long periods in vitro drug 
sensitivity patterns may become altered (Kaminsky and Brun, 1993).
Drug Incubation Infectivity Test
The drug incubation infectivity test (DIIT) is a combination of in vivo and in 
vitro techniques which does not require the adaptation of trypanosomes to 
culture. Trypanosomes are incubated for 24 hours in culture media containing 
various concentrations of trypanocidal drugs and subsequently inoculated into 
mice which are observed for 20 to 30 days for the development of parasitaemia. 
The technique is therefore limited to mouse infective trypanosomes, and has 
been used for 7. brucei (Kaminsky, Gumm, Zweygarth and Chuma, 1990) and 
7  congolense (Hill, 1965; Sutherland, Mounsey and Holmes, 1991).
3H-hypoxanthine Incorporation Assay
In this assay trypanosomes are incubated in culture medium lacking 
hypoxanthine, but containing various concentrations of trypanocidal drug for 24 
hours, after which tritiated hypoxanthine is added. After a further 16 hours 
incubation the incorporation of hypoxanthine by the trypanosomes is 
determined by scintillation counting. It has been used successfully with 7. 
brucei (Brun and Kunz, 1989) and 7. congolense (Ross and Taylor, 1990), but 
expensive equipment is required for cell harvesting and scintillation counting.
Growth Inhibition and Viability Assays
In the 24-hour growth inhibition assay, continuously growing bloodstream 
forms may be incubated in various concentrations of trypanocide for 24 (or 48) 
hours and simply counted to observe growth inhibition as compared to the 
controls. The test is relatively fast, but the 24 hour incubation may not be long 
enough for some drugs to show their trypanocidal effects (Kaminsky and Brun, 
1993). In long-term in vitro viability assay, trypanosomes are cultured in the 
presence of drug for 10 days, with replenishment of the drug containing medium 
as necessary, after which trypanosome growth and morphology are assessed. 
This test has been used for 7. brucei, 7. congolense and 7. vivax (Kaminsky 
and Brun, 1993).
In Vitro Derived Metacyclic Incubation Test
Metacyclic trypanosomes may be derived readily from most 7. congolense 
stocks and also 7. congolense infected tsetse flies, whereas to date 
bloodstream forms of this trypanosome species from naturally infected animals
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have not been adapted to culture. In this test metacyclic trypanosomes are 
incubated without feeder cells for 48 hours in the presence of various drug 
concentrations, after which they are transferred to bovine aortic endothelial 
monolayers to which they attach, enabling the medium to be replaced with fresh 
medium without drug. After 5 days these cultures are examined and the 
minimum inhibitory concentration (MIC) of drug which kills all the trypanosome 
population is determined (Gray and Peregrine, 1993). Although the 
development of metacyclic forms in culture may take as long as 12 weeks, the 
method has the advantage that populations of 7  congolense incapable of 
growth in rodents may be investigated.
Photometric assays
Two photometric assays have been described for in vitro trypanosome drug 
sensitivity which may be conducted in microtitre plates and read using a 
multichannel spectrophotometer. In one system the production of pyruvate by 
intact trypanosomes with consequent lowering of the pH of the culture medium 
and a colour change in phenol red indicator. Non-viable cultures, inhibited by 
the presence of trypanocide result in correspondingly less colour change 
(Zinsstag, Brun and Gessler, 1991). Alternatively, with 7. congolense cultures, 
the trypanosomes are adherent to the culture wells, and may be stained in situ 
at the end of the incubation period with sulforhodamine B, so that the 
absorbance measures at 540 nm is proportional to the number of trypanosomes 
present (Kaminsky and Wasike, 1992). A similar fluorometric assay which 
utilises an esterase substrate which is cleaved by intact trypanosomes to 
produce a fluorescent product has also been described (Obexer, Schmid and 
Brun, 1992).
Akinetoplastic Induction Test
Chitambo and Arakawa (1992) described a test which was used to assess 
the relative sensitivities of 7. congolense isolates to diminazene and 
isometamidium, in which drug sensitive isolates developed a higher proportion 
of akinetoplastic forms during incubation with the drug, and at lower drug 
concentrations than resistant isolates.
Unfortunately, very few laboratories in Africa have the resources for such 
demanding techniques. Furthermore, the correlation between in vitro and in 
vivo susceptibility of trypanosomes to drugs has yet to be clearly established.
79
Plate 5. Well-organised facilities for 
accurately weighing cattle for calculation of 
trypanocidal drug doses and estimating 
productivity under African field conditions. 
Portable equipment may be easily transported 
by four-wheel drive vehicle, and set up in 
minutes in a new location. Unfortunately such 
facilities are seldom available in Africa, with the 
result that underdosing is common.
a) Portable electronic weigh-bars being placed 
under a cattle crush.
b) Portable wooden weigh platform in position 
on top of weigh bars. Electronic read-out 
fastened to bonnet of Land-Rover.
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Plate 6. Intramuscular isometamidium 
chloride injection site, showing extensive 
fibrosis and central area of coagulative necrosis, 
within which dark purplish-brown deposits of 
the drug are visible.
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Constraints on the use of trypanocidal drugs
Drug Failure
One of the main constraints on the use of trypanocidal drugs is clearly drug 
failure due to trypanocidal drug resistance which has been discussed 
extensively above. However, there are other important reasons why the use of 
trypanocidal drugs may fail to achieve a satisfactory level of control of the 
disease, and these are especially important in the field assessment of whether 
drug resistance has in fact developed at a particular location. There has been a 
tendency for field workers to equate failure of drug regimens with resistance, 
but this may not always be the case, and the true importance and distribution of 
resistance is controversial (Holmes and Torr, 1988). Some possible reasons for 
drug failure in the field are listed in Table 5.
As well as being a factor in the development of drug resistance, 
underdosing per se may be one of the most frequent causes of apparent drug 
failure. In considering the role of underdosing in the development of drug 
resistance, Jordan (1986), considered the most important to be the 
underestimation of body weight (see Plate 5), and hence of the dose required, 
underestimation of the level of trypanosome challenge in establishing a 
chemoprophylactic regime, and irregular treatment with prophylactic drugs. The 
same author considered the problem of trypanocidal drugs appearing on the 
open market or through the black market, rather than through the appropriate 
veterinary authorities. This may lead to the dividing of doses intended for a 
single animal between a number of animals, either in an effort to save money, 
or as blatant profiteering on the part of an illicit vendor. Drug fraud is also 
considered to be a serious problem in many parts of Africa (Verhulst, A., 
personal communication), and may reach a level of considerable sophistication, 
so that the ineffective counterfeit products and their packaging are virtually 
indistinguishable from the genuine article, and may only be detected by 
examination of batch numbers (Bado, A., personal communication).
Errors in preparation and administration of trypanocidal drugs may also lead 
to underdosing, particularly where drugs are administered by inexperienced and 
untrained personnel. Trypanocidal drugs are generally sold in the form of 
powders for dissolution in water; sterile distilled water may not be available, and 
the means to measure volumes of water accurately may be lacking. A balance 
capable of accurately weighing small quantities of drug is not usually available, 
but the measured amount of drug as presented in the manufacturers original
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packaging may be greater than required on any particular occasion. Although, 
once prepared, any unused drug in solution should be discarded if not required 
for immediate use, in practice the drug is often likely to be saved for the next 
occasion it is required. This is understandable, considering the economic 
constraints pertaining in the countries affected by trypanosomiasis, but may 
result in prolonged storage of solutions under adverse conditions, such as 
exposure to high temperature and strong sunlight, and the efficacy of the 
product may have deteriorated to an unknown extent. Another problem of drug 
administration was suggested by Lewis and Thompson (1974) who considered 
that isometamidium solution might escape from the injection site along the 
needle track when the injection was in a severely fibrosed location. Finally, 
where large numbers of animals are to be treated it is possible that individual 
animals will be missed, either through problems of identification, difficulties in 
adequately restraining ranch cattle unused to handling, or straight forward 
human error.
Another important consideration in the failure of trypanocidal drug treatment 
is the possibility of relapse due to the persistence of infections in privileged 
sites or cryptic foci inaccessible to the drug. Jennings, Whitelaw and Urquhart 
(1979a,b) showed a relationship between the duration of infection with T. brucei 
and the efficacy of chemotherapy with a variety of drugs. Treatment of mice 
three days after infection resulted in permanent cure, but if treatment with the 
same drugs was delayed until 14 to 21 days after infection, none of the drugs 
cured the infections, even if dose rates were increased far in excess of those 
recommended; a period of aparasitaemia was followed by reappearance of 
trypanosomes up to seven months later. Jennings, Whitelaw, Holmes, 
Chizyuka, and Urquhart (1979) demonstrated that during this aparasitaemic 
period the only tissue of the treated mice capable of transferring infection to 
uninfected recipients was the brain. The failure of treatment is now considered 
to be due to the persistence of extravascular trypanosomes in the central 
nervous system (CNS) which are unaffected by drugs which are unable used to 
pass the blood brain barrier. When, later, the trypanocidal drug has been 
eliminated, these trypanosomes may re-invade the circulation. The treatment of 
late stage human African trypanosomiasis caused by T. brucei group parasites 
still relies mainly upon the trivalent arsenical melarsoprol which is able to cross 
the blood-brain barrier in sufficient quantity to eliminate trypanosomes from the 
CNS (Jennings, 1993).
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The 7. brucei-group trypanosomes are not generally considered to be as 
important as 7. congolense and 7. vivax in cattle, which are generally 
considered to be confined to the vasculature, apart from a brief period of 
development at the site of inoculation of metacyclic forms by the tsetse fly into 
the skin (Luckins and Gray, 1978). However, extravascular development of 7. 
congolense has been reported to occur in mixed infections with 7. brucei 
(Masake, Nantulya, Akol and Musoke, 1984). 7. congolense were detected in 
cerebrospinal fluid of Boran steers in mixed experimental infections with T. 
brucei, but not in single infections. Mixed infections may be more common than 
is generally recognised; 7. brucei may frequently detected if mouse 
subinoculation (Robson and Ashkar, 1972) or Ag-ELISA (IAEA, 1993) are used, 
but in practice the HCT-BCT, the sensitivity of which is considerably lower for T. 
brucei than 7. congolense or 7. vivax (Paris, Murray and McOdimba, 1982), is 
more commonly used. 7. wVax has also been reported in extravascular 
locations such as the marginal sinuses of lymph nodes and cardiac tissues 
(Bungener and Mehlitz, 1977; Masake, 1980). McLennan (1973) failed to infect 
cattle by subinoculation of blood from 7. v/Vax-infected cattle undergoing 
remission of parasitaemia following treatment with diminazene aceturate; this 
suggested the persistence of parasites during the period of remission in an 
extravascular site, possibly inaccessible to the drug. Similarly, Haase, Bernard 
and Guidot (1981) demonstrated infectivity for rats of brain tissue from cattle in 
remission from 7. congolense parasitaemia following diminazene treatment, 
whereas blood from the same animals was unable to establish infection. The 
possibility of relapse infections of 7. congolense and 7. vivax due to cryptic foci 
should therefore not be discounted, and requires further investigation.
Re-infection represents another possible explanation for the reappearance 
of parasitaemia following trypanocidal drug therapy. If the response to 
treatment with a trypanocidal drug is to be used as an index of the drug- 
sensitivity of the infecting trypanosomes, it is essential the animals be removed 
from the possibility of further challenge during the follow-up of the infection.
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Table 5: Reasons for apparent drug failure (After Holmes and Torr, 1988)
Underdosing 
Preparation 
Administration 
Fraud 
Not treated 
Cryptic foci 
Re-infection
Logistical and Economic constraints
The effective use of trypanocidal drugs is constrained in much of sub- 
Saharan Africa by severe logistical and economic restraints (Leach and 
Roberts, 1981). These include the difficulty in accessing extensively kept 
livestock distributed over large distances, frequently under nomadic systems of 
husbandry. Mass treatment campaigns may therefore be the most effective 
method of minimising the cost of individual treatments. Lack of 
communications, such as all weather roads, vehicles and fuel, facilities such as 
diagnostic laboratories and equipment, and trypanocidal drugs, needles, 
syringes all hamper control schemes (Holmes and Scott, 1982). The services of 
adequately paid and motivated personnel are also essential, but trained staff 
are rarely available in adequate numbers.
Adverse Effects
A significant constraint on the use of most trypanocidal drugs, both for use 
in human African trypanosomiasis and trypanosomiases of domestic livestock 
has been the problem of trypanocidal drug toxicity. Trypanocidal drugs, like 
other antimicrobial agents are effective because of a differential between the 
toxicity of the drug for the pathogenic micro-organism and that for the host. The 
ratio of the level of toxicity for the parasite to that for the host, may be 
expressed as the therapeutic index, the ratio of the maximum dose tolerated by 
the host, to the minimum dose curative of the parasite (Stephen, 1986). The 
therapeutic index may be very small for many trypanocidal drugs. This has the 
effect that the simple expedient of raising the dose of drug may not be possible 
as a means of countering the development of trypanocidal drug resistance.
Adverse reactions to isometamidium can be classified as either systemic or 
local to the injection site (see Plate 6). Following the conventional 
intramuscular injections in cattle systemic reactions are not generally reported 
(Toro, Leon, Lopez, Pallota, Garcia and Ruiz, 1983), although local reactions
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are considered almost inevitable (Williamson, 1970). To prevent lameness and 
damage to the hindquarters it is usually recommended that the drug be injected 
into the neck muscles, although this may cause special problems in draught 
oxen (Holmes and Scott, 1982). Histopathological examinations have shown 
that coagulative necrosis with inflammation, fibrosis and indurations cause 
damage at intramuscular injection sites (Braid and Isoun, 1980), and leakage of 
the drug to subcutaneous tissues may result in sloughing of the skin (Kinabo 
and Bogan, 1988d). The reaction, as well as being undesirable on animal 
welfare grounds, may result in an erratic and unpredictable pattern of drug 
absorption (Kinabo and Bogan, 1988d). Nevertheless, in twenty years of use at 
Mkwaja Ranch, Tanzania, intramuscular isometamidium had no deleterious 
effects on reproductive performance in terms of calving intervals, and multiple 
inoculation of the drug did not raise any serious problems of local reactions, 
increased requirement for treatment, or any decline in productivity (Trail et al., 
1985).
The problem of local tissue reactions has led some workers to investigate 
the use of the drug by the intravenous route (Toure, 1973; Dowler, Schillinger 
and Connor, 1989; Munstermann, Mbura, Maloo, and Lohr, 1992). However, 
intravenous injections may be associated with signs of acute systemic toxicity. 
Schillinger, Maloo and Rotcher (1985) investigated the toxicity of intravenous 
isometamidium in cattle, goats, dogs and camels, with a view to establishing the 
maximum tolerated dose in each species. Immature Boran steers, 
experimentally infected with T. vivax, were administered isometamidium chloride 
as a 1 % solution at three dose rates. Four steers given the drug at mgkg*1 body 
weight showed signs of tachycardia, salivation and lachrimation, and frequent 
urination and defecation. In addition to these signs, another steer given 1.5 
mgkg-1 body weight showed muscle tremors and diarrhoea. A further steer, 
given 2.0 mgkg-1 body weight, showed additionally, recumbency, convulsions 
and diminished reflex responses, and thus 1.5 mgkg-1 was considered to be the 
maximum tolerated dose.
Sutherland, Moloo, Holmes and Peregrine (1991) injected Boran steers 
experimentally infected with a drug-resistant clone of T. congolense 
isometamidium intravenously at doses of 0.25 - 1.0 mgkg-1. At 0.25 and 0.5 
mgkg-1 no adverse effects were observed, but various acute systemic reactions 
were observed in 10 steers administered the drug at 0.75 mgkg-1: six steers 
exhibited hyperlachrimation, three hypersalivated, and an excessive nasal
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discharge was observed in one steer. Eight of the cattle also exhibited 
immediate urination and diarrhoea. Four out of five steers given 1.0 mgkg*1 
exhibited all these signs. Unsteady and shuffling gaits were also observed in 
three steers. The signs described appeared within ten minutes of treatment, 
and disappeared within 1 5 - 2 0  minutes following treatment. Unexpectedly, 
there was no advantage to intravenous administration over intramuscular 
administration in its ability to clear the T. congolense infection; in fact there was 
some evidence to the contrary.
Marked, dose-dependent reductions in levels of the serum cations calcium, 
sodium and potassium to below normal values have been shown to occur within 
one hour of intravenous isometamidium treatment (Schillinger, Maloo and 
Rotcher, 1985), possibly due to the diarrhoea and hypersalivation; these ions 
do not combine with isometamidium which is itself a cation. (Schillinger, Maloo 
and Rotcher, 1985).
Philips, Sternberg, Cronin, Sodergren and Vidal (1967) considered the 
acute responses to isometamidium to be typical of agents containing 
quarternary ammonium groups and which involve stimulation or blockade of 
cholinergic effects. Typical of such signs are the vagal effects of salivation and 
intestinal hyperperistalisis (Schillinger, Maloo and Rotcher, 1985). Further 
evidence for this was the finding that the acute toxic effects of isometamidium in 
mice were reduced by atropine, which suggested at least some of its effects are 
mediated cholinergic activity, possibly through the inhibition of cholinesterase 
(Gimbi and Kinabo, 1992). Potentiation of histamine responses through the 
degranulation of mast cells is also a possible component of the acute toxicity 
response (Philips etal., 1967).
More long-term adverse effects of phenanthridinium drugs, including 
isometamidium were reviewed by Williamson (1970). The use of dimidium in 
particular caused a high incidence of delayed toxicity, and symptoms 
resembling photosensitization frequently appeared. Periportal fatty infiltration 
of the liver was thought to be of central importance in the development of this 
condition, but external factors such as climate, nutritional status and dietary 
photodynamic substances such as the chlorophyll derivative phylloerythrin were 
also considered significant. Homidium, pyrithidium, and metamidium were also 
considered capable of producing liver lesions, but only at doses considerably 
higher than the therapeutic level; delayed toxicity and photosensitization had 
not followed their use in the field. However, a severe wasting condition with
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high mortality and substantial liver damage evident post mortem which occurred 
in a group of experimental cattle on Galana ranch, Kenya, was attributed to use 
of isometamidium at a frequency that exceeded the manufacturer's 
recommendation (Dolan et at., 1992). Isometamidium had been administered 
intramuscularly at 1.0 mgkg-1 body weight at approximately monthly intervals 
over a period of eight months, together with another trypanocide, diminazene 
aceturate, in an attempt to control trypanosomiasis in a situation of very high 
challenge; T. vivax infections were frequently detected within a few weeks of 
treatment.
Drug Residues
There has been increasing concern in recent years about residues of 
veterinary drugs used in animals used for human consumption, and this applies 
particularly to prophylactic trypanocidal drugs which are likely to persist in the 
tissues of treated animals (Braide and Eghianruwa, 1980; Kinabo and Bogan, 
1988d). The Joint FAO/WHO Expert Committee on Food Additives (WHO, 
1993) has established international criteria to be applied in evaluating 
toxicological and residue data for use in assessing the safety of veterinary 
products present in human food. This is intended to set international standards 
for their safe use in human food, and to promote harmonisation and reduce 
technical barriers to international trade. Particularly in relation to older 
veterinary drugs with a long history of use, such as the trypanocides, the 
Committee decided that in order to establish maximum residue levels (MRLs) 
and acceptable daily intakes (ADIs) the following issues must be adequately 
addressed: pharmacological effects, general toxicity, reproductive toxicity, 
embryo-toxicity/fetotoxicity, genotoxicity, carcinogenicity, other effects identified 
as being of importance, metabolism, tissue residues, and analytical 
methodology. Isometamidium was evaluated for the first time by the Committee 
in 1989 (WHO, 1989; WHO, 1990) which was unable to establish and MRL or 
ADI for the drug because of a lack of available information in many of these 
areas. However, in 1992, the Committee evaluated new data from studies of 
the uptake of radiolabelled isometamidium from lyophilised bovine tissues, short 
term and teratogenicity studies in rats, and a range of genotoxicity assays. An 
ADI of 0 - 100pgkg-1 body weight was established, based on the non-toxic dose 
level of 50 mgkg-1 body weight per day in a 13 week rat study and a 500-fold 
safety factor. Similarly, the Committee evaluated new residue data from a 
metabolism study in lactating cows injected with ^C-labelled isometamidium, a
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bioavailability study in rats which were fed lyophilised calf tissues containing 
^C-labelled isometamidium, and a residue study in young bulls given an 
intramuscular injection of isometamidium at I.Omgkg-1 body weight, with 
analysis of tissues by high performance liquid chromatography (HPLC) at 1, 3 
and 6 months after treatment. Based on these studies the Committee 
recommended an MRL of 0.1 mgkg-1 for parent isometamidium in muscle and 
fat, 0.5 mgkg-1 in liver, 1.0 mgkg*1 in kidney and 0.1 mgkg-1 in milk.
Methods for the determination of trypanocidal drug 
concentrations
Any evaluation of the factors which influence the duration of 
chemoprophylaxis is particularly dependant upon a knowledge of the drug 
concentrations present in treated animals. In particular, the quantification of 
drug levels in treated cattle could be useful as a field method of assessing the 
presence of drug resistance. The presence of trypanosomes in prophylactically 
treated cattle in which the drug was above the minimum level normally 
considered to be trypanocidal, would be a valuable index of resistance (Holmes 
and Torr, 1988).
Colorimetric and spectrophotometric methods
Initial attempts to quantify isometamidium included the spectroscopic 
method of Philips et al., (1967), which was subsequently used in studies in 
goats (Braid and Eghianruwa, 1980) and camels (Ali and Hassan 1984). 
However this method was not sufficiently sensitive or specific to detect 
concentrations of less than 1 pgml-1 in plasma, and later studies (Kinabo and 
McKellar, 1990) cast doubts on its validity. Use of radio-isotope labelled drugs
High Performance Liquid Chromatography (HPLC)
Perschke and Vollner (1985) developed more sensitive methods for the 
detection of isometamidium, homidium and quinapyramine, using HPLC, 
although the method for isometamidium was indirect in that the drug needed to 
be converted to homidium before detection, and large volumes of plasma (10 
ml) were required. An improved ion-pair reversed-phase HPLC method 
developed by Kinabo and Bogan (1988a) overcame some of these 
disadvantages, but was still insufficiently sensitive to detect isometamidium 
more than a few hours following treatment of cattle with 0.5 mgkg-1 IM (Kinabo 
and Bogan 1988b).
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Radioimmunoassay
The development of immunoassay methods has revolutionised the 
detection of small molecules including drugs, and such methods have now been 
applied to trypanocidal compounds with considerable success. Kinabo and 
Bogan (1988c) developed a radioimmunoassay method for isometamidium, 
which was limited in sensitivity principally because of the low specific activity of 
the 14C-labelled isometamidium tracer.
Enzyme-linked immunosorbent assay (ELISA)
Since its development, the use of enzyme labels has steadily replaced the 
use of radioactive labels in the field of immunoassay (Chard, 1990). As with the 
detection of anti-trypanosomal antibodies and of trypanosome antigens in the 
diagnosis of infection, the ELISA is an attractive option for the detection and 
quantification of trypanocidal drugs. With a modest amount of suitable 
equipment, a high throughput of test samples in suitably equipped laboratories 
is possible (Luckins 1992). The feasibility of the use of microplate ELISAs in 
African institutes involved in tsetse and trypanosomiasis control was 
demonstrated during the Co-ordinated Research Programme of the Joint 
FAO/IAEA Division of Nuclear Techniques in Food and Agriculture, from 1987 
to 1992, in which ELISA-based diagnostics were successfully implemented in 
ten sub-Saharan countries (Ooijen, 1993).
Maes, Vanderveken, Hamers, Doua and Cattand (1988) developed an 
ELISA method for measuring and monitoring levels of the trypanocide 
melarsoprol, an organic arsenical used in the treatment of late-stage human 
African trypanosomiasis, in serum and cerebrospinal fluid. The assay had a 
working range of 200 to 2000 nannogrammes melarsoprol per ml of human 
serum, and was capable of detecting the drug in patients serum following 
treatment.
An early attempt at the development of an enzyme-linked immunosorbent 
assay (ELISA) for the detection of isometamidium, was reported by Whitelaw, 
Gault, Holmes, Sutherland, Rowell, Phillips and Urquhart, (1991). The work 
described in this thesis was initiated using this methodology as a starting point 
for the development of reliable, repeatable, reproducible and robust ELISAs for 
the determination of isometamidium concentrations in bovine serum with a view 
to the improvement of chemoprophylactic strategies for the control of African 
bovine trypanosomiasis.
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Chapter 2:
General Materials and Methods
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Reagents
Phosphate Buffered Saline (150 mM, pH 7.2)
The following salts were weighed out and distilled water added to a volume 
of 1L, and mixed well.
. NaCI 8.0g
. Na2HP04 1.48g
. KH2PO4 0.43g
The pH of the resulting buffer was checked with a pH meter, and the buffer 
stored at 4°C until use.
If large volumes of PBS were required it was found convenient to make up 
this solution at ten times the normal concentration, and to store it at 4°C. 
Before use, this 10 x concentrated stock solution was diluted 1/9 in distilled 
water and mixed well.
Washing buffer for ELISA
Buffer for washing ELISA plate wells was prepared by diluting PBS 1/5 in 
distilled water. Tween 20 (Sigma, Poole, UK) was added to a final 
concentration 0.05% (v/v) and mixed well. To aid the dispersion of Tween 20, it 
was first added to a small volume of PBS, mixed well, and then added to the 
remainder of the PBS and mixed again.
Carbonate/bicarbonate buffer (50 mM, pH 9.2)
To 900 ml of a solution of 4.2 g sodium bicarbonate made up to one litre in 
distilled water was added to 100 ml of a solution of 1.325 g sodium carbonate 
made up to 250 ml in distilled water. The buffer was mixed well, and by adding 
dropwise sodium bicarbonate solution to lower, or sodium carbonate solution to 
raise, the pH was adjusted to 9.2, using a pH meter.
5% (v/v) Acetic acid
One hundred and fifty millilitres of glacial acetic acid (BDH, Poole, UK) was 
added to 2850 ml of distilled water.
Dextran-charcoal
Two and a half grams (2.5g) decolourising charcoal (BDH) and 0.25 g 
dextran (Sigma) were added to 1L distilled water. The resulting suspension 
was mixed well and stored at 4°C until required for use.
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Acetate buffers
Anhydrous sodium acetate (BDH) and glacial acetic acid (BDH) were 
dissolved in distilled water to various concentrations, and the two solutions 
added together in various proportions to produce the following buffers:
0.015 M, pH 5.7
4.88 g sodium acetate made up to 4 I in distilled water.
0.86 ml glacial acetic acid made up to 1 I in distilled water.
380 ml acetic acid solution added to 4 I sodium acetate solution
0.06 M, pH 4.0
2.46 g sodium acetate made up to 500 ml in distilled water.
1.72 ml glacial acetic acid made up to 500 ml in distilled water.
500 ml acetic acid solution added to 500 ml sodium acetate solution
0.1 M, pH 5.7
8.20 g sodium acetate made up to 1 I in distilled water.
5.73 ml glacial acetic acid made up to 1 I in distilled water.
95 ml acetic acid solution added to 1 I sodium acetate solution
Potassium phosphate buffers, 0.3 M and 0.01 M, pH 8
Potassium dihydrogen orthophosphate (KH2P 04, BDH) and dipotassium 
hydrogen orthophosphate (K2HP04, BDH) solutions in distilled water were 
added together at a ratio of 2.2 : 17.8 (v/v). For 0.3 M buffer, KH2P 04 (40.8 gM) 
was added to K2HP04 (52.3 gM). For 0.01 M buffer, 0.3 M buffer was diluted 
1/30 in distilled water.
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Preparation of isometamidium conjugates
Dialysis Procedure
A length of dialysis tubing (BDH) of approximately 250 mm was cut from the 
roll with scissors. The tubing was hydrated by boiling in distilled water for thirty 
minutes. One end of the tubing was closed using a plastic clip, and a measured 
volume (usually 1 - 5 ml) of the material to be dialysed was placed into the 
tubing via the open end, using a Pasteur pipette. The open end of the dialysis 
tubing was then closed with a second plastic clip, ensuring no air remained 
within, and the tubing placed in a beaker containing 2.5 litres of the solution 
against which dialysis was to take place, usually PBS, for 24 hours at room 
temperature (18 - 22°C). During this incubation the dialysis solution was 
changed at least three times for fresh solution and agitated continuously using a 
magnetic stirrer. At the end of the period of dialysis the tubing was removed 
from the beaker, one of the plastic clips removed, and the dialysed material 
collected using a Pasteur pipette.
Preparation and Use of G25 Sephadex Column
A 300 mm x 20 mm glass chromatography column (Pharmacia Biosystems 
Ltd., Milton Keynes, UK) was packed with G25 Sephadex (Sigma) pre-soaked 
overnight in PBS (pH 7.2), and equilibrated by three sequential applications of 
one bed volume (30 ml) of the same buffer. The mixture to be separated was 
applied to the top of the column, and buffer pumped onto the column at a rate of 
60 ml per hour. The eluate from the column was collected in glass test tubes 
which were changed every two minutes, either using a fraction collector 
(Pharmacia) or manually. The optical density (OD) at 280 nm of all the fractions 
collected was recorded using a spectrophotometer (Perkin Elmer 550A, 
Beaconsfield, Bucks), and the approximate protein concentration calculated by 
multiplying the OD by 0.75. Fractions comprising individual peaks in OD were 
pooled, and their volumes and protein concentrations recorded.
When the material being separated was a crude preparation of an 
isometamidium-horseradish peroxidase conjugate, the coloured conjugate could 
be observed as it passed down the column. A dark brown band, consisting of 
unconjugated isometamidium was retained at the top of the column, while a 
paler but distinct brown band consisting of conjugated isometamidium moved 
rapidly down the column; this was collected after the passage of the void 
volume (approximately 9 ml). With experience it was possible to identify the
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fraction(s) containing purified conjugate on the basis of the passage of the 
coloured band alone, rather than using the ODs.
Diazotisation Procedure
Isometamidium was conjugated to two protein carriers, either porcine 
thyroglobulin (PTG) or chicken egg albumin (ovalbumin; both Sigma). All 
incubations were carried out in light-proof containers. Fifty milligrams 
isometamidium was dissolved in 1 ml hydrochloric acid (1 in 3 dilution 
concentrated HCI in water) to which 1 ml sodium nitrite (6.95 mgml*1) was 
added, and shaken gently for 10 minutes at 4°C. The isometamidium solution 
was then added to protein (PTG or ovalbumin) in 200mM phosphate buffer pH 
7.0, to a ratio of 0.2:1 (w/w) isometamidium:PTG or 0.0125:1 (w/w) 
isometamidium:ovalbumin, and incubated in the dark with stirring at 4°C for two 
hours. The conjugate was dialysed overnight against 5% acetic acid, and 
stored in aliquots at 4°C. Some aliquots of isometamidium-ovalbumin conjugate 
were mixed for 15 minutes with 0.5 ml dextran charcoal suspension, and 
centrifuged (Eppendorf) at 14,000 rpm to remove the charcoal; the supernatant 
was stored in aliquots at -20°C after mixing well with an equal volume of 
glycerol (Sigma).
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Immunisation of experimental sheep.
Experimental sheep
Scottish Blackface wethers aged six months to one year were obtained from 
a commercial farm, and loose housed in an indoor pen. They were fed on hay 
and concentrate and allowed access to water ad libitum.
Emulsification of immunogen in adjuvant
The immunising conjugate was emulsified in Freund's complete adjuvant 
(Sigma) or Freund's incomplete adjuvant (Sigma) as required, by adding 
together adjuvant and immunogen at a ratio of 2:1 (by volume), and repeatedly 
passing the mixture back and forth between two 2 ml syringes until a water-in-oil 
emulsion was obtained. This was evaluated by placing a drop of the emulsion 
on the surface of a beaker of distilled water: if the droplet did not disperse 
across the surface, but remained as an intact globule, it was considered to be a 
satisfactory water-in-oil emulsion (Goding, 1983).
Immunisation Protocol
Primary immunisation of Scottish Blackface wethers was by sub-cutaneous 
injection of conjugate emulsified in Freund's complete adjuvant. A total of 2 mg 
in a volume of 3 ml was divided between two sites in the inguinal region and the 
post-scapular flank, on the opposite sides of the body (i.e. right flank and left 
inguinal region).
Three to five subsequent sub-cutaneous booster immunisations of the same 
conjugate emulsified in Freund's incomplete adjuvant were administered over 
the following six to nine months. At each occasion of booster immunisation, a 
total of 1 mg in a volume of 3 ml was again divided between two sites in the 
inguinal region and the flank. Injection sites were used on the opposite sides of 
the body to those used in the previous immunisation.
Collection of hyperimmune serum
Blood samples were collected by jugular venipuncture into Vacutainers 
(Beckton-Dickinson, Meylan Cedex, France) without anti-coagulant, and placed 
in an incubator at 37°C for four hours to optimise clotting. After incubation 
overnight at 4°C to maximise clot retraction, the clots were removed, the serum 
centrifuged (Chilspin, MSE, Fisons, Crawley, UK) at 1000 rpm for 15 minutes, 
and the supernatant stored at -20°C until required.
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Purification of immunoglobulin.
Ammonium sulphate precipitation of immunoglobulin
To 20 ml hyperimmune sheep serum, 20 ml saturated ammonium sulphate 
was added slowly, dropwise, on a magnetic stirrer. The mixture was centrifuged 
(Chilspin) at 3000 rpm for 20 minutes, and the pellet resuspended in PBS. 
Residual ammonium sulphate was removed by dialysis against PBS for 24 
hours at 4°C.
Caprylic acid separation of immunoglobulin
Ten millilitres of hyperimmune sheep serum were added to 20 ml 0.6 M 
acetate buffer (pH 4.0), in a beaker with magnetic stirring. Three-hundred and 
thirty millilitres of caprylic acid (n-octanoic acid, BDH) were added and shaken 
vigorously. After a further thirty minutes stirring, the mixture was centrifuged 
(Chilspin) for 10 minutes at 3000 rpm. The supernatant was adjusted to pH 5.7 
using dilute sodium hydroxide solution, and then dialysed against 0.015 M 
acetate buffer (pH 5.7) for 24 hours at 4°C. Finally the immunoglobulin was 
centrifuged again to remove any precipitate formed during the dialysis stage.
Anion-exchange chromatography of immunoglobulin G
Immunoglobulin G (IgG) was purified from crude immunoglobulin fractions 
obtained by ammonium sulphate precipitation or caprylic acid separation by 
anion-exchange chromatography using diethylamino-ethyl (DEAE) cellulose, 
using either a batch separation method or a column method.
Batch separation method
DEAE-cellulose (DE 52, Whatman) was equilibrated by mixing into 0.1 M 
acetate buffer (pH 5.7), allowing the particles to settle for ten minutes 
and decanting and discarding the supernatant. The process was 
repeated once using the same buffer, and then a few more times using 
0.015 M acetate buffer (pH 5.7) until the discarded supernatant was pH 
5.7. The immunoglobulin solution was then stirred into the sedimented 
particles, and incubated at room temperature for two hours with 
occasional stirring. The mixture was then centrifuged (Chilspin) at 3000 
rpm for five minutes, and the supernatant dialysed against PBS for 24 
hours at 4°C.
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Column method
DEAE-cellulose (DEAE-Sephacel, Pharmacia) was added to 0.01 M 
potassium phosphate buffer (pH 8.0) and allowed to swell at room 
temperature overnight. A 300 mm x 20 mm glass chromatography 
column (Pharmacia) was packed with DEAE-cellulose, and equilibrated 
by the sequential application of three bed volumes (30 ml) of the same 
buffer. Twenty millilitres of crude immunoglobulin preparation were 
applied to the column and allowed to soak in for one hour. A linear 
elution gradient of potassium phosphate buffer (pH 8.0), starting molarity 
0.01 M, final molarity 0.3 M, was applied using a gradient mixer 
(Pharmacia), pump speed 25 ml per hour. The eluate was collected in 
glass tubes changed every ten minutes using a fraction collector 
(Pharmacia). The optical density (OD) at 280 nm of all the fractions 
collected was recorded using a spectrophotometer (Perkin Elmer 550A), 
and the approximate protein concentration calculated by multiplying the 
OD by 0.75. Fractions comprising individual peaks in OD were pooled, 
and their volumes and protein concentrations recorded. Purified IgG was 
dialysed against PBS for 24 hours at 4°C.
Immunoglobulin G preparation
Immunoglobulin was purified from hyperimmune sheep anti-isometamidium 
serum initially by ammonium sulphate precipitation, or caprylic acid separation. 
IgG was purified by anion-exchange chromatography of ammonium sulphate 
precipitated immunoglobulin using the column method, and of caprylic acid 
separated immunoglobulin using the batch method.
Following anion-exchange chromatographic separation by either method, 
the purity of the IgG was checked using immunoelectrophoresis against anti­
whole sheep serum (Sigma) and anti-sheep IgG (Sigma). IgG separation was 
considered satisfactory if a single precipitation line was observed in the same 
position with either anti-globulin reagent.
Before storage, IgG was concentrated to at least 2.0 mgmH using an 
immersible vacuum ultrafilter (CX 10, Millipore); the immunoglobulin 
concentration was checked by measuring the OD at 280 nm. Aliquots of 
purified IgG were stored at -20°C in polypropylene vials (Cryovials, Nunc).
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Chapter 3:
Evaluation and Improvement of an Enzyme-Linked 
Immunosorbent Assay (ELISA) for the Detection of 
Isometamidium in Bovine Serum
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Introduction
In spite of decades of control programmes, bovine trypanosomiasis remains 
one of the greatest constraints to agricultural production in sub-Saharan Africa. 
The few available chemoprophylactic and chemotherapeutic agents, of which 
isometamidium chloride (Samorin®) is one of the most widely used (Sutherland 
and Holmes, 1991; Leach and Roberts, 1981), remain the major means of 
control in most endemic countries. However, there are an increasing number of 
reports of suspected drug-resistant trypanosomes (Kupper and Walters, 1983; 
Pinder and Authie, 1984; Schonefeld, Rottcher, Moloo 1987; Holmes and Torr, 
1988), and with little prospect of new drugs becoming available, control 
schemes which optimise the usage of existing drugs are required.
A sensitive assay for quantifying isometamidium in bovine serum could 
provide a valuable tool for measuring the duration of protective drug levels 
under a variety of field conditions, and make a major contribution to rational 
drug usage. In conjunction with tests for the presence of trypanosome infection, 
such an assay could rapidly provide indirect evidence for drug resistance in the 
field, thereby enabling rationalisation of chemoprophylactic and 
chemotherapeutic regimes.
An enzyme-linked immunosorbent assay (ELISA) for isometamidium has 
been reported (Whitelaw, Gault, Holmes, Sutherland, Rowell, Phillips and 
Urquhart, 1991), although with increasing experience of its use, the following 
constraints on the method have become apparent. Firstly, dispensing small 
volumes (5 pi) of test sera directly into ELISA plate wells was inaccurate with 
commonly available air-displacement pipettes. Secondly, significant 
background reactions, observed with many bovine sera, lead to difficulty in 
interpreting results. Thirdly, quality assurance was not considered; assay 
calibration by linear interpolation of a limited number of standards was liable to 
considerable bias, methods for determining precision and the lower limit of 
detection were not considered, and the assay was not validated for use in 
Africa.
To overcome these difficulties a new isometamidium ELISA method has 
been developed and evaluated using a statistically based approach which is 
intended as the basis of a quality assurance programme for routine use with the 
assay. The new ELISA includes use of:
• pre-dilution of sera prior to addition to the wells of the ELISA plate
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• lower dilutions of test sample
• the most appropriate microtitre plates
• the biotin-streptavidin system for the detection of specific antibody
• peroxidase and tetramethylbenzidine for colour development
• four-parameter logistic curve-fitting for assay calibration.
The new ELISA has been optimised by investigating and minimising 
sources of response variance. Hence, assay precision and the limits of 
detection have been defined and improved.
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Materials and methods
Untreated cattle
Twenty-four 3 to 5-month old castrated male and female Friesian (Bos 
taurus) calves were kept loose housed and fed on hay and concentrates in 
Glasgow, U.K. Twenty-one 3 to 9 month old Boran (Bos indicus) calves, kept in 
a similar manner, and 20 adult Boran cattle, extensively managed, were 
maintained in a tsetse-free area of Kenya. These cattle were not treated with 
isometamidium.
Trypanosome-infected steer
A single 5-month old Boran steer, maintained as described above in a 
tsetse-free area of Kenya, was experimentally infected with Trypanosoma 
congolense KETRI 3211. Six weeks later, when the animal had been 
parasitaemic for 5 weeks, serum was collected. The animal was not treated 
with isometamidium.
Cattle treated with isometamidium chloride
Ten 9-month old Boran cattle, maintained as described above, were treated 
with isometamidium chloride (Samorin®, RMB Animal Health Ltd.) by deep 
intramuscular injection in the middle third of the neck at a dose rate of either 0.5 
(5 cattle) or 1.0 (5 cattle) mgkg*1 body weight. None of the cattle had previously 
been treated with isometamidium.
Serum samples
Blood samples were collected by jugular venipuncture into Vacutainers 
(Beckton-Dickinson) without anti-coagulant, and the serum separated by 
centrifugation and stored at -20°C until tested by ELISA.
Isometamidium-ovalbumin conjugate
An isometamidium-ovalbumin conjugate was prepared by diazotization at a 
ratio of isometamidium to ovalbumin of 0.0125:1, as described in Chapter 1.
Sheep anti-isometamidium IgG
Sheep anti-isometamidium IgG was prepared and purified as described in 
Chapter 1. To 1 mg aliquots of IgG was added 20 pg N-hydroxy- 
succinimidobiotin (Sigma) dissolved in 120 pi dimethyl sulphoxide (DMSO; 
Sigma). The mixture was incubated at room temperature for 4 hours and 
dialysed against two changes of phosphate buffered saline (PBS), pH 7.2.
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Biotinylated IgG was lyophilised in 400 pi aliquots and stored at +4°C for up to 6 
months until use. Prior to use, aliquots were reconstituted with sterile distilled 
water to the original volume, and mixed thoroughly with an equal volume of 
glycerol. In this form aliquots of biotinylated sheep anti-isometamidium IgG 
were stored at -20°C between assays for up to 6 weeks without loss of activity.
Bovine serum standards spiked with isometamidium chloride
Normal bovine serum (NBS) was obtained from cattle prior to treatment with 
isometamidium chloride, or from a commercial source (Gibco).
A 500 pgmM solution of isometamidium chloride (Samorin®, RMB Animal 
Health Ltd.) in distilled water was prepared using volumetric glassware, allowing 
time for the compound to dissolve fully, and stored in a dark glass bottle at room 
temperature for not more than 3 days. Before use this solution was further 
diluted 1/10 in distilled water, and diluted again in NBS to a final concentration 
of 1.5 pgmM. From this dilution a threefold serial dilution was performed in 
NBS, with vortex mixing after each transfer and a change of pipette tip after 
every third transfer.
The resulting spiked "standards" contained a range of isometamidium 
concentrations from 500 ngmM to 0.025 ngml*1, and contained not less than 
99% NBS. Standards were stored at 4°C for up to 7 days.
Enzyme-linked immunosorbent assay (ELISA)
Immulon 4 (Dynatech Laboratories Inc., Billingshurst, UK) 96-well microtitre 
ELISA plates were coated overnight at 4°C with 100 pi per well isometamidium- 
ovalbumin conjugate diluted in carbonate-bicarbonate buffer (pH 9.2). Plates 
were washed 5 times with a 1/5 dilution of PBS in distilled water containing 
0.05% (v/v) Tween 20 (Sigma), and blotted dry.
Bovine test sera or spiked NBS standards were pre-diluted 1/20, 1/10, or 
1/6 in biotinylated anti-isometamidium IgG optimally diluted (see below) in PBS 
containing 0.05% Tween 20 (PBST). Pre-dilutions were made in 1.0 ml 
polypropylene tubes racked in an 8 x 12 matrix with identical dimensions to a 
96-well microtitre plate (Microtubes, Alpha Laboratories). Racks of tubes were 
vortex mixed and the contents transferred to the coated microtitre plates by 
multichannel pipetting. Plates were incubated at 37°C on a shaker incubator 
(Varishaker, Dynatech) for one hour and washed as described above.
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A 1/3000 dilution in PBST of streptavidin-horseradish peroxidase (SA-HRP; 
Sigma) was dispensed into every well (100 pl/well), incubated with shaking for 
40 minutes at 37°C, and washed as described above. ELIS As were developed 
using 100 pi per well of substrate/chromogen solution prepared immediately 
before use by slowly adding 120 pi of a 42 mM solution of tetramethylbenzidine 
(TMB; Sigma) in DMSO, to 12 ml of 0.1 M sodium acetate/citric acid buffer (pH 
6.0), and adding hydrogen peroxide to a final concentration of 1.3 mM (17.5 pi 
of a 3% v/v solution). Ten minutes after adding this solution, the reaction was 
quenched with 100 pi per well of 2 M sulphuric acid.
Absorbances were read in a multichannel spectrophotometer (Multiskan 
Plus Mk 11, Labsystems, Oy, Finland) connected to a personal computer 
(Personal System/2 Model 50 Z, IBM). Calculations were performed using 
spreadsheet software (1-2-3 version 3.1, Lotus Development Corporation) for 
which various ELISA data analysis macro-language programs were written 
(M.C.E., unpublished).
Optimal dilutions of isometamidium-ovalbumin conjugate and biotinylated 
anti-isometamidium IgG were determined by titration using NBS 
(isometamidium-free) in place of test serum to end-points not less than 0.8 
optical density units.
The principle of this ELISA is illustrated in Plate 7.
Calibration curves
Programmed microcomputer spreadsheets were used for assay calibration 
and calculation of unknowns, using four-parameter logistic curve fitting (Healy, 
1972; Rodbard and Hutt, 1974; Ukraincik and Picknosh, 1981).
Parallelism assays
Serum samples from isometamidium-treated cattle, or isometamidium- 
spiked serum, were serially diluted in NBS, or in serum from a trypanosome- 
infected Boran steer. The concentration of each dilution, determined by ELISA, 
multiplied by the dilution factor (abscissa), was plotted against dilution (ordinate 
axis). Sera were considered to show parallelism when a horizontal line parallel 
with the ordinate axis was obtained.
Intra-sample variance
Intra-sample (intra-assay) response variance (aw2) was estimated using at 
least 20 replicate determinations of a single serum, or using the mean of the
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variances of duplicate wells for at least 20 individual sera whose absorbance 
results fell in a local segment of the calibration curve (Rodbard and Hutt, 1974).
Intra-sample variance associated with pre-dilution of sera
Individual pre-dilutions of NBS were tested in duplicate wells of an ELISA 
plate. Intra-predilution and inter-predilution (intra-assay) variance were 
compared by one way analysis of variance.
Intra-sample variance associated with the solid-phase
Variance associated with the solid-phase was assessed by measuring intra­
sample, intra-pre-dilution, (intra-assay) variance of pooled untreated bovine 
serum at zero-dose. All 96 wells of ELISA plates were treated identically 
through the coating, competition reaction, enzyme-conjugate and colour 
development stages. A single pre-dilution sufficient for all 96 wells (100 pi per 
well) was used.
The mean, standard deviation and coefficient of variation (CV) of the 
absorbances of entire plates, individual rows, columns, and quadrants of wells 
of plates, and non-edge and edge wells were calculated and compared. This 
procedure which was termed a "whole-plate B0 CV test", B0 representing the 
absorbance at zero-dose.
Inter-sample variance
Inter-sample (intra-assay) variance of the mean absorbances of duplicate 
determinations, ax2, was measured at zero-dose by testing untreated Friesian 
and Boran sera in the isometamidium ELISA in duplicate wells. Using aw2, 
calculated as described above from the mean of the variances of duplicate 
wells, cb2, the true inter-sample (intra-assay) variance was calculated from the 
equation:
ax2 = ab2 + aw2/r 1.
(Rodbard, 1974) where r is the number of replicate wells for each serum 
sample.
The significance of the difference between ab2 and aw2 was tested by one 
way analysis of variance.
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Plate 7. The four stages of indirect 
competition ELISA for the detection of 
isometamidium. Between each stage, unbound 
reagents are removed by washing.
a) The wells of a 9 6-well polystyrene 
microtitre ELISA plate are coated by passive 
adsorption of drug (isometamidium) conjugated 
to a carrier protein (ovalbumin).
b) The sample, containing an unknown 
quantity of drug, is incubated in the ELISA plate 
wells, together with a fixed quantity of 
biotinylated specific anti-drug IgG. Sample 
drug competes for specific antibody, reducing 
the amount available to bind to the immobilised 
drug-conjugate.
c) Streptavidin-horseradish peroxidase is 
used to detect biotinylated antibody.
d) In the presence of peroxidase and 
hydrogen peroxide, colourless
tetramethylbenzidine is converted into a 
coloured product.
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Results
Background reactions
Absorbances of background control wells from which specific IgG had been 
omitted from the PBST used to predilute test serum, and absorbances obtained 
using spiked standard sera containing excess isometamidium (500 ngml-1) were 
at most 10% of the zero-dose absorbance (B0); usually background reactions 
were 5% B0, or less.
Reagent titrations
The biotin-streptavidin system with TMB resulted in significantly higher 
absorbances than were obtained with the earlier ELISA method (Whitelaw et a/., 
1991). This allowed the use of higher dilutions of isometamidium-ovalbumin 
conjugate and anti-isometamidium IgG which significantly reduced the 
concentration of isometamidium at which B/B0 = 50% (B/B0 represents 
absorbance divided by B0l x 100%, after correction for background).
Calibration curves
Good curve fitting was obtained using the four-parameter logistic method, at 
all 3 dilutions of serum tested (1/6, 1/10, 1/20). A typical calibration curve 
obtained by this method is shown in Figure 1. The calibration curve varied with 
the dilution of serum used, so that the concentration at B/B0 = 50% increased 
with increasing serum dilution.
Parallelism assays
The assay showed parallelism when a) sera from isometamidium-treated 
Boran cattle, b) isometamidium-spiked untreated Boran calf sera, or c) 
isometamidium-spiked untreated Friesian calf sera, were diluted in commercial 
NBS (Gibco). Parallelism was also obtained when isometamidium-spiked 
untreated Boran calf serum was diluted in serum from a trypanosome-infected 
Boran steer.
Intra-sample variance
The numerical value of aw2 at zero-dose varied between individual assays, 
as did the mean zero-dose absorbances (B0). However, the corresponding CVs 
{gJB0 x 100%) were consistently between 5% and 10%. Results for sera from 
40 untreated Friesian calves, tested at 3 dilutions in the isometamidium ELISA, 
are shown in Table 6.
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At dose levels other than zero, ctw2 varied with absorbance, so that intra­
sample CVs were similar over most of the response range of the assay (data 
not shown). With the highest isometamidium concentrations aw2 was very small, 
although the corresponding CVs were sometimes greater than 10%.
Intra-sample variance associated with pre-dilution of sera
No significant difference was found between intra-predilution and inter­
predilution variance (p > 0.1). Hence the preparation of pre-dilutions did not 
make a significant contribution to intra-sample variance.
Intra-sample variance associated with the solid-phase
Whole plate B0 CVs between 5% and 10% were obtained. Very 
occasionally larger CVs occurred, in which case examination of the mean, 
standard deviation and CV of absorbances over various parts of the plate 
usually allowed identification of non-Gaussian error suggestive of pipetting 
error.
Inter-sample variance
Zero-dose values of ax2 varied between assays. However, the 
corresponding CVs (a jB0 x 100%) remained about 10%. Values for 24 
untreated Friesian calves, 21 untreated Boran calves, and 20 untreated adult 
Boran cattle are shown in Table 7. CVs derived from the variance components 
aw2 and ab2 (aJB0 x 100% and gJBq x  100%, respectively), calculated for 40 
untreated Friesian calf sera tested in duplicate at 3 different dilutions, are 
shown in Table 6. The difference between aw2 and ab2 was shown by analysis of 
variance to be significant (p < 0.01) at all 3 serum dilutions.
Samples from isometamidium-treated cattle
Mean serum isometamidium concentration profiles for two groups of Kenyan 
Boran cattle injected intramuscularly with isometamidium at 0.5 mgkg-1 (n = 5) 
and 1.0 mgkg-1 (n = 5) body weight are shown in Figure 2. An initial peak within 
the first 24 hours following treatment was followed by a smooth pattern of 
disappearance of drug which was similar at both dose rates. The rate of drug 
disappearance varied with time; the initial peak was followed firstly by a phase 
of relatively rapid reduction in concentration, then by a phase of more gradual 
decline. Isometamidium could be detected in sera for at least 140 days after 
treatment.
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Table 6. Intra-sample (intra-assay) and inter-sample (intra-assay) 
variance components, expressed as coefficients of variation, CVW and 
CVb , calculated for 40 isometamidium-free sera from normal Friesian 
calves tested in duplicate at 3 dilutions in the isometamidium ELISA; and 
inter-sample (intra-assay) coefficients of variation of the mean response
for r replicates (CVX).
Serum Dilution
1/6 1/10 1/20
CVW 7.2% 8.2% 7.8%
CVb 9.5% 9.3% 6.0%
c v x
r = 1 11.9% 12.4% 9.8%
2 10.8% 11.0% 8.1%
3 10.4% 10.4% 7.5%
4 10.2% 10.2% 7.2%
5 10% 10% 6.9%
Infinity 9.5% 9.3% 6.0%
CVW, CVb , CVX were calculated from the corresponding standard deviations ow, ab, ax using CV = <r 
/B0 x 100% where B0 is the overall mean response for isometamidium-free sera calculated for each 
ELISA plate.
CVX was calculated using <rx2 = cb2 + cw2/r.
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Table 7. Inter-sample (intra-assay) coefficients of variation (CVX) for the 
means of duplicate determinations for sera from untreated Boran and
Friesian cattle.
No. CVX(%)
Friesian calves 24 9.3%
Boran calves 21 9.4%
Boran adults 20 8.9%
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Figure 1. Calibration curve fitted by four-parameter logistic method.
a=1.331, b=1.3343, c=0.6579, d=0.0810
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Figure 2. Pharmacokinetic profiles of healthy Boran cattle treated with 0.5 and 
1.0 mgkg-1 isometamidium chloride (Samorin®) by deep intramuscular injection.
100-1
0.5 mg/kg (n=5)10 -
1 -
0.1
100
1.0 mg/kg (n=5)10 -
0.1
1500 10050
Days post injection
112
Discussion
The development of a new isometamidium ELISA, described here, has 
enabled many constraints on an earlier method (Whitelaw et a i , 1991) to be 
overcome. Furthermore, it has also allowed statistical parameters of assay 
performance to be defined, enabling the new ELISA to be validated for use on 
field samples in Africa.
Two years of experience with isometamidium ELISA development, both in 
the United Kingdom and in Africa, has revealed a number of serious limitations 
to the earlier method. Three aspects particularly unsuitable for large-scale 
testing of field samples were the methods of dispensing and dilution of serum 
samples and standards; the occurrence of unacceptably high background 
reactions; and the methods of assay calibration and data reduction. In the new 
assay, these 3 aspects have been modified appropriately, and in addition, 
quality assurance has been addressed by statistical analysis.
The isometamidium ELISA method described in this Chapter may be 
referred to as an indirect competition ELISA (ICE) by analogy with the indirect 
ELISA, of which it is essentially a modification. In the indirect ELISA, specific 
antibody is quantified by incubation with a predetermined quantity of antigen is 
adsorbed onto a solid-phase, unbound non-specific antibody removed by 
washing, and subsequent incubation first with an suitable enzyme-conjugated 
anti-globulin reagent, and secondly with a chromogenic substrate solution 
(Tijssen, 1985).
In the indirect competition ELISA (see Plate 7) the total quantity of specific 
antibody is also fixed, but the amount available to bind to the immobilised 
antigen may be modulated by the presence of analyte - essentially the same (or 
closely related) antigen in the liquid phase. Because the specific antibody is 
added in a fixed quantity from a defined source, rather than in unknown quantity 
from a biological sample, it is also possible to label the specific antibody 
reagent, in this case with biotin. Enzyme-conjugated streptavidin, rather than a 
conjugated anti-globulin reagent may then be used as the antibody detection 
system.
The biotin-streptavidin system for detection of specific antibody has a 
number of advantages over the use of an anti-globulin reagent. Firstly, the 
system is extremely sensitive and efficient, as the dissociation constant for the 
biotin-streptavidin interaction is one of the smallest known, at approximately IQ-
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15 (Tijssen, 1985). Secondly, streptavidin is more specific than anti-globulin 
reagents, which may cross react with immunoglobulins of animal species other 
than that against which they were raised. Finally, unlike anti-globulin reagents, 
which may vary between batches (unless monoclonal), streptavidin is a single 
defined molecule of consistent affinity and specificity.
The cause of unacceptably high background reactions observed with the 
earlier isometamidium ELISA method (Whitelaw et a i, 1991) was probably 
detection by anti-sheep IgG conjugate of bovine IgG adsorbed on the solid- 
phase. Evidence for this is that when PBST or foetal calf serum was substituted 
for bovine serum samples in the earlier isometamidium ELISA method, 
background reactions remained below 10% B0; additionally, polyclonal anti­
sheep IgG enzyme conjugates from a variety of sources cross-reacted strongly 
with bovine IgG (unpublished observations). Use of streptavidin enzyme- 
conjugate to detect biotinylated anti-isometamidium IgG overcame this problem. 
Biotinylated IgG was stable at 4°C for at least 6 months after lyophilisation, 
which is important in the context of use in, and delivery to, African laboratories 
where cold chain continuity may be unreliable.
Four-parameter logistic curve-fitting was found to be a suitable method of 
assay calibration, and is preferable to linear interpolation or the logit-log method 
(Ukraincik and Picknosh, 1981; Rodbard,1974 ). The use of a three-fold 
dilution series for the standards resulted in a greater number of data points 
within the dynamic range of the assay, compared to the 10-fold dilutions used 
with the earlier method (Whitelaw et al., 1991). This improved the reliability of 
the calibration curve.
The ELISA plates chosen for use in the new isometamidium ELISA 
(Immulon 4; Dynatech) were those which consistently had the lowest overall CV 
(5-10%), out of 9 types of plate from 4 major manufacturers (unpublished data). 
The plates chosen carried a manufacturer’s guarantee of CV, suggesting future 
batches could be expected to be of similar quality to those tested. They were 
also physically robust, an advantage for transportation in developing countries.
The variance of the means, ax2, of replicate determinations of a number of 
different untreated sera comprised an inter-sample component, ab2, attributable 
to non-specific effects of serum matrix components, and an intra-sample 
component, aw2, attributable to pipetting error and variation between wells of 
ELISA plates. Estimates of ax2 and aw2 were calculated, respectively, as the 
variance of mean responses, and the mean of variances of duplicates, of a
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representative sample of the untreated cattle population. Using Equation 1, ab2 
was calculated from ctx2 and aw2 (Rodbard, 1974).
From ab2 and aw2, the variance of the mean response ax2 could be predicted 
for any number of replicates (r) by substituting new values for r in Equation 1 
(Rodbard, 1974). Increasing r diminishes the term aw2/r, and as r -+  oo, ax2 tends 
to its limiting value ob2. Unless ab2 is considerably less than crw2, increasing r will 
have limited effect on ax2, and hence on assay precision. From Table 6 it may 
be observed that only a small decrease in CV of the mean (aJB0 x 100%) would 
be achieved by increasing the number of replicates from one to two; with 
further increases in r, increases in CV would be progressively smaller. Even 
with an infinite number of replicates only a limited decrease in CV would be 
possible. The use of duplicate wells is nevertheless worthwhile as it enables a 
w2 to be calculated as an ongoing, in-built quality control, and it facilitates 
identification of non-Gaussian or "catastrophic" errors (Chard, 1990), which may 
occur as a result of pipetting mistakes.
Using ax, r, and the assay calibration curve, the least detectable dose may 
be derived from the appropriate percentile of Student's t-distribution at the 
desired probability level. Using a modification of Rodbard's (1978) method, to 
allow for inter-sample variance, the least detectable dose for cattle within the 
populations tested in this work was approximately 0.1 ngmM.
A single dose of isometamidium may afford up to 6 months prophylaxis to 
cattle challenged by fully susceptible isolates of T. congolense (Whitelaw, Bell, 
Holmes, Moloo, Hirumi, Urquhart and Murray, 1986), although drug-resistant 
trypanosome stocks may result in break-through infections as little as one 
month following isometamidium treatment (Sutherland, Moloo, Holmes and 
Peregrine, 1991). lon-pair high performance liquid chromatography, the most 
sensitive technique described to date, detected isometamidium for only a few 
hours in treated cattle (Kinabo and Bogan, 1988). Hence in the investigation of 
isometamidium resistance the ELISA, which quantified drug levels for at least 
140 days, represents a significant improvement over earlier methods.
These investigations have shown the new isometamidium ELISA to be a 
powerful, sensitive and reproducible technique for the quantification of the drug 
in bovine sera. An integral calibration and quality assurance software package 
incorporating the data reduction and statistical analyses described here is 
envisaged for use with the assay. Potential uses of the assay include the 
development of rational chemoprophylactic drug regimens; the detection of
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isometamidium resistance in the field, by showing levels of drug normally 
considered to be prophylactic in the serum of parasitaemic animals; laboratory 
investigations on chemoprophylaxis in vivo; the extension of its use to other 
species and other biological fluids, enabling detection of isometamidium 
residues in meat and animal products; and investigation of suspected 
inappropriate use of trypanocides. Further work to validate the assay using 
field samples from trypanosomiasis endemic areas of Africa is described in later 
chapters.
Chapter 4:
Isometamidium concentrations in the sera of Boran 
cattle: correlation with prophylaxis against tsetse- 
transmitted Trypanosoma congolense
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Introduction
More than thirty years after the introduction of the trypanocidal drug 
isometamidium chloride (Berg, 1960) for prophylaxis and therapy of tsetse- 
transmitted trypanosomiasis in domestic livestock, its use remains the most 
widespread control strategy for this disease (Leach and Roberts, 1981; Holmes 
and Torr, 1988; Sones et al.t 1988; Jordan, 1992). In recent years, there has 
been increasing concern regarding the potential development of drug resistance 
in pathogenic trypanosomes (Sutherland and Holmes, 1991), and although this 
has been shown to occur in a number of situations (Kupper and Wolters, 1983; 
Pinder and Authie, 1984; Ainanshe et a!., 1992), the true prevalence of 
resistance remains largely unknown because of the lack of appropriate field 
tests.
A wide range has been reported in the prophylactic period afforded by 
intramuscular isometamidium chloride under field conditions of use. In studies 
conducted in the decade following the introduction of the drug, doses of 0.5 to 
1.0 mgkg-1 body weight afforded prophylaxis against natural tsetse challenge for 
periods as long as 14 to 36 weeks (Robson, 1962; Fairclough, 1963; Kirkby, 
1964; Wiesenhutter e ta i, 1968). More recently, however, prophylactic periods 
as short as 2 to 3 weeks have been observed (Dolan et a i, 1992, Munstermann 
et a/., 1992). When prophylactic periods are reduced in the field, the 
emergence of drug-resistant strains of trypanosomes is frequently suspected. 
However, when studying the variation in the duration of prophylaxis, it has not 
previously been possible to assess the relative contributions of either drug- 
resistance levels in trypanosomes, or of variability in drug levels. Measurement 
of drug resistance levels in trypanosomes is rarely possible under field 
conditions, for economic and logistical reasons (Sutherland and Holmes, 1991), 
and variability in drug levels has not been determined due to the lack of a 
method capable of measuring serum isometamidium concentrations during the 
prophylactic period.
The development of an enzyme-linked immunosorbent assay (ELISA) for 
the measurement of isometamidium concentrations in the sera of treated cattle 
(Chapter 3) has therefore provided a method which may contribute to the 
assessment of the relative importance of these factors. In order to evaluate 
data obtained using the ELISA on samples from the field, base-line data on the 
relationship between circulating drug concentrations and susceptibility to 
trypanosome infection is clearly required. This chapter describes an
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experiment in which the isometamidium ELISA described in Chapter three was 
used to investigate concentrations of the drug in the sera of Boran cattle under 
controlled laboratory conditions, which were challenged with stocks of T. 
congolense of varying susceptibility to the drug, by the application of 
experimentally-infected tsetse flies at regular intervals following administration 
of a single prophylactic dose.
119
Materials and methods
Cattle
Boran (Bos indicus) cattle were obtained from a trypanosomiasis-free area 
of Kenya, housed in fly-proof accommodation and fed on hay and concentrate 
as described by Whitelaw et al. (1986), and allowed water ad libitum.
Isometamidium administration
Isometamidium chloride (Samorin®) was administered at a dose rate of 1.0 
mgkg-1 body weight, by deep intramuscular injection of a 2% (w/v) aqueous 
solution into the middle third of the neck.
Blood samples
Blood samples for use in the isometamidium-ELISA were collected by 
jugular venipuncture into Vacutainers (Becton-Dickinson) prior to 
isometamidium treatment; daily for the first week after treatment, twice weekly 
for a further 2 weeks, and weekly thereafter. Sera were separated and stored in 
borosilicate glass tubes (Vial Files, Jencons Scientific Ltd., Leighton Buzzard, 
UK) at -60°C. Blood samples for monitoring of infections were collected three 
times weekly, as described above, into Vacutainers (Becton-Dickinson) 
containing potassium ethylenediamine tetra-acetate.
Trypanosomes
Three isolates of T. congolense were used to challenge cattle. T. 
congolense IL 3893 is a stock derived from an Ethiopian isolate: IL 3330 (Codjia 
et al., 1993). T. congolense IL 3889 is a derivative of KETRI 3302/E36, isolated 
at Nguruman, Kenya (Gray, Kimarua, Peregrine and Stevenson, 1993). T. 
congolense IL 1180 is a well-characterised, doubly cloned, derivative of an 
isolate made from a lion in the Serengeti National Park, Tanzania (Geigy and 
Kauffmann, 1973; Nantulya et al., 1984; Whitelaw et al., 1986; Peregrine et al., 
1988).
Infected tsetse flies
Six weeks before each challenge, goats were inoculated intramuscularly 
with one of the 3 isolates of T. congolense. Twelve to 14 days later, 
trypanosomes were detected in peripheral blood. Commencing a further 7 days 
later, teneral Glossina morsitans centralis were fed daily on the infected goats 
for 25 days. Flies were then starved for 2 days, and monitored for infection by
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microscopic examination of salivary probes. Tsetse flies with metacyclic 
trypanosomes in their saliva were used to challenge cattle (see Plate 4).
Parasitological monitoring
Following challenge, cattle were monitored for the appearance of 
trypanosomes using the phase-contrast buffy-coat technique (Murray et al., 
1977).
Isometamidium standards
Sera were collected from 33 Boran cattle (including the 25 experimental 
cattle, see below), prior to isometamidium treatment of any animal. Sera were 
pooled to provide a large batch for preparation of isometamidium-spiked 
standards for use in the ELISA. The pool was considered suitable for preparing 
standards as the mean absorbance for the pool in the isometamidium ELISA 
(see below) was similar to the mean of the absorbances for the individual sera. 
Standards were prepared as described previously (Chapter 3), aliquoted into 
microplate-format racked tubes (Microtubes, Alpha Laboratories), and stored at 
4°C until use.
Isometamidium determinations
Sera collected following isometamidium treatment were tested using the 
indirect competition ELISA for isometamidium (Chapter 3). Briefly, microtitre 
plates (Immulon 4, Dynatech) were coated by overnight incubation of 100 pi per 
well of a 1/2000 dilution of isometamidium-ovalbumin conjugate in carbonate- 
bicarbonate buffer (pH 9.2). Plates were washed 5 times using a 1/5 dilution of 
phosphate-buffered saline (PBS), pH 7.2, in distilled water containing 0.05% 
Tween 20 (Sigma), and blotted dry. Test sera, standards, and quality control 
sera were pre-diluted 1/10 in a 1/2400 dilution of biotinylated sheep anti- 
isometamidium IgG in PBS containing 0.05% Tween 20 (PBST), and vortex 
mixed. Each pre-dilution was added to duplicate wells of microtitre plates (100 
pi per well) which were incubated and shaken at 37°C for 1 h. Plates were then 
washed 5 times as described above, 100 pi of a 1/3000 dilution of 
streptavidin:horseradish peroxidase conjugate (Sigma) in PBST was added to 
every well, and plates were incubated and shaken at 37°C for 45 minutes. 
Plates were thereafter washed 5 times as described above, and 100 pi per well 
added of a solution containing 120 pi of 42 mM tetramethylbenzidine (TMB; 
Sigma) in dimethyl sulphoxide (Sigma), 12 ml of 0.1 M sodium acetate/citric acid 
buffer (pH 6.0), and hydrogen peroxide to a final concentration of 1.3 mM. Ten
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minutes later the reaction was quenched with 100 pi per well of 2 M sulphuric 
acid.
Absorbances were read using a multichannel spectrophotometer (Multiskan 
MCC Mk II, Labsystems), connected to a personal computer (386SX, AST).
Data analysis
Isometamidium concentrations in sera of treated cattle were calculated from 
the ELISA optical densities, with reference to the optical densities of 
isometamidium standards, using 4-parameter logistic curve fitting. Four- 
parameter logistic calibration curve-fitting, precision profiling, and calculation of 
drug concentrations of unknown samples, were performed using spreadsheet 
software (Lotus 1-2-3 R3.1) specifically written for this purpose (M.C.E., 
unpublished).
Drug profiles were fitted to a bi-exponential model by iterative curve 
stripping (Dunne, 1986), using the computer programme JANA (SCI Software, 
Lexington, KY, USA). Prepatent periods of infection in cattle were compared 
using the Wilcoxon rank sum test (Ott, 1988).
Experimental design
Twenty-five cattle were divided into 3 groups of 5 animals each (groups 1, 2 
and 3), and a further group of 10 animals (challenge controls). At the start of 
the experiment all cattle in groups 1, 2 and 3 received isometamidium. 
Isometamidium-treated cattle were then challenged repeatedly with one of 3 
different T. congolense populations at monthly intervals until they were detected 
parasitaemic; animals with patent infections were not challenged further. Cattle 
were challenged by the application of 5 7. congolense-infected tsetse flies (see 
Table 8). Cattle in Group 1 were challenged with 7. congolense IL 3893, 
Group 2 cattle were challenged with 7. congolense IL 3889, and Group 3 cattle 
were challenged with 7. congolense IL 1180. Challenge controls were used to 
confirm the infectivity of the tsetse flies: one for each challenge with each 7. 
congolense population. Details of the experimental design are summarised in 
Table 8.
122
Results
Parasitological findings
All cattle challenged with T. congolense IL 3893 (Group 1 and challenge 
control no. 16) and all cattle challenged with T. congolense IL 3889 (Group 2 
and challenge control no. 17) became parasitaemic following the initial monthly 
challenge (Table 9). By contrast, all cattle in Group 3, challenged with T 
congolense IL 1180, remained aparasitaemic following the first 5 monthly 
challenges, although challenge control animals (nos. 18 - 22) became infected 
after every challenge (Table 9).
The first trypanosomes detected in a Group 3 animal (no. 11) occurred 
following the sixth monthly challenge (Table 9). Two further animals in Group 3 
(nos. 12 and 13) became parasitaemic following the seventh monthly challenge. 
The remaining 2 cattle (nos. 14 and 15) became parasitaemic following the 
eighth monthly challenge (Table 9).
There were notable differences in the prepatent periods of infection (PPI) 
between animals in groups 1, 2 and 3 (Table 9); i.e., the time between 
challenge and first detection of trypanosomes. Group 1 animals were first 
detected parasitaemic 16 to 18 days following challenge. Group 2 animals 
exhibited significantly longer PPIs (p < 0.025), with trypanosomes not detected 
until 25 to 35 days following challenge. All cattle in groups 1 and 2 exhibited 
longer PPIs than the corresponding challenge controls, no. 16 (14 days) and 
no. 17 (11 days), respectively.
In Group 3 animals, challenged with T. congolense IL 1180, PPIs (mean, 
20.2 days) were significantly longer (p < 0.025) than the PPIs (mean,13.9 days) 
of the corresponding challenge controls (Group 6; Table 9). There was, 
however, some overlap in the range of PPIs for Group 3 (range, 1 5 - 3 2  days) 
and the corresponding controls (range, 1 3 - 1 5  days). Finally, the lengths of the 
PPIs for animals in Group 3 appeared to be related to the number of challenges 
an animal received before trypanosomes were detected; earlier break-through 
infections were associated with longer PPIs.
Drug profiles
The highest isometamidium concentrations, approximately 40 - 50 ngmM, 
were observed at the time of the first sampling, 24 hours following 
isometamidium administration. Serum concentrations then fell relatively rapidly
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for about 8 days post-treatment, and thereafter rather more gradually (Figures 1 
and 2). The mean serum drug concentrations in animals in all 3 groups were 
similar for the first 6 weeks following treatment, after which drug concentrations 
fell more rapidly in those cattle which succumbed to infection following the first 
tsetse challenge (groups 1 and 2). At the time of the first monthly challenge the 
mean isometamidium concentration in all three groups of treated cattle (groups 
1, 2 and 3) was 6.1 ngmM (range, 2 .8 -12  ngmM). By 100 days after treatment, 
serum drug concentrations in groups 1 and 2 had reached the limit of detection 
of the assay (0.1 - 0.2 ngmM). However, at that time, the mean drug 
concentration in Group 3 cattle was 0.75 ngmM (range, 0.51 - 0.89 ngmM), 
which was still well within the dynamic range of the assay.
The results of bi-exponential curve-fitting using the mean results for each of 
the 3 isometamidium-treated groups of cattle are shown in Table 10. Prior to 
the detection of parasites (days 0 - 45, 0 - 59 and 0 -104 for groups 1, 2 and 3, 
respectively), isometamidium concentrations in all treated groups closely fitted 
the bi-exponential model (R2 greater or equal to 0.98). Half-lives for the second 
phase were 29.4 days for Group 1, 22.5 days for Group 2, and 23.9 days for 
Group 3. Isometamidium concentrations in Group 3 cattle closely fitted the bi­
exponential model (R2, 0.99) over the entire period of measurement (days 0 - 
104, Figure 3). However, groups 1 and 2 showed divergence from the bi­
exponential model after times which corresponded with the appearance of 
trypanosomes (days 48 and 60 for groups 1 and 2, respectively [Figure 4]). 
Following the development of patent parasitaemias, therefore, the bi­
exponential model was no longer considered appropriate. An estimate of the 
new rate of disappearance of isometamidium over this period (days 52 - 104 
and days 62 -104 for groups 1 and 2, respectively) was obtained by performing 
linear regression (log mean concentrations on time post-treatment). This gave 
apparent drug elimination half-lives of approximately 14 days for both groups 
(R2 values both 0.92; Table 10 and Figure 4).
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Table 8. Experimental design: challenge groups
i.m. = intramuscular treatment.
Group Number 
of Cattle
Isometamidium 
Prophylaxis 
(1 mgkg-1 i.m.)
Challenge:
T. congolense 
stock
Number of cattle 
challenged each 
month*
1 5 + IL 3893 5
2 5 + IL3893 5
3 5 + IL 1180 5
Challenge
control
1 - IL3893 1
Challenge
control
1 - IL 3889 1
Challenge
control
8 - IL 1180 1
•Cattle challenged at monthly intervals until trypanosomes detected.
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Table 9. Outcome of tsetse challenge of isometamidium-treated Boran
cattle
CC = challenge control. PPI = prepatent period of infection; n.a. = not applicable
Group Animal number T. congolense 
challenge
PPI (days) Month of# 
challenge
1 1 IL 3893 16 1
1 2 IL 3893 16 1
1 3 IL 3893 16 1
1 4 IL 3893 18 1
1 5 IL 3893 18 1
mean 16.8 1
2 6 IL 3889 25 1
2 7 IL 3889 28 1
2 8 IL 3889 28 1
2 9 IL 3889 28 1
2 10 IL 3889 35 1
mean 28.8 1
3 11 IL 1180 32 6
3 12 IL 1180 18 7
3 13 IL 1180 21 7
3 14 IL 1180 15 8
3 15 IL 1180 15 8
mean 20.2 7.2
CC 16 IL 3893 14 1
CC 17 IL 3889 11 1
CC 18 IL 1180 14 1
CC 19 IL 1180 13 2
CC 20 IL 1180 15 3
CC 21 IL 1180 14 4
CC 22 IL 1180 13 5
CC 23 IL 1180 15 6
CC 24 IL 1180 14 7
CC 25 IL 1180 13 8
mean 13.9 n.a.
*Month of challenge resulting in infection.
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Table 10. Bi-exponential curve fitting and linear regression results for 
isometamidium concentration data.
Days = period of observations; n = number of observations; 
t% = half life; R2 = correlation co-efficient; ND = not determined.
Group 1 Group 2 Group 3
Bi­
exponential 
curve fitting:
Days 0 -4 5 0 - 5 9 0 -1 04
n 15 17 24
t* 29.4 22.5 23.9
R2 0.98 0.98 0.99
Linear
regression:
Days 52-104 62-104 ND
n 9 7 ND
t* 14.1 13.8 ND
R2 0.92 0.92 ND
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Figure 3. Mean isometamidium concentrations (ngml*1) in the sera of cattle 
challenged with T. congolense IL 1180 (Group 3). Line represents bi-exponential 
curve-fit. Tsetse fly symbols: T. congolense challenge.
100
10
1
0.1
0 20 40 60 80 100 120
Days post-injection
128
Figure 4. Mean isometamidium concentrations (ngml*1) in the sera of cattle 
challenged with T. congolense EL 3893 (Group 1), open symbols, and T. congolense 
EL 3889 (Group 2), closed symbols. Long lines: bi-exponential curve-fits. Short 
lines: linear regression. Lower long line and lower short line: Group 1. Upper long 
line and upper short line: Group 2. Tsetse fly symbol: T. congolense challenge.
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Discussion
In this experiment, all isometamidium-treated cattle challenged with 7. 
congolense IL 3893 or T. congolense IL 3889 became infected following the first 
monthly challenge, whilst those challenged with 7. congolense IL 1180 resisted 
at least 5 monthly challenges. Following treatment, isometamidium was 
detected in the serum of all the treated cattle for up to 3 months. Analysis of the 
pharmacokinetic profiles indicated that the development of parasitaemia was 
associated with accelerated drug elimination. The results therefore show that 
the isometamidium-ELISA is useful in the determination of isometamidium 
concentrations in the sera of treated cattle, and in correlating these 
concentrations with protection against isolates of T. congolense with various 
levels of drug resistance.
The three isolates of 7  congolense used to challenge cattle were chosen 
on the basis that they possessed differing levels of resistance to 
isometamidium. T. congolense IL 3893, which has been shown to possess a 
high level of resistance to a number of trypanocides, including isometamidium 
(Codjia et al., 1993), infected all challenged animals one month following 
treatment. 7. congolense IL 3889, isolated at a field site (Nguruman, Kenya) 
where resistant trypanosomes are believed to occur, was expected to show an 
intermediate level of resistance on the basis of in vitro tests (Gray et al., 1993), 
but behaved similarly to 7. congolense IL 3893 in that no animal withstood 
challenge one month post-treatment. Finally, intramuscular doses of 
isometamidium chloride at 1.0 mgkg-1 body weight have been shown to protect 
cattle against tsetse challenge with 7  congolense IL 1180 for up to 6 months 
(Whitelaw et al., 1986; Peregrine et al., 1988); the population behaved similarly 
in this experiment.
Although break-through infections with both 7. congolense IL 3893 and 
7. congolense IL 3889 occurred at the same stage of the experiment in 
isometamidium-treated cattle, differences in the PPIs indicated a difference in 
the resistance of these isolates. The prolonged PPI in treated cattle challenged 
with 7. congolense IL 3889 (mean 28.8 days), compared with 7. congolense IL 
3893 (mean 16.8 days), may suggest that although both parasite populations 
were resistant, the growth rate of the former population was initially relatively 
low due to a high drug concentration present at the time of challenge. 
Thereafter, the rate may have gradually increased as drug concentrations 
declined. Alternatively, differences in PPI may reflect elimination of different
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percentages of the initial infective metacyclic inoculum by isometamidium. The 
absence of antibody responses, skin reactions or local lymph node enlargement 
at the site of application of tsetse, following experimental T. congolense 
challenge of cattle rendered refractory to infection by isometamidium (Whitelaw 
e ta i , 1986), suggests that the drug exerts its effect on the parasites at the level 
of the skin.
The drug profiles in isometamidium-treated cattle were similar to those 
obtained previously in uninfected cattle (Chapter 3). Prior to the development 
of parasitaemias, the half-life (approximately 25 days) of the second phase of 
the disposition curves was similar to that previously described. The ELISA was 
thus shown to be reproducible and reliable.
Studies in cattle using the ELISA (M.C.E., unpublished), and high- 
performance liquid chromatography (Kinabo and Bogan, 1988), have shown 
that the maximum drug concentration occurs within 45 minutes of intramuscular 
administration of isometamidium. In the experiment described here, drug 
concentrations decreased with time after treatment. This suggested that the 
maximum drug concentration had preceded the first sampling at 24 h.
In cattle which were detected parasitaemic following the first tsetse 
challenge (groups 1 and 2), disappearance of drug was more rapid following the 
onset of parasitaemia than in cattle which resisted challenge over the same 
period (Group 3). The apparent half-life of the drug in animals detected 
parasitaemic with either T. congolense IL 3893 or T. congolense IL 3889 was 
approximately 14 days. (Drug concentrations at the time of, or following, break­
through infections with T. congolense IL 1180 were not determined). The 
increase in the rate of drug elimination following the development of patent 
infections may have resulted from direct interaction between the drug and the 
parasites. For example, in other work, one h after T. congo/ense-infected 
calves had been treated with 14C-labelled homidium bromide, when blood 
counts had reached a peak, 80% of the radioactivity was bound to 
trypanosomes (Gilbert, Curtis and Newton, 1979). However, since the tissue, 
blood levels, and excretion of radioactivity were similar in calves whether or not 
they were infected at the time of drug administration this would suggest that the 
trypanosomes did not have a significant effect on the drug pharmacokinetics. 
Similarly, isometamidium's period of prophylaxis in cattle was shown to be 
independent of the presence or absence of T. congolense at the time of 
administration (Peregrine et al., 1988). However, the pharmacodynamics of the
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trypanocides in these experiments, in which pre-existing infections were rapidly 
cleared by trypanocide, would have been very different to the present 
experiment, in which infections with drug-resistant parasites became 
established in spite of significant serum drug concentrations.
Increased drug elimination following patent infection may also have 
occurred as a result of changes in the pathophysiological state of the host For 
example, anaemia, increased circulating fluid volume, and changes in the 
composition of plasma proteins and lipids, which could alter the 
pharmacokinetics of isometamidium through changes in drug binding and 
distribution, have been documented in 7. congolense infections in ruminants 
(Katunguka-Rwakishaya, Murray and Holmes, 1992a, 1992b).
The mean isometamidium concentration in serum of cattle in groups 1, 2 
and 3 on the day of the first monthly challenge was 6.1 ngmM. This 
concentration was insufficient to protect cattle against tsetse challenge with 
either 7. congolense IL 3893 or 7. congolense IL 3889. However, the same 
concentration of drug was protective against challenge with 7. congolense IL 
1180, since cattle remained refractory to infection for a minimum of 4 further 
monthly challenges. Three months after isometamidium injection, the mean 
serum drug concentration in uninfected cattle was 0.75 ngmM, and on the basis 
of the elimination profiles obtained over the first 3 months, drug concentrations 
protective at the time of the fourth and fifth monthly challenges would have been 
even lower. The difference between the lowest mean drug concentration (0.75 
ngmM) determined protective against the sensitive isolate (7. congolense IL 
1180), and the highest mean concentration (6.1 ngmM) withstood by resistant 
populations (7  congolense IL 3893 and 7  congolense IL 3889) was 
approximately eight-fold.
In this study, the ELISA has permitted the relationship between serum 
concentrations of isometamidium and susceptibility to tsetse challenge with 7. 
congolense to be investigated in cattle. The results indicate that trypanosomes 
occurring in the presence of serum concentrations of 6 ngmM or higher are as 
resistant to isometamidium as 7. congolense IL 3893 and IL 3889, and that they 
therefore express marked drug resistance. Trypanosomes occurring where 
serum isometamidium concentrations are greater than 0.75 ngmM, but lower 
than 6 ngmM, are more resistant to isometamidium than 7. congolense IL 1180, 
and would be an indication of moderate drug resistance. Finally, the presence 
of trypanosomes where serum concentrations are below 0.75 ngmM should not
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at present be regarded as evidence of a significant level of drug resistance. 
However, it should be noted that T. congolense IL 1180 is not the most 
isometamidium-sensitive population that has been described (Peregrine, 
Knowles, Ibitayo, Scott, Moloo and Murphy, 1991).
The information obtained in the studies described in this chapter will enable 
interpretation of data arising from use of the isometamidium ELISA on serum 
samples taken from cattle under chemoprophylactic regimens in the field, 
thereby enabling investigations on the prevalence of trypanosomes of various 
degrees of resistance to isometamidium in such circumstances. The following 
chapter describes further work to investigate the relationship between 
circulating isometamidium concentrations and prophylaxis against T. 
congolense, using a cloned stock with a level of sensitivity to isometamidium 
intermediate between that of T. congolense IL 1180, and those of T. 
congolense IL 3893 and T. congolense IL 3889.
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Chapter 5:
Concentrations in the Serum of Boran Cattle of the 
Trypanocidal Drug Isometamidium Chloride Protective 
Against Tsetse Challenge with a Trypanosoma 
congolense Clone Possessing an Intermediate Level of
Drug Resistance
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Introduction
The ELISA for the detection and measurement of concentrations of the 
trypanocidal drug isometamidium chloride in the serum of treated cattle 
described in Chapter 3 has provided a valuable new method to enable the 
relationship between drug concentrations and prophylaxis against tsetse 
transmitted trypanosomiasis to be investigated. In an experiment, using tsetse 
challenge of Boran cattle with three stocks of Trypanosoma congolense under 
controlled laboratory conditions, an eight-fold difference was shown between 
the highest serum concentrations of isometamidium in the presence of which 
infections with drug-resistant trypanosomes could become established, and the 
lowest concentrations which were still protective against drug-sensitive 
parasites (Chapter 4). It had been hoped that all three trypanosome stocks 
would differ in their drug sensitivity, and that the experiment would include 
parasites of low, intermediate and high levels of drug-resistance. However, two 
of the populations, IL3893 and IL3889, established infection just one month 
following administration of isometamidium prophylaxis, while the third 
population, T. congolense IL 1180, required between six and eight monthly 
challenges before infection was established. The experiment may have 
investigated trypanosome populations at the two extremes of the drug sensitivity 
spectrum, but no parasites of intermediate drug sensitivity.
In the work described in this chapter, a similar experiment was conducted to 
investigate the relationship between circulating concentrations of 
isometamidium and protection against tsetse challenge of Boran cattle with two 
cloned populations of T. congolense: the drug sensitive population T. 
congolense IL 1180, and another population which possess a level of drug 
resistance intermediate between that of T. congolense IL 1180 and the drug- 
resistant parasites used previously (7. congolense IL3893 and 3889).
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Materials and methods
Cattle
Boran cattle (Bos indicus) were obtained from an area of Kenya free of 
tsetse-transmitted trypanosomiasis, and fed on hay and concentrate as 
described by Whitelaw et al., (1986), and allowed water ad libitum.
Isometamidium administration
Isometamidium chloride (Samorin®) was administered at a dose rate of 1.0 
mgkg-1 body weight by deep intramuscular injection of a 2% (w/v) aqueous 
solution into the middle third of the neck.
Blood samples
Blood samples for use in the isometamidium-ELISA were collected by 
jugular venipuncture into Vacutainers (Becton-Dickinson) prior to 
isometamidium treatment, daily for the first week after treatment and twice 
weekly for a further 2 weeks, and weekly thereafter. Sera were separated and 
stored in borosilicate glass tubes (Vial Files, Jencons) at -60°C. Blood samples 
for monitoring of infections were collected three times weekly, as described 
above, into Vacutainers (Becton-Dickinson) containing potassium 
ethylenediamine tetra-acetate.
Trypanosomes
Two cloned populations of 7. congolense were use to challenge cattle. 7. 
congolense IL 1180 is a well-characterised, doubly cloned, derivative of an 
isolate obtained from a lion in the Serengeti National Park, Tanzania (Geigy 
and Kauffmann, 1973; Nantulya eta!., 1984; Whitelaw et al., 1986; Peregrine et 
al., 1988). 7. congolense IL 3343 is a derivative of 7. congolense IL 1180, in 
which a moderate level of isometamidium resistance was induced in the 
laboratory by repeated subcurative treatment of infected mice, and has been 
shown to possess reductions both in sensitivity to the drug in mice, and in 
fluorescence following incubation with the drug in vitro, compared to the parent 
population (Sutherland, Peregrine, Lonsdale-Eccles and Holmes, 1991).
Infected tsetse flies and challenge of cattle.
Glossina morsitans centralis were infected with each of the two 7. 
congolense populations as described previously (Chapter 4). Cattle were 
challenged by the application of five tsetse flies, which had the presence of
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metacyclic trypanosomes in their saliva confirmed by microscopic examination, 
to a shaved area of the abdominal flank (see Plate 4).
Parasitological monitoring
Parasitological monitoring of challenged cattle was conducted using the 
phase-contrast buffy-coat technique (Murray et al., 1977).
Isometamidium determinations
The concentrations of isometamidium in bovine sera were determined using 
the indirect competition ELISA (Chapter 3). Standards prepared from 
isometamidium "spiked" pooled Boran cattle serum and incurred quality 
assurance samples were included on every ELISA plate. Assay calibration and 
calculation of concentrations of unknowns was by four-parameter curve-fitting, 
using in-house software (M.C.E., unpublished). Results from individual ELISA 
plates were only used if the dose-response curves and quality assurance 
samples were within limits of acceptability. Absorbances were read using a 
multichannel spectrophotometer (Multiskan MCC Mk II, Labsystems) connected 
to an IBM-compatible personal computer.
Data analysis
Drug profiles were fitted to a bi-exponential model by iterative curve- 
stripping (Dunne, 1986) using the computer program JANA (SCI Software). 
Prepatent periods of infection were compared using Student's t-test. 
Differences between mean drug concentrations were analysed by Student's t- 
tests on log10 concentrations (because variances were proportional to the 
square of concentrations), except in cases where any of the values comprising 
the means to be compared were zero, in which case the Wilcoxon rank sum test 
was used (Ott, 1988).
Experimental Design
Twenty-five cattle were allocated into four groups. At the start of the 
experiment (day 0), Group 1(ten cattle) and Group 2 (five cattle) were 
administered prophylactic intramuscular injections of isometamidium chloride. 
Group 3 (five cattle) and Group 4 (five cattle) were untreated challenge 
controls. One month later, and at monthly intervals thereafter, cattle were 
challenged by the application of five Glossina morsitans centralis. All Group 1 
and Group 2 cattle were repeatedly challenged each month until shown to be 
parasitaemic, while a single animal in each of Groups 3 and 4 was used to
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prove the infectivity of each monthly challenge. Group 1 and Group 3 were 
challenged with T. congolense IL 3343. Group 2 and Group 4 were challenged 
with T. congolense IL 1180. Animals were removed from the experiment when 
their packed red cell volume (PCV) decreased to below 15%. Details of the 
experimental design are summarised in Table 11.
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Results
Parasitological findings
The parasitological findings are shown in Table 12. One month following 
prophylactic administration of isometamidium, all cattle (Group 1) challenged 
with 7. congolense IL 3343 were refractory to infection. However, between 16 
and 30 days after the second monthly challenge, trypanosomes were detected 
in the blood of seven of these cattle (Group 1). The remaining three cattle 
became parasitaemic 18 to 21 days following the third monthly challenge. The 
mean prepatent period of those cattle (Group 1) which became infected 
following the second monthly challenge (20.1 days) was not significantly 
different (p = 0.84) from that of those which became infected following the third 
monthly challenge (mean 20.0 days).
By contrast, all five cattle (Group 2) challenged with 7. congolense IL 1180 
resisted four monthly challenges. As all cattle (Group 1) challenged with drug- 
resistant 7. congolense (IL 3343) had become infected by this time, further 
challenges of cattle (Group 2) with drug-sensitive T. congolense (IL 1180) were 
considered unnecessary; the duration of the period of prophylaxis that 
isometamidium at a dose rate of 1.0 mgkg-1 body weight confers against 7. 
congolense IL 1180 had been determined in several previous studies (Whitelaw 
et al., 1986; Peregrine et al., 1988; and Chapter 4), and hence monthly 
challenge with this 7. congolense population was discontinued after the fourth 
occasion.
All challenge control cattle (Groups 3 and 4) became infected with either 7. 
congolense IL 3343 or 7. congolense IL 1180 as expected, 14 to 18 days after 
challenge (Table 12), confirming the infectivity of the tsetse flies that were used 
for each challenge. The virulence of infections with 7. congolense IL 3343 was 
demonstrated by the drop in packed cell volumes of the three infected control 
cattle (Group 3), which occurred by days 37, 43, and 67 of infection. The 
virulence of 7. congolense IL 1180 has been documented previously (Nantulya 
et al., 1984; Whitelaw et al., 1986).
Drug profiles
The isometamidium ELISA results are shown in Figure 5, Figure 6 and 
Table 13. As on previous occasions bi-phasic drug disappearance curves were 
obtained, and the results of bi-exponential curve fitting using JANA are shown
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in Table 14. The mean apparent half-life of the terminal elimination phase was 
approximately 23 days. Mean drug concentrations at monthly intervals 
following treatment, predicted using the JANA results are shown in Figure 7.
Serum isometamidium concentrations measured on the occasion of the first 
tsetse challenge were similar in Group 1 (mean 5.9 ngmM) and Group 2 (mean 
4.9 ngmM), and the difference between them was not statistically significant (p 
= 0.79). Thereafter, drug concentrations remained similar in Group 1 and 
Group 2 cattle, both at the time of the second monthly challenge (means 2.2 
and 1.7 ngmM respectively; p= 0.42), and at the time of the third monthly 
challenge (means 0.75 and 0.64 ngmM respectively; p = 0.87). One month 
later, at the time of the fourth monthly tsetse challenge (applied only to Group 2 
cattle, as all Group 1 cattle were by this stage infected), serum concentrations 
of the drug were lower in Group 1 cattle (mean 0.12 ngmM) than Group 2 cattle 
(mean 0.40 ngmM). Using the Wilcoxon rank sum test, because of zero values 
for some of the concentrations in Group 1, this difference in concentrations was 
statistically significant (T 9, 5 = 56; p < 0.5). Hence it appeared that in spite of 
an initially higher mean value, drug concentrations in cattle which became 
infected with T. congolense IL 3343 fell more rapidly than those which resisted 
infection with T. congolense IL 1180.
At the time of the second tsetse challenge, the mean serum isometamidium 
concentration in the seven cattle challenged with T. congolense IL 3343 which 
succumbed to challenge (2.1 ngmM) was lower than that in the three which 
resisted (2.4 ngmM). However the difference was not statistically significant, 
and there was some overlap in the ranges of the individual concentrations, 
which are shown in Table 15.
One month after the third challenge, the mean concentration (0.05 ngmM) in 
the six Group 1 cattle surviving of the seven which had become infected 
following the second monthly challenge, was lower than that of the three cattle 
which had not become infected until after the third monthly challenge (0.25 
ngmM), and although the difference was not statistically significant (T 6, 3 = 21; 
p > 0.05), the number of animals being compared was small. The mean 
concentration in these six cattle was significantly smaller that in cattle (Group 2) 
resisting challenge with T. congolense IL 1180 (T 6,5 = 44; p < 0.05).
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Table 11. Experimental design: challenge groups.
Group Number of 
cattle
Isometamidium 
prophylaxis 
(1 mgkg-1 i.m.)
Challenge:
7. congolense 
clone
Number of 
cattle 
challenged 
each month
1 10 + IL 3343 10*
2 5 + IL 1180 5*
3 5 - IL 3343 1
4 5 - IL 1180 1
i.m. *  intramuscular injection
‘ Cattle challenged at monthly intervals until trypanosomes detected
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Table 12. Outcome of tsetse challenge of isometamidium treated Boran
cattle.
Group Animal
number
T. congolense 
challenge
T P I (days) Month of 
challenge*
1 1 IL3343 16 2
1 2 IL 3343 21 3
1 3 IL3343 16 2
1 4 IL3343 16 2
1 5 IL 3343 21 3
1 6 IL 3343 16 2
1 7 IL 3343 18 3
1 8 IL 3343 30 2
1 9 IL 3343 16 2
1 10 IL 3343 25 2
mean 20.1
2 11 IL 1180 ’NA NA
2 12 IL 1180 NA NA
2 13 IL 1180 NA NA
2 14 IL 1180 NA NA
2 15 IL 1180 NA NA
3 16 IL 3343 18 1
3 17 IL 3343 14 2
3 18 IL3343 16 3
mean 16
4 19 IL 1180 15 1
4 20 IL 1180 14 2
4 21 IL 1180 16 3
mean 15
1Pre-patent period of infection
’Month of challenge resulting in infection
’Not applicable as Group 2 cattle remained uninfected
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Table 13. Mean serum drug concentrations obtained using the 
indirect competition ELISA for isometamidium
All cattle Group 1 
(2 month)1
Group 1 
(3 month)2
Group 2 Groups 
1 & 2
DAY 28:
n 10 7 3 5 15
mean 5.94 7.11 3.19 4.94 5.60
sd 3.29 3.25 0.89 1.68 2.83
DAY 60:
n 10 7 3 5 15
mean 2.18 2.08 2.40 1.69 2.01
sd 0.90 1.07 0.32 0.75 0.86
DAY 88:
n 9 6 3 4 13
mean 0.75 0.54 1.17 0.64 0.72
sd 0.56 0.53 0.38 0.24 0.48
DAY
199:
9 6 3 5 14
n
0.12 0.05 0.25 0.40 0.22
mean
0.17 0.08 0.25 0.18 0.22
sd
n = number of samples.
mean = isometamidium concentration in ngmf . 
sd = standard deviation.
'Group 1 cattle which became infected following the second challenge. 
’Group 1 cattle which became infected following the third challenge.
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Table 14. Bi-exponential curve4itting of isometamidium concentration
vs. time data using JANA
Group 1 
All cattle
Group 1 
(2 month)1
Group 1 
(3 month)2
Group 2 Groups 1 & 2
n 10 7 3 5 15
constant B 11.1 12.5 7.7 9.0 10.4
constant A 43.8 48.7 32.2 31.7 39.8
exponent b 0.0321 0.0361 0.0228 0.0262 0.0301
exponent a 0.9302 0.8911 1.0216 0.8461 0.9022
Ty2el 21.6 19.2 30.4 26.4 23.0
Constants A and B and exponents a and b are fitted to the model: concentration = Ae + Be* 
T 2el 3 half-life of terminal phase.
Group 1 cattle which became infected following the second challenge.
Group 1 cattle which became infected following the third challenge.
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Table 15. Isometamidium concentrations in the serum of cattle 
challenged with T. congolense IL 3433 two months after prophylactic
treatment.
Two month breakthrough* Three month breakthrough*
Animal number ngml'1 Animal number ngml-1
1 3.67 2 2.08
3 0.58 5 2.39
4 1.95 7 2.73
6 1.44
8 1.33
9 2.73
10 2.86
Mean 2.08 2.40
s.e. 0.40 0.19
* Month of challenge with T. congolense IL 3343 resulting in infection, 
s.e. = standard error of the mean.
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Figure 5. Mean isometamidium concentrations in the serum of cattle after 
intramuscular treatment at 1.0 mgkgr1; Group 1 cattle, challenged with T. congolense 
IL 3343. Challenge with T. congolense represented by tsetse fly symbols. 
Error bars: standard deviation.
50
10
1
0.1
30 60 90 1500 120
days after isometamidium treatment
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Figure 6. Mean isometamidium concentrations in the serum of cattle after 
intramuscular treatment at 1.0 mgkg'1; Group 2 cattle, challenged with T. congolense 
IL 1180. Challenge with T. congolense represented by tsetse fly symbols. 
Error bars: standard deviation
a>a.
a>c
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Figure 7. Isometamidium concentrations at monthly intervals following 
treatment, predicted from a bi-exponential model fitted by iterative curve-stripping 
using JANA
Group 1 (2M): cattle which became infected following the second tsetse 
challenge with T. congolense IL 3343
Group 1 (3M): cattle which became infected following the second tsetse
challenge with T. congolense IL 3343
Group 2: cattle challenged with T. congolense IL 1180
Error bars: standard deviation.
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Discussion
In this study, significant new information has been obtained about the 
relationship between serum concentrations of the chemoprophylactic drug 
isometamidium chloride and protection of cattle against tsetse challenge with 7  
congolense possessing an intermediate level of drug resistance. Cattle which 
had been treated with a single prophylactic intramuscular injection of 
isometamidium were subsequently challenged at monthly intervals with 7. 
congolense infected tsetse flies, and the relationship between susceptibility to 
infection and the circulating drug concentration investigated using the 
isometamidium-ELISA.
When Boran cattle, which had not received prophylactic isometamidium 
chloride, were challenged with cloned populations of 7. congolense (either IL 
3343 or IL 1180) by the application of five infected Glossina morsitans centralis, 
all developed patent and virulent infections, with the onset of parasitaemia 
between 14 and 18 days following challenge. However, the outcome of 7. 
congolense challenge of cattle to which isometamidium chloride had been 
administered at a dose rate of 1.0 mgkg-1 body weight by intramuscular 
injection depended upon the parasite population and the interval between 
prophylaxis and challenge. Ten cattle challenged with 7. congolense IL3343, a 
cloned population possessing an intermediate level of drug resistance (as 
judged by experiments in mice and in vitro [Sutherland et a/., 1991]), were 
refractory to infection one month after isometamidium administration, but seven 
cattle became infected when challenged again one month later. The remaining 
three cattle became infected after a third challenge, three months after drug 
treatment. In contrast to 7. congolense IL3343, isometamidium-treated cattle 
challenged with a drug-sensitive clone of 7. congolense, IL 1180 (Whitelaw et 
a/., 1986; Peregrine et al., 1988; and Chapter 4) were refractory to infection for 
at least four monthly challenges.
The concentration of isometamidium in the sera of treated cattle (Groups 1 
and 2), measured by ELISA, at the time of the first monthly challenge was 5.6 (± 
2.83) ngmM. This value is similar to that found previously at this time after 
treatment at the same dose rate (Chapter 4). In the work described here, the 
overall mean concentration in treated cattle had fallen to 2.0 (± 0.86) ngml-1 by 
the time of the second monthly challenge. Among those cattle which were 
challenged with the drug-resistant 7. congolense clone, IL 3343, there was no 
obvious relationship between the serum isometamidium concentration in
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individual cattle, and the outcome of the second challenge (Table 15). 
Nevertheless some observations could be made about these concentrations. 
Firstly, none of the three cattle which were refractory to infection at this 
challenge (nos. 2, 5 and 7) had concentrations below 2.0 ngml*1. Secondly 
concentrations in all but one of the cattle (nos. 3, 4, 6, 8, 9) which became 
infected were similar to, or below the mean of those which did not (2.4 ngml*1).
There are two considerations in interpreting these data. One is the degree 
of inherent variability in the ELISA results. Construction of the response-error 
relationship (Ekins, 1983), using data for duplicate measurements pooled from 
all the assays conducted on these samples, showed the coefficient of variation 
in response (absorbance) at this concentration to be as little as 4.4%. As the 
assay is capable of measuring isometamidium over a fairly wide range of 
concentrations (0.1 to 10 ngml*1), the gradient of the dose-response curve is 
relatively small, and using this gradient to construct a precision profile (Ekins, 
1983) showed that at 2.0 ngml*1 the expected coefficient of variation in 
concentration was 10.7%. In an attempt to allow for some of the variability in 
individual measurements, concentrations were predicted for each individual 
animal at the time of the second challenge, using bi-exponential curve fitting of 
all the data points for that animal (data not shown). Again there was no 
significant difference (p = 0.92) between the modelled serum isometamidium 
concentrations in cattle succumbing to the second challenge with T. congolense 
IL 3343, and those refractory.
The second of these considerations is the fact that protection against 
tsetse-challenge with T. congolense may involve factors other than the serum 
isometamidium concentration. While there is some evidence that 
isometamidium prophylaxis is believed to prevent the development of 
metacyclic trypanosomes at the site of inoculation (Whitelaw et a/., 1986), the 
relationship between the drug concentration in serum and the concentration at 
the tsetse bite site is unknown. In addition, there is a growing body of evidence 
that host resistance factors contribute to the efficacy of chemotherapeutic 
agents (Doenhoff et al., 1991); for example, drug doses required to clear 
trypanosome infections may be greater in immunosuppressed than in 
immunocompetent mice (Frommel, 1988). Similarly, in the present work, 
individual variation in host resistance factors may have contributed to the 
variation in the efficacy of isometamidium chemoprophylaxis against the second 
challenge of cattle with the drug-resistant T. congolense clone, IL 3343.
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Gray, Kimarua, Peregrine and Stevenson (1993) have shown that 
metacyclic forms of 7. congolense derived in vitro from various field isolates 
possess a range of susceptibilities to isometamidium chloride in the incubation 
medium; a 200-fold difference was demonstrated between the minimum drug 
concentration to which some isolates were sensitive (5 ngml*1) and the 
maximum drug concentration to which others were resistant (1000 ngml-1), and 
two levels of drug sensitivity were observed between these extremes. In the 
previous experiment (Chapter 4), an eight-fold difference was demonstrated 
between the highest mean isometamidium concentrations (6.1 ngml*1) measured 
in sera of cattle susceptible to tsetse challenge with drug-resistant populations 
of 7  congolense (IL 3889 and IL 3893), and the lowest mean concentration 
(0.75 ngml*1) measured in sera of cattle protected against tsetse challenge with 
a drug sensitive population (7. congolense IL 1180). In the experiment 
described in this chapter, the lowest mean isometamidium concentration which 
could be measured in sera of cattle protected against tsetse challenge with 7. 
congolense IL 1180 was 0.4 ngml*1 (at the time of the fourth monthly challenge), 
approximately 15-fold less than the highest concentration (6.0 ngml-1) withstood 
by drug resistant parasites in the previous experiment.
The concentrations of isometamidium to which 7. congolense IL 3889 and 
7  congolense IL 1180 were either resistant or sensitive (IL 3889 [= KE 3302] 
resistant to 100 ngml*1; IL 1180 sensitive to 10 ngmM) in vivo (Gray et a/., 1993) 
were over ten times greater than those observed in cattle. The difference 
between these upper and lower "critical concentrations" for the two parasite 
stocks observed in vitro (10-fold) was, however, similar to that observed in cattle 
in the experiments described in this and the previous chapter (8 to 15-fold). 
Further experiments would be required to test whether this relationship holds for 
stocks of 7. congolense at other levels of drug sensitivity, such as IL 3898. On 
the basis of experiments which used three strains of 7. congolense, which 
differed in sensitivity to the drug, isometamidium doses in mice were considered 
to give only a broad indication of the sensitivity of a strain in cattle (Sones et al., 
1988).
The absolute difference in these "critical concentrations" between the in 
vitro system and cattle (over 10-fold) was a similar to the 10 to 100-fold 
difference between doses of isometamidium curative for 7. congolense 
infections in mice and those curative for infections with the same parasites in 
cattle (Sones et al., 1988). The striking difference in the magnitude of drug
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concentrations of significance in cattle and in vitro might be explained in part by 
the fact that, in vivo, other host factors may contribute to the efficacy of 
trypanocidal drugs (Doenhoff et al., 1991). For example, immunosuppression 
substantially reduces the efficiency of isometamidium in curing T. evansi 
infections in mice (Osman, Jennings and Holmes, 1992). Furthermore, drug 
concentrations at the tsetse bite site are probably related to, but not necessarily 
the same as those in the circulation.
T  congolense have been demonstrated in extravascular sites within the 
skin (Luckins and Gray, 1978), where localised proliferation may occur before 
dissemination into the bloodstream (Akol and Murray, 1982), and there is 
evidence that isometamidium may exert its prophylactic effect before 
trypanosomes enter the circulation; Whitelaw et al. (1986) found skin reactions 
(i.e. development of a chancre), local lymph node enlargement, and detectable 
antibody responses, only in cattle which succumbed to experimental tsetse 
challenge with T. congolense, but not in challenged cattle which were protected 
successfully by isometamidium.
Whereas the levels of isometamidium present in organs such as liver, 
kidney and spleen, and at the intramuscular injection site have been the subject 
of a number of investigations (Hill and McFadzean, 1963; Philips et al., 1967; 
Kinabo and Bogan, 1988b; Kinabo and McKellar, 1990; Kinabo, McKellar and 
Eckersall, 1991), investigators have generally neglected to consider the 
concentrations present in the skin. The rate of entry of a drug from the 
circulation into any particular tissues of the body will depend upon the rate of 
blood flow through the capillary beds supplying that tissue, and the permeability 
of the capillaries for the particular drug molecules. The greater part of the 
isometamidium present in the circulation is probably bound to plasma 
macromolecules, especially albumin (Philips et al., 1967; Smith et al., 1991), 
and this fraction of the total drug is probably unable to pass through the 
capillary endothelium.
In the absence of specific channels or carriers, unbound isometamidium, a 
quartemary ammonium compound, is unlikely to pass through the cellular 
membranes which form the capillary endothelial surface. In considering the 
accumulation of isometamidium in hepatocytes, Phillips et al. (1967) proposed 
the existence of a mechanism capable of transporting isometamidium into cells, 
to explain the rapid entry of a cationic substance which is firmly bound to serum 
proteins. Such a mechanism appears to operate in the accumulation of
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isometamidium in trypanosomes (Sutherland, Mounsey and Holmes, 1992; 
Zilberstein, Wilkes, Hirumi and Peregrine, 1993). Whether or not such a 
mechanism exists to permit or assist the passage of the drug through the 
cellular membranes of capillary endothelial cells, unbound isometamidium, like 
other small, water-soluble ionic species, is probably able to pass readily 
through the junctions between these cells (Goldstein, Aranow and Kalman, 
1974).
Having escaped the capillary bed as unbound drug, isometamidium may 
once again bind strongly to tissue macromolecules and ground matrix 
components, as suggested by the importance of the intramuscular injection site 
as the primary depot of isometamidium resulting in the prolonged period of 
prophylaxis (Hill and McFadzean, 1963), and the low bioavailability of 
isometamidium in goats following intramuscular injection (Kinabo and McKellar, 
1990).
The relationship between circulating concentrations of isometamidium 
measured in serum samples using the ELISA, and concentrations in cutaneous 
tissue fluid, where the drug appears to exert its prophylactic effect, may 
therefore be fairly complex, and involve dissociation constants for binding of the 
drug to macromolecules in both serum and cutaneous tissues. Additional 
investigations of this relationship would be desirable, possibly by comparing 
drug levels in serum with those in interstitial fluid. Techniques such as 
implantation of Silastic tissue cages have been used for the study of the 
concentration of antibacterial agents in interstitial tissue fluid (Chisolm, 
Waterworth, Calnan, and Garrod, 1973), and attempts have been made recently 
to use lymphatic cannulation in the study of the distribution of the trypanocide 
diminazene aceturate in tissue fluid (Mamman, McKeever and Peregrine, 1993).
Although T. congolense IL 1180 is not necessarily representative of the 
most drug-sensitive naturally occurring T. congolense populations, as five out 
of seven field isolates possessed greater sensitivity to the drug in vitro (Gray et 
al., 1993), its inability to establish infection for over five months following a 
single prophylactic dose of isometamidium (Whitelaw et al., 1986; Peregrine et 
al., 1988; and Chapter 4) supports its use as a standard "sensitive" population 
in these experiments.
These investigations have significantly added to the information available 
regarding circulating isometamidium concentrations and protection of cattle 
against tsetse-transmitted trypanosomiasis. While previous work demonstrated
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that T. congolense occurring in the presence of serum concentrations above 6 
ngml-1 express marked drug resistance, this work has shown that trypanosome 
infections occurring in the presence of serum concentrations between 2 and 6 
ngml-1 are at least as resistant to isometamidium prophylaxis as T. congolense 
IL 3343, and therefore possess moderate drug resistance. Infections occurring 
in the presence of between 0.4 and 2 ngml-1 can be considered more resistant 
than T. congolense IL 1180, and these too may be considered to possess a 
modest level of resistance. Finally, the serum isometamidium level below which 
no inference regarding drug-resistance in T. congolense populations infecting 
cattle can be made can be considered to be 0.4 ngml-1.
In the work described in this and the previous chapter (Chapter 4), the 
relationship between serum isometamidium concentrations and prophylaxis 
against tsetse-transmitted trypanosomiasis has now been investigated using 
three populations of T. congolense of differing levels of sensitivity to the drug. 
Further investigations will be required to investigate the relationship between 
isometamidium concentrations in serum and prophylaxis of cattle against the 
other tsetse-transmitted species of trypanosomes which affect them, particularly 
Trypanosoma vivax.
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Chapter 6:
Efficacy of Prophylactic and Therapeutic Trypanocidal 
drugs in Dairy Cattle under Natural Tsetse Challenge in 
Coastal Kenya; Use of the Isometamidium ELISA to 
measure Serum Concentrations of the Drug
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Introduction
Isometamidium chloride is the only drug with clearly established 
chemoprophylactic activity against tsetse-transmitted bovine trypanosomiasis, 
and its use is one of the principal methods of trypanosomiasis control in most 
countries in sub-Saharan Africa. Following a single isometamidium treatment, 
up to six months prophylaxis has been demonstrated in carefully controlled 
laboratory experiments using defined tsetse challenge of cattle with stocks of 
Trypanosoma congolense (Whitelaw et al., 1986; Peregrine etai ,  1988). In well 
managed chemoprophylactic situations in the field, isometamidium enabled 
cattle to survive in areas of heavy tsetse challenge (Trail et al., 1985). There 
are however reports of apparent failure of isometamidium prophylaxis (Pinder 
and Authie, 1984; Schonefeld et al., 1987; Fox, Mbando and Wilson, 1991; 
Dolan et al., 1992; Munstermann et al., 1992), although the reason for this 
failure has not always been clearly established.
Whereas in a successful chemoprophylactic situation circulating drug levels 
are by definition adequate to protect against trypanosome challenge, break­
through infections may occur where drug levels are inadequate, possibly as a 
result of an inappropriate dosage regimen. Alternatively, infections may occur 
where the challenge population of trypanosomes expresses drug resistance 
(Holmes and Torr, 1988). Both causes have important implications for the 
management of cattle in tsetse-infested areas, but their relative importance may 
be difficult to evaluate in field situations because, until recently, there has been 
no method available to measure drug levels in treated animals.
The development of an enzyme-linked immunosorbent assay (ELISA) for 
the measurement of isometamidium chloride in the sera of treated cattle was 
described in Chapter 3, and its evaluation in cattle under experimental tsetse 
challenge was described in Chapters 4 and 5. The assay was shown to be 
capable of quantifying circulating levels of isometamidium for at least three 
months after treatment.
In coastal Kenya and neighbouring regions, trypanosomiasis has a serious 
effect on cattle productivity both through direct effects of infections on 
production (Trail et al., 1985; Dowler et al., 1989; Munstermann et al., 1992), 
and through indirect effects resulting from the limitations on the cattle breeds 
which may be utilised in the area; the current population is mainly Small East 
African Zebu cattle, managed in traditional smallholder systems (Maloo, Chema,
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Connor, Durkin, Kimotho, Maehl, Mukendi, Murray, Rarieya and Trail, 1988). 
Although isometamidium prophylaxis has been shown to significantly reduce the 
prevalence of trypanosomiasis and the associated losses in productivity in 
cattle in this region (Trail et a/., 1985; Maloo et al., 1988), more recent reports 
from the field in coastal Kenya and Tanzania have suggested a reduction in the 
efficacy of chemoprophylaxis (Dolan et al., 1992; Fox et al., 1993; Maloo, 
Thorpe and Nantulya, 1993).
This chapter describes the results of use of the isometamidium ELISA in a 
study conducted in coastal Kenya, in which serum samples were collected on a 
regular basis from a herd of Jersey cattle in which trypanosome infections 
occurred in spite of an isometamidium chemoprophylactic regimen. The study 
provided an opportunity to use the ELISA on sera from cattle under natural 
tsetse challenge, and to evaluate its potential as a tool for discriminating 
genuine break-through infections by drug-resistant trypanosomes from failure of 
prophylaxis due to inadequate drug levels.
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Materials and methods
The study was conducted between July 1990 and January 1992 on the 
Jersey herd of the Regional Research Centre of the Kenya Agricultural 
Research Institute, at Mtwapa, located in the coconut-cassava agro-ecological 
zone of the high rainfall coastal strip (Jaetzold and Schmidt, 1983) of the 
Kenya’s Coast Province. The area is approximately 15m  above sea level, and 
has a mean annual rainfall of 1,100 mm which reaches its peak between April 
and June. Mean monthly temperatures reach 27 to 32°C, with a corresponding 
minimum of 20 to 24°C.
A general description of the herd and its management practices are given 
by Njubi, Rege, Thorpe, Collins-Lusweti and Nyambaka (1992). The breeding 
herd consisted of lactating and dry cows (see Plate 8), grazing day and night on 
natural pastures with shade trees, or under cashew nut and coconut palm tree 
crops. Cattle were hand milked twice daily, with recording of all milk yields 
(calves were fed from buckets), and the animals were weighed monthly, thus 
enabling determination of productivity. Cattle were vaccinated annually against 
rinderpest, foot and mouth disease, lumpy skin disease, anthrax and 
blackquarter, and sprayed weekly with acaricide. The herd was immunised 
against East Coast fever by the infection and treatment method in 1987.
Prior to this study, chemoprophylaxis and treatment of trypanosomiasis was 
conducted using isometamidium chloride and diminazene aceturate 
respectively. Nevertheless fatalities were common and ten cows died from 
trypanosomiasis during the three months prior to the study. Isometamidium was 
administered intramuscularly at a dose rate of 0.5 mgkg*1 body weight between 
one and four times a year, depending on an assessment of trypanosomiasis 
risk; when the prevalence of infections diagnosed on a clinical basis reached 
approximately 10%, isometamidium was administered to the entire herd.
The tsetse challenge at Mtwapa was considered to be low, with seasonal 
peaks. Glossina pallidipes and G. austeni were the main species of tsetse 
present, although biting flies (Stomoxys sp. and Tabanids) were possibly more 
abundant (Maloo, 1993). Increasing pressure from human settlement was 
believed to be responsible for a recent reduction in tsetse challenge, through 
the destruction of fly habitat.
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Study design and procedures
A full description of the study design and procedures, and of herd health, 
trypanosome incidence and milk production was given by Maloo (1993). At the 
beginning of the study in June 1990, 78 post-weaning female Jersey cattle were 
treated with diminazene aceturate (Berenil®) at a dose rate of 7.0 mgkg'1 body 
weight. In July 1990 these animals were divided at random within age and 
lactational status groups into two equal sized groups: one Group received 
regular chemoprophylactic treatments, the other served as non-prophylaxis 
controls. Isometamidium chloride (Samorin®) was administered every 90 days 
to the chemoprophylaxis group by intramuscular injection at a dose rate of 
0.5 mgkg'1 body weight, with the last treatment administered in October 1991. 
Any animal found to be parasitaemic in either the chemoprophylaxis group or 
the control group was treated on the same day, or the following day, by 
intramuscular injection of diminazene aceturate (7.0 mgkg'1 body weight). 
Blood samples were taken once weekly for detection of trypanosomes by the 
buffy-coat technique (Murray, Murray and McIntyre, 1977) and for measurement 
of the packed cell volume. Serum samples were collected monthly from 
September 1990 until December 1991, and stored at -20°C until analysis using 
the isometamidium ELISA.
Trypanosomiasis was found to be the most frequent cause of ill-health in 
the study herd. The majority of trypanosome infections occurred in the first and 
third prophylactic periods (i.e. the 90-day periods following the first and third 
prophylactic isometamidium injections), and all trypanosome parasitaemias 
detected by the buffy-coat method were found to be due to T. vivax. The 
incidence of parasitaemia in the isometamidium-treated group did not differ 
significantly from the incidence in the non-prophylactic group. Finally, the 
occurrence of trypanosome parasitaemia was shown to be associated with 
significant depression in packed red cell volumes and in daily milk yield, but not 
in live-weight gains.
For analysis using the isometamidium ELISA, the sera were divided into 
four groups. Sera from cattle in the non-prophylaxis group were allocated into 
Groups UN and UP. Sera from cattle in the prophylaxis group were allocated 
into Groups PN and PP. Groups UN and PN comprised sera from cattle which 
were never found to be parasitaemic during the study. Groups UP and PP 
comprised sera from cattle which were found to be parasitaemic on at least one 
occasion. Group UN, Group PN and Group PP sera were tested by ELISA. In
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addition a pool was prepared from the Group UN sera which was used in a test 
of parallelism with the standards used in the ELISA. Sera were available for 
testing from ten cattle in Group PN and from six cattle in Group PP. Group UP 
sera were not tested.
Enzyme-linked Immunosorbent Assay
Sera collected following isometamidium treatment were tested using the 
indirect competition ELISA for isometamidium (Chapter 3). Briefly, microtitre 
plates (Immulon 4, Dynatech) were coated by overnight incubation of 100 pi per 
well of a 1/2000 dilution of isometamidium-ovalbumin conjugate in 
carbonate-bicarbonate buffer (pH 9.2). Plates were washed 5 times using a 1/5 
dilution of phosphate buffered saline (PBS, pH 7.2) in distilled water containing 
0.05% Tween 20 (Sigma), and blotted dry. Test sera, standards, and quality 
control sera were pre-diluted 1/10 in a 1/2400 dilution of biotinylated sheep 
anti-isometamidium IgG in PBS containing 0.05% Tween 20 (PBST), and vortex 
mixed. Pre-dilutions were added to duplicate wells of microtitre plates (100 pi 
per well) which were then incubated with shaking at 37°C for 1 hour. Plates 
were washed 5 times as described above, and 100 pi of a 1/3000 dilution of 
streptavidin:horseradish peroxidase conjugate (Sigma) in PBST was added to 
every well. After incubation with shaking at 37°C for 45 minutes, plates were 
washed 5 times as described above, and 100 pi per well of 
substrate/chromogen solution added. This solution contained 120 pi of 42 mM 
tetramethylbenzidine (Sigma) in dimethyl sulphoxide (Sigma), 12 ml of 0.1 M 
sodium acetate/citric acid buffer (pH 6.0), and hydrogen peroxide to a final 
concentration of 1.3 mM. The colour reaction was quenched ten minutes after 
adding this solution with 100pl per well of 2 M sulphuric acid.
Assay standards were prepared from pooled, untreated Boran cattle serum. 
Absorbances were read using a multichannel spectrophotometer (Multiskan 
MCC Mk II, Labsystems), connected to a personal computer (386SX, AST).
Data Analysis
Four-parameter logistic calibration-curve fitting, precision profiling, and 
calculation of drug concentrations of unknown samples, were performed using 
spreadsheet software (Lotus 1-2-3 R3.1) specifically programmed for this 
purpose (M.C.E., unpublished).
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Plate 8. Jersey dairy cattle at the Regional 
Research Centre of the Kenya Agricultural 
Research Institute, at Mtwapa, in the coconut- 
cassava agro-ecological zone of the high rainfall 
coastal strip of the Coast Province of Kenya.
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Results
Untreated Controls, Parallelism and Assay Standards
Sera from Jersey cattle which had not been treated with trypanocidal drugs 
(Group UN) were tested using the isometamidium ELISA, and gave negative 
results. A pool prepared from these sera showed parallelism with the assay 
standards. Hence these standards were appropriate for assay calibration in the 
testing of sera from isometamidium-treated Jersey cattle in the same population 
(Group PN and PP sera).
Isometamidium-Treated Cattle
Sequential serum samples were available for ELISA testing from ten 
isometamidium-treated cattle which became infected with trypanosomes (Group 
PP sera), and from six isometamidium-treated cattle which remained uninfected 
over the six prophylactic periods (Group PN sera). No serum samples were 
taken before the last third of the first prophylactic period. Each sample was 
tested in at least two assays. Mean isometamidium concentrations for Group 
PN and PP sera determined by ELISA for each sampling date are shown in 
Figure 8.
Data from all six prophylactic periods were pooled by calculating the mean 
of all determinations made during the first 30 days of a prophylactic period, the 
mean of all determinations made between days 30 to 60 of a prophylactic 
period, and the mean of all determinations made after day 60 of a prophylactic 
period. Pooled data were calculated for sera from cattle undergoing at least 
one break-through trypanosome infection (Group PP sera; n = 10), for sera from 
cattle never detected parasitaemic (Group PN sera; n = 6), and for sera from 
both Groups. The results are shown in Figure 9.
In general, mean isometamidium concentrations increased following 
prophylactic treatments, and decreased thereafter. Drug levels varied between 
lower than the limit of detection of the ELISA, and approximately 2 ngml'1. Most 
observations were below 1 ngml’1, and frequently concentrations were below 0.5 
ngml"1, or were undetectable.
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Figure 8. Isometamidium concentrations determined by ELISA in sera from 
Jersey cattle under a regular prophylactic treatment regimen. Solid line: mean 
concentration in cattle undergoing at least one break-through trypanosome 
infection (n = 10). Dashed line: mean concentration in cattle never detected 
parasitaemic (n = 6). Arrows indicate dates of isometamidium treatments.
2.5
E
m
s  2-°
c
o
* 5
COh.
coo
c
oa
E3
2
E
id
© 0.5
E
o
CO
0.0
01/07/90 1/10/90 1/01/91 1/04/91 1/07/91 1/10/91 1/01/92
163
Figure 9. Isometamidium concentrations in sera from treated Jersey cattle 
pooled from six prophylactic periods (i.e. inter-treatment intervals) determined by 
ELISA. Data were pooled by calculating the mean of all determinations made 
during the first 30 days of a prophylactic period, the mean of all determinations 
made between days 30 to 60 of a prophylactic period, and the mean of all 
determinations made after day 60 of a prophylactic period. Pooled data were 
calculated for sera from cattle undergoing at least one break-through trypanosome 
infection (Group PP sera; n = 10), for sera from cattle never detected parasitaemic 
(Group PN sera; n = 6), and for sera from both Groups.
Group PP Group PN PP and PN
0 9
C
2
E
C B
®
Eo
in 0 - 30 30 -6 0  6 0 -  105
Days post - isometamidium treatment
164
9998
Discussion
In this study, for the first time, levels of circulating isometamidium have 
been quantified in cattle maintained under a chemoprophylactic regime in the 
face of virulent natural trypanosome challenge, using the isometamidium ELISA. 
The concentrations measured were similar in magnitude to concentrations 
measured by the ELISA in cattle under experimental conditions (Chapters 3 and 
4). This assay has therefore been shown to be useful for the investigation and 
rationalisation of chemoprophylactic strategies in the field.
The concentrations of isometamidium determined in the sera of treated 
Jersey cattle (Groups PN and PP) were within the range of values previously 
determined in Boran cattle treated at the same isometamidium dose rate (0.5 
mgkg*1 body weight by intramuscular injection) under controlled laboratory 
conditions (Chapters 3 and 4). Together with the demonstration of parallelism 
between pooled untreated Jersey (Bos taurus) serum and the assay standards 
prepared using pooled untreated Boran (Bos indicus) serum, this suggested that 
the genotype of the cattle under test had no effect on the ELISA.
The level of cross-reactivity (10'3) of diminazene aceturate in the 
isometamidium ELISA is relatively low (M.C.E., unpublished data). Hence the 
smallest concentration of diminazene which might interfere with the 
isometamidium ELISA would be 1000 times greater than the minimum 
detectable concentration of isometamidium. Studies on the pharmacokinetics of 
diminazene (Aliu, Mamman and Peregrine, 1993) show that levels present more 
than 5 days after intramuscular treatment of Boran cattle at a dose rate of 3.5 
mgkg'1 body weight would not interfere with the isometamidium ELISA. 
Assuming that the absorption and disposition kinetics are similar in Jersey cattle 
administered diminazene at 7.0 mgkg'1 body weight, interference due to 
diminazene would not have occurred in this study more than 10 days after 
treatment. Cross-reactivity was not likely to have occurred, since in fact no 
sample was tested within two weeks of diminazene treatment.
All trypanosome infections detected in isometamidium-treated and 
untreated cattle using the buffy-coat technique were found to be caused by T. 
vivax, and some were characterised by a haemorrhagic syndrome (Maloo, 
1993).
In general, isometamidium concentrations followed a similar pattern in both 
uninfected cattle (Group PN sera) and in cattle in which infections were
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detected (Group PP sera). The occurrence of infections (Group PP sera) did 
not appear to be associated with lower drug concentrations than were 
measured in uninfected cattle (Group PN sera). Hence, factors other than 
differences in isometamidium concentrations were probably more significant in 
determining whether individual animals became infected.
The lowest isometamidium concentrations in isometamidium-treated cattle 
occurred, as would be expected, towards the end of each prophylactic period. It 
was also generally in the latter stages of prophylactic periods that new 
infections were detected in the animals investigated by ELISA: all but one of 
the infections in isometamidium-treated cattle occurred in the last third of a 
prophylactic period, the remaining one occurring in a middle third. This 
distribution of new infections over time was probably related more to the level of 
challenge than to the drug concentrations, because the distribution of new 
infections over the course of each prophylactic period was similar in the 
prophylaxis group and in the non-prophylaxis group (Maloo, 1993). The 
concentrations measured in the last third of each prophylactic period were less 
than the minimum concentration shown to be protective against a drug- 
sensitive stock of T. congolense (0.4 ngml*1, Chapter 5). Although data on 
protective values are not yet available for T. vivax, the work of Peregrine et al. 
(1987, 1991) suggests that these may need to be higher for this species of 
pathogenic trypanosome, which appears to be less sensitive to the prophylactic 
activity of isometamidium than it is to the therapeutic use of the drug. As all 
parasitaemic cattle at Mtwapa were treated with diminazene, regardless of 
whether they were receiving isometamidium prophylaxis, it was not possible to 
assess whether the isometamidium dosage regimen would have been beneficial 
as a result of the therapeutic effect of the drug.
On the basis of the isometamidium ELISA results, there was no evidence of 
drug resistance at Mtwapa over the period for which serum samples were 
available; most trypanosome challenge occurred during the last third of an inter­
treatment interval, when isometamidium concentrations in cattle under 
prophylaxis were relatively low. Over this period, the apparent failure of 
isometamidium chemoprophylaxis to prevent virulent trypanosome infections 
could be attributed, in part, to low levels of circulating drug, which suggests that 
the dosage regimen used in this study was inappropriate for the local T. vivax 
populations. Either the dose of Samorin® administered (0.5 mgkg'1 body 
weight), the lower of two doses recommended by the manufacturer, was
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inadequate, or the inter-treatment interval was too long. It would therefore be 
appropriate to test the effectiveness of isometamidium prophylaxis at a .dose 
rate of 1.0 mgkg'1 body weight in dairy cattle exposed to natural tsetse 
challenge in coastal East Africa.
It was unfortunate that serum samples from the first and middle thirds of the 
initial prophylactic period were not available for the isometamidium-ELISA, as 
the distribution of challenge over time was noticeably different during this period 
(Maloo, 1993): the majority of infections which occurred over this period were 
during the first and middle thirds. If serum isometamidium concentrations 
during the first prophylactic period were similar to those in subsequent 
prophylactic periods, then indirect evidence for drug-resistance would have 
been obtained, as infections occurred when drug concentrations would be 
expected to be protective against drug-sensitive trypanosomes (Chapters 4 and 
5).
This work has shown that the isometamidium ELISA is appropriate for field 
studies, and can provide novel information in treated cattle. In the present 
study, drug levels at the time of maximal trypanosome challenge were found to 
be lower than might be expected to provide protection against Kenyan T. vivax, 
even in the absence of a particular drug-resistance problem. The result of 
these ELISA investigations is concordant with the conclusions of a complex 
statistical evaluation of epidemiological data from same study (Maloo, 1993) 
which similarly suggest that the chemoprophylactic regime in use was not 
effective in protecting against tsetse challenge. This indicates that the ELISA 
can provide useful information in other African situations in which detailed 
epidemiological information is not normally available.
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Chapter 7:
A Simple Competitive Enzyme Immunoassay for the 
Detection of the Trypanocidal Drug Isometamidium
168
Introduction
Isometamidium chloride is one of only a few drugs widely available for use 
in the control of African bovine tsetse-transmitted trypanosomiasis (Holmes and 
Torr 1988), and the only one of these proven to have useful chemoprophylactic 
activity (Trail et a i, 1985; Whitelaw et al.t 1986; Peregrine et at., 1988; and 
Chapter 4). However the lack of analytical methods sufficiently sensitive to 
quantify levels of drug in treated cattle has limited efforts to improve 
prophylactic drug regimens, and to confirm that apparent drug-resistance is not 
due to inadequate dosage, or variation in pharmacokinetics between individual 
animals.
An enzyme-linked immunosorbent assay (ELISA) capable of measuring the 
concentration of isometamidium in the sera of treated cattle has been described 
in Chapter 3, and evaluated using isometamidium-treated cattle under 
experimental (Chapter 4) and natural (Chapter 6) tsetse challenge. This ELISA 
was capable of detecting isometamidium for at least three months following 
treatment, and had a mid-point of detection of approximately 1.5 ngml*1. 
However, it was considered possible to improve on a number of aspects of the 
assay. Firstly, every run of the assay involves four incubation stages; an 
overnight coating incubation, two subsequent hour long incubations, and a final, 
short, colour development incubation (Chapter 3). Clearly, the more steps the 
assay involves, the more susceptible it is to the possibility of technical errors, 
and the more time and materials are wasted if the assay needs to be repeated 
because of these errors. Secondly, coated plates could not be stored without 
deterioration in the quality of the results obtained, and thus a new batch of 
coated plates was used for every run of the assay. This in turn may have been 
a contributing factor to the day to day variation in the B0 absorbance values 
(Chapter 3), which was a further feature of the ELISA regarding which 
improvement was considered possible.
This chapter describes a new competitive enzyme immunoassay (CEIA) for 
isometamidium, which was developed as an alternative to the indirect 
competition ELISA (ICE) described in Chapter one. The CEIA offers distinct 
advantages over the ICE in terms of reagent preparation, assay procedure, and 
day to day variability in absorbances.
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Materials and methods
Normal bovine sera
Sera were obtained from normal healthy cattle of mixed breeds (Bos 
taurus), age and sex from both Scotland and Northern Ireland. None of these 
cattle had ever received treatment with isometamidium.
Isometamidium-spiked bovine sera
Assay standards were prepared as described for use in the indirect 
competition ELISA (Chapters 3). Briefly, 50 mg isometamidium chloride 
(Samorin®) were dissolved in 100 ml distilled water and stored in a dark glass 
bottle at room temperature (approximately 20 - 22°C). The solution was further 
diluted 1/10 in distilled water, and immediately diluted again in normal bovine 
serum (NBS) to a final concentration of 1.5 pgmM. From this dilution a threefold 
serial dilution was performed in pooled NBS, to produce ten spiked "standards" 
ranging in concentration from 500 to 0.025 ngmM, which were stored at 4°C for 
up to 7 days.
Isometamidium chloride treatment
Isometamidium chloride (Samorin®) was administered to cattle by injection 
of a 1% aqueous solution into the jugular vein, following the method of Dowler 
et a/., (1989), or by deep intramuscular injection of a 2% aqueous solution into 
the middle third of the neck, except in animals in which the musculature of the 
neck was poorly developed, in which case the gluteal muscles were used. 
Injections were given using a 11/2 inch 19 gauge needle at a dose rate of 1.0 
mgkg*1 body weight.
Cross-reactivity with other trypanocidal compounds
Cross-reactivities of diminazene aceturate (Berenil®, Hoechst Veterinar 
Gmbh, Frankfurt am Main, Germany) and homidium bromide (Ethidium®, 
Cameo) were determined by spiking pooled NBS with a range of concentrations 
of these compounds. Cross-reactivity was assessed by comparing the 
concentration of each drug which resulted in 50% inhibition of the optical 
density obtained in the absence of competing drug. Cross-reactivity was 
expressed as the concentration of isometamidium divided by the concentration 
of cross-reacting drug x 100%.
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Hyperimmune sheep anti-isometamidium serum
Four Scottish Blackface wethers were immunised using an isometamidium- 
porcine thyroglobulin conjugate as described previously (Whitelaw et al., 1991). 
Briefly, isometamidium chloride (Samorin®) was conjugated to porcine 
thyroglobulin by a diazotization reaction, and primary immunisation was by sub­
cutaneous injection of conjugate emulsified in Freund's complete adjuvant Five 
subsequent booster immunisations of the same conjugate emulsified in 
Freund's incomplete adjuvant were given by sub-cutaneous injection at intervals 
over the following six months. Blood was collected into plain Vacutainers 
(Beckton-Dickinson), and serum separated by centrifugation, and stored at -20° 
C until use.
Isometamidium : horseradish peroxidase conjugate
One-ethyl-3-(3-dimethylaminopropyl)carbodiimide (Sigma) dissolved in 
distilled water (40 mgml-1) was added, with constant mixing, in 50 pi aliquots to 
0.5 ml of a 38 mM solution of isometamidium chloride in 50% (v/v) pyridine 
(Sigma) in distilled water. The resulting solution was added in 200 pi aliquots 
over 15 minutes with constant mixing, to 10 mg of horseradish peroxidase 
(HRP; Boehringer Mannheim) dissolved in 1 ml distilled water, and the 
resulting mixture was incubated at 37°C for 20 hours. The mixture was then 
dialysed against phosphate buffered saline (PBS), pH 7.2, and passed down a 
G-25 Sephadex (Sigma) column (bed volume 30 ml), and the coloured portion 
of the void volume collected. Finally the conjugate was mixed for 15 minutes 
with 0.5 ml of a 0.25% (w/v) suspension of activated charcoal (Sigma) 
containing 0.025% (w/v) dextran T70 (Pharmacia, Milton Keynes, UK) in 
distilled water, then centrifuged (Eppendorf) at 14,000 rpm, and the supernatant 
removed and stored in aliquots at -20°C after mixing well with an equal volume 
of glycerol (Sigma).
Microtitre plate coating and storage
Ninety-six well microtitre plates (Immulon 4, Dynatech) were coated 
overnight at 4°C with 100 pi per well of hyperimmune sheep anti-isometamidium 
serum diluted optimally (see below) in 0.1M carbonate/bicarbonate buffer, pH 
9.2. Plates were then frozen with the coating solution in situ and stored at -20° 
C for up to two months.
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Competitive enzyme immunoassay
Test sera, standards and quality controls were prediluted 1/10 in an optimal 
dilution (see below) of isometamidium-HRP conjugate in PBS containing 0.05% 
Tween 20 (Sigma), in 8 x 12 racks of polypropylene tubes (Micronics systems, 
Muratech Scientific, Aylesbury). Coated plates were allowed to thaw and 
equilibrate to room temperature before washing five times in a 1/5 dilution of 
PBS in distilled water containing 0.05% Tween 20. Racked predilutions were 
vortex mixed and transferred to duplicate wells of microtitre plates (100 pi per 
well). Plates were shaken for ten minutes at room temperature, and then 
incubated overnight at 4°C. Plates were allowed to equilibrate to room 
temperature before washing five times as described previously. Enzyme levels 
were determined using 100 pi per well of a two-component horseradish 
peroxidase substrate containing 3,3,5,5 tetramethylbenzidine (Cambridge 
Veterinary Sciences, Littleport, UK) pre-warmed to 37°C. After 10 minutes 
incubation at 37°C with orbital shaking (Varishaker, Dynatech), the colour 
reaction was quenched by the addition of 100 pi per well of 2M sulphuric acid. 
Absorbances were read at 450 nm using a multichannel spectrophotometer 
(Multiskan Plus Mk II, Labsystems Oy, Helsinki, Finland).
For the testing of unknown samples, 8 standards were included in duplicate 
wells of every microtitre plate, at the following concentrations (ngmM): 500, 
18.5, 6.17, 2.06, 0.686, 0.229, 0.762, 0.0254. Three quality control samples 
were each included twice (in duplicate) on every microtitre plate, once at the 
beginning of the series of unknown samples, and again at the end. The quality 
controls comprised one normal (untreated) bovine serum, and two dilutions, 1/2 
and 1/5, in normal bovine serum, of serum from a particular steer treated 
intramuscularly with isometamidium, as described above, at a dose rate of 0.5 
mgkg*1.
The principle of the CEIA is illustrated in Plate 9.
Reagent titrations
Optimal dilutions for hyperimmune sheep anti-isometamidium serum and 
isometamidium-HRP conjugate were determined by checkerboard titration of the 
two reagents using the CEIA as described above, using pooled isometamidium- 
free NBS, or pooled NBS spiked with 0.69 ngmM isometamidium. The optimal 
combination of reagent dilutions was considered to be that resulting in a B0 
absorbance (i.e. the absorbance obtained with isometamidium-free NBS) of 
approximately 1.0 optical density units, and with the highest percentage
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competition (i.e. absorbance obtained with isometamidium-spiked NBS divided 
by B0 absorbance, x 100%).
Data Analysis
Data were downloaded from the multichannel spectrophotometer via the 
RS232C serial connection to an IBM-compatible microcomputer. Calculation of 
the mean and coefficient of variation of absorbances of duplicate wells, four- 
parameter logistic curve-fitting of calibration standards, and calculation of 
concentrations of unknowns were obtained using an executable program 
("Quikfit", M.C.E., unpublished) written in C++ (Turbo C++, Boorland 
International), and additional statistical calculations and precision profiling (see 
below) were performed using macro-language programs (M.C.E., unpublished) 
for three-dimensional spreadsheets (1-2-3 for Windows, Lotus Development 
Ltd, Staines, UK).
Precision profiling
The mean CEIA responses (absorbances) of duplicate standards, quality 
control samples and unknowns were allocated into eight "bins" of equal width 
(i.e. local segments of the graph) within the range between the highest and 
lowest values, and the median standard deviation of duplicates within each bin 
calculated (Rodbard, 1981). The response-error relationship was modelled 
using simple linear regression of the median standard deviation against the 
mean response within each bin. Precision profiles were calculated using the 
method of Ekins ((1983)), from the response-error relationship of individual 
assays, and from pooled responses in a series of 28 assays.
Response variance calculations
Fifty-seven normal bovine sera were tested using the CEIA to assess the 
variability of the mean response at zero-dose (variance of sample means, g*x). 
Each serum was tested in accordance with the test protocol, except that from 
each serum two predilutions were prepared (each of which was pipetted into 
duplicate wells of a microtitre plate), on four different days. This allowed 
partitioning of the overall variance into a variability component associated with 
the use of duplicate wells (intra-predilution variance, C^ wd ), a variability 
component associated with the predilution of sera (inter-predilution variance, a 
2M), and a component associated with true inter-sample variance (o^ bs)- 
Variances were calculated according to the model:
c^ x =a2bs + a2bd/ri+o2wd/r2 
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where n is the number of predilutions prepared from each serum, and r2 is 
the number of replicate wells filled from each predilution.
Additionally, the inter-assay response variability was assessed by 
calculating the mean variance of the mean responses for each sample on each 
day. Outlying data points were rejected using Cochran's one-sided outlier test 
(Anon. 1987). Analysis of variance was performed using Genstat 5 Release 2.2 
(Numerical Algorithms Group Ltd., Oxford).
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Plate 9. The three stages of the competitive 
enzyme immunoassay for the detection of 
isometamidium. Between each stage, unbound 
reagents are removed by washing.
a) The wells of a 96-well polystyrene 
microtitre ELISA plate are coated with specific 
antibody by passive adsorption of hyperimmune 
sheep anti-isometamidium serum.
b) The sample, containing an unknown 
quantity of the drug, is incubated in the ELISA 
plate wells together with a fixed quantity of 
drug-horseradish peroxidase conjugate. Sample 
drug competes for immobilised specific 
antibody, reducing the amount available to bind 
to drug-horseradish peroxidase.
c) In the presence of drug-horseradish 
peroxidase and hydrogen peroxide, colourless 
tetramethylbenzidine is converted into a 
coloured product.
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Results
Reagent titrations
All four Blackface wethers responded well to the isometamidium-porcine 
thyroglobulin conjugate immunisation. Anti-isometamidium hyperimmune 
serum from the wether which had the highest titre was used in subsequent 
assays. Optimal dilutions determined by checkerboard titration were 1/12000 
for anti-isometamidium hyperimmune serum, and 1/2000 for isometamidium : 
horseradish peroxidase conjugate.
Calibration curves
Calibration curves fitted well to the four-parameter logistic model, with 
adjusted r2 values usually greater than 0.98, and outlying data points occurred 
rarely. There was relatively little day to day variation in the four parameters, 
which indicated that the B0 and background absorbances, the drug 
concentration resulting in 50% competition, and the dynamic range of the assay 
were consistent. Mean B0 and background responses, the four parameters (A, 
B, C, D), and concentrations corresponding to 10%, 50% and 90% B0 values 
obtained over a series of 28 assays are shown in Table 16. The corresponding 
calibration curve is shown in Figure 10.
Precision profiling
The response-error relationship and resultant precision profile for pooled 
data over a series of 28 assays are shown in Figure 11. As the regression 
constant was small (0.002), and the response-error relationship linear (r2 = 
0.97), the response CV was relatively consistent across the response range, 
with CV = 3.4% at absorbance 1.00 and CV = 5.1% at absorbance 0.10. This 
resulted in a precision profile giving dose CV less than 25% between 
approximately 0.5 and lOOngmM, with the most precise dose estimates 
occurring between 5 and 10 ngmM (dose CV approximately 5%). Similar 
response-error relationships and precision profiles were derived from individual 
assays (data not shown).
Response variance of untreated cattle
The partitioned response variances of 57 normal bovine sera are shown in 
Table 17. The overall response variance (i.e. variance of sample means, c^ x), 
based on a single predilution from each serum, was low, with a corresponding 
CV of approximately 10%. True inter-sample variability accounted for 76.9% of
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this overall variance, giving a corresponding CV of 8.7%. Inter-predilution 
variability accounted for an additional 9.6% of overall variance, with 
corresponding CV of 3.1%. The remaining 13.5% of the overall variance was 
accounted for by intra-predilution variability, with a corresponding CV of 5.2% 
for duplicate wells prepared from a single predilution.
The variability of responses between identical assays conducted on 
different days was also low, giving a CV of 10.9%.
Similar results were obtained with other normal bovine sera, tested using 
the normal assay procedure (i.e. only one predilution per serum). For example 
the CV of the sample means of 34 normal bovine sera was 9.0% (results not 
shown). It was not possible to partition the variance for these sera.
Isometamidium-treated cattle
Isometamidium could be detected in the sera of cattle treated with 
isometamidium by the intramuscular route for up to ten weeks following 
administration of the drug. Concentrations were similar to those obtained using 
the indirect competition ELISA (Chapters 3, 4 and 5). One hundred and 
seventy one samples from isometamidium treated cattle were analysed using 
both the ICE and the CEIA; the results of these determinations are shown in 
Figure 12. Linear regression of log concentration determined by the CEIA on 
log concentration determined using the ICE resulted in an adjusted r2 value of 
0.96 indicating close agreement between the two methods.
Determinations performed on two separate days on 108 individual samples 
from isometamidium-treated cattle were analysed by linear regression as a 
measure of the reproducibility of the method. The results of these 
determinations are shown in Figure 13. An adjusted r2 value of 0.94 was 
obtained, signifying a high level of reproducibility.
Cross-reactivity with other trypanocidal compounds
The CEIA showed only very low levels of cross-reactivity with diminazene 
aceturate, so that concentrations of diminazene required to reduce B/B0 to 50% 
were approximately 1000 times greater than those for isometamidium. 
Calibration curves obtained with homidium chloride were non-sigmoidal, which 
made it difficult to calculate a cross-reactivity factor. However, significant cross 
reactivity with homidium chloride did occur in these assays. All four immunised 
sheep showed similar patterns of cross reactivity.
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Table 16. Mean B0 and background responses, the four parameters of 
logistic curve-fitting (A, B, C, D), and concentrations corresponding to 
10%, 50% and 90% B0 values obtained over a series of 28 assays.
Parameter Value:
A 0.933
B 0.393
C 1.19
D 0.035
B0 0.968
Signal to noise ratio 
(B0 / background)
27.5
10% B0 (ngmM) 13.90
50% B0 (ngmM) 2.19
90% B0 (ngmM) 0.35
B0 = absorbance at zero dose
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Table 17. Response variance of untreated cattle
Day c^bs <**bd
Variance CV Variance CV Variance CV Variance1 CV
component component component component
1 100% 10.3% 73.2% 8.8% 8.0% 2.9% 18.8% 6.3%
2 100% 10.0% 70.5% 8.4% 20.9% 4.6% 8.6% 4.1%
3 100% 10.4% 87.7% 9.7% 1.0% 1.1% 11.2% 4.9%
4 100% 8.9% 72.9% 7.6% 8.5% 2.6% 18.5% 5.4%
ALL 100% 9.9% 76.9% 8.7% 9.6% 3.1% 13.5% 5.2%
o*x = variance of sample means (based on single predilutions) 
cr^j = true inter-sample variance 
a*bd = inter-predilution variance
^wd = intra-predilution variance (1based on two replicate wells per predilution)
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Figure 10. Calibration curve for the isometamidium CEIA. Mean responses 
(absorbances at 450 nm) for isometamidium-spiked standards prepared using normal 
bovine serum were fitted to the four-parameter logistic equation using "Quikfit". The 
parameters for the curve are shown in Table 16.
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Figure 11(a). Intra-assay response-error relationship constructed using pooled 
data from 28 assays. Mean responses of duplicate wells were divided into eight 
evenly spaced categories between the maximum and minimum values. Within each 
category, the median standard deviation (S.D.) of duplicates was plotted against the 
mean response (X). The line represents that of best fit obtained by linear regression 
(S.D. = 0.032X + 0.002, adjusted r2 = 0.96). Figure 11(b): see overleaf.
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Figure 11(b). Precision profile obtained using the response-error relationship 
shown in Figure 11(a), and the calibration curve shown in Figure 10. The y-axis 
shows the predicted coefficient of variation (%) of concentrations determined in the 
isometamidium CEIA, obtained by dividing the standard deviation predicted at each 
concentration by that concentration, and multiplying by 100. Standard deviation of 
measured concentration, as a function of concentration (H), was predicted by dividing 
the response-error relationship function by the gradient (T) of the calibration curve 
calculated from the equation:-
r  = (AB CH1 /c)/( 1+2BHC+B2H2C) 
where A, B, C are three of the four parameters of the calibration curve.
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Figure 12. Results in ngml*1 of determinations on 171 serum samples from 
isometamidium-treated cattle using the indirect competition ELISA (Chapter 3) 
(x-axis) and the competitive enzyme immunoassay (y-axis). The line shows best 
fit by linear regression of log concentrations; adjusted r2 = 0.96.
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Figure 13. Results in ngml-1 of two determinations in separate assays on different 
days on 108 serum samples from isometamidium-treated cattle. The line shows best 
fit by linear regression, adjusted r2 = 0.94.
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Discussion
The competitive enzyme immunoassay (CEIA) for isometamidium has been 
shown to be a useful new analytical method for the detection and quantification 
of the drug in bovine serum.
The CEIA differs from the indirect competition ELISA (ICE) for 
isometamidium (Chapter 3 and Plate 7) in the strategy adopted to quantify the 
level of analyte. Whereas in the ICE there is competition between solid phase- 
bound isometamidium conjugate and liquid phase isometamidium for specific 
antibody in the liquid phase, in the CEIA, competition for solid phase-bound 
specific antibody is between conjugated and unconjugated isometamidium both 
in the liquid phase (see Plate 9). Whole hyperimmune serum, suitably diluted in 
carbonate/bicarbonate buffer is passively adsorbed onto the solid phase, 
namely high quality, 96-well polystyrene microtitre plates. In the competition 
reaction, test samples containing unknown quantities of isometamidium are 
diluted in buffer containing a fixed amount of enzyme-conjugated 
isometamidium and incubated overnight in the wells of coated microtitre plates. 
Finally, after washing to remove unbound reagents, the substrate-chromogen 
solution is added.
The CEIA has a number of advantages over the ICE in terms of reagent 
preparation, repeatability, the number of assay steps, and in the "waiting time" 
during incubations. Firstly, the use of hyperimmune sheep anti-isometamidium 
serum in the CEIA, rather than the anti-isometamidium biotinylated IgG used in 
the ICE, obviates the need for immunoglobulin purification and biotinylation. 
Secondly, whereas in the ICE plates needed to be coated each day for use the 
following day, in the CEIA plates may be coated as a large batch using a single 
aliquot of coating solution. This reduces the day to day variability in optical 
density seen in the ICE. As coating is no longer part of the assay protocol per 
se, the CEIA effectively consists of only two stages, firstly the incubation of 
samples with isometamidium-HRP conjugate, and secondly the colour 
development step. In comparison the ICE has four separate stages for each 
assay. Finally the CEIA is less time consuming as the first stage has in effect 
zero "waiting time", being an overnight incubation, and the second stage, colour 
development, takes only ten minutes. By contrast the ICE has an overnight 
incubation, and three subsequent incubation stages, a total of almost two hours 
"waiting time".
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The inter-sample response variation (cr2*) of isometamidium-nai’ve normal 
bovine sera in the CEIA was found to be low, with a corresponding CV of 
approximately 10%. Partitioning of variance showed the within-predilution 
variability (o2^ ), attributable to the CEIA method per se (excluding variability 
associated with preparation of predilutions) to be relatively low, with a 
corresponding CV of approximately 5%, and using duplicate wells, accounting 
for approximately 13.5% (o2^ /  2.o2x x 100%) of overall variability. Predilution of 
samples did not introduce much additional variability as inter-predilution 
variance (a2* )  accounted for only 9.5% of overall variance, and the overall 
within sample variability (o ^  + o2^  / 2) accounted for only 23% of overall 
variance.
The main contribution to overall inter-sample variability was attributable to 
the isolated, true inter-sample variability (a2^ ), or sample matrix effect (Chard, 
1990). This is a result of the inclusion of a relatively high concentration (10%) 
of serum sample in the reaction mixture. Investigations at other sample 
concentrations (unpublished data) suggest that the sample inclusion rate of 
1/10 is the best compromise between reducing inter-sample variability by 
diluting out the sample matrix, and reducing detectability by diluting out the 
analyte. At the chosen sample dilution (1/10), sample matrix effect occurs but is 
acceptable as it results in only slight inter-sample variability, which still permits 
a relatively low limit of detection.
Rodbard (1978) discussed the use of a one-tailed Student's t statistic for 
the estimation of the minimum detectable concentration or sensitivity of 
radioligand assays. However, the approach taken did not allow for inter-sample 
variability, cr2^ . It may not, therefore, be appropriate for the CEIA for 
isometamidium, in which the response variance of unknown samples at or 
around zero-dose which does include a2^  as a component, may be greater than 
the variance of the estimate of B0, which does not. We suggest 0.5 ngmh1 as an 
approximation of the limit of detection, obtained using B0 - 1.6 x o2, as an 
estimate of the greatest response significantly different to zero.
The CEIA was found to give results in close agreement with those obtained 
in the ICE (Figure 12). The new immunoassay technique was also shown to 
have a high level of reproducibility (Figure 13).
One potential disadvantage of the CEIA compared to the ICE for 
isometamidium is the greater sensitivity of the latter method (approximately 0.1 
ngmM, Chapter 3). However it should be possible to increase the sensitivity of
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the CEIA should this be found necessary. Studies underway in this laboratory 
indicate that high titre antisera against isometamidium may be raised in rabbits, 
and that these antisera may produce assays with sensitivities similar to that of 
the indirect competition ELISA. Furthermore, if it is considered necessary to 
detect smaller (sub-nannogramme) quantities of isometamidium, an extraction 
and concentration step could be employed (Kinabo and Bogan, 1988). Such a 
step was not used in the work described here because of the importance of 
keeping the procedure as simple as possible for use in African laboratories. 
Finally, investigations into the relationship between isometamidium 
concentrations circulating in treated cattle and prophylaxis against tsetse- 
transmitted trypanosomiasis (Chapter 4) suggest the CEIA has adequate 
sensitivity to detect concentrations in the range of interest in field situations.
In these studies, the CEIA for the detection of isometamidium in bovine sera 
has been shown to be a simple and reliable method, both in terms of the in vitro 
characteristics of the assay using sera from isometamidium-naive European 
cattle, and in terms of the repeatability of the determinations of the drug in the 
sera of treated European cattle. Other studies have shown it to be a useful and 
reliable method for use in the investigation of the pharmacokinetics of 
isometamidium, and in the determination of concentrations of the drug in African 
cattle under field situations. The results of these studies are presented in 
subsequent chapters.
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Chapter 8:
Pharmacokinetics of the Chemoprophylactic and 
Chemotherapeutic Trypanocidal Drug Isometamidium
Chloride in Cattle
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Introduction
Of the few drugs available for use in African bovine trypanosomiasis, 
isometamidium chloride (Samorin®, Trypamidium®) is the only one widely used 
for its prophylactic and therapeutic activity. The drug has been widely used 
under field conditions for over thirty years, and its effectiveness in a commercial 
situation has been demonstrated (Trail et al., 1985). In controlled laboratory 
experiments in cattle, up to six months prophylaxis against tsetse challenge with 
Trypanosoma congolense has been demonstrated following a single 
intramuscular dose (Whitelaw et al., 1986; Peregrine et al, 1988; and Chapter 
3).
In spite of a long history of widespread use, the approach to dosage 
regimens with isometamidium has remained empirical, as until recently 
analytical techniques capable of determining drug concentrations in the 
circulation of treated cattle were not available and meaningful pharmacokinetic 
analyses were not possible. Philips et al. (1967), used a spectrophotometric 
method of analysis which was not sufficiently sensitive to determine 
concentrations less than 0.7 ngmM in plasma. Perschke and Vollner (1985) 
developed a high performance liquid chromatography (HPLC) method in which 
isometamidium was converted to homidium before separation and detection, 
and thus the method was not specific. Using this method, concentrations as low 
as 20 ngmM could be detected, but this required as much as 5 ml of serum per 
sample. Kinabo and Bogan (1988a) developed a more sensitive and specific 
ion-pair reverse-phase HPLC method for isometamidium, which could detect as 
little as 10ngmM, but even with this improved level of sensitivity the drug could 
only be detected in the serum of treated cattle for two hours following 
intramuscular doses of 0.5 mgkg-1. Similarly a radioimmunoassay for 
isometamidium was relatively insensitive because of the low specific activity of 
the 14C-labelled tracer, and was unable to detect the drug in serum of calves 
treated at the same dose rate for more than four hours (Kinabo and Bogan, 
1988d).
More recently two ELISA methods for isometamidium (Chapters 3 and 7) 
have been shown to be capable of detecting sub-nannogramme quantities of 
isometamidium in the sera of treated cattle for several weeks following 
intramuscular treatment at 0.5 or 1.0 mgkg-1; one of these ELISAs has been 
used to investigate the relationship between circulating concentrations of 
isometamidium following the administration of prophylactic injections, and
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protection against experimental tsetse challenge with Trypanosoma congolense 
(Chapter 4). In this study another ELISA technique for isometamidium, the 
competitive enzyme immunoassay (CEIA) described in Chapter 7, has been 
used to determine the disposition kinetics of isometamidium following 
intramuscular and intravenous injection.
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Materials and methods
Cattle
Three to six month old Friesian (Bos taurus) steers weighing 92 - 122 kg 
were maintained on hay, and a commercial concentrate ration, and had access 
to water ad libitum. These cattle were raised and maintained in a country 
without tsetse (UK), and had never previously been exposed to trypanocidal 
drugs.
Isometamidium chloride treatment
Isometamidium chloride (Samorin®) was administered to cattle by injection 
of a 1 % aqueous solution into the jugular vein, following the method of Dowler 
et al. (1989), or by deep intramuscular injection of a 2% aqueous solution into 
the middle third of the neck, except in animals in which the musculature of the 
neck was poorly developed, in which case the gluteal muscles were used. 
Injections were given using a 11/a inch 19 gauge needle at a dose rate of 1.0 
mgkg-1 body weight.
Serum collection
Blood samples were collected using indwelling intravenous jugular 
cannulae for the first forty-eight hours following isometamidium treatment. 
Thereafter blood samples were collected using plain Vacutainers (Becton- 
Dickinson). Blood samples were incubated for approximately four hours at 
37°C, and then overnight at 4°C, before separation of serum by centrifugation. 
Serum samples were stored at -25°C until required for testing.
Isometamidium determinations
Serum isometamidium concentrations were determined using the 
competitive enzyme immunoassay (CEIA) described in Chapter 7.
Briefly, sera were prediluted 1/10 in a 1/2000 dilution of isometamidium- 
HRP conjugate in phosphate buffered saline (PBS), pH 7.2, containing 0.05% 
Tween 20 (Sigma). Ninety-six well microtitre plates (Immulon 4, Dynatech) 
which had previously been coated overnight with 100 pi per well of an 
appropriate dilution of hyperimmune sheep or rabbit anti-isometamidium serum 
in carbonate/bicarbonate buffer, pH 9.2, and then frozen and stored at -20°C 
with the coating solution in situ, were allowed to thaw and equilibrate to room 
temperature. Plates were then washed five times in a 1/5 dilution of PBS in 
distilled water containing 0.05% Tween 20. Serum predilutions were vortex
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mixed and transferred to duplicate wells of microtitre plates (100 pi per well). 
After shaking for ten minutes at room temperature, plates were incubated 
overnight at 4°C, and then allowed to equilibrate to room temperature before 
five washes as described previously. Enzyme levels were determined using 
100 pi per well of a two-component horseradish peroxidase substrate containing
3,3,5,5 tetramethylbenzidine (Cambridge Veterinary Sciences, Littleport, UK) 
pre-warmed to 37°C. After 10 minutes incubation at 37°C with orbital shaking 
(Varishaker, Dynatech), the colour reaction was quenched by the addition of 
100 pi per well of 2M sulphuric acid. Absorbances were read at 450 nm using a 
multichannel spectrophotometer (Multiskan Plus Mk II, Labsystems Oy, 
Helsinki, Finland).
A series of eight standards, ranging in concentration from 0.025 to 500 
ngmM, were prepared using commercially available normal bovine serum from a 
single batch (Equine and Ovine Blood Products Ltd., Bonnybridge, Stirlingshire) 
which had been shown to give a response in the CEIA close to the mean of the 
responses obtained with sera from the experimental cattle prior to any 
trypanocidal drug treatment, and were included in duplicate wells of every 
microtitre plate. Three quality control samples, comprising one normal 
(untreated) bovine serum, and two dilutions, in normal bovine serum, of serum 
collected from a single steer 48 hours after intramuscular treatment with 0.5 
mgkg-1 isometamidium chloride, were each tested twice (and in duplicate) on 
every microtitre plate. Samples were tested in duplicate, and concentrations of 
unknowns and quality control samples were derived by four-parameter logistic 
curve-fitting of calibration standards on the same ELISA plate. Results from 
individual ELISA plates were only included in the final data analysis if the 
standards and quality controls gave the results expected.
Data Analysis
Data were downloaded from the multichannel spectrophotometer via the 
RS232C serial connection to an IBM-compatible microcomputer. Calculation of 
the mean and coefficient of variation of absorbances of duplicate wells, four- 
parameter logistic curve-fitting of calibration standards (Rodbard and Hutt, 
1974), and calculation of concentrations of unknowns were obtained using the 
program "Quikfit" (M.C.E. unpublished) and additional statistical calculations 
and precision profiling were performed using macro-language programs 
(M.C.E. unpublished) for three-dimensional spreadsheets (1-2-3 for Windows, 
Lotus Development Ltd, Staines, UK).
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Pharmacokinetic analysis
The serum isometamidium concentration data obtained using the CEIA was 
analysed using the exponential curve stripping program JANA (SCI Software), 
and the nonlinear regression/pharmacokinetic modelling program PCNONLIN 
(SCI Software). Data from cattle treated intravenously was analysed using a 
three compartment open model (Kinabo and McKellar, 1989). The suitability of 
the model was assessed using the Akaike (Yamaoka, Nakagawa and Uno, 
1978) and Swartz (1978) information criteria. Data from cattle treated 
intramuscularly was analysed using a non-compartmental model (Kinabo and 
McKellar, 1989). Pharmacokinetic parameters are calculated by the software 
using standard methods (Gibaldi and Perrier, 1982) and are expressed using 
the preferred symbols (Rowland and Tucker, 1980). Data were weighted using 
weights equal to the square of the reciprocal of concentration.
Arithmetic means were calculated for pharmacokinetic parameters obtained 
for cattle treated by the same route of administration, except in the case of half- 
lives, for which geometric means were calculated. Differences between 
pharmacokinetic parameters calculated for two individual cattle were considered 
to be statistically significant, when greater than twice the mean of their 
respective standard errors.
Experimental design
Five cattle were treated with isometamidium chloride by the intramuscular 
route. Blood samples were collected from these cattle at 20, 40, 60, 80, and 
100 minutes after injection, then at 2, 3, 6, 12, and 24 hours after injection, then 
at 12 hourly intervals until 7 days after injection, then daily until 18 days, then 
biweekly until 50 days after injection, and thereafter weekly until isometamidium 
could no longer be detected in the serum.
Another similar five cattle were treated with isometamidium chloride by the 
intravenous route. Blood samples were collected from these cattle at similar 
times after injection to the intramuscularly treated cattle, with an additional 
sampling at 10 minutes after injection.
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Results
Intravenously Treated Cattle
Isometamidium could be detected using the competitive enzyme 
immunoassay (CEIA) for over 14 days in all five intravenously treated cattle. 
Mean isometamidium concentrations determined in the sera of intravenously 
treated cattle are shown in Figure 14.
Pharmacokinetic parameters obtained using a three compartment open 
model of isometamidium concentrations determined with the CEIA in the sera of 
cattle treated with isometamidium chloride by the intravenous route are shown 
in Table 18. Only data from serum samples collected up to the time that the 
measured concentration fell below twice the limit of detection of the CEIA (1.0 
ngmM) were used in the pharmacokinetic analysis. Hence the analysis was 
conducted for the first 14 days (2 cattle, nos. 111 and 112), 15 days (no. 113), 
42 days (no. 114), and 21 days (no. 115) following treatment.
Of the five cattle to which isometamidium had been administered by the 
intravenous route, most of the pharmacokinetic parameters calculated for one 
animal (no. 114) were statistically significantly different from those of the other 
four animals. This animal was one in which difficulty had been experienced in 
administering the intravenous injection and at least part of the injection may 
have had been extravascular. The pharmacokinetic parameters for this animal 
were therefore excluded from the calculation of the mean values.
The volume of the central compartment (Vc) was large (mean 0.70, range 
0.59 - 0.95 Ikg-1). The mean area under the curve (AUC) was 143 ng.h.mM 
(range 129 - 170), and the total body clearance (Cl) of isometamidium was 4.9 
ml/min/kg (range 4.1 - 5.4 ml.min-1kg-1). The mean residence time (MRT) was 
long at 3.4 days (range 2.6 - 5.2 days) and the volume of distribution at steady 
state (Vss) was very large (mean 24.5, range 18.6 - 39.3 Ikg-1). The half-life of 
the elimination phase was 5.8 days (range 5.1 - 6.9 days).
Intramuscularly Treated Cattle
Isometamidium could be detected by the CEIA in intramuscularly treated 
cattle for up to 64 days after treatment. Mean isometamidium concentrations 
determined in the sera of intramuscularly treated cattle are shown in Figure 15.
Pharmacokinetic parameters obtained by non-compartmental modelling of 
drug concentrations determined using the isometamidium-CEIA in the sera of
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cattle treated with isometamidium chloride by the intramuscular route are shown 
in Table 19. Only data from serum samples collected up to day 30 following 
treatment were used in the pharmacokinetic analysis, as beyond this time 
concentrations fell below 1.0 ngml-1 (twice the limit of detection of the CEIA).
The maximum isometamidium concentrations (Cmax) were attained rapidly, 
mean time to maximum observed concentration (Tmax) was 36 minutes (range 20 
- 60 minutes). Values of Cmax varied considerably, with values in two cattle 
(nos. 5 and 6; Cmax = 197ngml*1 and 191 ngml-1 respectively) considerably higher 
than in the other three (nos. 7, 8 and 9; Cmax = 53 ngml-1, 77 ngml-1 and 37 ngml- 
1 respectively). Thereafter concentrations fell rapidly, and by 24 hours were not 
greater than 10% of C max. The mean concentration fell by a further 50% over 
the next 24 hours, but thereafter the rate of drug disappearance diminished so 
that a further 6 days were required for another 50% reduction in concentration.
The apparent bioavailability (F) of isometamidium following intramuscular 
injection was 63%, and the mean absorption time (MAT) was 7.8 days.
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Table 18. Pharmacokinetic parameters obtained from cattle treated with 
isometamidium chloride by intravenous injection at a dose rate of 1.0
mgkg’1.
Parameter Units Mean Range
Czero ngml'1 1496 1049 - 1708
VCc
io> 0.695 0.586 - 0.953
K21 - 5.96 3.21 - 8.89
K31 - 0.202 0.181 - 0.221
K10 - 10.5 8.0 - 13.2
K12 - 12.6 6.8 - 17.8
K13 - 6.31 5.23 - 7.54
K 1 0 -V h 1.61 1.26 - 2.08
Alpha-t%* h 0.528 0.408 - 0.673
Beta-t%* h 5.56 4.35 - 8.40
Gamma-ty,* h 136 123 - 165
AUC ng.d.ml'1 143 129 - 170
Cl ml.min'1.kg*1 4.90 4.07 - 5.37
AUMC ng.d2.ml*1 490 363 - 679
MRT h 82.75 63.42 - 123.91
___ VSS Ikg'1 24.5 18.5 - 39.3
'Means of half-lives are geometric means
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Table 19. Pharmacokinetic parameters obtained from cattle treated with 
isometamidium chloride by deep intramuscular injection at a dose rate of
1.0 mgkg*1.
Parameter Units Mean Range
tmax h 0.605 0.336 - 1.01
Cmax ngml"1 111 37 - 197
Beta - 0.103 0.054 - 0.144
Beta* d 7.22 4.81 - 12.8
AUC,ast ng.d.ml"1 84.6 43.3 - 131
AUCimf
(observed)
ng.d.ml"1 97.6 64.0 - 140
AUCimf
(predicted)
ng.d.ml"1 90.4 57.0 - 133
AUMC,ast ng.d2.ml"1 645 392 - 808
AUMCinf
(observed)
ng.d2.ml"1 1186 982 - 1387
AUMCinf
(predicted)
ng.d2.ml"1 890 775 - 991
MRT|ast d 8.26 6.16 - 11.1
MRTinf
(observed)
d 13.6 8.2 - 20.2
MRTinf
(predicted)
d 11.2 6.6 - 17.4
Bioavailability % 63.0 NA
MAT d 7.78 NA
* Mean half-life is geometric mean
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Figure 14. Mean isometamidium concentrations (ngml*1) in the sera of 4 cattle 
treated with 1.0 mgkg*1 by the intravenous route, determined using the CEIA. 
Error bars: standard deviation.
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Figure 15. Mean isometamidium concentrations (ngml*1) in the sera of 5 cattle 
treated with 1.0 mgkg*1 by the intramuscular route, determined using the CEIA. 
Error bars: standard deviation.
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Discussion
The isometamidium CEIA has permitted, for the first time, a comprehensive 
pharmacokinetic analysis of the disposition and kinetics of the drug in treated 
cattle.
Although a cross-over experimental design is usually considered desirable 
in pharmacokinetic studies, two different groups of cattle were used for the 
intramuscular and intravenous studies. In view of the extremely long period of 
biological activity following a single dose of isometamidium chloride (Whitelaw 
et al.t 1986), the length of the washout period required between repeat 
treatments of the same animals by different routes would have been impractical. 
Overall mean values for bioavailability (F) and mean absorption time (MAT), 
could nevertheless be calculated, although the experimental design precluded 
estimation of individual values, and hence variability, of these parameters.
Weighting of data using weights equal to the square of the reciprocal of 
concentration was considered necessary because of the wide disparity (over 
1000-fold) between the highest and lowest concentrations measured, resulting 
in a tendency for the non-linear least squares method to fit the earlier data 
points (the highest concentrations) better than the later data points (the lowest 
concentrations) for which the residual values (i.e. the difference between the 
concentrations observed and those predicted by the model) were far smaller. 
This weighting scheme is justifiable on mathematical grounds because of the 
error structure of the determination of concentrations, as predicted by the 
precision profile of the assay (Chapter 7). Because the coefficients of variation 
of the concentrations are relatively uniform over the dynamic range of the 
assay in which they are determined, the corresponding standard deviation tends 
to be related to concentration linearly, and hence the variance tends to be 
linearly related to the square of the concentration. Weighting on the basis of 
the reciprocal of the square of the concentration is thus proportional to 
weighting on the basis of the reciprocal of the variance (in practice weights are 
"normalised" by multiplying by a factor such that the sum of the weights equals 
the number of observations).
The large volume of the central compartment (mean 0.70 Ikg-1) exceeded 
both the plasma volume (0.028 - 0.037 Ikg-1) and the extracellular fluid volume 
(0.26 - 0.37 Ikg-1) of cattle (Tasker, 1980). The extremely large volume of 
distribution at steady state (mean 24.5 Ikg-1, range 18.6 - 39.3 ) was greater
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than the total body water (0.502 - 0.645 Ikg-1) of cattle (Tasker, 1980), and 
probably reflected extensive uptake of the drug into specific tissues. The 
prolonged mean residence time (83 h) and terminal phase half-life (136 h) 
following intravenous injection were consistent with the formation of secondary 
drug depots. In rats, 41% of a 1.0 mgkg-1 dose of isometamidium administered 
by the intravenous route was present in the liver within 1 minute of injection, 
and by 10 minutes, 62% of the dose was present in the same organ (Philips et 
al., 1967). In addition, approximately 5% of the dose administered was 
detected in kidney as early as 1 minute after injection. Kinabo and Bogan 
(1988b) using HPLC analysis, confirmed the presence of secondary 
isometamidium depots in liver, kidney and spleen, one, three and six weeks 
following intramuscular treatment of cattle. Uptake of isometamidium into these 
tissues may be due to binding of the drug to proteins, to acid phospholipids and 
to DNA (Kinabo and Bogan, 1987), or to an isometamidium-specific active 
transport mechanism as was proposed by Philips et al. (1967); such a 
mechanism has been demonstrated in T. congolense (Sutherland et al., 1992; 
Zilberstein et al., 1993).
The absolute bioavailability (F) of isometamidium following intramuscular 
injection was found to be approximately 60%. In experiments on the use of 
isometamidium in pigs, the bioavailability could not be calculated because 
animals which received the drug via the intravenous route died (Kinabo et al.,
1991). In goats, the mean absolute bioavailability of intramuscularly injected 
isometamidium was 27% (Kinabo and McKellar, 1990), approximately half that 
obtained in cattle in the study described here. The value of tmax following 
intramuscular injection of cattle (0.6 h) was considerably less than that in goats 
(6 h) implying absorption of isometamidium was slower in the latter species, at 
least in the initial phase following injection. In spite of the relatively short time 
to maximum concentration in cattle, the mean absorption time (MAT) in cattle 
was prolonged (7.8 d), and considerably longer than that observed in goats (13 
h). The low F value and slow absorption rate in goats were considered to be 
due to binding of the drug to tissue macromolecules and ground matrix 
components at the injection site (Kinabo and McKellar, 1990), and the same 
probably holds true, possibly to a lesser extent, in cattle. One possible 
explanation of the large differences observed between cattle and goats in MAT 
and F values might be the high sensitivity of the CEIA (detection limit 0.5 ngml- 
1) which enabled pharmacokinetic parameters to be determined using 
concentration-time data up to 30 days after intramuscular treatment and 15
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days after intravenous treatment. The goat study used the less sensitive HPLC 
method (detection limit 5 ngml-1), which was unable to detect isometamidium in 
plasma samples more than 24 hours after intravenous treatment, and 48 hours 
after intramuscular treatment. This might have led to underestimation of the 
value of the terminal phase rate constant (p) and consequently inaccuracy in 
the parameters derived from it, including AUC, MAT and F.
The relative importance of the injection site and other secondary drug 
depots in the prophylaxis of isometamidium afforded to rats was investigated by 
Hill and McFadzean (1963). Following amputation of the injection site in the 
tail, the period of prophylaxis afforded was reduced from 16 to 2 weeks. 
Although the tail of a rat may not be a particularly good model of an 
intramuscular injection in the bovine, that experiment clearly indicated the 
importance of the primary depot, while also demonstrating a not insignificant 
period of prophylaxis following its removal.
In the present work the time required for drug concentrations to fall to 1.0 
ngml'1 following intravenous treatment (mean 16 days) was approximately half, 
when compared with intramuscular treatment (mean 30 days). Isometamidium 
has been shown to possess prophylactic activity for up to 48 days following 
intravenous administration to cattle (Toure, 1973).
In this study C max was over ten times greater following intravenous 
administration (mean C0 [= Cmax] 1.3 pgmH) than intramuscular administration 
(mean C max 110 ngml-1) of a 1.0 mgkg-1 dose. Dowler et al. (1989) considered 
that achievement of initial high blood levels of isometamidium may be important 
in the elimination of cryptic infections. Intravenous administration of 
isometamidium also has the advantage of avoiding the severe inflammatory and 
subsequently fibrotic tissue reaction associated with intramuscular use of the 
drug (Kinabo and Bogan, 1988b), which may result in loss of value of the 
carcass (Dowler et al., 1989). The intravenous route may be preferable in 
slaughter cattle for this reason (Eyidi, 1971; Dowler et al., 1989).
The pharmacokinetic results obtained here with isometamidium are not 
dissimilar to those obtained with the related trypanocide diminazene aceturate 
(Aliu et al., 1993) in female Boran cattle, in that following intravenous injection, 
drug concentrations fell rapidly during a biphasic period of drug distribution, and 
more slowly during a prolonged elimination phase. The elimination half-life of 
intravenous isometamidium (137 hours) was, however, far longer than that of
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diminazene (31.7 hours), a finding consistent with the prolonged period of 
biological activity observed with the former drug.
Kinabo and McKellar (1989) reviewed the models available for veterinary 
pharmacokinetic studies, and proposed a physiological pharmacokinetic model 
for isometamidium. One of the reasons for the development of this model was 
that of the very low concentrations present in serum, below the limit of detection 
of the available methods of determination (Kinabo and Bogan, 1988a, 1988b), 
which precluded a compartmental analysis. The improved sensitivity of 
detection afforded by the ELISA (CEIA) has allowed this constraint to be 
overcome, and has allowed the major pharmacokinetic parameters to be 
derived for isometamidium. The studies reported here were conducted in 
Friesian cattle (Bos taurus). Although further work will be required to 
investigate whether there are any significant differences in the 
pharmacokinetics of isometamidium in Bos indicus cattle, earlier studies failed 
to reveal any evidence of differences between the two species of cattle in the 
rates of disappearance of the drug from the sera following treatment via the 
conventional intramuscular route (Chapter 3 and 4).
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Chapter 9:
Isometamidium Concentrations in the Sera of Cattle 
Under a Chemoprophylactic Regime in a Tsetse- 
Infested Area of Zimbabwe
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Introduction
At present, the use of trypanocidal drugs is the mainstay of control of 
bovine trypanosomiasis in much of sub-Saharan Africa (Jordan, 1992), and is 
likely to remain so for the foreseeable future.
Isometamidium chloride (Samorin®, Trypamidium®) is the most widely used 
drug for chemoprophylaxis of bovine trypanosomiasis in Africa. The use of 
isometamidium until the present has been largely empirical, because of the lack 
of a suitable analytical method for the determination of its concentration in the 
circulation of cattle. However, recently developed ELISA techniques for the 
determination of isometamidium concentrations in bovine serum (Chapters 3 
and 6) should provide opportunities to rationalise and improve strategies for the 
use of this drug by allowing drug levels to be quantified following treatment. 
This is of particular importance in view of the increasing number of reports of 
drug-resistant trypanosomes (Kupper and Wolters, 1983; Pinder and Authie, 
1984; Ainanshe et al., 1992; Codjia et al., 1993), which may arise as a result of 
inappropriate use of trypanocidal drugs (MacLennan, 1970; Leach and Roberts, 
1981).
The indirect competition ELISA for isometamidium (Chapter 3) was used to 
measure concentrations of the drug in the sera of cattle that were treated and 
maintained under controlled laboratory conditions (Chapters 3, 4 and 5). In 
such animals the assay could detect the drug for up to four months after 
treatment (Chapter 5). Furthermore, the relationship between serum 
concentrations of isometamidium and the degree of protection against tsetse 
challenge with various populations of Trypanosoma congolense was 
investigated (Chapters 4 and 5). This ELISA was also shown to be capable of 
measuring concentrations of isometamidium in the sera of Jersey dairy cattle 
under a chemoprophylactic regimen in the field (Chapter 6).
A simpler, more robust, competitive enzyme immunoassay (CEIA) for 
isometamidium was described in Chapter 7. The CEIA was shown to have a 
high level of repeatability and reproducibility, and gave results which 
corresponded closely with those obtained in the indirect competition ELISA for 
isometamidium (Chapter 7).
In the work described in this Chapter, the CEIA for isometamidium was 
further evaluated in an experiment carried out under field conditions to 
determine the concentrations of isometamidium present in the sera of cattle
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maintained under an isometamidium chemoprophylactic regimen in the face of 
natural tsetse challenge.
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Materials and methods
Study site
The experiment was carried out at the Rekomitjie Research Station; a 
tsetse-infested area of the Zambezi valley, Zimbabwe. Glossina pallidipes is the 
predominant tsetse fly species in this area, with smaller numbers of Glossina 
morsitans morsitans. The area supports abundant populations of game animals 
and a few cattle kept for research purposes (Woolhouse, Hargrove and 
McNamara, 1993).
Cattle
Twenty-four clinically normal adult cattle were obtained from the tsetse-free 
area of Makuti, situated on the Zambezi escarpment. A further eighteen cattle, 
maintained permanently at Rekomitjie, were used as challenge controls during 
the experiment.
Serum collection
Every two weeks, jugular venous blood was collected into plain Vacutainers 
(Becton Dickinson), and the serum separated and stored at -20°C until analysis 
by the competitive enzyme immunoassay for isometamidium.
Trypanocidal drug treatments
Isometamidium chloride (Samorin®) was administered as a 2% (w/v)
aqueous solution by deep intramuscular injection into the gluteal muscle mass 
at a dose of 1.0 mgkg-1 body weight (body weight). Diminazene aceturate 
(Berenil®* Hoechst AG) was administered as a 7% (w/v) aqueous solution by 
deep intramuscular injection at a dose of 7.0 mgkg-1 body weight
Parasitological monitoring
Every two weeks blood samples were collected from an ear vein of each 
animal into potassium ethylenediamine tetra-acetate. Thereafter, the samples 
were examined for trypanosomes using the haematocrit centrifugation - buffy 
coat technique (Murray et al.t 1977). Identification of the species of 
trypanosome was confirmed using Giemsa-stained thin-blood films.
Isometamidium determinations
Serum isometamidium concentrations were determined using the 
competitive enzyme immunoassay described in Chapter 7. Briefly, sera were 
prediluted 1/10 in a 1/2000 dilution of isometamidium-HRP conjugate in
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phosphate-buffered saline (PBS) containing 0.05% Tween 20 (Sigma). Ninety- 
six well microtitre plates (Immulon 4, Dynatech) which had previously been 
coated overnight with 100 pi per well of a 1/12000 dilution of hyperimmune 
sheep anti-isometamidium serum in carbonate/bicarbonate buffer, pH 9.2, then 
frozen and stored at -20°C with the coating solution in situ, were allowed to thaw 
and equilibrate to room temperature. Plates were then washed five times in a 
1/5 dilution of PBS, pH 7.2, in distilled water containing 0.05% Tween 20. 
Serum predilutions were vortex mixed and transferred to duplicate wells of the 
microtitre plates (100 jil per well). After orbital shaking (Varishaker, Dynatech) 
for ten minutes at room temperature, plates were incubated overnight at 4°C, 
then allowed to equilibrate to room temperature before being washed five times 
as described previously. Enzyme levels remaining in each well were then 
determined by adding 100 pi per well of a two-component horseradish 
peroxidase substrate containing 3,3,5,5 tetramethylbenzidine (Cambridge 
Veterinary Sciences, Littleport, UK) pre-warmed to 37°C. After 10 minutes 
incubation with orbital shaking at 37°C, the colour reaction was quenched by 
the addition of 100 pi per well of 2M sulphuric acid. Absorbances were then 
read at 450 nm using a multichannel spectrophotometer (Multiskan Plus Mk II, 
Labsystems Oy, Helsinki, Finland).
Eight calibration standards containing a range of isometamidium 
concentrations from 500 to 0.025 ngml-1 were prepared using a serum pool 
prepared from an equal volume of serum that was collected from each of the 24 
cattle prior to administration of any trypanocidal drug. Thereafter, they were 
included in duplicate wells on every microtitre plate. Three quality control 
samples, comprising one normal (untreated) bovine serum sample, and two 
dilutions, in normal bovine serum, of serum from a steer treated with 
isometamidium chloride under laboratory conditions, were each tested twice 
(and in duplicate) on every microtitre plate. Samples were all tested in 
duplicate, and concentrations were derived by four-parameter logistic curve- 
fitting of calibration standards on the same ELISA plate. Results from individual 
ELISA plates were only included in the final data analysis if the standards and 
quality controls gave the expected results.
Data Analysis
Four-parameter logistic curve-fitting and calculation of concentrations were 
performed using in-house software (M.C.E., unpublished). Data collation and
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statistical analyses were performed using spreadsheet software (Lotus 1-2-3 
Release 4 for Windows) on an IBM-compatible personal computer.
The disappearance of isometamidium from the sera of individual cattle, over 
the first twelve weeks following treatment, was modelled using linear regression 
of log concentration against time. The regression coefficients were converted 
into apparent half-lives (t%) using the formula:
= - log 2 / coefficient.
Experimental design
On 2nd February 1993, 22 cattle in the tsetse-free area of Makuti were 
examined for the presence of trypanosomes using the method of Murray et al. 
(1977); only one animal was detected parasitaemic. Thereafter, diminazene 
aceturate was administered to all the cattle. Two weeks later, the cattle were 
moved to the tsetse-infested area of Rekomitjie, and isometamidium chloride 
was administered to each animal as described. The cattle were then 
maintained at Rekomitjie for the following six months. As mentioned, 
parasitological monitoring and serum collection were carried out fortnightly 
throughout the experiment. During the study, any animal found to be 
parasitaemic was treated intravenously with isometamidium chloride at a dose 
of 0.4 mgkg-1 body weight, using a 1% (w/v) solution, and removed from the 
experiment.
In order to determine the level of trypanosome challenge, eighteen 
challenge control cattle were maintained together with the drug-treated cattle at 
Rekomitjie. These animals were not treated with isometamidium chloride, but 
were monitored on a fortnightly basis throughout the experiment period for the 
presence of trypanosomes.
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Results
Parasitological findings
At the initial screening of the 22 cattle in the tsetse-free area of Makuti, only 
one trypanosome infection was detected; 7. vivax in animal number P243. No 
parasites were detected in the blood of the animal two weeks later, or at any of 
eleven subsequent fortnightly parasitological screenings.
Table 20 lists the monthly incidence of trypanosome infections in the 
isometamidium-treated cattle and challenge control cattle at Rekomitjie. No 
trypanosomes were detected in isometamidium-treated cattle for 126 days 
following treatment. Thereafter, trypanosomes were detected in only three 
animals; 7  vivax was diagnosed in one animal (P225) on day 140; on day 154, 
mixed infections were detected in two animals, 7. brucei/T. congolense in J437 
and 7  brucei/T. vivax in P239. One isometamidium-treated animal (P229) died 
from anaplasmosis, between four and six weeks following arrival at the tsetse- 
infested area.
By contrast, over the same period, the monthly incidence of 
trypanosomiasis in the eighteen challenge control cattle, that were not under 
isometamidium prophylaxis, was as follows: February, nil; March , two cases; 
April, one case; May, four cases; June , two cases; July, nil (see Table 20).
Isometamidium concentrations
The mean isometamidium concentrations determined using the CEIA in the 
sera of the 24 drug-treated cattle, over the twelve-week period following 
intramuscular treatment, are shown in Table 20 and Figure 16. Isometamidium 
could be detected using the CEIA in the sera of all but one of the 24 cattle 
following treatment. In one animal (T478), isometamidium, if present, was at 
concentrations below the limit of detection of the assay (0.5 ngml-1). Two weeks 
after treatment, the concentration of isometamidium in sera of the 23 cattle in 
which the drug could be detected ranged between 2.4 and 9.1 ngml-1. 
Excluding the animal which died (P229), and the animal in which isometamidium 
was not detected (T478), the drug could be detected in all the remaining 22 
cattle for eight weeks following treatment, and in most (20 cattle) for 10 weeks 
following treatment. In 12 cattle, the drug could still be detected 12 weeks 
following treatment. Finally, in five cattle it could be detected after 14 weeks 
following treatment.
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Linear regression of log isometamidium concentrations against time for the 
first 12 weeks following treatment accounted for between 78% and 99% 
(median 92%) of the total variance in log concentrations. The range in apparent 
half-lives calculated from the regression coefficients in 22 individual cattle 
(regressions could not be calculated for the animal which died, or the animal in 
which isometamidium was not detectable) was 15.7 to 58.3 days, and the 
geometric mean half-life was 23.2 days. Among these 22 cattle, the half-life of 
isometamidium in the majority (20 cattle) were between 15.7 and 27.1 days, 
while the half-lives in the other two cattle were somewhat longer at 37.8 and 
58.3 days.
In all three isometamidium-treated cattle in which trypanosome infections 
were detected (J437, P225 and P239), isometamidium concentrations had 
fallen below the limit of detection of the CEIA (0.5 ngml*1) by the time 
trypanosomes were detected. In animal number P225, the last serum sample in 
which isometamidium could be detected was collected 16 weeks after treatment; 
the trypanosome infection in this animal was not diagnosed until four weeks 
later (week 20). In animal number J437, isometamidium was last detected eight 
weeks following treatment, whereas the trypanosome infection was not 
diagnosed until 14 weeks later (week 22). This animal was the one in which 
isometamidium could be detected for the least length of time and was therefore 
the one in which isometamidium had the shortest apparent half-life (15.7 days). 
Finally, in animal number P239, isometamidium could be detected for 12 weeks 
following treatment, whereas the trypanosome infection was not detected until 
ten weeks later (week 22).
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Discussion
In this study, concentrations of isometamidium were determined using the 
competitive enzyme immunoassay (CEIA) in the sera of 24 cattle that were 
treated with a prophylactic dose of isometamidium chloride (1.0 mgkg-1 body 
weight) and exposed to natural tsetse challenge at Rekomitjie, Zimbabwe. 
Trypanosome infections were not detected in any of the drug-treated cattle for 
18 weeks following treatment; in 20 of the cattle infections were not detected for 
at least 22 weeks. By contrast, 9 trypanosome infections were detected in 18 
untreated control cattle during the same period, indicating a low to medium 
tsetse challenge (Whiteside, 1962b).
Isometamidium could be detected in the sera of all but one of the 24 treated 
cattle. Failure to detect isometamidium in one animal may have resulted from 
failure to administer the drug, or failure to inject it into the centre of a muscle 
mass. Intramuscular injections may inadvertently be made into the facial planes 
between individual muscle groups, which would be likely to result in relatively 
poor absorption from the injection site. Folkers (1966) attributed the failure of 
isometamidium to cure a trypanosome infected steer to be due to poor 
absorption of the drug due to an inflammatory reaction at the injection site. 
However injections of isometamidium into the subcutaneous connective tissue 
of the dewlap are apparently effective in prophylaxis against bovine 
trypanosomiasis (Williamson, 1970). An alternative possibility, that of 
inadvertent intravascular injection, would not readily explain failure to detect the 
drug, as the CEIA has been shown to be capable of detecting the drug for over 
three weeks following intravenous injection of cattle at the same dose rate 
(Chapter 8).
The isometamidium concentrations measured using the CEIA in the sera of 
treated cattle showed a drug disappearance rate that was similar to that 
observed in sera of cattle treated with isometamidium chloride at the same dose 
rate (1.0 mgkg-1 body weight) under laboratory conditions; the mean half-life of 
elimination, 23 days, was similar to the value of 23.9 days measured in non­
infected cattle (Chapters 3 and 4). The initial peak in drug concentration could 
not be detected because the first occasion serum was sampled was not until 
two weeks after isometamidium treatment; the initial peak occurs within the first 
hour after intramuscular treatment (Kinabo and Bogan, 1988; and Chapter 8).
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In contrast to drug disappearance rates, the isometamidium concentrations 
determined in this study were slightly lower than those previously observed in 
cattle treated under laboratory conditions with the same dose of isometamidium 
chloride (Chapters 3 and 4). For example, 28 days after treatment, the mean 
concentration in this study (2.75 ngml-1) was significantly lower (p < 0.001) than 
the mean concentration of 6.1 ngml-1 measured in the experiment described in 
Chapter 4. One explanation for this difference might be the fact that the work 
described here used the CEIA (Chapter 7), whereas the previous work had 
used the indirect competition ELISA (Chapter 3). However, it was shown in the 
work described in Chapter 7 that there was a close correlation (r* value of 0.96) 
between the results obtained using the two methods (see Figure 12), and 
therefore it is unlikely that the slightly lower values for the serum levels in the 
present study were in part due to the methodology used.
It is also possible that the lower concentrations observed in this study were 
due to differences between the two experimental situations. Firstly, the cattle 
used in this study were of a breed different to the pure-bred Boran cattle used in 
previous laboratory experiments (Chapters 4 and 5); although previous studies 
have failed to reveal significant differences between isometamidium 
concentrations in different breeds of cattle (Chapters 4 and 6) there is as yet 
insufficient data to rule out entirely the possibility of breed effects. Secondly, 
the cattle in this study were maintained under field conditions and potentially 
exposed to environmental stresses such as ectoparasite and endoparasite 
challenge, and poor nutrition. Their full history, particularly in terms of both 
management and disease, was not known, and at least one animal (P243) was 
found to be harbouring a trypanosome infection at the start of the experiment. 
In contrast, the cattle used in the experiments described in Chapters 4 and 5 
were kept under laboratory conditions where environmental stresses were 
intentionally kept to a minimum, and nutrition was adequate. These stresses 
can have marked effects on body weight and body condition, and are also likely 
to affect body composition; the distribution of the relatively lipid insoluble drug 
isometamidium could for example be susceptible to changes in the overall 
proportion of body fat.
Treatment of the cattle at Rekomitjie with isometamidium chloride at a dose 
of 1.0 mgkg*1 body weight prevented development of trypanosome infections in 
the majority of cattle for the entire six-month period of the experiment, in spite of 
a moderate trypanosome challenge. Since the ELISA could no longer detect
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isometamidium in the sera of the majority of cattle by 16 weeks following 
treatment, it was not possible to correlate drug levels with the degree of 
protection obtained. However, it was possible to make the observation that 10 
to 12 weeks after a single treatment with isometamidium chloride at the 
aforementioned dosage, concentrations of the drug of 0.5 ngml-1, or greater, 
were sufficient to protect cattle against potentially virulent trypanosome 
challenge. This result was therefore in agreement with laboratory experiments 
(Chapters 4 and 5) in which it was shown that four months after isometamidium 
treatment, concentrations in the sera of cattle as low as 0.4 ngml"1 were 
protective against experimental tsetse challenge with a drug-sensitive 
population of T. congolense. There was therefore no evidence of drug-resistant 
trypanosomes at Rekomitjie; perhaps not a surprising observation, as the area 
supports abundant populations of game animals, but only a few cattle 
(Woolhouse efa/., 1993).
This study has demonstrated the competitive enzyme immunoassay for 
isometamidium to be a useful technique for the demonstration of prophylactic 
isometamidium concentrations in cattle under natural tsetse challenge in the 
field. It has also demonstrated that protective levels of isometamidium may not 
be present in the circulation of all cattle following a treatment protocol carried 
out under field conditions; isometamidium could not be detected in one of the 
treated animals (T478). Although the reason for this was not discovered, in 
many situations in the field it might be the result of failure to administer the 
drug, of failure to calculate the dose correctly, or it might follow the use of 
adulterated or counterfeit drug; all of which are recognised as problems 
affecting the use of trypanocidal drugs in sub-Saharan Africa (Jordan, 1986). In 
view of widespread concern in tsetse-infested areas about the possibility of 
increasing numbers of drug-resistant trypanosomes, it is important to distinguish 
whether trypanosome infections occurring in spite of isometamidium prophylaxis 
are due to genuine drug-resistance, or whether they are due to other factors 
resulting in inadequate circulating drug concentrations. The results obtained 
here suggest that the CEIA for isometamidium would be capable of making this 
distinction, since circulating drug levels believed to be protective could be 
detected in most but not all of the treated cattle. Further studies are required to 
investigate isometamidium concentrations in sera of cattle in areas where drug- 
resistant trypanosomes are believed to occur.
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Table 20. Mean and standard deviation of isometamidium concentrations 
in the sera of cattle treated intramuscularly with isometamidium chloride 
at a dose of 1.0 mgkg*1 body weight and exposed to natural tsetse 
challenge at Rekomitjie.
Weeks after treatment Mean isometamidium 
concentration
(ngml*1)
Standard deviation
2 4.25 1.79
4 2.75 0.88
6 1.99 0.63
8 1.19 0.36
10 0.78 0.36
12 0.52 0.27
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Figure 16. Mean isometamidium concentrations (ngml-1) in the sera of 24 cattle 
exposed to natural tsetse challenge at Rekomitjie over a twelve week period following 
intramuscular treatment with isometamidium chloride at a dose rate of 1.0 mgkg-1 
body weight, determined using the CEIA. Error bars: standard deviation.
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Chapter 10:
Concentrations of the Trypanocidal Drug 
Isometamidium Chloride in the Sera of Maasai Zebu 
Cattle Following Frequent Repeated Intramuscular
Treatments
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Introduction
Control of African bovine trypanosomiasis continues to rely heavily on the 
use of a small number of therapeutic and prophylactic drugs. Of these, 
isometamidium chloride is the most widely used chemoprophylactic agent, and 
has been used successfully in many situations (Bourn and Scott, 1978; Leach 
and Roberts, 1981; Trail et a/., 1985). Recently, however, reports of less than 
satisfactory isometamidium prophylaxis have been attributed in part to the 
development of drug resistant trypanosomes (Kupper and Wolters 1983; Pinder 
and Authie, 1984; Schonefeld et al., 1987; Ainanshe et al., 1992), and an 
indirect competition ELISA for the detection and quantification of isometamidium 
in bovine serum has been developed (Chapter 3) to elucidate the relationship 
between circulating concentrations of the drug, and susceptibility to tsetse 
challenge with pathogenic trypanosomes (Chapters 4 and 7).
Increased frequency of administration of isometamidium has been used as 
a means of countering the problem of drug resistance (Fox et al., 1991), but has 
under some circumstances been associated with a wasting syndrome with high 
mortality (Stevenson, Dolan, Okech, Heath and Njogu, 1990; Dolan et al.,
1992). In the study described in this Chapter, the competitive enzyme 
immunoassay (CEIA) for isometamidium described in Chapter 7 was used to 
investigate a possible role for the drug in the pathogenesis of a similar 
syndrome induced experimentally in cattle.
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Materials and methods
The experiment was carried out in the Nguruman area of Kajiado District in 
South West Kenya.
Cattle
Maasai Zebu cattle were purchased from Maasai pastoralists at the foot of 
the Nguruman escarpment and maintained on natural grazing in the same area 
for the duration of the experiment. As the area had suffered a period of drought 
for two years, grazing was poor at the start of the experiment (23/8/91).
Trypanocidal drug treatments
Isometamidium chloride (Samorin®) was administered as a 2% aqueous 
solution by deep intramuscular injection into the middle third of the neck at a 
dose rate of 1.0 mgkg-1 body weight. Diminazene aceturate (Berenil®. Hoechst 
AG) was administered as a 7% aqueous solution by deep intramuscular 
injection at a dose rate of 7.0 mgkg-1 body weight.
Prior to the study, cattle had been maintained on an isometamidium 
prophylactic regimen. However, no isometamidium treatments had been 
administered within 5>2 months of the start of the study. During this 514 month 
period, trypanosome infections had been treated with diminazene aceturate. 
No diminazene treatments were administered within eight weeks of the start of 
the study.
Parasitological monitoring
Blood samples collected from an ear vein were examined weekly for 
trypanosome infections using the haematocrit centrifugation - buffy coat 
technique (Murray et al., 1977). During the study, any animals found to be 
parasitaemic were treated with diminazene aceturate.
Serum collection
Jugular venous blood was collected into plain Vacutainers (Becton 
Dickinson), and the serum separated and stored at -20°C until testing.
Isometamidium determinations
Serum isometamidium concentrations were determined using the 
competitive enzyme immunoassay (CEIA) described in Chapter 7.
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Briefly, sera were prediluted 1/10 in an optimal dilution of isometamidium- 
HRP conjugate in phosphate buffered saline (PBS) containing 0.05% Tween 20 
(Sigma). Ninety-six well microtitre plates (Immulon 4, Dynatech) which had 
previously been coated overnight with 100 pi per well of an optimal dilution of 
hyperimmune sheep anti-isometamidium serum in carbonate/bicarbonate buffer 
pH 9.2, frozen and stored at -20°C with the coating solution in situ, were allowed 
to thaw and equilibrate to room temperature. Pates were then washed five 
times in a 1/5 dilution of phosphate buffered saline (PBS, pH 7.2), in distilled 
water containing 0.05% Tween 20. Serum predilutions were vortex mixed and 
transferred to duplicate wells of microtitre plates (100 pi per well). Plates were 
shaken for ten minutes at room temperature, and then incubated overnight at 4° 
C. Plates were allowed to equilibrate to room temperature before washing five 
times as described previously. Enzyme levels were determined using 100 pi 
per well of a two-component horseradish peroxidase substrate containing
3,3,5,5 tetramethylbenzidine (Cambridge Veterinary Sciences, Littleport, UK) 
pre-warmed to 37°C. After 10 minutes incubation at 37°C with orbital shaking 
(Varishaker, Dynatech), the colour reaction was quenched by the addition of 
100 pi per well of 2M sulphuric acid. Absorbances were read at 450 nm using a 
multichannel spectrophotometer (Multiskan Plus Mk II, Labsystems Oy, 
Helsinki, Finland).
Eight standards prepared using pooled serum from isometamidium-naive 
Kenyan Boran cattle were included in duplicate wells of every microtitre plate. 
Three quality control samples, comprising one normal (untreated) bovine 
serum, and two dilutions, in normal bovine serum, of serum from an 
isometamidium steer, were each tested twice (in duplicate) on every microtitre 
plate. Samples were tested in duplicate, and provided the standards and quality 
controls had given the results expected, concentrations were derived by four- 
parameter logistic curve-fitting of calibration standards on the same ELISA 
plate.
Glutamate dehydrogenase concentrations
Serum glutamate dehydrogenase concentrations were determined as an 
index of hepatocellular damage (Mullen, 1976), using a test kit (GLDH Test Kit, 
Boehringer Mannheim GmbH Diagnostica).
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Experimental design
At the start of the experiment (23/8/91), 40 cattle were allocated into five 
groups of eight cattle. Group 2 comprised cattle in better body condition at the 
start of the experiment than Groups 1, 3, 4 and 5, and were maintained in an 
area of better grazing for the duration of the study (4 months). Groups 1, 2 and 
3 received treatment with isometamidium chloride at the start of the experiment, 
and monthly thereafter for four consecutive months. In addition, Groups 1 and 
2 received treatment with diminazene aceturate, three days after the third and 
fourth isometamidium treatments. Group 4 cattle were treated with diminazene 
but not isometamidium at the same times as Groups 1 and 2. Group 5 cattle 
served as untreated controls. The drug administration to the different groups is 
summarised in Table 21.
Serum isometamidium concentrations and GLDH levels were measured 
approximately two weeks following the second, third and fourth isometamidium 
treatments. The precise dates were 16 days (8/10/91) following the second 
isometamidium treatment, 14 days (4/11/91) following the third isometamidium 
treatment, and 12 days (3/12/91) following the third isometamidium treatment. 
Body weights were determined on these occasions, and on others such as the 
dates of isometamidium administration.
Statistical analysis
For the purposes of analysis the experiment could be considered in two 
parts. Firstly, Groups 1, 3, 4, and 5 comprised a factorial experimental design, 
with isometamidium treatments being applied to Groups 1 and 3, diminazene 
treatments applied to Groups 1 and 4, and Group 5 as untreated controls (Table 
21). Secondly, the performance of two groups of animals (Groups 1 and 2), 
which were differentiated on the basis of starting body condition and quality of 
grazing, but which received identical drug treatments (isometamidium and 
diminazene), were compared. The effects of isometamidium treatment, 
diminazene treatment and their interaction (using data from Groups 1, 3, 4 and 
5), and the effects of body condition and nutrition (using data from Groups 1 
and 2) on serum isometamidium concentrations, GLDH levels, and body weight 
losses were investigated by analysis of variance, using a matrix of orthogonal 
contrasts.
The experiment was divided into four periods (1 to 4), each following an 
isometamidium treatment. Percentage daily body weight changes were 
calculated for periods 1 to 3 using the formula:
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(body weight at end of period - body weight at start of period) + (weight at start of experiment * number 
of days in period) *  100.
In the case of four animals which died during the second half of period 3, 
and all animals surviving in period 4, percentage daily body weight change was 
calculated over the first two weeks of the period only. Serum isometamidium 
concentrations and GLDH levels measured approximately two weeks following 
the second, third and fourth isometamidium treatments were compared with 
percentage daily body weight changes over the corresponding periods, using 
linear regression. Body weights were modelled as dependent variables, 
isometamidium concentrations, and GLDH concentrations were analysed as 
independent variables, and treatment groups and periods as fixed effects. The 
significance of differences between results for particular groups on particular 
dates was determined by t-tests. Statistical analyses were performed using 
Genstat 5 Release 2.2 (Numerical Algorithms Group Ltd., Oxford).
Results
Trypanosome infections
Four animals were found to be infected on the first day of the study 
(23/8/91), one in Group 1 (T. vivax), two in Group 2 (both T. brucei / T. 
congolense mixed infections), and one in Group 3 (T. brucei). Thereafter, only 
two trypanosome infections were detected, both on 16/10/91, both T. vivax, and 
both in Group 4 cattle. These infections were treated with diminazene aceturate.
Body weight changes
During the first treatment period percentage daily body weight changes 
were small (mean = 0.021 % per diem), and were not significantly different (p > 
0.1) between groups, nor did isometamidium treatment or body 
condition/nutrition have any significant effect on body weight changes.
During the second treatment period, percentage daily body weight changes 
were significantly different between groups (p < 0.001), and body weight losses 
were significantly greater (p < 0.001) in isometamidium treated cattle (Group 1 
and 3 means respectively: -0.49 and -0.55 % per diem) than in cattle which had 
not received isometamidium (Group 4 and 5 means respectively: -0.34 and 0.39 
% per diem). As no diminazene treatments had yet been given, treatments for 
Groups 1 and 3, and Groups 4 and 5 were identical at this stage in the 
experiment. Isometamidium treated cattle in better body condition at the start of 
the experiment, and obtaining better nutrition, (Group 2) suffered significantly 
smaller (p < 0.001) weight losses (mean -0.19 % per diem) than either the 
remaining isometamidium treated cattle (Groups 1 and 3), or untreated cattle on 
a lower plane of nutrition (Groups 4 and 5).
During the third treatment period, the increased weight loss associated with 
isometamidium treatment remained highly significant (p < 0.001): cattle given 
isometamidium and diminazene (Group 1) had higher weight losses (mean: - 
0.58 % per diem) than those given only diminazene (Group 4; mean: -0.16 % 
per diem), and cattle given only isometamidium (Group 3) had higher weight 
losses (mean: -0.38 % per diem) than those which received neither drug (Group 
5; mean: -0.13 % per diem). Although mean weight losses were higher in cattle 
given diminazene (Group 1 compared with Group 3, and Group 4 compared 
with Group 5), these differences were of marginal significance (p = 0.065), and 
the interaction between the two drugs was not significant (p = 0.19). There was 
no effect of better nutrition, and better body condition at the start of the
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experiment, on cattle treated with both trypanocidal drugs (Group 2, mean -0.59 
% per diem, compared with Group 1, mean: -0.58 % per diem ) during this 
period (p > 0.89).
During the fourth treatment period, body weight increases (overall mean 
0.62 % per diem), rather than decreases were observed in all Groups. The 
main effect of isometamidium on body weight change ceased to be significant (p 
= 0.68) during this period, whereas the main effect of diminazene became 
significant (p < 0.01), as did the interaction between the two trypanocidal drugs 
(p < 0.001). Cattle given isometamidium and diminazene (Group 1) had smaller 
weight gains (mean 0.36 % per diem) than cattle given only diminazene (Group 
4; mean: 0.67 % per diem), whereas cattle given only isometamidium (Group 3) 
had higher weight gains (mean: 0.86 % per diem) than cattle given neither drug 
(Group 5; mean: 0.61 % per diem). These results must be interpreted taking 
into consideration that four Group 1 cattle, including three (B16, B19 and B59) 
which had the highest drug concentrations during the third treatment period, 
died during the second half of that period (i.e. prior to the fourth drug 
administration). Finally, cattle in better body condition at the start of the 
experiment and with better nutrition (Group 2), had significantly smaller weight 
gains (mean: 0.07 % per diem) than all the other treatment groups (p < 0.01), 
except Group 1 in which too few animals (n = 4) had survived for a meaningful 
comparison.
Isometamidium concentrations
Isometamidium concentrations in sera collected from each of the treated 
groups (Groups 1, 2 and 3) during the second, third and fourth treatment 
periods were determined using the CEIA. Comparisons of concentrations 
between treatment groups were conducted using analysis of variance and t- 
tests, and comparisons over time of concentrations within treatment groups 
were made using paired t-tests. Mean and standard deviation isometamidium 
concentrations are shown in Table 22 and Figure 17.
Isometamidium concentrations were not determined following the first drug 
administration as sera were not collected.
During the second treatment period (see Table 22), the mean 
isometamidium concentration found in the serum of Group 1 cattle (5.3 ngmM) 
did not differ significantly (p > 0.1) from those of the other two treated groups 
(Group 2 mean: 3.0 ngmM; Group 3 mean: 7.8 ngmM).
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During the third treatment period, the mean isometamidium concentrations 
in Group 1, 2 and 3 (respectively 8.8, 7.1 and 10.4 ngmM) did not differ 
significantly from each other (p > 0.05), but were all higher than the previous 
determinations for the same groups, significantly so in the case of Groups 2 and 
3 (p < 0.05).
During the fourth treatment period, the mean isometamidium concentration 
in Group 2 (11.8 ngmM) was significantly higher (p < 0.05) than that of Group 3 
(5.6 ngmM). The mean of Group 1 (8.5 ngmM) fell between and was not 
significantly different (p > 0.1) from the means of either Groups 2 and 3. Only in 
Group 2 was the mean drug concentration in period 4 significantly greater (p < 
0.05) than that of period 3, in spite of the deaths of two cattle (B6 and B61) 
during the fourth treatment period (on 26/11/91 and 30/11/91) which had the 
highest drug concentrations during the third treatment period. In Groups 1 and 
3 the mean concentrations in period 4 were actually lower than their previous 
values. The deaths of four cattle in Group 1, including three (B16, B19 and 
B59) which had the highest drug concentrations during the previous period, 
should be taken into account in interpreting the data: excluding the cattle which 
died, there was a rise in the mean concentration in the 4 surviving cattle from 
5.8 to 8.5 ngmM. There were no deaths in Group 3 during the period in 
question, and the fall in mean drug concentration could not be attributed to the 
effect of two animals (B26 and B68) in which no isometamidium was detectable 
following the fourth administration: the fall in concentration was significant (p < 
0.05) whether or not these two animals were included in the analysis.
There was no effect (p > 0.1) of diminazene treatment on concentrations of 
isometamidium (p > 0.1) during any of the treatment periods during which it was 
determined (periods 2, 3 and 4).
Finally, cattle (Group 2) in better body condition at the start of the 
experiment and with better nutrition than Group 1 cattle, were not significantly 
different (p > 0.1) to them in terms of serum isometamidium concentrations, in 
any of the three relevant treatment periods, although by the fourth period too 
few animals (n = 4) in Group 1 had survived for a meaningful comparison.
Isometamidium concentration - body weight relationship
The relationship between isometamidium concentration and percent daily 
body weight change was analysed by linear regression. Weight was modelled 
as the response variable using the main effects and interactions of treatment
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group and isometamidium concentration as explanatory variables. This 
analysis was conducted for each of the three periods during which 
isometamidium concentrations were determined (periods 2, 3 and 4). Animals 
not treated with isometamidium (Groups 4 and 5) were excluded from the 
analysis.
During the second treatment period, the relationship between 
isometamidium concentration and body weight change was not significant (p > 
0.1). However during the third and fourth treatment periods the relationship was 
significant, and body weight change was best described by the model
constant + isometamidium concentration.Group
The model accounted for 54% and 68% of the overall variance in 
isometamidium concentrations during the third and fourth periods respectively. 
The regression coefficients, standard errors and associated probabilities are 
shown in Table 23. During the third and fourth treatment periods, the 
regression coefficients were significantly different to zero in Groups 1 and 2 (p < 
0. 01), but not in Group 3 (period 3: p > 0.08; period 4: p > 0.8). The regression 
coefficients for Groups 1 and 2 did not differ significantly in either period. All 
the significant regression coefficients (p < 0.05) were negative, implying an 
inverse relationship between isometamidium concentration and body weight 
change.
GLDH concentrations
All serum GLDH levels measured at the start of the experiment fell into the 
normal range (up to 13 uM, Rushton 1981), except for one animal in Group 8, in 
which the level was marginally higher (13.8 uM). There were no significant 
differences (p > 0.1) between the treatment groups at that time. GLDH levels in 
Groups 4 and 5 were never significantly elevated (p > 0.5) above their initial 
values during the experiment, nor did they differ significantly (p > 0.5) from each 
other.
During the second treatment period, GLDH levels were not significantly 
elevated (p > 0.1) above their starting values in any of Groups 1 to 5 (overall 
mean 6.1uM), nor were there any significant differences (p > 0.1) between the 
groups.
During the third treatment period, elevations in GLDH levels became 
apparent in Groups 1, 2 and 3 (means respectively: 15.9, 21.land 19.9 uM). 
These were significantly higher than the GLDH concentrations in Groups 4 and
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5 (means respectively 6.5 and 5.0 uM; p < 0.05), and their initial levels (p < 
0.01). The differences in GLDH levels between Groups 1, 2 and 3 were not 
significant (p > 0.1) during this period.
During the fourth treatment period, GLDH levels in Group 2 increased 
further (mean 38.4 ul*1) to become significantly greater (p < 0.001) than their 
previous values, and the levels in all the other groups. The levels in Groups 1 
and 3 actually decreased slightly (means respectively 11.9 and 15.8 ul-1), but 
not significantly so (p > 0.1), and, of these, only those in Group 3 remained 
significantly elevated (p < 0.05) above their starting values. Again, the deaths 
of four cattle in Group 1, and two cattle in Group 2 need to be taken into 
consideration in the interpretation of the results for this period.
GLDH level - body weight relationship
The relationship between GLDH level and percent daily body weight 
change was analysed by linear regression in a similar way to that used for 
isometamidium concentrations. Weight was modelled as the response variable 
using the main effects and interactions of treatment group and GLDH level as 
explanatory variables. This analysis was conducted for the same three periods 
used in the analysis of isometamidium concentrations (periods 2, 3 and 4). 
Animals not treated with isometamidium (Groups 4 and 5) were excluded from 
the analysis.
During the second and third treatment periods, the relationship between 
GLDH level and body weight change was not significant (p > 0.1). During the 
fourth treatment period GLDH level was best described by the model:
Group constant + GLDH.Group
This model accounted for 74% of the total variance in GLDH levels during 
the fourth period.
The regression constants, standard errors and associated probabilities are 
shown in Table 24. Only in Group 1 was the GLDH regression constant 
significantly different to zero (p < 0.001). The sign of the regression constant 
was negative, indicating an inverse relationship between GLDH levels and body 
weight changes.
Isometamidium concentration - GLDH concentration relationship
The relationship between serum isometamidium concentration and GLDH 
levels was examined using linear regression. The response variable in the
227
model was GLDH level, while the terms of the model examined as explanatory 
variables were the main effects and interactions of isometamidium 
concentration, group, and treatment period. The best fitting model accounted 
for 37% of overall variance, and included the terms:
constant + isometamidium concentration.group + isometamidium concentration.treatment period.
The regression constants, standard errors and associated probabilities are 
shown in Table 25. Overall there was a significant positive relationship 
between isometamidium concentration and GLDH level (p < 0.01). No effect of 
isometamidium was seen during the second treatment period (p > 0.9), but 
significant effects became apparent during the third and fourth treatment 
periods (p < 0.05). The effect in the fourth treatment period was greater than 
that in the third, although this difference was not significant (p > 0.4). Finally, 
the effect of isometamidium concentration on GLDH levels was significantly 
greater (p < 0.01) in Group 2, from that observed in either Group 1 or Group 3.
Mortality
Overall, nine cattle died during the experiment, and a further six cattle were 
considered unlikely to survive because of general weakness, emaciation, 
collapse or recumbency, and were therefore slaughtered after 3/12/91. Four of 
the deaths occurred in Group 1 cattle during the second half of the third 
treatment period, within a period of four days (11/11/91 to 14/11/91). Four 
deaths occurred in Group 2, two during the first two weeks of the fourth 
treatment period (26/11/91 and 30/11/91), and two five to ten days later 
(5/12/91 and 10/12/91). The remaining death occurred ten days later still 
(20/12/91), in an animal in Group 3. Of the cattle which were slaughtered, two 
were in Group 1, and there was one in each of Groups 2, 3, 4 and 5.
The relationship between mortality, and body weight changes, 
isometamidium concentrations, and GLDH levels was investigated in 
isometamidium treated cattle (Groups 1, 2, and 3). Body weight changes over 
the first, second, third, and fourth treatment periods, and isometamidium 
concentrations and GLDH levels during the second, third, and fourth treatment 
periods in cattle which died were compared with those in cattle which survived. 
Of these comparisons, only body weight changes over the third treatment period 
showed a significant difference (p < 0.001). The mean body weight change 
during this period was -0.73 % per diem in cattle which died, whereas in the 
survivors it was -0.39 % per diem. If the four cattle in Groups 1, 2 and 3 which
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were slaughtered were included in the analysis, GLDH levels during the fourth 
treatment period were also significantly greater (p < 0.05) in animals which died 
or were slaughtered (mean 38.3 ul*1), than those which survived (mean 12.4 ul-
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Table 21. Experimental design: drug treatments
Isometamidium:
+
Diminazene:
+ Groups 1 & 2 Group 4
- Group 3 Group 5
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Table 22. Isometamidium concentrations in cattle following repeated
treatments.
Treatment period 2 2 3 4
Date of isometamidium 
treatment
23/8/91 22/9/91 21/10/91 21/11/91
Date of serum collection Not done 8/10/91 4/11/91 3/12/91
Days after treatment - 16 14 12
Isometamidium concentrations: 
mean & (standard deviation)
ngml'1 ngml'1 ngml'1
Group 1 - 5.3 (4.0) 8.8 (5.1) 8.5 (3.5)
Group 2 - 3.0 (1.9) 7.1 (2.7) 11.8(4.8)
Group 3 - 7.8 (5.6) 10.4(4.1) 5.6 (4.3)
►
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Table 23. Regression coefficients, standard errors and associated 
probabilities for the linear regression of isometamidium concentrations
on body weight changes
Treatment Term regression standard error probability
Period coefficient
2 Group 1 -0.043 0.0090 < 0.001
Group 2 -0.051 0.0125 < 0.001
Group 3 -0.016 0.00851 0.083
constant -0.217 0.0814 0.015
3 Group 1 -0.060 0.0198 0.009
Group 2 -0.061 0.0129 < 0.001
Group 3 0.0041 0.0204 0.84
constant 0.827 0.131 < 0.001
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Table 24. Regression coefficients, standard errors and associated 
probabilities for the linear regression of GLDH levels on body weight 
changes during treatment period 4.
Term regression standard error probability
coefficient
GLDH.Group 1 -0.0488 0.0141 0.005
GLDH.Group II -0.0011 0.0033 0.742
GLDH.Group III 0.0103 0.0126 0.427
Group 1 constant 0.935 0.203 <0.001
Group II constant 0.111 0.157 0.491
Group III constant 0.693 0.215 0.007
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Table 25. Regression coefficients, standard errors and associated 
probabilities for the linear regression of isometamidium concentrations
on GLDH levels.
Term regression standard error probability
coefficient
concentration.period 2 -0.009 0.456 0.985
concentration.period 3 0.768 0.382 0.049
concentration.period 4 1.096 0.446 0.017
concentration.Group 1 -0.172 0.385 0.657
concentration.Group II 1.287 0.422 0.003
concentration.Group III NA NA NA
Constant 8.61 2.67 0.002
Figure 17. Mean isometamidium concentrations in sera of repeatedly treated 
cattle (treatment Groups 1, 2 and 3) during the second, third and fourth treatment 
periods. For explanation of treatment groups, see text. Error bars: standard 
deviation.
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Discussion
In this study the use of a regimen of frequently repeated intramuscular 
treatments with the trypanocidal drug isometamidium chloride, with and without 
concurrent administration of a second trypanocide, diminazene aceturate, was 
investigated in Maasai Zebu cattle. Parameters measured were body weight 
change, levels of the hepatocellular leakage enzyme GLDH, and circulating 
isometamidium concentrations. The effect of body condition and nutrition on 
the treatment regimen involving both trypanocides was also investigated. A 
recently developed competitive enzyme immunoassay (CEIA) for the 
determination of isometamidium concentrations in bovine serum (Chapter 7) 
enabled circulating concentrations of the drug to be measured for the first time 
in the context of a possible overdose problem.
The experiment was primarily designed in an attempt to recreate a 
syndrome believed to be associated with repeated isometamidium and 
diminazene treatments in cattle under poor nutritional conditions (Dolan and 
Stevenson, 1992). As the experiment was apparently successful in this respect 
(Stevenson, et al., in preparation), the relationships between the parameters 
listed above were investigated, in spite of some deficiencies in the data 
available. To repeat the experiment in order to restore these deficiencies would 
be difficult to justify because of considerations of animal welfare and expense.
It should be emphasised that the experiment was deliberately conducted in 
a location where, and during a period when, poor grazing would result in weight 
loss even in the absence of heavy trypanocidal treatment. The results, 
therefore, do not necessarily indicate what would happen in cattle on a more 
adequate plane of nutrition and in positive energy balance.
In Maasai Zebu cattle under conditions of poor grazing and negative energy 
balance, while a single intramuscular treatment with isometamidium chloride at 
a dose rate of 1.0 mgkg-1 had no significant effect on body weight, two or more 
such treatments at monthly intervals caused significant increases in weight loss. 
The additional weight loss in isometamidium treated cattle (Groups 1 and 3) 
over the month following two treatments, compared to that of untreated cattle 
(Groups 4 and 5) over the same period was over 0.25 kg per diem. The effect of 
isometamidium on body weight changes was maintained following a third 
isometamidium treatment, whether diminazene was administered 2 days after 
that isometamidium treatment (Group 3) or not (Group 1). However, whether
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cattle had previously received three isometamidium treatments (Group 1) or 
none (Group 3), diminazene itself had no significant effect on body weight
Cattle in better body condition at the start of the experiment, with access to 
better grazing, and treated similarly with two doses of isometamidium (Group 2), 
had smaller body weight losses than either treated cattle (Groups 1 and 3) or 
untreated cattle (Groups 4 and 5) on poorer nutrition. The sparing effect on 
body weight losses afforded by better initial body condition and better nutrition 
was no longer apparent following three monthly isometamidium treatments and 
one diminazene treatment. Weight losses during the third treatment period 
were greater under this treatment regimen (Group 2) than in untreated controls 
on poorer nutrition (Group 5). By the end of the this treatment period, the mean 
percentage of body weight lost since the start of the experiment in Group 2 
cattle (31.2%) had surpassed that of cattle (Group 1) under an identical drug 
regimen but with poorer nutrition and initial body condition (mean 26.5%).
During the fourth and final treatment period, body weights increased in all 
treatment groups, reflecting improved grazing following the onset of the rains. 
The comparison of the drug treatment regimens in this period was additionally 
complicated by the deaths of six animals, four in Group 1, and two in Group 2. 
The effect of four successive isometamidium treatments appeared to depend on 
whether diminazene had also been administered. Cattle which received only 
isometamidium (Group 3) had significantly higher weight gains than untreated 
controls (Group 5), whereas cattle given both trypanocides (Group 1) had lower 
weight gains than either untreated controls, or those receiving only diminazene 
(Group 4). The apparent growth promoting effect of isometamidium on Group 3 
cattle may have been a "rebound effect" resulting from the greater weight losses 
experienced during the previous treatment periods when grazing was scarce.
Although there was no evidence that one or two monthly treatments with 
diminazene alone had any effect on body weight change, there was some 
evidence that two diminazene treatments following the third and fourth of four 
isometamidium treatments had a negative effect on body weight. Cattle under 
this treatment regimen, which had been in better body condition at the start of 
the experiment, and which had access to better grazing for the entire duration of 
the experiment (Group 2), had significantly lower weight gains than all other 
treatment groups and controls (Groups 1, 3, 4,and 5) during the fourth treatment 
period. The adverse effects of four monthly treatments with isometamidium, 
and two of diminazene, may have been more than an improvement in nutritional
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status at the onset of the rains could compensate. The high levels of GLDH in 
this group of cattle during this period, indicating hepatocellular damage, appear 
to support this explanation.
Isometamidium concentrations were measured to investigate differences in 
concentrations between the different treatment regimens, to investigate whether 
there was evidence of drug accumulation, and to determine the relationship 
between drug concentrations and weight loss, liver damage, and survival. 
Differences in serum isometamidium concentrations between the various 
treatment groups were not observed until all four monthly administrations of the 
drug had been given. Isometamidium concentrations following up to three 
doses of the drug at monthly intervals were not influenced by initial body 
condition and nutritional status, nor by the additional administration of 
diminazene following the third of these monthly doses.
Isometamidium concentrations following four monthly doses of the drug 
were influenced by either initial body condition and nutritional status, or by the 
additional administration of diminazene shortly after the third and fourth doses 
of isometamidium. During the fourth treatment period, isometamidium 
concentrations in Group 2 cattle were found to be significantly higher than those 
in Group 3. The difference might have been related to the additional 
administration of diminazene to cattle in Group 2, or the difference in the 
nutritional status of these two treatment groups. Unfortunately, the comparison 
of isometamidium concentrations in similarly nourished cattle with and without 
diminazene (Group 1 and Group 3 cattle, respectively), and the comparison of 
cattle treated with both trypanocides with poorer or better initial body condition 
and nutrition (Group 1 and Group 2 cattle, respectively) were biased by the 
deaths of four cattle in Group 1 and two cattle in Group 2. The reduction in the 
sizes of the treatment groups reduced the sensitivity of statistical tests, and the 
results were further confounded by the non-random nature of the experimental 
drop-out: five of the six cattle that died had concentrations above average for 
their treatment groups in both previous determinations. Hence it seems 
reasonable to conjecture that had more cattle in Group 1 survived, the mean 
isometamidium concentration in that group would have been higher, and similar 
to that in Group 2, and therefore the difference between Groups 2 and 3 was 
more likely to be related to diminazene than nutritional status.
There was evidence of accumulation of isometamidium following 
intramuscular treatments repeated at monthly intervals. Following the third such
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treatment, the mean concentrations in ail treated cattle (Groups 1, 2 and 3) 
were higher than those following the second treatment (significant in Groups 2 
and 3). In cattle treated with both isometamidium and diminazene (Groups 1 
and 2), still further increases in isometamidium concentrations (significant in 
Group 2) still were observed in those which survived following the fourth 
isometamidium treatment until the date of sampling. However, in cattle treated 
with isometamidium alone (Group 3), there was a significant decrease in the 
mean isometamidium concentration over the same period, which was paralleled 
by a decrease in GLDH level. This was consistent with the explanation that 
improved nutritional status during this period permitted recovery of hepatic 
function which may have been part cause, and part effect, of increased 
elimination of the additional drug burden.
Although there was no evidence that better initial body condition or better 
grazing had any effect on isometamidium concentrations (Group 2 compared 
with Group 1), there was, however, evidence of a significant relationship 
between isometamidium concentrations and body weight changes during the 
third and fourth treatment periods, in cattle treated with both isometamidium and 
diminazene (Groups 1 and 2). There was no significant differences in this 
relationship between these groups, implying that it was not influenced by the 
differences in initial body condition and nutritional status.
The hepatocellular enzyme GLDH was measured as an indicator of liver 
damage (Mullen, 1976). Evidence of liver dysfunction was obtained in 
isometamidium treated cattle following three monthly doses of the drug. In all 
three groups of cattle given this trypanocide, GLDH levels increased 
significantly during the third treatment period, and, like isometamidium 
concentrations, GLDH levels in Group 2 cattle continued to rise during the 
fourth period. Diminazene administration had no effect on GLDH levels during 
any treatment period. A relationship between GLDH levels and body weight 
was less apparent than that between isometamidium and body weight. 
Evidence found for such a relationship was found only during the fourth 
treatment period, and only in one treatment group (Group 1), by which time 
comprised only four cattle. There was however a significant positive 
relationship between isometamidium concentrations and GLDH levels during 
the third and fourth treatment periods. The relationship was significant in all 
three isometamidium treated groups of cattle, and significantly greater in Group 
2 than in Groups 1 or 3.
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Altogether nine cattle died during the experiment, of which all had been 
treated with isometamidium, and eight also with diminazene. Unsurprisingly, 
cattle which died following the fourth isometamidium treatment had lost more 
weight over the previous (third) treatment period than those which survived. 
The same number of cattle (four) died in each of the two groups treated with 
both trypanocides (Groups 1 and 2), a mortality rate of 50%. Nutritional status 
and initial body condition did not, therefore, appear to influence the mortality 
rate, although deaths occurred slightly later (26/11/91 to 10/12/91) in cattle with 
better initial body condition and nutritional status (Group 2) than those without 
(Group 1; 11/11/91 to 14/11/91). Neither isometamidium concentrations nor 
GLDH levels during the third treatment period were significantly different in 
cattle which subsequently died to those which survived. When animals which 
were slaughtered because of general weakness, emaciation, collapse or 
recumbency were included in the analysis with those which died, GLDH levels, 
but not isometamidium concentrations, during the fourth treatment period were 
significantly greater in cattle which died or were slaughtered than in the 
survivors.
Weight loss and mortality was observed in improved Boran steers at 
Galana Ranch, Kenya treated with three doses (1.0 mgkg-1 body weight), and 
between 1 and 3 doses of diminazene (7.0 mgkg-1 body weight) over a five 
month period of poor grazing (Dolan et al., 1992). Although the diminazene 
treatments were administered on the basis of diagnosis of trypanosome 
infections in individual steers, other infected steers treated with diminazene, 
which were not on isometamidium prophylaxis, did not loose weight, and 
suffered significantly lower mortality. The study described here has shown that 
trypanosome infections are not an essential factor for weight losses or death to 
occur in cattle under nutritional stress treated frequently with these 
trypanocides.
Elevated GLDH levels were regarded as evidence of hepatotoxicity as a 
mechanism for the weight loss and mortality associated with these frequent 
treatments. Other phenathridinium derivatives (homidium, prothidium and 
metamidium) have been shown capable of capable of causing liver damage at 
doses higher than the therapeutic level (Williamson 1970). The liver has been 
shown to be one of the main sites of accumulation of isometamidium in cattle 
(Kinabo and Bogan 1988a). While there was no evidence of increases in either 
y-glutamyl transferase (y-GT) or aspartate aminotransferase (AST) in cattle
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following intravenous administration of isometamidium (Schillinger et al., 1985), 
significant increases in y-GT and alanine aminotransferase were found in pigs 
following large toxic intramuscular doses of the drug (Kinabo et al., 1991). In 
the present study, in spite of elevations in GLDH, there was no evidence of 
elevation in y-GT levels (data not shown), findings consistent with 
hepatocellular rather than hepatobiliary pathology.
The ELISA techniques for the determination of isometamidium 
concentrations in bovine serum described in Chapters 3 and 6 have been used 
to investigate the relationship between circulating concentrations and protection 
against tsetse transmitted trypanosomiasis challenge (Chapter 4 and 7). The 
mean concentration of the drug found in the circulation of Boran cattle under 
laboratory conditions one month after intramuscular administration of a dose of 
1.0 mgkg-1 was 6 ngmM (range 3 to 12 ngmM). In the present study 
concentrations were determined to investigate concentrations of the drug in 
Maasai Zebu cattle under conditions of poor grazing, following frequent 
repeated intramuscular treatments at the same dose rate. Although samples 
were not collected for isometamidium determination after a single dose of the 
drug, two weeks after two, three or four similar doses, the concentrations found 
were not dissimilar to those observed in the laboratory experiment at the same 
interval after treatment. Although there were no obviously marked elevations in 
concentration which might have allowed the use of the CEIA as a predictor of a 
potential toxicity problem, the small but significant increases in concentration 
which occurred with successive treatments did suggested drug accumulation, 
and should be considered in the context of the low therapeutic index of 
isometamidium (Kinabo and Bogan 1988b).
In this study the CEIA for isometamidium has been successfully used to 
investigate the relationship between circulating concentrations of the drug, and 
a syndrome associated with repeated trypanocidal treatments. As few as two 
isometamidium treatments one month apart were shown to be associated with 
significant weight loss in cattle under conditions of poor nutrition. Cattle treated 
with diminazene aceturate after three or four isometamidium treatments suffered 
a 50% mortality rate. Isometamidium concentrations in cattle treated repeatedly 
at monthly intervals increased significantly with the number of treatments 
administered, and were significantly higher in cattle to which diminazene had 
also been administered. In cattle treated with both trypanocides, body weight 
losses and GLDH levels were correlated with isometamidium concentrations.
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These observations support the hypothesis that the syndrome observed was 
related to the use of repeated doses of isometamidium in conjunction with 
diminazene aceturate, and the pathogenesis involved a component of hepatic 
damage. On the basis of these findings it is recommended that cattle, 
particularly under nutritional stress, are not subjected to repeated treatments 
with isometamidium at intervals a short as one month, and where frequently 
repeated treatments with isometamidium are considered unavoidable, the 
concurrent use of diminazene should be avoided.
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Chapter 11: 
General Discussion
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Summary of achievements
In the work described in this thesis two new enzyme-linked immunosorbent 
assay (ELISA) procedures for the detection and quantification of isometamidium 
in bovine serum were developed. The first of these assays was an indirect 
competition ELISA (ICE) and was capable of detecting isometamidium to 
approximately 0.1 ngml-1. Following the treatment of cattle with isometamidium 
chloride by intramuscular injection at the recommended prophylactic dose rate 
of 1.0 mgkg-1, the drug could be detected in serum samples for up to four 
months.
In experiments described in Chapters 4 and 5, the concentrations of 
isometamidium in the circulation of Boran cattle treated with isometamidium 
were related to the ability of the cattle to withstand tsetse challenge with 
populations of T. congolense of various degrees of resistance to the drug. 
These experiments were conducted to enable the interpretation of 
isometamidium concentration data obtained using serum samples from cattle in 
the field. If cattle in the field are found to be harbouring T. congolense 
infections in spite of measurable isometamidium concentrations greater than 
those found to be protective against the drug-sensitive T. congolense clone 
IL1180, these trypanosome infections may be considered to possess a degree 
of resistance to the drug; the higher the isometamidium concentration, the 
greater the degree of drug resistance which may be inferred. T. congolense 
which are established in the presence of circulating drug concentrations greater 
than 6 ngml*1 may be considered to be markedly resistant, by comparison to the 
two highly isometamidium-resistant T. congolense populations IL 3893 and IL 
3889 which were able to establish break-through infections at this drug 
concentration (Chapter 4). Similarly T. congolense which are able to establish 
infections at concentrations greater than 2 ngml-1 may be considered 
moderately resistant by comparison with the moderately isometamidium- 
resistant T. congolense population IL 3343 (Chapter 5). T. congolense which 
are able to establish infections in the presence of concentrations greater than 
0.4 ngml*1 may be considered to possess a low level of drug resistance, since 
this concentration was protective against challenge with the drug-sensitive 
clone T. congolense IL 1180 (Chapter 5).
The ICE was used to examine serum samples collected on a regular basis 
from a herd of Jersey cattle in coastal Kenya in which trypanosome infections 
occurred in spite of an isometamidium chemoprophylactic regimen. The study
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provided an opportunity to use the ELISA on sera from cattle under natural 
tsetse challenge, and to evaluate its potential as a tool for discriminating 
genuine break-through infections by drug-resistant trypanosomes from failure of 
prophylaxis due to inadequate drug levels. Isometamidium concentrations 
could be determined in the samples, and an attempt was made to relate the 
isometamidium concentrations to the incidence of trypanosome infection over a 
number of three month prophylactic periods. The distribution of trypanosome 
challenge over the period of the study was uneven, and it was perhaps 
unfortunate, both for the cattle and the purposes of this investigation, that 
almost all challenge (based on the infection rate in a control group of cattle not 
given isometamidium) occurred at the end of prophylactic periods. 
Unsurprisingly therefore, at the time of challenge, drug concentrations in the 
treated group were at their lowest and no inferences could be made about drug 
resistance in the infecting trypanosomes on the basis of the results obtained 
using T. congolense in the laboratory studies described in Chapters 4 and 5. In 
fact, all infections diagnosed during in this study were caused by T. vivax which 
is possibly inherently less sensitive to the prophylactic activity of isometamidium 
(Peregrine et ai, 1987, 1991). It should be emphasised that failure to 
demonstrate drug resistance using the ELISA was not due any failure of the 
ELISA per se; had serum samples been collected during the first prophylactic 
period, in which trypanosome infections occurred relatively soon after treatment, 
a rather different result might have been obtained.
Another simpler ELISA procedure for the determination of isometamidium in
bovine serum was developed using isometamidium-enzyme conjugates
(Chapter 7). This assay, described as a competitive enzyme immunoassay
(CEIA) had a number of advantages over the ICE in terms of reagent
preparation, assay procedure, and day to day variability in absorbances. The
purification of immunoglobulin from whole serum is not required, and there are
fewer steps to the assay. The method was shown to be highly repeatable and
reproducible, and gave results similar to those obtained with the ICE. It was
however slightly less sensitive, with a detection limit of approximately 0.5 ngml- 
1
The CEIA was used to investigate the pharmacokinetics of isometamidium 
in Friesian cattle (Bos taurus) treated via the intravenous and intramuscular 
routes at a dose rate of 1.0 mgkg-1 body weight (Chapter 8). The major 
pharmacokinetic parameters were calculated using non-linear curve-fitting of
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standard pharmacokinetic equations. The large volume of distribution at steady 
state (mean 24 Ikg-1), the prolonged mean residence time (83 h) and the 
terminal phase half-life (136 h) following intravenous injection were consistent 
with extensive uptake of the drug into specific tissues such as liver, kidney and 
spleen. The relatively low bioavailability (60%), and prolonged mean 
absorption time (7.8 days) following intramuscular injection was consistent with 
formation of a primary depot at the site of injection due to binding of 
isometamidium to tissue macromolecules and ground matrix components.
The ability of the CEIA to quantify isometamidium concentrations in serum 
samples taken from cattle under field conditions in Africa was evaluated in an 
experiment conducted at the Rekomitjie Research Station in a tsetse-infested 
area of the Zambezi valley, Zimbabwe. Twenty-four cattle were treated with a 
prophylactic dose of isometamidium chloride (1.0 mgkg-1 body weight) and 
exposed to natural tsetse challenge. Isometamidium could be detected in the 
sera of all but one of the 24 treated cattle for up to 14 weeks following 
treatment; drug was detectable in 22 cattle for eight weeks, in 20 cattle for 10 
weeks, in 12 cattle for 12 weeks and in five cattle for 14 weeks following 
treatment. The geometric mean apparent half-life of isometamidium in 22 
individual cattle was 23.2 days (range 15.7 to 58.3 days). Although 
trypanosome challenge was judged to be a low to medium on the basis of 
infection rates in untreated control cattle, few trypanosome infections occurred 
in the prophylaxis group. Infections were not detected in any of the 
isometamidium-treated cattle for 18 weeks following treatment, after which three 
infections were detected. By this time isometamidium concentrations had fallen 
below the limit of detection of the CEIA (0.5 ngml-1), and there was no evidence 
therefore of drug resistance at this site.
Finally, the CEIA was used to investigate a possible role for the 
isometamidium in the pathogenesis of a wasting syndrome induced 
experimentally in Maasai Zebu cattle under a regimen of frequently repeated 
trypanocidal drug treatments. Other parameters measured were body weight 
change and the hepatocellular leakage enzyme Glutamate dehydrogenase 
(GLDH). The effect of body condition and nutrition on a treatment regimen 
involving two trypanocides was also investigated. As few as two isometamidium 
treatments one month apart were shown to be associated with significant weight 
loss in cattle under conditions of poor nutrition, and cattle treated with 
diminazene aceturate after three or four isometamidium treatments suffered a
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50% mortality rate. In cattle treated with both trypanocides, body weight losses 
and GLDH levels were correlated with isometamidium concentrations. Although 
there were no obviously marked elevations in isometamidium concentration 
which might have allowed the use of the ELISA as a predictor of a potential 
toxicity problem, small but significant increases in concentration occurred with 
successive treatments. These suggested accumulation of the isometamidium 
may have occurred; this should be considered in the context of the drug's low 
therapeutic index. It was therefore recommended that such frequently repeated 
treatment regimens be avoided wherever possible.
Recommendations for further scientific investigation
Protection against T. vivax
There are, as yet, no data available to relate isometamidium concentrations 
to protection against T. vivax. There have been fewer controlled laboratory 
studies on the prophylaxis afforded by isometamidium to cattle against 
challenge by 7. vivax, although the limited evidence available suggests 7. vivax 
may be less sensitive to the prophylactic activity than the therapeutic activity of 
the drug (Peregrine et al., 1987, 1991). Isometamidium prophylaxis 
experiments in cattle under controlled laboratory conditions, similar to those 
described in Chapters 4 and 5, with tsetse challenge using isometamidium- 
sensitive and resistant 7  vivax populations should therefore be given a high 
priority among future investigations.
Influence of level of challenge on duration of prophylaxis
It has often been suggested on the basis of field observations, that the 
duration of prophylaxis afforded by isometamidium is dependant upon the level 
of tsetse challenge (Fiennes, 1953; Davey,1957; Whiteside, 1962a). However, 
challenge experiments using intradermal titrated doses of metacyclic forms of 7. 
congolense IL1180 failed to demonstrate any relationship between the duration 
of isometamidium prophylaxis and the level of challenge (Whitelaw et al., 1986; 
Peregrine, et a/.,1988). These experiments did not represent the field situation 
closely, firstly, because experimental challenge with metacyclic trypanosomes 
took place on a single occasion (Whitelaw et al., 1986) or on a single day each 
month (Peregrine et al., 1988), and secondly, because a single clone of 7. 
congolense was used for challenge, whereas in the field, challenge by a wide 
variety of strains of trypanosomes of the three species pathogenic to cattle
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would be expected. Nevertheless, it is difficult to envisage why the duration of 
prophylaxis should be related to the level of challenge.
In the work described in Chapters 4  and 5, there was some evidence of a 
potential interaction between trypanosome infection and the circulating 
concentrations of isometamidium in cattle which appeared to decline more 
rapidly in infected animals. However, this phenomenon was only observed after 
the onset of parasitaemia caused by resistant trypanosomes and therefore it 
would not appear to explain how a high level of challenge might overwhelm 
prophylaxis. Moreover, the duration of isometamidium prophylaxis against T. 
congolense IL 1180 observed when the drug was administered to cattle already 
infected with an unrelated serodeme was the same as observed in similarly 
challenged cattle which had not previously experience trypanosome infection 
(Peregrine et al., 1988). In this situation, trypanosomes would have been 
exposed to the initial peak in concentration following intramuscular 
isometamidium administration (range approximately 40 - 200 ngml-1, Chapter 8), 
so that the proportion of the overall circulating drug taken up by the 
trypanosomes might be expected to be significantly less than that taken up 
during later stages of the prophylactic period, and that isometamidium which 
was taken up by these trypanosomes would be expected to be released on lysis 
of the parasites.
There is evidence that effective isometamidium prophylaxis prevents the 
entry of viable trypanosomes into the circulation (see below). Although 
trypanosome multiplication has been demonstrated at the site of the tsetse bite 
(Luckins and Gray, 1978; Akol and Murray, 1982), it is difficult to imagine a 
biomass of trypanosomes at this location sufficient that it could significantly 
influence the pharmacodynamics of isometamidium in an animal as large as an 
ox, and thereby reduce the prophylactic period afforded by the drug.
Drug concentrations in tissue fluid
Trypanosome challenge which is prevented from establishing infection 
because of isometamidium prophylaxis appears not to progress beyond the 
location of the tsetse-fly bite in the skin; skin reactions (chancre), enlargement 
of local drainage lymph nodes, and the development of measurable antibody 
responses did not occur in cattle protected by isometamidium against tsetse 
challenge or intrademnal metacyclic challenge with T. congolense IL 1180 
(Whitelaw et al., 1986; Peregrine et al., 1988). In view of the site of 
prophylactic action of isometamidium being apparently located at the fly bite,
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investigations of the relationship between isometamidium concentrations in 
tissue fluid and those in the circulation would be particularly interesting. 
Possible methods for such investigations (tissue cages or lymphatic 
cannulation) were suggested in Chapter 8. Of critical importance would be 
whether circulating drug concentrations are representative of skin tissue fluid 
concentrations, and whether the relationship between drug concentrations in 
these two locations was consistent or variable among animals.
Endogenous drug binding and extraction
The extraction of an analyte from a biological matrix often results in the 
measurement of only a proportion of the total analyte present in the matrix. 
This is usually described as the free fraction, to distinguish it from the 
remainder which is bound to a macromolecular element of the matrix 
(endogenous binder). The bound and free fractions normally exist in a state of 
dynamic equilibrium dependant on the dissociation constant of the interaction 
with the endogenous binder. The concentration of free analyte is frequently of 
greater significance than the total, as this may be the fraction having biological 
activity; for example many drugs and hormones can interact with their receptors 
only in the free state.
Isometamidium is believed to be highly bound to serum macromolecular 
components such as albumin (Philips et al., 1967; Smith et al., 1991), and this 
binding probably contributes to the sample matrix effects seen in the indirect 
competition ELISA (Chapter 3) and the competitive enzyme immunoassay 
(Chapter 7). When used therapeutically, the principal interaction of 
isometamidium with trypanosomes probably takes place in the circulation, at 
least in infections with T. congolense and T. vivax. It is not certain to what 
extent the bound fraction of drug is involved in this interaction, or whether the 
free fraction alone is taken up by trypanosomes. In T. brucei infections, and 
more importantly, in chemoprophylaxis, the interaction of isometamidium with 
parasites outside the circulation will be important; drug concentrations in these 
extravascular sites will be likely to be related to the free drug concentrations in 
the circulation, but will also depend upon the mechanism by which 
isometamidium exits the capillaries.
The ELISAs for isometamidium were developed with a view to their use in 
laboratories in African countries, and the inclusion of an extraction step was 
considered undesirable on the grounds of the additional materials, equipment, 
technical expertise and expense involved. However, an extraction procedure
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could assist in quantifying macromolecular binding of isometamidium in bovine 
serum, and would remove the analyte from interfering substances in the sample 
matrix. This might allow the evaluation of effects of endogenous binding and 
other matrix components on the precision and accuracy of assays without an 
extraction step. An extraction procedure would also be an important stage in 
the preparation of tissues samples for estimation of isometamidium residues; 
although outside the scope of this thesis, the determination of residues in 
animal products intended for human consumption could prove to be an 
important use of the isometamidium ELISAs.
Some preliminary attempts to extract isometamidium from bovine sera have 
already been made. The method of partitioning drug into inorganic solvents 
immiscible with water, following which, the solvent phase is dried down and 
reconstituted in a defined, matrix-free, aqueous assay buffer, is widely practised 
in steroid hormone immunoassay (Chard, 1990). This methodology was found 
to be unsuitable for use with isometamidium which, being highly polar, is 
generally insoluble in solvents which are immiscible with water. An alternative 
technique was investigated, utilising the property of certain water-miscible, 
polar organic solvents such as methanol, ethanol and acetonitrile to precipitate 
serum proteins (data not shown). Following addition of such polar solvents 
samples containing 14C-isometamidium could be centrifuged and the quantity of 
isometamidium in the supernatants determined measured by liquid scintillation 
counting (Tri-Carb 1600-TR, Packard, Groningen, the Netherlands).
Recoveries of 14C-isometamidium in supernatants over a fairly wide range 
of concentrations (10 - 160 ngml-1) were approximately 30% using methanol 
precipitation, and 70% using acetonitrile precipitation. Consideration of the law 
of mass action suggests that this plateau in percentage binding would continue 
at lower drug concentrations (Goldstein, Aranow and Kalman, 1974), although 
this could not be verified experimentally because of the limited specific activity 
of the labelled drug. On redissolving methanol precipitates in aqueous buffer, 
the presence of 60 to 65% of the non-recovered isometamidium could be 
demonstrated. Unlike methanol precipitates, acetonitrile precipitates could not 
be redissolved readily in aqueous buffer, and hence the higher recovery of 
drug (and lower apparent percentage binding) obtained using acetonitrile might 
be accounted for by denaturing of serum proteins. The methanol precipitation 
data were thus considered to be the better estimate of reversible drug binding 
occurring in vivo, and were relatively consistent with data obtained by Philips et
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al. (1967) which showed 66% to 74% of isometamidium was bound in solutions 
of 0.2% bovine serum albumin.
The relatively high recovery of isometamidium in supernatants obtained 
following using acetonitrile precipitation suggested that this might be a suitable 
extraction method use with ELISA for estimation of total drug. Accordingly, 
these supernatants evaporated to dryness, and reconstituted in suitable buffer. 
Acetonitrile extracts tested in the ICE for isometamidium gave quantitative 
responses over a range of concentrations. However, following precipitation of 
drug-free normal bovine serum and reconstitution of the dried down extract in 
assay buffer there was attenuation of the absorbance obtained in the ICE, when 
compared with the absorbance obtained with buffer alone. This implied that 
during the extraction procedure there was carry over either of matrix 
components capable of interfering in the ICE, or acetonitrile. Because of the 
absorbance quenching effect the extraction procedure showed no advantage 
over the original assay methodology described in Chapter 3. The use of these 
extracts in the CEIA could be tested but would be expected to have similar 
drawbacks.
Solid-phase extraction methods are being used increasingly for sample 
clean up prior to immunoassay and HPLC analyses. The extraction of 
isometamidium from bovine serum using substituted silica solid-phase 
cartridges was used successfully in the development of an HPLC system for 
isometamidium (Kinabo and Bogan, 1988a) and further investigations in the use 
of this sample preparation technology with the isometamidium ELISAs are 
clearly warranted.
An alternative strategy to preparation of biological samples for 
immunoassay by the use of extraction procedures is the so called "direct" 
approach in which the analyte is assayed within the biological matrix in which it 
was collected. Such direct assays avoid the inconvenience and expense of an 
additional sample extraction procedure, and both the bound and free fractions 
may be measured, although the extent to which the bound fraction is measured 
in an immunoassay will depend on whether the endogenous binder competes 
with binding by the specific antibody reagent, and on the relative affinities of the 
two forms of binding. The two ELISAs for isometamidium described in this 
thesis fall into this category.
In order to increase the proportion of bound drug measured in a direct, 
unextracted immunoassay, another ligand with high affinity for the endogenous
251
binder, but not the specific antibody may be added to displace the analyte from 
its binding site (Ratcliffe, 1983). In an ELISA for melarsoprol, 
chlorophenoxyisobutyric acid was used to displace the drug from human serum 
albumin (Maes et al.t 1988). In preliminary experiments neither this agent, nor 
aspirin, phenylbutazone, danazol or 8-anilino-1-naphthalene sulphonic add  
(Ratcliffe, 1983) influenced the position of displacement curves in the 
isometamidium ELISAs. This suggested that either none of these agents were 
capable of displacing the drug from the endogenous binder, or that the ELISAs 
already measure the total drug concentration. The latter explanation is quite 
plausible in view of the high affinity of the specific antibodies used. Further 
investigations to confirm this would of course be warranted.
Other supporting work
Further investigations in a number of areas related to the use of the 
isometamidium ELISAs would support their continued development and 
application. In many of these areas some preliminary work have already been 
conducted during the preparation of this thesis.
In the work described in this thesis, ELISAs for isometamidium were 
developed for the investigation of concentrations of the drug in serum rather 
than whole blood or plasma. The rationale for this was that samples of serum 
are easiest to collect under African conditions. Anticoagulant is not required for 
the collection of serum, whereas for plasma or whole blood samples use of one 
of various possible anticoagulants is essential. The quality, quantity, type and 
availability of anticoagulants used are all extra variables over which the 
laboratory investigator would have little control. In addition, a centrifuge is 
desirable, but not essential for the preparation of serum, as clots may be 
removed manually. Centrifugation is essential for the preparation of plasma 
samples, and must be performed within a relatively short period of sample 
collection if haemolysis is to be avoided. In this respect, blood samples 
collected for serum preparation are relatively more robust. The possibility of 
successfully establishing serum banks in Africa from cattle in the field has been 
proven under programmes such as the Pan-African Rinderpest Campaign. 
Finally, the trypanosome antigen ELISA uses serum samples, and it would 
clearly be useful if the same sample could be analysed both for evidence of 
trypanosome infection, and for the presence of isometamidium.
The above notwithstanding, investigations to determine whether there are 
differences between isometamidium concentrations in serum and plasma would
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be warranted. Differences in levels between serum and plasma might be due to 
binding of isometamidium to fibrinogen or other plasma proteins which are 
involved in the clotting process. If binding of isometamidium to fibrinogen 
occurs, the increases in fibrinogen levels that have been shown to occur in 
cattle in response to many inflammatory conditions could have a significant 
effect on drug determinations. Similarly, disseminated intravascular coagulation 
which has been proposed as an important pathogenic mechanism in bovine 
trypanosomiasis (Forsberg, Valli, Gentry and Donworth, 1979) and in which 
circulating fibrinogen levels are often severely depleted could be influential.
Theoretical considerations suggest that there may be loss of the positively 
charged quaternary ammonium compound isometamidium during storage in 
glass containers, through ionic absorption onto negatively charged silanol 
groups of the glass. Perschke and Vollner (1985) avoided the use of glass 
containers for storage of isometamidium solutions for this reason. The recovery 
of 14C-labelled isometamidium following short term storage of solutions of the 
drug in various media and containers was investigated to enable the validity of 
various experimental procedures to be determined (data not shown). It was 
found that the recovery of isometamidium, measured by liquid scintillation 
counting (Tri-Carb 1600-TR), in phosphate buffered saline (PBS) was less than 
50% even after very brief periods (a few hours) of storage in polyethylene flip- 
top tubes (Eppendorf). The addition of 20% normal bovine serum (NBS), or 
0.1% gelatin to the PBS improved recovery to between 95% and 100% and 
such solutions could be stored for at least 10 days without significant loss in 
recovery. In addition recovery of isometamidium solutions stored in glass tubes 
was better than in the plastic Eppendorf tubes. The improvement in recovery 
obtained with NBS or gelatin is probably in part due to the fact that the drug has 
greater affinity for these macromolecules than for the walls of the container, and 
in part due to a blocking effect of these proteins on the binding sites of the glass 
or plastic.
In accordance with these results, the immunoassay studies described in this 
thesis were designed to avoid the need to prepare and store isometamidium in 
aqueous solution without the addition of proteins such as serum or gelatin; if 
preparation of such solutions was necessary glass rather than plastic 
containers were be used, and the solutions were used immediately, without 
storage. Bovine sera containing isometamidium are unlikely to suffer problems 
of poor recovery because of the presence of serum proteins such as albumin.
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Phillips et al. (1967) found that isometamidium bound to, but did not pass 
through dialysis tubing. Nevertheless dialysis of isometamidium has been used 
in a number of experimental protocols including preparation of isometamidium- 
protein conjugates (Chapter 2). A few simple experiments were conducted to 
investigate whether dialysis of isometamidium is effective under various 
conditions. These confirmed that dialysis of isometamidium is only partially 
effective, and is less effective at higher concentrations of the drug. A difference 
in colour is apparent visually between the dialysate and the starting material; 
whereas solutions prepared from Samorin® have a characteristic dark reddish- 
brown colour, the dialysate is purple. This suggests dialysis may favour 
particular constituent isomers of the product, especially the purple isomer. 
Other methods, such as gel filtration and use of dextran-charcoal have been 
shown to be more effective in the removal of free drug from enzyme-conjugates 
(Chapter 2).
A radioimmunoassay (RIA) method for isometamidium using 14C- 
isometamidium tracer and charcoal separation of the bound and free fractions 
was described by Kinabo and Bogan (1988c). For various reasons, particularly 
the lack of sensitivity of the method, and the lack of availability of 14C-labelled 
drug it has not found widespread use. However, RIA remains a useful tool in 
the development of ELISA techniques because it permits the determination of 
the bound and free fractions of the tracer, with which information Scatchard 
analysis may be used to determine affinities of antibodies in various 
hyperimmune sera and immunoglobulin preparations. In contrast, the 
configuration of ELISA generally precludes the use of these analyses. RIA thus 
has a potential role as a reference method with which reagents for use in the 
ELISA may be evaluated quantitatively.
A new RIA for isometamidium has been developed, incorporating several 
improvements over the earlier version (Kinabo and Bogan, 1988c). These 
improvements include the use of superior isometamidium conjugates and 
hyperimmune sera produced during the development of the isometamidium 
ELISAs, and a superior better method of separating bound and free drug. The 
new radioimmunoassay method used 14C-isometamidium, hyperimmune sheep 
anti-isometamidium IgG, and a polyethylene glycol separation step, and was 
successful in detecting and quantifying isometamidium (data not shown). 
Scatchard analysis of the data was used to estimate the affinity of antibodies in 
hyperimmune sheep serum at approximately 1085 ImoM.
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The studies on isometamidium described in this thesis were conducted 
using the commercial product, isometamidium chloride (Samorin®, RMB Animal 
Health Ltd.) for the treatment of cattle, and the production of reagents (specific 
antibody, plate-coating conjugates, enzyme conjugates and assay standards) 
for use in the immunoassay of the drug. Samorin®, however, is a mixture of 
similar compounds (see Chapter 2); the commercial product contains 
approximately 70% of a red isomer (i.e. true isometamidium chloride), 20% of a 
purple isomer, 10% of a bis species, small quantities of a positional isomer, and 
traces of homidium (J. Wilkes, personal communication). The most abundant, 
red isomer has also been shown to be the one possessing the greatest 
trypanocidal effect against T. congolense both in vivo, in prophylactic and 
therapeutic trials in mice (Wragg, Washbourne, Brown and Hill, 1958), and in 
vitro (A.S. Peregrine, personal communication), using a photometric growth 
inhibition assay (Zinsstag, Brun and Gessler, 1991).
The reactivities of the individual constituent isomers of the commercial 
product isometamidium chloride has been tested (result not shown) in the 
competitive enzyme immunoassay for isometamidium described in Chapter 7. 
Individual purified isomers were shown to react to differing degrees in the CEIA 
on a weight basis. The red isomer, true isometamidium, reacted to the greatest 
extent, and was shown to be the constituent responsible for the greater part of 
the response observed with whole Samorin® in the CEIA. Thus, of the 
compounds present in Samorin®, the CEIA appears to have the greatest 
sensitivity for the one which is both the most abundant and the most 
trypanocidal. The less trypanocidal constituents are present in lesser quantities 
(together representing only approximately 30% of the total), and those amounts 
which are present are poorly detected by the CEIA. The next best detected 
constituent, the positional isomer, is approximately five times less reactive (by 
comparison of drug concentrations resulting in 50% competition), and the 
purple isomer ten times less reactive than the red isomer on a weight basis. 
The bis-species shows comparatively little cross-reactivity, approximately 1000 
times less than the red isomer.
The use of monoclonal antibodies as primary immunoassay reagents offers 
certain theoretical advantages in terms of continuity of supply of a reagent of 
defined specificity. Two murine monoclonal antibody secreting cell-lines were 
raised against isometamidium-porcine thyroglobulin conjugate (Peregrine, 
Eisler, Katende, Gault, Flynn, Kinabo, and Holmes, In press). Competition
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ELISAs were developed using these antibodies, but were less sensitive than the 
ELISAs using polyclonal hyperimmune sheep serum. Similarly, no advantage in 
terms of assay specificity was obtained. In fact good high titre hyperimmune 
sera are preferred by many investigators in the immunoassay field because of 
their greater stability, and generally higher affinity. In competitive 
immunoassays, as opposed to sandwich-type assays (which are not generally 
applicable to molecules as small as isometamidium), the law of mass action 
dictates that the sensitivity of the assay will depend upon the affinity of the 
antibody used. Obtaining a satisfactory monoclonal antibody secreting cell line 
is to some extent a question of luck as resources normally allow only a finite 
number of candidate hybridomas to be screened. The production of monoclonal 
antibody based immunoassays for isometamidium could therefore be 
considered further, but with no guarantee of success.
Genetic and environmental influences on the efficacy of
isometamidium prophylaxis
Isometamidium prophylaxis may be used in cattle over a very large area of 
Africa, encompassing some 37 countries affected by bovine trypanosomiasis. 
There are accordingly a wide variety of cattle breeds which may be involved. 
The effect of the breed of cattle on the disposition kinetics of isometamidium 
could therefore be an important factor in the efficacy of chemoprophylaxis in 
different locations. Most obviously, there is the difference at species level, 
between the Bos taurus breeds of trypanotolerant cattle which are reared in 
much of West and Central Africa, and the Zebu-type Bos indicus cattle also 
found in West and Central Africa and which predominate in the rest of the 
continent. Although trypanotolerant cattle are so called because of a degree of 
genetic resistance to the disease, they are nevertheless susceptible to infection 
and may be severely affected in high challenge situations, unless their genetic 
resistance to disease is supplemented by the use of trypanocidal drugs 
(Roelants, 1986; Otesile, Akpokodje and Ekwuruke, 1991). There may also be 
differences within each of the two species of cattle between the many different 
breeds. Some differences may be physiological, based on size, weight, and 
body composition, and other s related to unknown genetic factors. Other 
differences may be related to the physiological status of individual animals, 
such as age, sex, growth rate, gestation, lactation and nutritional status, or to 
the effects of other diseases or parasites. These factors all merit further 
investigation.
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Recommendations for application of the 
isometamidium ELISAs in Africa
The development of the ELISAs for the determination of isometamidium in 
bovine serum has provided a valuable new tool for the improvement of the 
chemoprophylactic control of African bovine trypanosomiasis. 
Chemoprophylactic drug dosage regimens can now be based on a 
understanding of the levels of drug achieved in the circulation of treated 
animals, rather than on the empirical basis used hitherto. Furthermore, the 
ELISAs appear to be promising as a technique to investigate the appearance of 
resistance to isometamidium in the field, by allowing treatment failure to be 
distinguished from true drug resistance as a cause of apparent drug failure. 
The simultaneous demonstration in the same animal of trypanosome infection 
and levels of isometamidium which would under normal circumstances be 
considered protective, would provide strong circumstantial evidence that drug 
resistance had developed. In such a situation the use of a "sanative" drug, i.e. 
diminazene aceturate, in an attempt to eliminate isometamidium-resistant 
parasites, and the integrated deployment of tsetse control techniques, of which 
the most promising and environmentally sound currently appear to be the use of 
insecticide impregnated traps and targets and the application of insecticides 
onto cattle, should be considered.
Extension of the technology through international programmes
The provision of the trypanocidal drug technology to African veterinary 
laboratories concerned with the diagnosis and control of bovine 
trypanosomiasis is envisaged through the programmes of international 
organisations such as FAO and IAEA. Between 1987 and 1992 a Co-ordinated 
Research Programme of the Joint FAO/IAEA Division of Nuclear Techniques in 
Food and Agriculture successfully implemented the trypanosomiasis Ag-ELISA 
in Veterinary laboratories in ten sub-Saharan countries (Ooijen, 1993). The 
equipment necessary for conducting ELISAs, and training in its use was given 
to a large number of participating scientists and technicians. This Programme 
has now entered a second phase, involving an even greater number of 
countries, and it is hoped that during this phase trypanocidal drug ELISAs will 
be distributed, in kit form, to suitable laboratories. With the financial assistance 
of the ODAs Animal Health Programme, this transfer of technology has already 
commenced in the case of the Kenya Trypanosomiasis Research Institute, and
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plans are underway to do likewise in laboratories in Tanzania and Zambia in 
the near future.
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General List of Abbreviations
Ab Antibody
ADI Acceptable daily intake
Bo Absorbance at zero dose
BCT Phase contrast / buffy coat technique
CEIA Competitive enzyme immunoassay
CV Coefficient of variation
DMSO Dimethyl sulphoxide
ELISA Enzyme-linked immunosorbent assay
GLDH Glutamate dehydrogenase
HCT Haematocrit centrifugation technique
HPLC high performance liquid chromatography
ICE Indirect competition ELISA
ig Immunoglobulin
IM Intramuscular
IV Intravenous
Mab Monoclonal antibody
MRL Maximum residue level
NBS Normal bovine serum
OD Optical density or absorbance
PBS Phosphate buffered saline
PBST PBS containing 0.05% Tween 20
PTG Porcine thyroglobulin
SA-HRP Streptavidin-horseradish peroxidase
TMB T etramethylbenzidine
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List of Pharmacokinetic Abbreviations
AUC
AUMC
Cl
Cm ax 
Czero 
F
K21
MAT 
MRT 
RIA 
T % 
Tmax
Vcc
Vss
Area under the concentration-time curve 
Area under the moment curve 
Clearance
Maximum concentration 
Concentration at time zero 
Bioavailability
Rate constant for movement of drug from compartment two to 
compartment one of the three compartment pharmacokinetic 
model. K3i, K10, K12 etc. likewise, such that Kxy is the rate 
constant for movement of drug from compartment x to 
compartment y.
Mean absorption time
Mean residence time
Radioimmunoassay
Half-life
Time to maximum concentration 
Volume of central compartment 
Volume of distribution at steady state
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